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Children with Down’s syndrome (DS) are at increased risk of autoimmune conditions including 
diabetes, coeliac and thyroid disease. Autoimmune diabetes occurs earlier in children with DS 
compared with the general population despite decreased levels of the typical genetic 
susceptibility factors. During this PhD, FADES (Feeding and Autoimmunity in Down Syndrome 
Evaluation Study) was established to examine early life and the development of 
autoimmunity. This was a UK wide feasibility study for which infants with DS were recruited 
under eight months of age. Parents completed detailed feeding and medical questionnaires 
at recruitment, seven months, 12 months and yearly thereafter. Sampling protocols were 
optimized for national collection by post. A DNA sample was collected as well as longitudinal 
samples for urine C-peptide, stool for gut microbiome and blood for antibodies. As part of the 
overall feasibility a qualitative study was undertaken to determine the potential barriers to 
recruitment of young infants with DS into research.  
Between September 2014 and September 2017, 70 participants were recruited. At two years, 
61% of participants had completed all the requested questionnaires and samples. Initial 
analysis of clinical samples proved their adequacy for HLA genotyping and antibody testing. 
The questionnaires revealed that exclusive breastfeeding rates at six months in the cohort 
was comparable to rates in the general population (4% vs 1%). Issues with feeding were 
explored revealing at least half of the babies had received naso-gastric tube feeds.  
This study has established one of the largest longitudinal birth cohorts of children with DS. 
The bank of samples and data to explore early life and autoimmunity in DS is unique. Findings 
will be used to inform parents and professionals on early feeding. Ongoing expansion of this 
cohort will aim to increase understanding of the mechanisms and pathogenesis of 
autoimmune-mediated conditions and may provide important insights for research. 
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Chapter 1  





Chapter 1 – Introduction and Background 
 Introduction 
Individuals with Down’s syndrome (DS) are at increased risk of autoimmune conditions 
including Type 1 diabetes (T1D), coeliac disease (CD) and autoimmune thyroid conditions 
(Gillespie et al. 2006, Sánchez-Albisua et al. 2002). This is despite children with DS and T1D 
having a lower prevalence of high risk human leukocyte antigen (HLA) genotypes than those 
with T1D alone (Aitken et al. 2013). Children with DS have inherent defects in their immune 
system but mechanisms underlying the increased risks of autoimmunity are poorly 
understood.  
The Feeding and Autoimmunity in Down’s Syndrome Evaluation Study (FADES) has been 
designed to determine the feasibility of a UK wide birth cohort of babies with DS, and to 
explore potential influences in the development of autoimmunity in DS. In time this may also 
lead to a better understanding of autoimmunity in the general population. 
 Overview of Chapter 1  
Chapter 1 includes the clinical and immunological features of Down’s Syndrome and the 
epidemiological data for the UK population of people with DS. Autoimmunity, TID, CD and 
thyroid conditions are described both within the general population and in people with DS. 
An introduction to how the gut microbiome, infections, breastfeeding and weaning might 
influence the development of autoimmunity is given. Chapter 1 also provides background on 





The aims, feasibility objectives and secondary objectives of this PhD are given at the end of 
the chapter. 
 Down’s Syndrome and Immunity 
 Definition and Description 
Down’s Syndrome (DS) is caused by an additional copy of chromosome 21 (Trisomy21). The 
phenotypical features of DS combined with learning difficulties were first described by Dr 
John Langdon Down in 1867 (Down 1867), and the discovery that individuals with DS had 3 
copies of chromosome 21 was made in 1959 (Lejeune, Gautier, and Turpin 1959).  
DS is usually diagnosed within the first few days of life with typical features including: 
epicanthic folds, single palmar crease, hypotonia, an enlarged or protruding tongue and wide 
spacing of the first and second toe. Approximately 44% will have cardiac abnormalities, the 
most common being atrioventricular septal defect (AVSD) (Freeman et al. 1998). DS carries 
an increased risk of autoimmune conditions including T1D, autoimmune thyroid disease and 
CD (Karlsson et al. 1998, Sánchez-Albisua et al. 2002, Gillespie et al. 2006). Hearing loss is also 
a feature of many DS individuals (Balkany et al. 1979), as are a variety of ophthalmological 
problems including cataract, strabismus, refractive errors and nystagmus (Da Cunha and 
Moreira 1996). There is also an increased risk of haematological disorders and malignancies 
particularly leukemia and transient myeloproliferative disorder (Hasle, Clemmensen, and 
Mikkelsen 2000). Other conditions that are more common in people with DS include arthritis, 
atlanto-axial subluxation, obstructive sleep apnoea, seizures and early dementia particularly 




few decades with average life expectancy now around 50 years for a person with DS living in 
the USA (Yang, Rasmussen, and Friedman 2002). 
People with DS have inherent defects in their immune system but mechanisms underlying the 
increased risk of autoimmunity are under-investigated. A study of the potential influences in 
the development of autoimmunity in DS may lead to a better understanding of autoimmunity 
in the general population. 
 Epidemiology of DS in the United Kingdom. 
The availability of epidemiological data for diagnoses and live births of infants with DS for 
each of the individual countries in Great Britain varies.   
England and Wales 
Statistics on the number of diagnoses of DS in England and Wales are collected by the National 
Down’s Syndrome Cytogenetic Register (NDSCR) (Morris and Springett 2014b). Since 1989 the 
NDSCR has collected notifications from all the cytogenetic laboratories across England and 
Wales of cases diagnosed with Patau’s syndrome (Trisomy 13), Edwards’ syndrome (Trisomy 
18) and Down’s Syndrome (Trisomy 21). The NDSCR does not have contact with any of the 
parents and is therefore unable to provide any contact details for recruitment to research 
studies. The executive summary from the NDSCR 2013 annual reported (Morris and Springett 
2014a): 
• in 2013 there were 1,886 diagnoses of Down syndrome, 65% of which were made 




• in 2013 there were an estimated 728 DS live births, a live birth rate of 1.0 per 1,000 
live births.  
Of those women who received a prenatal diagnosis of DS, 90% terminated the pregnancy. Of 
those continuing with their pregnancy, a proportion had natural miscarriages or still births 




Table 1: DS cases diagnosed in England and Wales in 2013* according to time of diagnosis 
and outcome. Taken from (Morris and Springett 2014a) 
 
Northern Ireland 
There is currently no formal register of DS diagnoses in Northern Ireland and few studies 
which describe the epidemiology of DS within Northern Ireland.  Although abortions are legal 
in Northern Ireland, they are only permitted in circumstances where the mother’s life is 
directly at risk if the pregnancy continues (1945 Criminal Justice (Northern Ireland) Act). The 




within the UK, does not extend to Northern Ireland. It may therefore be expected that rates 
of live births of babies with DS within Northern Ireland would be higher than in other parts of 
the UK. From January 1997 until December 2001 there were 208 cases of Down’s syndrome 
diagnosed postnatally in Northern Ireland giving a prevalence of 167.9 per 100 000 (or 1 in 
595 births) (Devlin and Morrison 2004). 
Scotland 
In Scotland there is only one congenital anomaly register based in Glasgow and therefore 
there are few data available for the number of DS diagnoses for Scotland as a whole. The 
Glasgow Register of Congenital anomalies reported 33 diagnoses of DS during the period from 
1st April 2013 until 1st March 2014 an incidence of 1:403 maternities. Over a more extended 
period of time they reported a  DS pregnancy prevalence of 1.24 per 1000 total births from 
1980 – 1996 (Iliyasu, Gilmour, and Stone 2002). Down’s Syndrome Scotland stated in 2014 
that 50 - 60 babies a year are born with DS in Scotland (personal communication). 
 Immunity and Down’s syndrome 
Individuals with DS have defects in their immune system with increased risk of developing 
haematological malignancies (Øster and Nielsen 1975) and increased incidence of 









Increased incidence of infections, particularly respiratory (Øster and Nielsen 1975) 
Increased incidence of lymphatic leukaemia (Hasle, Clemmensen, and Mikkelsen 2000) 
High incidence of Hep B surface antigen positivity (Ugazio et al. 1977) 
High incidence of thyroid autoantibodies (Ugazio et al. 1977, Karlsson et al. 1998) 
 
 
Immunologic Findings  
Diminished number of blood lymphocytes (Kusters et al. 2009) 
Diminished phagocytic activity (Rosner, Kozinn, and Jervis 1973) 
B cells 
Normal number (Levin et al. 1979) 
Immunoglobulin production (Burgio et al. 1975, Stiehm and Fudenberg 1966, 
Sutnick, London, and Blumberg 1969) 
IgG level, normal or increased 
IgA level, normal or increased 
IgM level, normal or decreased 
Defective antibody response to bacteriophage ФX174 (Lopez et al. 1975) 
T cells 
Diminished number (Kusters et al. 2009) 
Diminished blast transformation with phytohemaglutinin (PHA) (Sasaki and Obara 
1969, Burgio et al. 1975) 




Small with severe lymphocyte depletion  
Contracted, depleted cortex 
Giant and cystic Hassall’s corpuscles 
Increased cellularity around some Hassall’s corpuscles 
Spleen 
T-zone lymphocytes depleted. 
 








Various aspects of the immune system have been studied in those with DS. Levin found no 
differences in the percentages of B cells or immunoglobulin levels in children and newborns 
with DS compared with examining those without DS (Levin et al. 1979). The function of  B cells 
has also been studied by the phagocytic function of leukocytes and the adhesiveness of 
neutrophils, both of which are reduced in DS (Rosner, Kozinn, and Jervis 1973, Costello and 
Webber 1976). These differences in function are however small and are not consistently 
found in other studies. 
Significantly reduced numbers of T cells have been reported in people with DS and there is 
also evidence of reduced function. T cells do not undergo the normal pattern of massive 
expansion in the first year of life, suggesting that they are not responding normally to the 
multiple antigens to which they are exposed at this stage (Kusters et al. 2009). The number of 
T lymphocytes does improve with age but although normal numbers might be reached, their 
function is poor.  
The thymus is smaller in people with DS, (Levin et al. 1979), there are fewer mature 
thymocytes (Murphy, Lempert, and Epstein 1990), lymphocyte numbers are depleted, and 
the cortex is poorly demarcated and contains large Hassall’s corpuscles. Hassall’s corpuscles 
are made up of epithelial cells and are normally present, but these very large Hassall’s 









Figure 1: Comparison of Hassall’s Corpuscle in the normal thymus and in an individual with 
DS. Adapted from (Levin et al. 1979)  A - “Normal thymus (hematoxylin-eosin x 120) showing 
lymphocyte concentration in cortex, good corticomedullary demarcation, and a single 
Hassall’s corpuscle (arrow).” B - “Thymus (hematoxylin-eosin x 120) of patient with DS 
showing lymphocyte depletion and contraction of cortex, loss of corticomedullary 
demarcation, and large cystic Hassall’s corpuscles, many surrounded by sheath of 
lymphocytes.” 
 
Hassall’s corpuscles play an important role in the generation of regulatory T cells within the 
thymus. T regulatory (Treg) cells which express the transcription factor FOXP3 (Forkhead Box 
P3) suppress immune response to self antigens (see Figure 2). Norihiko Watanabe described 
the ability of the dendritic cells within the corpuscles to “induce the proliferation and 
differentiation of  CD4+ CD8- CD25- thymic T cells into CD4+ CD25+ FOXP3+ regulatory T cells” 
(Watanabe et al. 2005).  Tregs are increased in the peripheral blood in DS, but their capacity 







Figure 2: The role of Treg cells. Adapted from (Sakaguchi 2005)  Treg cells which express FoxP3 
are vital for self-tolerance. They are produced in the thymus, work in the periphery and 
alterations in either in their quantity or functional ability may lead to autoimmunity, rejection 































 Background and epidemiology 
Autoimmune conditions cause significant morbidity and mortality. The total estimated 
prevalence of autoimmune disease in the general population is approximately three percent 
(Cooper and Stroehla 2003).  
Autoimmune conditions are thought to be caused by a combination of genetic predisposition 
and environmental triggers or risk factors. They involve a defect in immune regulation where 
self-antigens are not recognised, leading to damage and destruction of specific tissues. The 
damage occurs in the pancreas in T1D, in the joints in rheumatoid arthritis, the myelin sheath 
which covers nerves in multiple sclerosis (MS) and the uvea of the eye in uveitis. In some 
autoimmune conditions, several systems can be damaged as autoantibodies are directed 
against proteins found in many cells. For example, in systemic lupus erythematosus, 
antibodies are found against proteins in the cell’s nucleus, and damage to the heart, kidney, 
lungs, liver, blood vessels, skin and joints is observed.  
 Incidence and prevalence  
As well as the variety observed in the clinical manifestations of autoimmunity, there are 
variations in the prevalence of certain conditions between ethnic groups and geographical 
areas. The variation in incidence and prevalence in T1D will be discussed in more detail later 
but interestingly there are similar differences in T1D and multiple sclerosis (MS). Higher 
incidence rates in both T1D and MS are seen in Northern Europeans and lower rates amongst 
Japanese, Chinese and Black Africans (Rosati 2001). There are increased frequencies of HLA 




(Schmidt, Williamson, and Ashley-Koch 2007) and HLA DQ2-DQ8 and HLA DQ4-DQ8 in T1D 
(Rönningen, Keiding, and Green 2001). As with T1D, the incidence of MS appeared to be 
affected in part by latitude, but this does not explain the significant variations in incidence 
rates that are seen within some individual countries. Ethnicity clearly plays a role, but 
migratory studies show that incidence rates change when ethnic groups migrate from areas 
of high to low incidence, highlighting the importance of environmental determinants (this is 
covered in further detail in Section 1.4.5.2 Epidemiology of Type 1 Diabetes).  
The risk of childhood T1D is similar amongst females and males (Cooper and Stroehla 2003) 
but in nearly all other autoimmune conditions females are much more likely to be affected 
than males with an estimated 65% of patients being female (Cooper and Stroehla 2003). 
Other differences between these pathogenically similar diseases are in age of onset with T1D 
presenting in childhood and adulthood with the peak ages at onset occurring around puberty 
(Atkinson, Eisenbarth, and Michels 2014) and other conditions presenting at older ages such 
as myasthenia gravis presenting at the age of 30 to 50 years. Incidence rates over time vary, 
the incidence of T1D had been rising over the past couple of decades (Patterson et al. 2009) 
whereas the rate of rheumatoid arthritis (RA) both juvenile and adult onset has reduced 
(Cooper and Stroehla 2003). 
 Genetic prediction 
There is evidence of genetic predisposition for many of the autoimmune diseases. For most, 
this genetic predisposition lies within the human leukocyte antigen (HLA) genes of the major 
histo-compatibility complex (MHC) on the short arm of chromosome 6 (Fernando et al. 2008) 




mount an immune response. In the thymus, MHC class II presents self-peptides to the 
immune system to ensure that they are recognized as “self”. This process is however defective 
in autoimmunity and autoreactive T cells are released into the periphery where they are not 
sufficiently influenced by Tregs. In autoimmune disease, it is thought that the particular 
autoantigen that is presented may determine the type of autoimmune disease (Fernando et 
al. 2008).  
 
 
Figure 3: HLA genes of the major histo-compatibility complex (MHC) on the short arm of 
chromosome 6. The MHC on the short arm of chromosome 6 is comprised of class I, II and III. 
Risk haplotypes for TID are DRB1*03 - DQA1*0501 – DQB1 0201 (DR3-DQ2) and DRB1*04 – 
DQA1*0301 – DQB1 0302 (DR4 – DQ8) (Adapted from Todd  (Todd 2010)) 
 
Fernando et al carried out a pooled analysis of the studies determining the MHC genes 
associated with six autoimmune, infectious and inflammatory diseases: MS, T1D, SLE, 
ulcerative colitis (UC), Crohn’s disease and RA. HLA DR4 haplotypes were found to be a risk 
allele in all conditions apart from UC. HLA DR3 haplotypes predispose to SLE, MS and T1D 
while DR9 is associated with both T1D and RA.  Genome wide association studies (GWAS) 




many of these overlap between autoimmune conditions. This has provided evidence for the 
role of particular genes in autoimmunity and has also given targets for research into casual 
mechanisms and potential future therapies (Lettre and Rioux 2008). See Appendix 1 for table 
of common autoimmune conditions and associated HLA genotypes and autoantibodies.  
 Autoimmunity and Down’s syndrome  
Autoimmunity occurs at an earlier age and is more exaggerated in DS children (Aitken et al. 
2013). CD associated antibodies are present in 10% of DS children, thyroid autoantibodies are 
found in between 13% and 34% and islet autoantibodies in 8%  (Karlsson et al. 1998, Sánchez-
Albisua et al. 2002, Gillespie et al. 2006). The cause of this increase in risk is not yet 
understood. However, intrinsic defects in the immune system particularly with abnormalities 
in the thymus are likely to play a significant role.  
A study to measure gene expression in DS showed that there is not a 50% increase in 
expression in chromosome 21 genes as might be expected. Some genes are expressed by 
more than 150% (Li et al. 2006) while others are not overexpressed. 
There are several candidate genes located on chromosome 21 that could contribute to 
increased risk of autoimmunity. Ubiquitin associated and SH3 domain containing A 
(UBASH3A) gene which is located on chromosome 21 (21q22.3) has been found to be 
associated with T1D in those that already carry the at risk HLA genotype HLA DR3/4, 
DQB1*0302 (Johnson et al. 2012). UBASH3A has also been shown to be linked to CD through 
GWAS (Zhernakova et al. 2011). UBASH3A is also known as Suppressor of T cell signaling 2 
(Sts-2) and it has a role in suppressing T cell receptor signaling which is important in regulating 




Another candidate gene is AIRE (autoimmune regulator) which is also located on chromosome 
21(21q22.3). Mutations in AIRE are already known to be responsible for autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a condition which has 
several overlaps with DS. Both conditions involve an increased risk of pancreatic 
autoimmunity, thyroid autoimmunity, alopecia, hepatitis, mucocutaneous candidiasis and 
dental and nail dystrophy. In APECED, they are also at risk of autoimmune disease of the 
parathyroid and adrenal cortex. The possibility of the presence of two APECED at risk alleles 
being inherited twice from a single parent “disomic homozygosity” leading to an increased 
risk of T1D in DS was investigated by Shield et al (Shield et al. 1999). Their results showed no 
evidence of increased disomic homozygosity in the APECED locus when comparing DS patients 
with T1D with DS alone. Lima et al examined the expression of AIRE within 42 DS thymuses 
and found that it was significantly reduced together with a number of other genes also 
involved in the immune system and cell proliferation (Lima et al. 2011). Giménez-Barcons et 
al also showed reduced expression of AIRE and peripheral restricted Ag genes within the 
thymus of individuals with DS. It therefore appears that AIRE does play a role in autoimmunity 
in DS but this needs more detailed studies to understand the underlying mechanisms 
(Giménez-Barcons et al. 2014). AIRE has also been shown to be associated with autoimmune 
Addison’s disease (Eriksson et al. 2018) and with rheumatoid arthritis (Feng et al. 2015). 
Interestingly GWAS have not highlighted AIRE as a susceptibility gene for organ specific 
autoimmune diseases such as T1D and CD (Colobran et al. 2016). 
Interferon signalling is increased in DS with the overexpression of interferon-related factors 
in the lymphocytes of people with DS (Sullivan et al. 2016). Increased interferon signalling has 




al. 2018). There is a gene cluster on Chromosome 21 which includes four interferon receptors 
(IFNAR1, IFNAR2, IFNGR2 and IL10RB). These genes may also therefore be candidates for 
explaining the mechanisms underlying autoimmunity in this population.  
It is known that environmental factors influence the development of autoimmunity in the 
general population and these effects will be discussed in more detail later in this chapter. 
Children with DS may experience different levels of exposure to these environmental factors 
early in life compared to the rest of the population as a result of their physical, cognitive and 
medical needs. For example, babies with DS are more at risk of infections as previously 
described, which may have an effect in themselves or due to the use of frequent antibiotics. 
Antibiotic use may alter the gut microbiome which in turn may influence the developing 
immune system. An understanding of the early life environmental influences of these children 
may help to explain why they are at increased risk of certain autoimmune conditions. 
 Type 1 diabetes 
 Definition and Description 
T1D is an autoimmune condition in which the insulin producing beta cells in the islets of 
Langerhans within the pancreas are destroyed. When approximately 70% to 80% of beta cells 
have been killed, the body is no longer able to maintain glucose homeostasis. Instead of 
glucose being metabolized and stored, it is lost in the urine and the body enters a catabolic 
state which eventually results in diabetic ketoacidosis. As the amount of insulin being 
produced declines, the classical symptoms of polyuria, polydipsia, weight loss and lethargy 
ensue, and it is hoped that the diagnosis of T1D is made before the patient becomes critically 




mimics natural insulin excretion from the pancreas in response to meals, activities, illness and 
rest. This means that insulin injections need to be given throughout the day or alternatively 
the person with T1D needs to use an insulin pump.  
 Epidemiology of Type 1 Diabetes 
As with other autoimmune and atopic conditions, the causes of T1D are multifactorial with a 
combination of genetic susceptibility and environmental influences. There is a geographical 
and temporal variation in the incidence of T1D.  
The variation between different populations is huge with incidence in China and Venezuela 
of 0.1/100 000 per year compared to 36.8/100 000 per year in Sardinia and 36.5/100 000 per 
year in Finland (Karvonen et al. 2000). This variation is not simply a North / South divide as 
previously thought and large differences have been noted in different ethnic groups living 
within the same geographical area. For example, Jewish and Arabic populations living in Israel 
have markedly different incidence rates. The difference in incidence therefore appears more 
likely to represent genetic variation between ethnic groups compounded by environmental 
exposures which act as triggers. A study of changing incidence in immigrant populations over 
time demonstrates the importance of environmental determinants. The incidence of diabetes 
in children of Asian immigrants born in the United Kingdom and living in Bradford, increased 
to match that of the general population in Bradford (Bodansky et al. 1992). The differences 
seen in the seasonality of diagnosis also supports environmental triggers (Durruty, Ruiz, and 
de los Rios 1979, Green, Patterson, and Group 2001). 
The incidence of T1D is increasing, with the number of new cases in children aged 0-5yrs 




that the increase cannot be explained by the proportion of people with high risk HLA 
genotypes, as this has decreased over time in people with newly diagnosed T1D. There has 
however been an increase in those with intermediate risk genotypes (Gillespie et al. 2004, 
Knip and Simell 2012). There have been a number of hypotheses to try and explain this rise in 
incidence (Knip and Simell 2012), and a reduction in early exposure to microbial antigens 
(Rook 2009) and increased exposure to complex proteins early in life is thought to affect the 
development of the immune system. These exposures take place mostly in the gut associated 
lymphoid tissue which is exposed to luminal contents providing protection against pathogenic 
antigens but also has a role to play in developing tolerance to non-harmful antigens. Viruses 
have been considered as environmental triggers that could also explain the geographical and 
temporal variation including rotavirus and enterovirus (Knip and Simell 2012). Dietary 
exposures which may also act as “triggers” are discussed in detail in “breastfeeding and 
weaning” (Sections 1.5.3 and 1.5.4). 
The concordance of T1D has been reported to be between 23% and 50% in monozygotic twins 
(Kaprio et al. 1992, Barnett et al. 1981) with one long term study quoting up to 70% (Redondo 
et al. 2008). This relatively low percentage reflects the significant contribution that factors 
other than genetics must have on progression to disease. Between dizygotic twins the 
concordance was found to be between 5% and 10%. In a study of risk within families, a child 
who has one parent with T1D has a 3% risk of developing multiple autoimmunity by the age 




Genetics of Type 1 Diabetes and HLA Genotyping 
As with other autoimmune conditions, genes located in the MHC on chromosome 6 play a 
significant role. The MHC class II genes which confer the strongest susceptibility to diabetes 
are HLA- DQB1 and HLA-DRB1 (Nejentsev et al. 2007). 90% of children with T1D will have one 
of the predisposing HLA class II haplotypes DRB1*04-DQB1*0302 and DRB1*03-DQB1*02 
(Todd 2010). The HLA class II genotype is the strongest indicator of predisposition to 
developing T1D and this has been confirmed by GWAS (Nejentsev et al. 2007) which have 
resulted in more than 60 genetic associations with T1D. A child with the highest risk HLA 
genotype, HLA DRB1*03-DQB1*02/*04-DQB1*0302 where parents both have T1D will have 
a risk of up to 50% (Bonifacio et al. 2004). There are also HLA haplotypes which have been 
found to be protective, particularly DQA1*0102- DQB1*0602 (DQ6) haplotype (Thorsby and 
Rønningen 1993). In addition, the HLA class 1 gene HLA A*24 is associated with rapid 
progression and early onset of diabetes (Nakanishi et al. 1993). 
Islet autoantibodies 
Risk of future T1D is most accurately predicted from islet autoantibody status. Antibodies to 
combinations of insulin (IAA), glutamic acid decarboxylase antibodies (GADA), the tyrosine 
phosphatase antibodies (IA2-A) and zinc transporter 8 (ZnT8A) are present in 90% of 
childhood cases of T1D (Ziegler et al. 1999). The development of autoantibodies marks the 
pre diabetic phase and the presence of two or more islet autoantibodies is associated with 
increased risk of future diabetes (Ziegler et al. 2013). De novo autoantibodies are usually are 
not detected before the age of six months (Ziegler et al. 1999). In The Environmental 




in ten babies (0.1%) at the age of three months (Ziegler et al. 1999, Krischer et al. 2015) it is 
important to note that these were not maternal antibodies. Maternal antibodies can be 
transferred to the neonate across the placenta and have been found to be present up to 9 
months of age (Ziegler et al. 1999, E. Naserke, Bonifacio, and Ziegler 2001). GAD antibodies 
are more likely to be acquired from the mother across the placenta but by nine months insulin 
auto antibodies (IAA) are not normally maternal (E. Naserke, Bonifacio, and Ziegler 2001). 
There are some rare exceptions when neonates may develop autoantibodies at a very young 
age including in immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 
(Rubio-Cabezas et al. 2009). 
 Down’s Syndrome and Type 1 Diabetes 
Children with DS have approximately a three to four-fold increased risk of developing T1D 
compared to the general population. Bergholdt et al observed an odds ratio of 4.12 for T1D 
in a DS group compared to a non-DS group (Van Goor, Massa, and Hirasing 1997, Bergholdt 
et al. 2006). T1D in people with DS is diagnosed earlier than in those without DS (Bergholdt 
et al. 2006). A larger proportion are diagnosed before the age of two years (22% vs 4% p < 
0.0001 (Aitken et al. 2013)) suggesting a more aggressive autoimmune response (Shield et al. 
1999, Aitken et al. 2013, Rohrer et al. 2010). As shown in Figure 4, the HLA genotypes of 
children with DS and diabetes do not show a high frequency of the highest risk genotype DR3-
DQ2 / DR4-DQ8 when compared to those with T1D without DS, including in those diagnosed 





Figure 4:  The frequency of T1D associated HLA class II haplotypes in DS and Diabetes. Taken 
from Aitken et al (Aitken et al. 2013). The proportion of people with the highest risk HLA 
genotype DR3/DR4 is similar in the DS and control population. Although an increase is seen 
in the DSD population it is not as high as the proportion with DR3/DR4 seen in those with TID. 
 
 Coeliac Disease 
 Definition and Description 
CD is an autoimmune condition in which innate and adaptive immune responses are triggered 
by the presence of proline rich or glutamine rich proteins in the diet (gliadin and glutenins 
which come from wheat, hordeins which come from barley and secalins which come from 
rye). In susceptible people, peptides from these proteins pass into the lamina propria of the 
small intestine where they can then be presented to CD4+ cells by DQ2 or DQ8 bearing 
antigen presenting cells. If these peptides have been deamidated first by tissue 
transglutaminase, they bind more strongly. Once T helper cells are activated, they induce 
cytotoxic T cells which cause tissue damage including villous atrophy and crypt hyperplasia. 
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production against tissue transglutaminase and gliadin. Gluten also causes a non T cell 
dependent immune reaction by triggering the release of cytokines within the mucosa 
particularly interleukin 15 which causes several inflammatory responses including the 
maturation and proliferation of dendritic cells and activation of cytotoxic lymphocytes causing 
epithelial damage (Di Sabatino and Corazza 2009). CD has a genetic predisposition 
determined by the HLA genotype. CD is linked to HLA DQ2 and DQ8 with more than 95% of 
people with CD having one or the other (Kaukinen et al. 2002). 
The worldwide prevalence of CD is 1 in 266 (Fasano and Catassi 2001). There has been a 
recently reported rise in incidence of CD although this may be partly due to an increased 
recognition of the disease in those with atypical symptoms and better diagnostic tests 
(Rewers 2005). CD causes intestinal and non-intestinal symptoms. Intestinal symptoms do not 
need to be present for the diagnosis of CD to be made. Intestinal symptoms include diarrhoea 
and a bloated abdomen. The non-intestinal manifestations are diverse and can include weight 
loss, lethargy, metabolic bone disease, infertility and anaemia (Green and Jabri 2003). CD is 
associated with an increased risk of developing intestinal lymphoma and other malignancies. 
This risk is reduced by maintaining a gluten free diet. It is therefore extremely important that 
CD is diagnosed and treated with a gluten free diet that excludes wheat, barley and rye.   
The diagnosis of CD may be made by a combination of clinical suspicion, serological testing 
for antibodies to endomysium (EMA), tissue transglutaminase (tTG) and gliadin (in the 
presence of IgA deficiency, IgG antibodies should be measured) and the presence of typical 
histological features on jejenul/ duodenal biopsy. The presence of villous atrophy is typical 




DQ2/DQ8 as an alternative to having a biopsy performed (Kaukinen et al. 2002, Murch et al. 
2013) but this is unsuitable for those with established T1D given shared susceptibility 
haplotypes.  
 Down’s Syndrome and Coeliac disease 
CD is present in five to seven percent of individuals with DS (Carnicer et al. 2001, Book et al. 
2001, Bonamico et al. 2001). The symptoms of CD in DS can be silent, making it difficult to 
diagnose. Although screening for CD is recommended for individuals with DS by the European 
Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) (Husby et al. 
2012), it is not included in the routine screening recommended by the DSMIG or NICE 
(DSMIG , Downey et al. 2015). Both do state however that clinicians should be vigilant in 
looking out for any symptoms or signs that may be suggestive. The reason for the increased 
prevalence of CD in DS is not known. Early weaning and potentially cessation of breastfeeding 
that may happen in children with DS could be a contributing factor. Norris et al showed that 
there was an increased risk of CD if gluten is introduced into the diet before the age of three 
months (Norris et al. 2005). Ivarsson et al showed that in children under the age of two years 
old, if gluten was introduced whilst children were still breastfeeding, the risk of coeliac disease 
was reduced (Ivarsson et al. 2002).   
 Thyroid Autoimmunity 
 Definition and Description 
Thyroid disease is the most common of the autoimmune conditions affecting two to five 
percent of the general population (Simmonds and Gough 2004). Thyroid autoimmunity can 




Thyroid autoimmunity is much more common in women than in men (McLeod and Cooper 
2012, Manji et al. 2006). Thyroid autoimmunity is also caused by a combination of genetic risk 
and environmental influences. There is a HLA associated risk genotype, and for autoimmune 
hypothyroidism this association is with DR3 (Simmonds and Gough 2004). Thyroid 
autoantibodies can be against thyroglobulin, thyroid peroxidase and the thyroid stimulating 
hormone (TSH) receptor. When they are directed against the TSH receptor, they lead to 
hyperthyroidism (Weetman 2004). 
Down’s Syndrome and Thyroid Autoimmunity 
The prevalence of thyroid autoimmunity in people with DS is reported to be between 13% 
and 34% (Karlsson et al. 1998). The symptoms of hypothyroidism may not be recognised in 
patients with DS as poor growth, hypotonia and intellectual impairment are features of both. 
It is extremely important that hypothyroidism is recognised as early treatment is known to be 
beneficial to long term outcomes. In a study of people with DS less than 20 years old, they 
were found to have a higher prevalence of thyroid autoantibodies. Antibodies to tyroxine 
peroxidase (TPO) and antithyroglobulin were two fold higher in DS participants with T1D than 
in participants with T1D only (Rohrer et al. 2010). In another study of children with DS, 
although a third developed hypothyroidism, TPO antibodies were only found in one child 
(n=85) under the age of eight and none had antithyroglobulin antibodies until they were older 
than eight. Over the age of eight, autoimmune hypothyroidism became more common, as is 
also seen in the general population where the onset of autoimmune thyroid disease is usually 
seen in early to mid-puberty (Karlsson et al. 1998, Hunter et al. 2000). From these studies 




thyroid gland in children with DS appears to be normal on ultrasound scan suggesting that 
the problem is not structural, and dyshormonogenesis is less likely in the absence of a goitre 
(Kennedy, Jones, and Cuckle 1992).  
 Autoimmunity and Early Life Influences 
 Background 
The rising incidence of autoimmune diseases is best explained by environmental risk factors. 
The increase particularly in the younger age groups with T1D, together with the knowledge 
that in those children who are diagnosed with T1D under the age of ten, they produce 
autoantibodies before the age of two, suggest that this is likely to be an exposure during 
pregnancy or early life (Kimpimaki et al. 2001).  Various factors have been postulated 
including, the increase in caesarean sections and concomitant alterations in the gut 
microbiome, reduction in rates of breastfeeding, early introduction of formula feeds and 
more sanitized living conditions potentially leading to a more self-reactive immune system.  
  Microbiome 
The human gut microbiome consists of trillions of bacterial cells. As evidence for its underlying 
role in health and disease emerges, interest in its constituents and function are increasing 
(Turnbaugh et al. 2007, Vatanen et al. 2016).  The initial microbial colonization of the 
gastrointestinal tract during the first few years of life appears to be key to the development 
of the host’s immune system regulation. Perturbations in the function or composition of the 
microbiota has been associated with inflammatory and autoimmune conditions (Kostic et al. 
2015, Vatanen et al. 2016, Giongo et al. 2011, Morgan et al. 2012). Although studies of the 




children at risk of autoimmunity is different from the general population with, less diverse 
and less stable colonisation. In contrast, in children who do not develop autoimmunity, the 
gut microbiome changes and stabilises in the first two years with diverse colonies of bacteria 
(Giongo et al. 2011, de Goffau et al. 2013, Vaarala 2013). Children from the Diabetes 
Prediction and Prevention study (DiPP) in Finland, who were genetically at risk of developing 
T1D provided stool samples every three months from birth until they developed 
autoantibodies for T1D, these stool samples were compared to control samples taken from 
non- autoimmune children. Although there were only a small number who developed two 
autoantibodies for T1D (n=8), their gut microbiome showed a much higher ratio of Firmicutes 
to Bacteroidetes compared with controls (Giongo et al. 2011).  
Differences in the gut microbiome between those born via caesarean section and those born 
via normal vaginal delivery is thought to explain the 20% increased risk of T1D in those born 
via C section (Norris et al. 2003). Further research to understand how the microbiome affects 
autoimmunity mechanistically and to what degree small alterations in composition lead to 
changes in disease progression is required.  
 Breastfeeding 
Prolonged exclusive breastfeeding may be protective against some autoimmune conditions 
including T1D and CD (Malcova et al. 2006, Sollid 2002, Akobeng et al. 2006).  When formula 
feeds are introduced the baby is exposed to cow’s milk proteins for the first time and 
antibodies against bovine serum albumin (BSA) will be produced. This immune response to 
the cow’s milk proteins has been suggested as one of the triggers for pancreatic autoimmunity 




BSA have been shown in one study to be much higher in patients with T1D (Karjalainen et al. 
1992). Another study found that this is not just specific to T1D but is seen in other 
autoimmune and inflammatory conditions (Atkinson et al. 1993). T cells in T1D however are 
not specific for BSA. From this it was concluded that the increase in antibodies to BSA in T1D 
may represent a general immune defect (Atkinson et al. 1993). Recent data from our 
laboratory demonstrates that levels of antibodies to BSA are elevated in children with DS 
(manuscript in preparation) and these antibodies are of low affinity, perhaps reflecting 
immature B cell responses. 
  Weaning 
The current WHO recommendation is that babies should be exclusively breast fed until the 
age of 6 months, this is based on the health benefits that breast feeding brings to the mother 
and baby. It is generally recommended that babies should then be introduced to solid food 
around the age of 6 months (Norris et al. 2003). There is an association between the 
development of CD and the development of T1D, with an increased risk of developing islet 
autoantibodies in those with CD. As gluten is known to be a trigger for CD, it has also been 
postulated to be involved in the development of T1D. Introduction of foods containing cereals 
either before the age of four months or after the age of seven months has been associated 
with an increased risk of developing islet autoantibodies (Norris et al. 2003). This study in 
contrast with other studies (Virtanen et al. 1993, Malcova et al. 2006) did not however find a 
link between islet autoimmunity and the introduction of cow’s milk. Interestingly 
breastfeeding during the introduction of gluten into the diet appears to protect against CD in 




  Infections 
The hygiene hypothesis suggests that a reduction in exposure to pathogens, due to the more 
sanitized conditions that infants develop in, has led to the immune system becoming more 
disordered and self-reactive (Rook 2009). Viral infections however have also been postulated 
as the environmental trigger for autoimmune conditions in those in at risk groups.  
In the Diabetes Autoimmunity Study in the Young (DAISY), the development of islet 
autoantibodies in relation to childhood infections was examined. DAISY found that 
gastrointestinal infections were related to an increased risk of developing islet autoantibodies 
but only in children who were exposed to barley or wheat for the first time either before four 
months of age or after seven months (Snell-Bergeon et al. 2012). Children who went to 
daycare during the day got more infections in general but that this was not related to an 
increase in islet autoimmunity amongst these children. 
 Feeding and Down’s syndrome 
Babies and children with DS may have several oral, anatomical and physiological 
abnormalities which may affect their ability to feed normally, as with other features of DS 
there is phenotypic variability. The following features have previously been described (Desai 
1997, Kumin and Bahr 1999):  
• palate abnormalities (Hard palate reduced in length, depth and height. Soft palate 
insufficiency); 
• hypotonia in the lip, tongue, soft palate and jaw areas; 




• malocclusion (Malalignment between the dentition of the lower and the upper jaw); 
• lax ligaments in tempero-mandibular joint; 
• relative macroglossia (tongue is large relative to small oral cavity) or true macroglossia 
(enlarged tongue); 
scalloped and fissured tongue, which affects latch; 
• open mouth posture at rest leading to desiccated tongue; 
• poor neuromotor control of the tongue; 
• mouth breathing; 
• chewing difficulties; 
• bruxism (i.e. teeth grinding); 
• abnormal dentition including hypoplasia and hypocalcification and partial anodontia. 
To breastfeed effectively, a tight seal needs to be made. This is achieved by the tongue making 
a groove and the lips sealing around the nipple. For a baby with DS, the flattened shape of the 
tongue and low tone in the oral structures means that establishing breastfeeding may be 
challenging and take longer to establish.  
Weaning may also be complicated with babies with DS finding it difficult to manage different 
textures due to poor tongue control and oral hyper or hyposensitivity. Babies with DS may 
experience choking and gagging during weaning on to solid feeds and may reject certain 
textures. Feeding is also affected by generalized hypotonia with poor posture affecting ability 
to feed. Kumin et al describe the importance of good positioning for feeding (Kumin, Von 




These potential oro-motor complications may lead to babies with DS being exposed to cow’s 
milk protein-based formulas earlier than their peers. Gluten might also be introduced earlier 
due to the introduction of solids at a younger age.   
 Cohorts of people with Down’s Syndrome 
Many countries have registers including cytogenetic registries which provide data on the 
diagnosis of people with DS. These registers have facilitated retrospective studies providing 
statistics on aspects of DS including birth and death rates and congenital anomalies. However 
longitudinal prospective birth cohort studies of infants with Downs’s Syndrome are rare. A 
summary of the largest and most recent cohorts is given below. 
The LonDownS Consortium 
A current cohort recruiting in the UK, the LonDownS Consortium ((LonDownS Consortium), is 
a group of research studies aiming to understand dementia in people with DS. The consortium 
includes a longitudinal cohort of 150 babies, age six to forty months with DS. Low and high 
functioning subgroups within this cohort will be used to explore the neurocognitive 
phenotypes of infants with DS to determine the potential to predict protective/risk markers 
for Alzheimer’s disease. 
Children with Down’s Syndrome Study 
Another recent birth cohort in the UK was the Children with Down Syndrome Study (CDSS). 
This study was set up in May 2006 by paediatricians and haematologists from St James 
University Hospital in Leeds and the Epidemiology and Genetics Unit at the University of York 




specific aim of characterizing the haematology in neonates with DS (James 2011). The study 
used a two-stage approach when recruiting families. Initially new-borns were recruited to the 
study after birth but before they went home by neonatologists from six regional neonatal 
networks. If parents consented at this stage, a blood sample could be taken, the mother’s 
maternity notes could be reviewed, and it also permitted the study team to contact the 
parents again once they were home to ask if they were willing to take part further in the 
study. If parents consented to the second stage, the child’s records could be accessed. Parents 
were asked to complete questionnaires about the child’s health and background, further 
blood samples collected and a buccal mouth swab for DNA. Between 2006 and 2011, 479 
children were recruited to the CDSS providing 234 neonatal blood samples (49%). However, 
during follow up only ten blood samples were available from children aged two years old (2%) 
and five at four years of age (1%). 
Down Syndrome: A Novel Risk Factor for Respiratory Syncytial Virus Bronchiolitis— A 
Prospective Birth-Cohort Study 
Bloemers et al recruited 219 infants with DS into a nationwide, Dutch prospective birth cohort 
to study the incidence of hospitalizations associated with respiratory syncytial virus lower 
respiratory tract infections amongst this population (Bloemers et al. 2007). These babies were 
identified through the Dutch Paediatric Surveillance Unit and were followed up until they 
were two years old.  The researchers also did a retrospective observational study of 276 
children with DS. The study concluded that DS is an independent risk factor for respiratory 




The Manchester Downs Syndrome Study and Dr Janet Carr’s Cohort 
There have also been two well established longitudinal cohorts of children with DS in England 
studying the educational, social, psychological and psychiatric aspects of having Down’s 
syndrome. The Manchester Downs Syndrome Study recruited 181 families between 1973 and 
1980 (85% to 90%) of all the infants born with DS in the Manchester area)(Cunningham 1996). 
Although there had been some attrition over the years, 100 participants were followed until 
early adulthood.  The other cohort was established by Dr Janet Carr who recruited 54 babies 
born with DS between December 1963 and November 1964 in Surrey and the London 
boroughs of Camberwell and Lewisham. The participants in this cohort were followed up from 
the age of six weeks until they were 21 years old, with 41 participants with DS remaining in 
the study at the age of 21 years old (Carr 1988).  
 The need for a new cohort of babies with DS 
To study the clinical / pathological features of DS, there needs to be more longitudinal birth 
cohorts in which serial biological samples are collected together with clinical data.  Each of 
the studies above were designed to focus on an aspect of DS. Two of the studies (LonDownS 
Consortium and The Manchester Downs Syndrome Study) explore the neuro cognitive and 
psychological aspects of DS including the development of Alzheimer’s. The CDSS study studied 
early haematological findings and Bloemer’s study on respiratory syncytial virus lower 
respiratory tract infections. Excluding Bloemer’s retrospective study, the challenges for each 
of these cohorts lie in recruiting and maintaining participants and reducing attrition rates. The 
Feeding and Autoimmunity in Down’s Syndrome Evaluation Study (FADES) developed in this 




recruitment and retention for cohorts of babies with DS whilst uniquely focusing on early 
feeding and the development of autoimmunity. Unlike the other studies, it is UK wide.  It will 
build a longitudinal biobank of samples including urine, stool and blood samples which can be 
linked to well characterised feeding and medical data (including infections and antibiotic use).  
 Feasibility Studies 
The distinction between pilot and feasibility studies is often blurred and the definitions given 
have altered over the last few years, including those given by funding bodies (Arain et al. 
2010, Thabane et al. 2010). In 2016, a conceptual framework was developed and validated 
(through a Delphi study, international expert consensus meeting and systematic review) for 
defining feasibility studies for randomised controlled trials (RCTs) (Eldridge, Lancaster, et al. 
2016). Feasibility studies may be iterative and can be adjusted and improved if aspects of the 
study design are not adequate (Bowen et al. 2009, Hagen et al. 2011, Orsmond and Cohn 
2015). A well-designed feasibility study will set objectives to determine whether the main 








Figure 5: The features of a feasibility study. Adapted from “The distinctive features of a 
feasibility study:objectives and guiding questions” (Orsmond and Cohn 2015) 
 
The following examples are parameters and areas that can be assessed from a feasibility study 
(NIHR Evaluation, Trials and Studies Coordinating Centre (Bowen et al. 2009, Thabane et al. 
2010, Orsmond and Cohn 2015, NIHR 2019): 
• acceptability, how do the target population and the researchers view the study,  
• number of eligible patients, 
• recruitment and consent, assessing the ability to recruit at the desired recruitment 
rate using the proposed methods, 
• willingness of clinicians to recruit participants, 
• implementation and practicality, whether a study can be conducted as planned and 
whether there are any constraints such as time and resources, 




• sample characteristics and generalizability, 
• characteristics of the proposed outcome measure and in some cases feasibility studies 
might involve designing a suitable outcome measure, 
• standard deviation of the outcome measure (may be needed to estimate sample size 
in the main study), 
• follow-up rates, response rates to questionnaires, adherence/compliance rates. 
The feasibility objectives can also test whether the research team has the appropriate skills 
and resources to run the main study. A feasibility study is not designed to test a hypothesis 
and therefore a power calculation is not required. However the sample size should be large 
enough to determine the feasibility objectives (Orsmond and Cohn 2015). 
The Consolidated Standards of Reporting Trials (CONSORT) guidelines are used to standardise 
and improve the reporting of randomised controlled trials. In 2010 there was an extension to 
the guidelines to include randomised pilot and feasibility studies (Eldridge, Chan, et al. 2016). 
Although not all feasibility studies are randomised, the guidelines make relevant points which 
should be considered in planning and reporting. A review of 54 pilot and feasibility studies 
published between 2007 and 2008 found that many studies incorporated hypotheses testing 
(Arain et al. 2010). This is despite recommendations that statistical analysis should be mostly 
descriptive or should be focused on sample size calculation for a future study (Lancaster, 
Dodd, and Williamson 2004).  
Qualitative research which is used to explore certain aspects of a study design is recognised 
as an important feature of feasibility, and can be used alongside quantitative methods 




particularly important when assessing the acceptability of a study protocol for the 
participants. In the extended CONSORT statement the need to link published qualitative work 
with the other aspects of the feasibility study is highlighted (Eldridge, Chan, et al. 2016).   
This present study was a feasibility study with clearly defined feasibility objectives (see 
Section 1.12). An iterative approach was taken throughout, with changes made to improve 
aspects of the study design.  
 Qualitative Research  
As part of the feasibility of FADES, a qualitative study was undertaken to understand how to 
maximise recruitment of young infants with DS into research, through qualitative interviews 
with parents and care providers (This qualitative research study was published (Williams et 
al. 2018)).The diagnosis of DS is relatively rare, an individual’s experience of being a parent of 
a child with DS varies and there is little available prior research into recruiting this population. 
Qualitative research allowed in depth social inquiry which enabled a better understanding of 
the participants’ perspectives and experiences. This is presented in Chapter 3 with a more 
detailed introduction to qualitative research and thematic analysis. 
  Aim of PhD: 
The aim of this project was to develop a family acceptable study protocol and establish the 
feasibility of creating a national cohort of infants with DS to study the longitudinal 
associations between early infant feeding, infections, antibiotic usage and the development 
of autoimmunity in DS. The study was entitled Feeding and Autoimmunity in Down’s 





• Establish the feasibility of creating a UK wide cohort of infants with DS (See section 
1.12 for feasibility objectives) 
• Determine the acceptability of the study protocol for families 
• Determine the ability to collect appropriate questionnaire data and samples for the 
exploration of factors associated with the development of autoimmune conditions, 
specifically (T1D, autoimmune thyroid disease and coeliac disease) (See section 1.12).  
As a feasibility study this PhD was not designed to test a hypothesis. However, the potential 
factors involved in the development of autoimmunity in this population which underlie the 
data collected are: 
• differences in early feeding due to oromotor difficulties and hypotonia which may lead 
to cow’s milk protein being introduced earlier, 
• timing of weaning and introduction of gluten, 
• Infections and use of antibiotics 
• alterations in the gut microbiome, 
• HLA genotype   
 Summary of initial protocol 
The initial study protocol is summarized below (the full protocol is in Appendix 2). This is 
included here to provide a basic overview prior to outlining the feasibility and secondary 
objectives. The protocol was modified over the course of the last three years and further 





The initial protocol planned for participants to be recruited through flyers sent out by the 
Down’s Syndrome Association (DSA) and Down’s Syndrome Scotland (DSS). Families would 
register their interest through the online expression of interest (EOI) form and the consent 
forms were sent out to them by post. (Changes were made to this recruitment strategy 
Material and Methods Chapter 2). 
 Eligibility Criteria 
Inclusion Criteria: 
• Babies recruited antenatally or in the first eight months of life born with DS (three copies 
of chromosome 21) as confirmed by karyotype after birth. 
Exclusion Criteria 
• Babies with DS who have a child protection plan or who are no longer with birth mother. 
• Babies with DS over eight months of age. 
• Babies with DS in whom the parents do not speak English. The study recruits families who 
are trying to cope with a potentially difficult diagnosis and may wish to have conversations 
with the research staff to establish what the implications of recruitment would involve for 
them. Participants are also required to fill out seven questionnaires over five years in 
English. 
 Sample Collection 
Parents collected the samples from their infant/ child at home using kits sent through the 




microbiome analysis (a maternal stool sample was later added to the protocol see Chapter 2) 
and a urine sample for C-peptide after a feed as close to birth as possible, at 12 months and 
yearly until the age of five. Families were then asked for further stool samples from the child 
at six months, 12 months and yearly thereafter until the age of five. 
The parents were provided with a kit for the blood sample and sampling was then arranged 
to coincide with already existing appointments if possible. The aim was for the blood sample 
to be collected as close to birth as possible, at six months, 12 months and yearly until the age 
of five years.  
 Feeding and Medical Online Questionnaires 
Parents were asked to complete detailed feeding and medical questionnaires, close to birth, 
at seven months (when most babies will have weaned onto solids) and at a year. They then 
completed medical questionnaires annually until the age of five years old. The questionnaires 
were available online through the University of Bristol’s REDCap system (University of Bristol 
REDCap) (Questionnaires are in Appendices 14 to 17).  
 Feasibility objectives 
A summary of the feasibility objectives for the study are set out below (Lancaster, Dodd, and 
Williamson 2004, Eldridge, Chan, et al. 2016). More detailed objectives and how they will be 
assessed are described in the relevant sections in the Methods Chapter 2.  
Objectives relating to feasibility of recruitment: 
• to assess the rate of recruitment; 




• to understand the reasons why participants consented to take part in the study.  
Objectives in relation to feasibility of sample collection: 
• to test the validity of the sample collection methods; 
• to assess the ability of families to collect all the samples within the desired timeline; 
and 
• to assess the suitability and quality of the samples which are received. 
Objectives relating to medical and feeding questionnaires 
• the feasibility of the questionnaires to collect the required data within the desired 
timeline. 
Objective relating to retention of participants and overall acceptability  
• the feasibility of retaining participants in the study, which in parallel also determines 
the overall acceptability of the study.  
The main objective of the qualitative research was to  
• explore the views and opinions of healthcare professionals and support workers about 
potential barriers to families taking part in research and how these may be overcome. 
 Secondary objectives  
The following were secondary objectives; 
1. to characterise the cohort in relation to: 
a) maternal age, socio-economic background, ethnicity; 




2. to determine the numbers and types of infections experienced during early life and 
antibiotic usage; 
3. to describe early feeding and weaning; 
4. to measure levels of urine C-peptide levels longitudinally; 
5. to measure anti-BSA antibodies longitudinally; and 
6. to profile the gut microbiome during early childhood.  
Characterisation of the cohort is important to show that study population is representative 















Chapter 2 Materials and Methods 
 Overview of Chapter 2  
Key steps for determining the feasibility of a potential study protocol are the planning and 
consultation phases. These phases and the patient and public involvement (PPI) throughout 
this study are covered in this chapter. The processes involved in setting up a UK wide birth 
cohort of infants with DS (FADES) to meet the standards of Good Clinical Practice (GCP) and 
ethics, and the administrative and organisational infrastructure for the study are explained. 
Recruitment methods and the changes that were made to maximise recruitment, reflecting 
the iterative nature of this feasibility study, are detailed. Description of the design of the 
feeding and medical questionnaires, and their web-based functionality is highlighted.  
The methods for collecting, storing and analysing the samples are included in this chapter. 
Two mini feasibility studies were completed within this PhD to refine the sample collection 
methodologies. One was for the collection of the gut microbiome samples and the other for 
the collection of the urine samples. Both feasibility studies are presented in full in this chapter. 
The qualitative research methods used for the interviews exploring the potential barriers and 
motivations to parents of a new baby with DS to taking part in research are given. The design 
and processes for analysis of participant and non-participant questionnaires, which were used 
to study why parents decided to enrol in FADES or decided not to enrol in FADES, are also 




Details of the statistical analysis and the descriptive analysis for the feasibility outcomes, 
questionnaire data, samples and qualitative research are all described in the relevant 
sections. 
 The research team 
The study research team were multi-disciplinary covering a broad range of skills, knowledge 
and expertise. The study was based at the NIHR Bristol Nutrition Biomedical Research Unit 
(BRU) (now the NIHR Biomedical Research Centre (BRC) Nutrition Theme) allowing access to 
experienced health researchers outside of the core team. The processing, storage and analysis 
of samples were undertaken by the Diabetes and Metabolism team (Bristol Medical School, 
Translational Health Sciences). Table 3 shows the different roles and involvement of the 




Table 3: The research team, roles and activity within the study.    
Footnote: *These activities were also completed by GW during the course of the stud
Name  Initials Job Title / Role / Expertise Activity 
Professor Julian Hamilton- Shield JHS PhD supervisor / Professor of diabetes 
and metabolic endocrinology / 
Paediatrician 
PhD Supervision 
Advised on study protocol  
Expert review of study documentation / questionnaires 
Dr Kathleen Gillespie KG PhD supervisor / Reader in molecular 
medicine 
PhD Supervision 
Advised on study protocol  
Expert review of study documentation / questionnaires 
Dr Sam D. Leary  SDL PhD supervisor / Senior lecturer in 
statistics 
PhD Supervision 
Expert review of study questionnaires 
User testing of questionnaires  
Advised on the statistical analysis 




Admin assistant  FADES emails* 
Sent out participant consent forms and questionnaires (online links)* 
Updated database / CPMS* 
Sent participant reminders* 
User testing of questionnaires – KB 
Stu Toms ST Database manager Development of database, online forms (EOI, REDCap) and online questionnaires* 
Georgina Mortimer 





Laboratory technician  Sent out sample packs to families* 
Received, logged, processed and stored samples* 
Updated database* 
HLA genotyping on DNA samples (GM and SCK) 
Sian Grace  SG Laboratory technician LPS analysis of anti-BSA antibodies from blood samples 
Shirley Jenkins SJ Management assistant  Set up webpage 
Dr Patricia Neville  PN Sociologist / Lecturer Advised on design of qualitative study 
Reviewed topic guide for qualitative study 
Dr Aidan Searle AS Senior research associate in 
qualitative studies 
Advised on analysis of qualitative research 





 Planning and consultations 
 Patient and Public Involvement (PPI) 
There has been patient and public involvement (PPI) during the design stages, the piloting of 
questionnaires, in study promotion and in the assessment of the feasibility of the study. PPI 
has been in the form of consultations (with parents and charitable organisations) and 
collaboration (with charitable/ voluntary sector organisations including the DSA, DSS and 
DHG). The consultations were organised and conducted between me and members of the 
charities / voluntary sector organisations. The valuable role of PPI in clinical research studies 
has become established and is now a requirement of many funding bodies (Robinson and 
Otology 2014). PPI improves the success and quality of studies, by providing key insights. 
These include the values and priorities of the population of interest and how the research 
might fit into their lives (Bate et al. 2016). It is also important for producing an ethically sound 
protocol. 
 Consultation with the Down’s Syndrome Association (DSA) and Down’s Syndrome 
Scotland (DSS) 
The DSA and DSS are both members led organisations with many committee members being 
parents of a child or adult with DS. They were consulted throughout the planning stages of 
FADES as well as during the study (organisational approvals from DSA and DSS Appendix 9 
and 10). The DSA and DSS initially provided statistics on their members and the families that 




The DSA reported that they send out approximately 500 information packs per year and could 
promote the study in the packs. The DSA offered to include the FADES flyer in their 
“continuing pregnancy booklet” which is given to parents who have had a prenatal diagnosis 
of DS for their baby. DSS were also consulted and they reported that approximately 50 to 60 
babies are born each year with DS in Scotland. In 2012 they visited or provided information 
to 30 parents. Of these parents, less than 10% had received a prenatal diagnosis of DS for 
their baby. DSS provided information packs to every maternity unit in Scotland and the 
families then contacted them. They did not agree to include the FADES study information 
within this pack but were happy to let families know about the study once they had registered 
with DSS. They visited at their home all families who registered with them and took the 
information about the study on these home visits. They were also happy to promote the study 
on their website, in their newsletter and e-bulletins. 
The DSA and DSS were both consulted regarding the acceptability of the study protocol and 
the documentation that would be sent to participants. DSS asked one of their mothers to 
review the FADES study documentation. The feedback from the parent was that the flyer and 
information sheet were “straight forward and clear although not engaging” they suggested 
using photos of babies or babies feeding to engage more parents. The mother and other 
members of the DSS suggested a simplified diary that they could use once enrolled in the 
study to keep information that would be useful when the time came to complete the 
questionnaires. The final comment from the mother was that although it is a lot of 
documentation, they probably would have been willing to complete the paperwork if their 
child was still the correct age for the study. They also highlighted the need for reminders. The 




Both the DSA and DSS provided feedback on the questionnaire which is described in Section 
2.13.1. Ongoing collaboration and consultations between myself the DSA and DSS continued 
throughout the conduct of the study and will be discussed further through this thesis. 
 Consultation with Bristol Area Down’s Syndrome Support 
The DSA’s local Bristol branch, Bristol Area Down’s Syndrome Support (BADSS) kindly agreed 
for me to attend their committee meeting on the 10th February 2014. The committee 
members were all parents of children with DS and included new members who were parents 
of young infants with DS. The study background and outline were presented, and committee 
members had the opportunity to review the study documentation that would be provided to 
families. There was then time for everyone to discuss the study in an open forum. The 
committee members were asked how acceptable they felt the study was and the best way to 
improve recruitment and work with families. Overall the feedback was very positive. They felt 
that it would be difficult recruiting families when they are coming to terms with the diagnosis 
of DS for their baby but that engaging in research may offer an opportunity for families to get 
extra support. Attending the meeting was extremely beneficial providing an insight into the 
experiences of families of children with DS and the role that research may play.  
 Standards, Study Ethics and R&D approval 
Good Clinical Practice (GCP) are internationally recognised standards for conducting research. 
GCP includes study design, study conduct, monitoring, audit and reporting of trials. 
Compliance with GCP is a UK/European legal requirement for clinical studies investigating 
medicinal products (Gill 2004). Although this study did not include any medicinal products, 




accurate and credible and that the rights of the participants and their families had been 
respected. To comply with the standards of GCP, all clinical research studies are required to 
have the correct approvals from the Research Ethics Committee (REC) and Research and 
Development (R&D).  
The study also complied with the Human Tissue Act (HTA) 2004 (The Human Tissue Act 2004) 
with respect to the use, storage and disposal of human tissue. The study protocol and the 
consent process ensured that the requirements of the HTA were met. 
 Integrated Research Application System (IRAS) 
Research studies conducted in the UK use the Integrated Research Application System (IRAS) 
which enables researchers to enter online all the required information for seeking approvals 
from a number of organisations avoiding duplication (IRAS). The online form uses filter 
questions to ensure the data entered is appropriate for the study type and meets the 
necessary requirements of the regulatory bodies. For this study IRAS was used to apply for 
NHS REC approval, adoption onto the NIHR Portfolio (see Section 2.4.3) and NHS R&D 
permissions. 
 Ethics 
The study was presented to the National Research Ethics Service (NRES) Committee South 
West – Central Bristol by me and JHS on the 28th February 2014. The ethics committee had 
several queries and clarifications, these included assessment of inclusion criteria, clarification 
of samples, estimation of time taken to complete questionnaires and option for storage of 




committee were happy with the changes made in response to their queries and approved the 
study on 23rd April 2014 reference 14/SW/0030 (Appendix 7). 
 The NIHR Clinical Research Network (NIHR CRN) Portfolio of Studies 
The NIHR Clinical Research Network’s Portfolio of Studies (CRN portfolio) are high-quality 
clinical research studies which have met the eligibility criteria to be approved for NIHR Clinical 
Research Network Support (CRN)(NIHR CRN Portfolio 2014). The NIHR Comprehensive Clinical 
Research Network (CCRN) is made up of 25 Comprehensive Local Research Networks (CLRN) 
which cover the whole of England. The infrastructure support that is afforded to studies on 
the portfolio includes access to experts for help in setting up studies within NHS organisations, 
particularly information on capability and capacity within research sites, an important aspect 
in the feasibility of a research study. There is also access to NHS service support resources 
including research nurses and data managers through the CRN. However, the availability of 
these resources for this study varied by geographical area, and in many instances was not 
accessible. The study was adopted as an NIHR portfolio study on the 14th May 2014 (UKCRN 
study ID is 16735).  
As an NIHR CRN portfolio study, monthly recruitment data were entered by me, KB and SL 
onto the Central Portfolio Management System (CPMS) (a cloud-based management system). 
This allows research sites to claim their accruals and monitor their performance against 
targets set by the Department of Health.  
 NIHR Coordinated System for gaining NHS Permission (NIHR NHS CSP) 
Recruitment of participants into FADES was initially through the DSA information packs and 




UK. Following a consultation between myself and the study sponsor (University of Bristol, 
Research Enterprise and Development (RED), Dr Rachel Davies), to comply with GCP, R&D 
permissions were sought from all primary and secondary care sites. This meant that wherever 
a potential family was located they would have a local NHS organisation/ trust who would be 
engaged in the study and could hopefully assist with the taking of the blood samples.  
The structure of the NHS varies between the devolved nations. There are around 400 NHS 
organisations (primary and secondary care sites) in England. In Wales primary and secondary 
care organisations are coordinated by seven health boards, in Scotland there are 14 regional 
NHS Boards and there are six Health and Social Care (HSCT) trusts in Northern Ireland. To 
request approval from these sites, the NIHR NHS Co-ordinated system for gaining NHS 
permission was used (NIHR NHS CSP was decommissioned in 2016). In order to access NIHR 
NHS CSP, studies needed to be eligible for the NIHR portfolio. In the devolved nations, the 
local NIHR NHS CSP Coordinating Centre for that country was used. For Wales this was the 
National Institute for Social Care and Health Research (NISCHR) Permissions Coordinating Unit 
(PCU) and for Scotland was the NHS Research Scotland Coordinating Centre (NRS CC).  The 
processes that were involved in gaining R&D approvals through CSP for this study are 
illustrated in Figure 6.  
The system for gaining R&D and ethical approval was changed in March 2016 to Health 







Figure 6: The approximate steps that were taken in gaining REC and R&D 
permission from primary and secondary care sites across the UK.  
Footnote: As some of the steps were completed by the NIHR CRN organisations (which have 
now been decommissioned) rather than me, this is an approximate schematic. 
Governance report produced by CLRN and sent to 
local Trust R&D offices through CSP  
Local trusts granted R&D permission 
CLRNs and Trust R&D offices performed local 
checks 
CLRNs contacted local trusts 
NIHR CRN CC performed global checks and 
forwarded documents to CLRNS across England, 
to NRS CC and NISCHR PCU 
Single SSI approved for English sites and Lead 
LCRN informed participating LCRNs of 
imminent Single SSI. Submitted completed R&D 
application. 
Approval by NIHR CRN CC to use CSP. Meeting 
with Lead LCRN and UH Bristol R&D lead/local 
trust to discuss study and use of Single SSI.  
Forms submitted via IRAS requesting NIHR CSP. 
All documents forwarded to NIHR CRN CC 
Completion of IRAS which included NIHR 
Portfolio Application Form and ethics form for 
REC approval 
Copies of all documents for ethics sent to REC 
NISCHR PCU, NRS CC and Northern Ireland 
HSC R&D contacted to request the use of a 
single SSI. Approval for single SSI given by 
NRS CC. Separate SSIs required for the seven 
health boards in Wales. Unclear response from 
Northern Ireland.   
NRS CC forwarded documents to local R&D 
offices in relevant Health Boards in Scotland 
R&D offices in Scotland performed local 
checks and granted R and D permission 
Approval from REC – approval letter 




R&D permissions in England 
Approvals were sought from all primary secondary care organisations in England via a single 
generic Site-Specific Information form (SSI).  Most research studies seeking approval prior to 
March 2016, required a separate SSI form for each research site, detailing the activities, 
resources required and the personnel that will be involved. A study which used NHS CSP might 
be identified as being suitable for a single generic SSI which could be used for all sites (generic 
SSI’s were introduced to expedite gaining R&D permissions during the Swine Flu outbreak). 
For a generic SSI the activities taking place in each site needed to be the same, needed to be 
considered “low risk” and needed the central research team to be undertaking the research 
procedures without the need for a local research team. The lead CLRN, which for this study 
was West of England CRN, identified that the study was suitable, and agreed the process with 
me (as the chief investigator (CI)) and with the NIHR CRN CC. Authorisation for the SSI form 
was given by me as the CI taking on the responsibility for the activity at each of the sites 
negating the necessity for local Principal Investigators (PIs). During the approvals process this 
was a contentious issue with many sites (this is explored more in Chapter 4). 
The lead CLRN and the lead NHS Site for this study was University Hospitals Bristol NHS 
Foundation Trust. They assessed the documents submitted via IRAS and completed global 
checks, validating the application form. Once signed as approved on the CSP system on the 
(20th May 2014) trusts within England were able to approve or reject the study. Once the R&D 
application had completed checks by local CLRN and R&D offices, they had a target set by the 
Department of Health to respond within 21 days (the time taken to receive approvals is 




R&D permissions in Wales 
The NISCHR Permissions Co-ordinating Unit (PCU) were contacted by me to discuss FADES and 
gaining R&D approvals in Wales. They advised that a generic SSI was not accepted for R&D 
permissions in Wales. Each of the seven health boards in Wales needed to be contacted 
separately and a named person for each Health Board was needed for the IRAS form which I 
did. A proof of the scientific review was also requested (scientific review letter Appendix 8) 
(See Chapter 4 Results for permissions granted). 
R&D permissions in Scotland 
NHS research Scotland Coordinating Centre (NRS CC) were contacted and they accepted a 
generic SSI which covered all the 14 regional health boards (See Chapter 4 Results for 
permissions granted).  
R&D permissions in Northern Ireland 
Northern Ireland Health and Social Care (HSC) R&D initially said that they did not accept 
generic SSIs and that a PI would be needed at each site. They provided contact details for the 
primary care sites coordinator, NI CRN adoption. There was then a query as to whether they 
would accept a single SSI, which led to delays in requesting permission in Northern Ireland 
and in May 2014, clarification was still awaited. A NI CRN adoption form was completed. (See 
Chapter 4 Results for permissions granted). 
Liaison and discussions with the coordinating centres, Welsh Health Boards and R&D sites 
were all through me. Listed on the IRAS form were fourteen research sites, University 
Hospitals Bristol NHS Foundation Trust for England, a single generic SSI for the Scottish Health 




and secondary care) and five Health and Social Care Trusts in Northern Ireland covering 
secondary care sites only. GW was listed as the investigator at each site on the R&D form.  
 International Standard Randomised Controlled Trial Number (ISRCTN) Registration 
The study was registered as International Standard Randomised Controlled Trial Number 
(ISRCTN) registration number (ISRCTN12415856). Although not a randomised control trial, 
registration with an ISRCTN may be required by ethics and registration is standard practice 
for studies within the NIHR portfolio. 
 Amendments 
During the period from the start of the study in September 2014 until the end of September 
2017 seven amendments were made to the study. Amendments may be changes to the study 
protocol, documentation or personnel. Amendments were classified as either substantial or 
non-substantial, the study sponsor (for this study the University of Bristol) classified the 
amendment once they have received the relevant documentation. GW discussed each 
amendment for this study with a member of the RED at the University of Bristol. Substantial 
amendments required REC and R&D approvals before they could be implemented whereas 
non- substantial amendments merely required the researchers to inform the REC and R&D 
sites of the amendment. A summary of the amendments is given in Table 4 the details and 









Date of amendment Summary  
1 Substantial 30th March 2015 • Addition of a maternal stool sample collection / consent for maternal stool sample 
• Recruitment by local collaborators 
• Letter to community paediatricians 
• Process for reminding participants  
2 Substantial  9th June 2015 • Sample collection method for gut microbiome feasibility study changed 
• Addition of photos to the FADES flyer 
3 Non-substantial 5th August 2015 • FADES consent form typographical error corrected 
4 Substantial  8th September 2015 • Addition of Qualitative Research Study 
• Addition of feasibility objectives to study protocol 
• Modification of EOI/ registration form 
5  Substantial 4th August 2016 • Anonymised participant / non-participant questionnaires  
• Change to methodology for the collection of stool samples to include using OMNIgene GUT collection 
kits. 
• Addition of quarterly newsletters 
• Modification of study Flyer 
6 Non- substantial  13th March 2017 • Extension to recruitment deadline until September 2017 
7 Substantial  25th July 2017 
(Approved through 
HRA) 
• Extension of recruitment until January 2020 – tapered follow-up until 2022 
• Re-consent participants for follow-up until 2022 
• Birthday cards with annual packs  
• Modified all documents to say NIHR Bristol Biomedical Research Centre Nutrition Theme. 
• Addition of DS Ireland and collaborators in the Republic of Ireland. 
• Letter to repeat inadequate mouth-swab samples. 









The change to HRA approvals was partly designed to speed up and streamline the amendment 
process for studies. The timescales involved in gaining approval for amendments are 
discussed in Chapter 4. 
 Study Management  
As the CI for the study, I organised and chaired regular FADES management meetings. These 
were held quarterly and agendas and minutes for the meetings were produced. The meetings 
were attended by all members of the research team depending on availability. At each 
meeting, a study update was presented, and issues were discussed. These meetings were also 
used to plan amendments, review participant facing documentation and for expert opinions 
on study protocol.  
Training new members of the research team including local collaborators was completed by 
me. For local members of the research team this was done face to face, for local collaborators 
this was completed over the phone or via email.  
 Communication and access to study 
The complete study protocol is in Appendix 2 and the eligibility criteria and brief overview 
were given in Chapter 1 Section 1.11. In the following sections the processes involved in the 
setup and running of recruitment and data collection (questionnaire and samples) are 
described. 
As this was a UK wide research study, potential participants needed a secure route to be able 




FADES email was therefore setup and a FADES webpage was created within the NIHR Bristol 
Nutrition BRU’s website as described in the sections below. 
 FADES Website 
The FADES webpage (NIHR Bristol BRU) was designed by me and set up by ST and SJ. The 
website contained a link to a web-based expression of interest (EOI) form where potential 
participants could register their details (see Section 2.13.2 on REDCap). Figure 7 is a screen 
shot of the FADES webpage with the link for the EOI is marked by a red arrow. They were also 





Figure 7: Screenshot of FADES webpage with link to Expression of Interest (EOI) shown by red 






 FADES email 
The FADES mailbox was setup by me through the University of Bristol IT services. This was a 
shared mailbox which could only be accessed by members of the research study team to 
whom I had granted access. Participants, potential participants and local collaborators were 
able to communicate with the study team via email and the study mailbox was checked at 
least twice a week. Emails from this mailbox were used to: 
• send links to questionnaires; 
• inform participants that sample packs were being sent out; 
• determine dates when blood tests might be coordinated; 
• send reminders; 
• send newsletters; 
• send links to participant / non-participant questionnaires; and 
• answer queries, for example on sample collection or completion of questionnaires.  
The use of a shared mailbox also enabled members of the research team to access the contact 
history for participants wherever they were based. This was particularly relevant when trying 
to organize samples and liaison between the admin team and the laboratory technicians.  The 
mailbox also provided an audit trail and was used in the assessment of feasibility.  
 
 Development of Feasibility Objectives  
Clear feasibility objectives were developed to assess key aspects of the study design, set-up 




(Eldridge, Chan, et al. 2016). These are described below together with an explanation of how 
they were developed. 
 Feasibility objectives for recruitment  
Rate of Recruitment - Objective: to assess the rate of recruitment, with an initial target of 
100 participants per year over a two-year period (this represents 20% of the DS families who 
are in contact with the Down’s Syndrome Association (DSA) per year). 
The target of 100 participants per year was based on the initial information that had been 
provided by the DSA. The initial study protocol planned for recruitment to take place through 
the DSA and DSS. The figure of 20% was based around other studies which included families 
of children with DS. These showed recruitment at around 30% of the eligible population 
(Fortnum et al. 2014) or similar rates in a multi-centre study of around one hundred 
participants per year (The CDSS study recruited around this number of new-born per year 
(CDSS 2018)). As this study was similarly recruiting babies shortly after birth and required 
considerable input from families, the figure of 20% was deemed appropriate.  
Recruitment Methods - Objective: to consider the feasibility of novel recruitment methods, 
including recruitment through websites and social media.  
As relatively novel methods of recruitment were used in the study it was important to assess 
these (Orsmond and Cohn 2015). Participants were asked on their initial registration form 
how they heard about the study, so that the success of different recruitment approaches 
could be compared. Any issues relating to online systems which prevented or delayed 
participants being recruited were recorded on the study database. Timelines between 




Motivations and Barriers to joining the study - Objective: to understand the reasons why 
participants consented to take part in the study.  
Participants were asked to complete a short survey exploring why they joined the study and 
their overall opinion of FADES. Families who had registered an interest in the study but who 
did not then go on to take part (non-participant), were also asked why they felt unable to 
participate in the study, and to comment on the study design. These objectives aimed to 
assess the ‘demand’ and ‘acceptability’ of the study as described by Bowen at al. (Bowen et 
al. 2009), the use of surveys and qualitative methods can be used to understand who in the 
target population is interested in the study and whether the study design is acceptable to this 
population. This also provides information regarding the validity and suitability of the study.   
 Feasibility objectives for sample collection 
Sample Collection - Objective: to assess the ability of families to collect all the samples 
within the desired timeline, determined by the percentage of participants who return the 
requested samples in the time requested.  
The collection methodology would be deemed feasible if: 
• at least 75% of participants provide the requested initial samples before eight months 
of age; 
• at least 75% of participants provide the requested 12-month samples before 14 
months of age;  
• at least 50% of participants to provide all samples up to the age of five years; and 




The figure of 75%  for both the initial and 12 month samples were based on other birth cohort 
studies which collect longitudinal markers of autoimmunity at similar time points and had 
either obtained or predicted similar or better adherence (Ziegler et al. 2013, TEDDY Study 
Group 2007, Group 2008, Lönnrot et al. 2000). Studies collecting biological samples from 
babies with DS were however rare, especially ones in which parents had collected samples at 
home. Therefore, there was limited pre-published data from which these targets could be 
derived. The target of 50% at five years was decided as an appropriately sufficient proportion 
for a birth cohort. Compared to other cohorts of babies with DS, longitudinal data for five 
years would make the study compelling. The CDSS collected longitudinal blood samples but 
published longitudinal studies which include the collection of biomarkers are rare (CDSS 
2018).  
The sample collection methods had either been successfully used before or had been tested 
in the internal feasibility studies (Section 2.15). Excluding unavoidable incidences (e.g. 
spillage) the samples received were expected to be adequate for analysis. A feasibility target 
of 90% of samples received being adequate for analysis was therefore set.  As part of the 
feasibility assessment, any issues or problems that occurred with sample collection were 
recorded.  
 Feasibility objectives for medical and feeding questionnaires 
Feeding and Medical Questionnaires - Objective: to assess the ability of the online 
questionnaires and paper questionnaires to collect the required data: 
• for at least 75% of recruited participants to complete initial questionnaires, the 




• for at least 50% of participants to complete the annual questionnaires up until the age 
of five years;  
• for at least 60% of participants to opt to use the online questionnaire rather than the 
paper questionnaire; and  
• for the data produced to be valid and easily converted into a format, which is ready for 
analysis.  
The target of 75% was based upon the return rate seen in other studies which also required 
detailed responses from parents when their babies were young. The most relevant being the 
Infant Feeding survey (IFS) which had a response rate of 51% for the initial questionnaire and 
a response rate of 80% for the second questionnaire at age four to six months (McAndrew et 
al. 2012). The FADES study has families who likely have self-identified to be recruited and may 
therefore be already motivated, thus 75% seemed appropriate for these initial 
questionnaires. As for the collection of the samples, the target of 50% completing at five years 
of age was set as the level that would be acceptable to provide compelling findings.   
A feasibility target of at least 60% was set for the web-based questionnaire as it was a novel 
aspect of this study. The use of web-based questionnaires in clinical research is relatively new 
and therefore there are no publications studying this or similar populations. It was hoped that 
over two-thirds of participants would select the web-based questionnaires to prove its value.  
 Feasibility objectives for retention of participants 
Retention of Participants - Objective: The feasibility of retaining participants in the study, 
which in parallel also determines the overall acceptability of the study questionnaires was set 




1. for compliance with the study protocol up until the age of five years old with a target 
of retaining at least 50% of participants.  
The objective target above was set in line with the ‘50% at five years targets’ for the data 
collection (samples and questionnaires see sections above). As a longitudinal cohort study of 
children with DS, to retain 50% of participants would be a considerable achievement making 
this an important cohort providing contemporaneous data and a bank of longitudinal samples 
for this population.  
 Analysis of Feasibility objectives  
The main access database recorded the dates at which samples were received and 
questionnaires completed. For the feasibility targets relating to the samples and 
questionnaires, a query was created to show the age of the participant for each of the samples 
and questionnaires. These data were then converted into an Excel spreadsheet from which 
proportions (percentage), median ages and interquartile ranges were calculated. The 
proportion of participants who provided longitudinal samples could also be determined. 
These were then compared to the targets set in the feasibility objectives. Binomial exact 
95% confidence intervals were calculated for proportions using the cii proportion command 
in Stata. This is an immediate command and only requires the number of observations and 
number of successes to be inputted. As the study had not been running for five years 
completion of samples and questionnaires for five years could not be determined but 
completion of longitudinal samples was used as a proxy for this. Determining retention of 




were fully active (completing all questionnaires and samples) or partially active (completing 
at least some of the requested questionnaires or samples) was determined as an indication.  
 Secondary Objectives 
Characterisation of the cohort - Objective:  
1.  Ability to characterise the cohort in relation to: 
a) maternal age, socio-economic background, ethnicity; 
b) medical conditions related to a diagnosis of DS; 
2. to determine the numbers and types of infections experienced during early life and 
antibiotic usage; and 
3. to describe early feeding and weaning in the cohort. 
The characterisation of the cohort was undertaken in order to determine whether the cohort 
was representative of the general population in the UK and particularly the general 
population of children with DS. Maternal characteristics were compared to those reported by 
the Office of National Statistics and other published reports for mother’s in the UK (Office for 
National Statistics (ONS) 2015, NHS Digital 2017). Published papers describing the 
epidemiology of medical conditions within the population of people with DS were used to 
compare the proportion of babies seen with conditions known to be associated with DS 
(Freeman et al. 1998, Freeman et al. 2009, Roizen and Patterson 2003, Yumura-Yagi et al. 
1992). 
Sample Analysis – Objective 
1. to measure levels of urine C-peptide levels longitudinally; 




3. to profile the gut microbiome during early childhood.  
Samples were tested to show the adequacy of the samples having been collected by the 
families at home (blood samples were collected by health care professionals), posted in the 
standard post and then stored frozen at -800C.   
 Recruitment 
The initial protocol stated that participants would be recruited through the DSA and DSS as 
described previously. Once the study started, it was promoted through a variety of media as 
listed below. These promotional activities were organised by myself in collaboration with the 
DSA, DSS, DHG and DSMIG. Promotional materials were written by me with feedback from 
the study team and the relevant organisation. Figures 8 to 10 are screen shots of just some of 
the web-based promotional activities. 
• Flyers in DSA new parent packs (throughout the study) 
• Flyers given to parents in contact with DSS (throughout the study) 
• DSS e- bulletin article (July 2014) 
• Study featured on DSA website on their research page (Aug 2014) (www.downs-
syndrome.org.uk/about/research-campaigns/current-research-projects/feeding-and-
autoimmunity-in-downs-syndrome-evaluation-study-fades/) 
• Study featured within the newsfeed on the first webpage of the DSA website (August 
2014) 

















Figure 10a and 10b: Screenshots from DSA Facebook page showing “Likes” of up to 231 people and shared by 27. Figure 10c: Screenshot of post from 





Recruitment began in August 2014 but within a couple of months it was clear that recruitment 
was slow. The Down’s Syndrome Medical Interest Group (DSMIG) is a network of around 160 
doctors from across the UK and Republic of Ireland who all have a special interest in the 
medical care of people with DS. The DSMIG hold bi-annual scientific meetings. FADES had 
been presented to the DSMIG meeting in June 2014 by KG. At this meeting, members of the 
DSMIG had highlighted how they might help with recruitment by providing their expertise 
and connections. A teleconference was organised with the DSMIG, KG and myself. They 
advised that their members would be interested in promoting the study and providing further 
support. The director of research for the DSMIG Dr Jill Ellis agreed to send a letter to all 
members of the DSMIG informing them about the study.  
A decision was made to include the use of local collaborators to actively engage in participant 
identification and recruitment. Local collaborators would include community paediatricians, 
neonatologists and research nurses. The necessary substantial amendment was made on the 
30th March 2015 to approve this. Local collaborators were recruited throughout the course of 
the study through a variety of approaches summarised below: 
• Letters were sent separately to all members of the DSMIG requesting their 
involvement and informing them that a substantial amendment was being submitted 
to approve the use of local collaborators in recruitment (June 2014) 
• Flyers to recruit local collaborators at DSMIG meeting (June 2015) 




• Royal College of Paediatrics and Child Health (RCPCH) annual conference, poster (April 
2016) and oral presentation (May 2017). The DSMIG held their scientific meeting at 
the RCPCH conference April 2016 and May 2017.  
The two routes via which a participant could enter the study and the administrative steps 
involved are shown in Figure 11 and 12. Figure 11 describes how participants who were 
recruited through social media, websites or flyers were consented and enrolled into the study 








Figure 11: Summary of the administrative / management processes from the point when a 
potential participant first contacts the study to being fully enrolled in the study 
 
Study advertised 
Potential participant contacted study  
On website 
Potential participant followed 
link on FADES webpage to 
register on web-based EOI 
form (PIS can also be 
downloaded)  
Via Email 
Potential participant emailed study. 
Study team answered any questions 
and directed the potential 
participant to complete the web-
based EOI.  
Phone call 
Potential participant called study. 
Study team answered any 
questions and directed the 
potential participant to complete 
the web-based EOI. 
Completion of web-based EOI  
Completion of EOI generated an email prompt which was sent to the 
FADES mailbox and specified members of the study team.  
Participant information sheet (PIS) and two copies of consent form sent to 
potential participant together with a stamped addressed envelope to return 
consent form.   
After four to five days (to allow time to read PIS and consider) potential 
participant was emailed or phoned to ask if they had any queries regarding 
the study and if not to ask them to complete two consent forms sending 
one copy back in the SAE and keeping one copy for their records. 
Consent form received 
Study team entered details onto the main FADES database (see section 
2.12.1) which generated a random five, digit ID number. Consent form filed 





Figure 12: Summary of the administrative / management processes for participants identified 




Potential participant identified by local collaborator 
Signposting  
Local collaborator advertised study to 
potential participant (Flyer, information 
leaflet) and signposted them towards the 
EOI on the webpage.  
Consented by Local collaborator 
Consent forms completed by local 
collaborator and sent to study team. Either 
directed participants to complete web-
based EOI or helped them to complete the 
EOI. 
Completion of web-based EOI  
Completion of EOI generated an email prompt which is sent to the FADES 
mailbox and specified members of the study team. Local collaborator also 
emailed the study team to inform them if they had identified or recruited 
a participant 
For those not consented by local collaborator the PIS and two copies of 
consent form were sent to the potential participant together with a 
stamped addressed envelope to return consent form.   
After four to five days (to allow time to read PIS and consider) potential 
participant emailed or phone to ask if they had any queries regarding the 
study and if not to ask them to complete two consent forms sending one 
copy back in the SAE and keeping one copy for their records. 
Consent form received 
Study team entered details onto the main FADES database (see section x) 
which generated a random five, digit ID number. Consent form filed in site-






A variety of promotional activities continued throughout this study. To reach a cross section 
of families from across the UK, multiple recruitment methodologies were adopted. These 
included: 
• Blog on DSA website (May 2015) written in collaboration with Dr Marder from the 
DSMIG and Vanda Ridley from the DSA. 
• New flyers which included photos, packs sent to DSA and DSS and local collaborators 
(July 2015). 
• FADES on DSA Facebook and Twitter feeds – ‘liked’ and ‘shared’ by contacts, 
collaborators and families (Aug 2015). Discussed with DSA who agreed to put the study 
on their social media feeds every other month (Jan 2017). 
• FADES featured in DSA e-newsletter (September 2016) and DSS e bulletin (Jan 2017) 
• Study updates provided to charities families and local collaborators. Updates added 
to the DSA research webpage (October 2015, Aug 2016).   
• FADES featured in the newsletter for the Down’s Heart Group (DHG) (November 
2016). 
• FADES promoted as part of an article written by me on autoimmunity in DSS  
newsletter (Feb 2017). 
• FADES advertised on DHG website (Feb 2017). 
• Study promoted and discussed at NIHR CRN Champions meetings (NIHR CRN Eastern 
research champions meeting, conference call with me Feb 2017) (Kent, Surrey and 




• FADES quarterly newsletter sent to all participating families and collaborators 
(December 2016, March 2017, July 2017). 
• World Down’s Syndrome Day March 2017: FADES study team raised money for the 
DSA and DSS. Photos of the research team on the day posted on social media by the 
DSA. 
One local participant who met with me kindly offered to write a piece about the study for use 
in any promotional material for the study or in any study publications. She consented for her 
and her son’s name to be included. This was added to the research page of the DSA website 
and put in the March 2017 newsletter. The quote from the mother is below:  
"We found out about the FADES study not long after Alexander was born, through 
our local Down syndrome support group. After I found out more about it, we were 
very keen to take part. The research being undertaken could be crucial to 
understanding the nutritional needs of children with Down syndrome.  
It is very easy to take part in the study. Every six months, we fill in a questionnaire 
and they have a blood, stool and urine sample test.  
The extra support we have had with questions and queries around other areas of 
Alexander's health have been wonderful, and we feel privileged to be part of 
improving the lives of children with Down syndrome.  We would encourage anyone 
thinking about joining the study to take the plunge!" 
The success of these methods in recruiting participants to the study was assessed by 




the study on the EOI form, the question asked, “how did you hear about the FADES study?” 
the drop down box for the answers gave the options of: 
• Through the DSA website 
• From the flyer in the DSA new parent pack 
• From a support worker from DSS 
• From the flyer in the DSS new parent pack 
• From a community paediatric doctor 
• From a neonatal doctor 
• Through a friend 
• Through social media 
• Other 
Recruitment methods were also assessed in the Participant and Non-participant 
questionnaires (see Section 2.11). 
 Qualitative Research Methods 
The methods for the qualitative study “What factors influence recruitment to a birth cohort, 
of infants with Down’s Syndrome” are covered in Chapter 3. The qualitative study was 
published in Archives of Disease in Childhood (Williams et al. 2018).  The methods are not 
presented here as they do not apply to the main study participants. The qualitative study is 




 Participant and non-participant questionnaires 
The qualitative interviews provided information on the experiences and opinions of 
professionals and support workers about recruiting families into research studies, but not on 
the experiences of the families themselves. Therefore, participants who engaged and non-
engagement participants (parents who contacted the study but then did not go on to join the 
study (non-participants)) were asked to complete a short questionnaire to explore motives 
for joining or declining the study.  
The questionnaires were designed to be short and included a combination of open questions 
and ones with Likert scale options (copies of the questionnaires are Appendix 19 and 20). The 
questionnaires were designed by GW following consultation with members of the research 
study team. Draft questionnaires were checked for face validity by members the research 
team including SD (statistician), JPH (consultant paediatrician) and ST (database manager). 
The web-based versions of the questionnaires were hosted via the REDCap system as 
described in Section 2.13.2.   Families were asked how they heard about the study, what 
interested them in taking part and to comment on the study website and information that 
was provided about the study. For the non-participant questionnaire, they were asked why 
they chose not to take part.  
The questionnaires were anonymised and could be completed on the web-based format or 
as a paper version if requested. The questionnaire links were emailed to the engaged 
participants and the non-engaged participants in bulk so that the responses would be 
unidentifiable. No one requested a paper version. Participant questionnaires were sent out 




recently joined the study were not included as they had not had time to demonstrate that 
they were actively taking part or not. Non-participant questionnaires were sent out to 26 
families who had contacted the study either via an email or by completing the EOI form but 
that who had not then gone on to consent to being in the study. 
 Analysis of participant and non-participant questionnaires  
Proportions (percentages) were calculated for closed questions and those where a Likert scale 
was used in the participant and non-participant questionnaires. For open questions, common 
themes were found, and illustrative quotes were used. Unusual answers were also noted.  
  Data collection, storage and data protection 
All the data collected in the study were maintained and stored in strict accordance with data 
protection regulations. All participant identifiable information (i.e. names, addresses, dates 
etc.) was stored in a dedicated password protected Access database which is referred to as 
the Main Database in this thesis. Once a web-based EOI (see section 2.13.2 on REDCap for 
data storage and data protection within REDCap) was completed by a potential participant, 
an automatic email alert (which did not contain any participant data) was sent to the study 
mailbox and specified members of the research team including myself. Consent forms would 
then either be sent out to the participant and returned to the study team, or if the participant 
had been recruited by a local collaborator the consent form would be sent in by them. Once 
the consent form had been received, the personal data could be entered manually onto the 
Main Database. By entering this information, a five-digit ID would be created by a random 
number generator, the main database therefore acted as the “key” (Figure 13).  A separate 




and urine analysis. Therefore, unauthorised persons would need to circumvent the security 
of both databases, to obtain and link to both patient details and results of investigations. All 
databases used in the study were password protected and the university network itself is 
firewalled, IP and password authenticated. Questionnaires did not contain participant 
identifiable information, the five-digit study ID number was given to the participants and 
could only be linked to their personal details by authorised members of the research team. 
Any paper versions of the questionnaire and the consent forms were locked in a secure filing 










Figure 13: Illustration of the systems for secure data storage.  
 
 Main Database and Alert system 
The organisation of the study was complex, with multiple samples being collected and 
questionnaire data being recorded at different time points. It was not possible to predict 
when a participant might join the study and therefore each participant had their own 
individual timeline. The need for an alert system was identified and discussed at the FADES 




light” system (as illustrated in Figure 14). Conditional formatting was used so that once a study 
participant was entered onto the database their date of birth provided the “condition” for 
the other cells. When a participant was within two weeks of a data collection time point a red 
box would appear in the column for that data, either samples and /or questionnaires (A in 
Figure 14), alerting the study team to send out a sample pack and/or a questionnaire. The 
only caveat to this would be if a sample of the same type had been received late and was 
within two months of the next data time point. In this case the box would turn grey (B Figure 
14). Once the sample collection pack and/or questionnaire had been sent out to the 
participant and logged, the box would turn to yellow (C Figure 14). Finally, once the sample 
collection and/or questionnaire had been completed, samples received at Southmead, and / 






Figure 14: Screenshot of Main Database with participant identifiable data removed. A red box indicated that a participant was due a sample pack 
or questionnaire (A), a grey box indicated that the previous sample had been returned less than two months prior to the next due date (B), a 
yellow box indicated that a sample pack or questionnaire had been sent to the participant but not yet returned (C) and a green box meant that 





  Feeding and medical questionnaires   
The next sections describe how the questionnaires were designed and put into a web-based 
format. The piloting of the questionnaires both paper and web-based, is explained and the 
analysis methods are given. 
Participants were given the option on the EOI of completing the questionnaire on paper or 
using the web-based questionnaire. Both versions asked the same questions however, the 
web-based questionnaire automatically bypassed irrelevant questions depending on the 
answers that were provided. Certain questions on the web-based form had limits set on the 
responses to reduce errors. Parents were asked to complete the initial medical and feeding 
questionnaire as close to birth as possible. Depending on the preference they expressed on 
the EOI, parents were either sent a paper version of the initial questionnaire (together with a 
stamped addressed envelope) or a link to the web-based questionnaire. They were then 
asked to complete further medical and feeding questionnaires at seven months and 12 
months. After the first year they completed annual medical questionnaire around the time of 
their baby’s birthday. Blank versions of the questionnaires are in Appendix 13 - 16.   
 Questionnaire design and piloting 
The feeding and medical questionnaires were carefully designed and tested to produce data 
that were valid. It was important that questions measured what they were planned to 
measure. The questionnaires set out to characterise the cohort in terms of their birth history, 
medical background, infection rate, antibiotic use and early feeding history. As will be 




both of feeding their baby and of their child’s medical needs. Any questionnaire therefore 
needed to be reliable and sensitive to change. The use of different question types (both open 
and closed) and repeated questions facilitated this.  
The steps taken in the initial design of the questionnaire are shown in Figure 15. Following a 
literature review of feeding surveys and other cohort studies designed to explore the 
development of autoimmune conditions key questions were identified (Snell-Bergeon et al. 
2012, TEDDY Study Group 2007), and sources of previously validated questions were sought. 
The feeding aspect of the questionnaires were designed based on the questions used in the 
2010 IFSs from the Health and Social Care Information Centre (McAndrew et al. 2012). The 
IFSs aimed to provide statistics on the incidence, prevalence and duration of breastfeeding 
and other infant feeding methods during the first eight to ten months of life for infants in the 
UK. The IFSs were conducted every five years from 1975 until 2010, they have since been 
discontinued. IFF Research carried out the 2010 survey in partnership with Professor Mary 
Renfrew, Professor of Mother and Infant Health, College of Medicine, Dentistry and Nursing, 
University of Dundee. The use of questions from the IFS provides construct validity and the 
findings from the FADES questionnaires should therefore be comparable. Questionnaires 
were completed at three time points for the 2010 IFS, initially when the babies were six to 
eight weeks old, again when they were six months old and finally when the infants were aged 
eight to ten months old. The FADES questionnaires were designed to also be completed early 
in life, at six to eight months and then again at 12 months. 
The FADES questionnaires contain a combination of some questions from the 2010 IFS and 




with DS, feeding issues that are specific to DS and questions specific to the development of 
autoimmune conditions of interest.  
To check for face and content validity, draft questionnaires were initially discussed in detail 
with members of the FADES research team which included a statistician, dietician and 
consultant paediatrician. The resulting second draft was then sent to and discussed with Dr 
Jenny Ingram (a senior researcher at the University of Bristol with experience in infant feeding 
research). Dr Ingram made several suggestions to reduce the number of questions. The 
questionnaire was again modified, and the resulting version was sent to the DSA. 
The DSA gave feedback on the documentation for the FADES study including the 
questionnaires. The draft versions of the paper questionnaires were reviewed by mothers 
(members of the DSA) and they were asked what they thought of the questionnaires and any 
suggestions for improvements. They commented that there were a lot of questions but that 
they agreed a web-based system for the questionnaires which automatically skips irrelevant 
questions would help considerably in making the questionnaires feel shorter. They suggested 
that more information was required to explain why certain questions were being asked, and 
the questionnaires were therefore modified accordingly.  By making these changes, the face 
validity was improved. They also asked that we remove the question “Is your baby no longer 
with you?”. This question was originally included to check eligibility as babies who had been 
taken into care or adopted were not eligible to be in the study due to parents being unable 
to provide details regarding ongoing feeding and medical care. This question was removed 
and instead the consent form was changed to ask, “are you the birth mother?”. It was also 




never be used. In all circumstances, this was changed to “a baby with Down’s Syndrome”. 
Overall, they felt there was a bias towards breast feeding and were concerned that the 
questions regarding antibiotics would make parents think that taking antibiotics is a bad thing. 
They also found the question about whether the mother was currently in work judgmental. 
The revised questionnaires were then sent back to the DSA for approval. 
 
 
Figure 15: Initial steps in the design of medical and feeding questionnaire.  
Footnote:*(McAndrew et al. 2012) **As described a statistician, consultant paediatrician, dietician, members of 




Further validation and piloting of the questionnaires (both paper and web-based was 
completed once the web-based version of the questionnaire had been constructed (see 
sections below) 
  REDCap and web-based questionnaires 
The use of apps and the internet for data collection in research studies is increasing and the 
potential benefits are being recognised; 
• accessibility is improved as questionnaires can be accessed from mobile devices 
wherever the participant might be located, 
• questionnaires are customisable allowing the addition of branching questions which 
reduce the amount of content seen by participants making them potentially less 
overwhelming, 
• intrinsic validation – limits can be set on the numerical value of responses for some 
questions, 
• questionnaires are less easily lost than paper,  
• no issues with postage, 
• and reduction in human error as no manual transfer of data.  
This study recruited new parents, who are a demographic recognised as having a preference 
for web-based communication methods (Bernhardt and Felter 2004, Plantin and Daneback 
2009). Trialling the use of web-based questionnaires in this study as part of the feasibility 
seemed wholly appropriate. 
For FADES it was decided that the REDCap system (Harris et al. 2009) would provide the 




and feeding questionnaires. REDCap is a web based electronic data capture system designed 
and developed at Vanderbilt University. These features were: 
• Security – user authentication through username and passwords. University of Bristol 
Central IT Services manages REDCap for research taking place at the university and it 
therefore meets its policies regarding security, resilience and backups (University of 
Bristol)  
• Access to data across departments (laboratory, researcher and admin access) 
• Electronic questionnaires / case report forms which were intuitive 
• Different field types, filtering and branching logic 
• Audit and validation capabilities 
• Data storage and backups 
• Data export functions to allow data to be exported to statistical packages including 
Stata 
 Separate “projects” were created on REDCap by ST, these were: 
1. collecting the personal information on the EOI form,   
2. the initial, seven-month and 12-month questionnaires (which contained both medical 
and feeding questions), 
3. the annual questionnaires (completed at age two years and then annually until 2022, 
these contained only medical questions), 
4.  and the participant/non-participant questionnaires. 
The separate projects ensured that personal identification data were kept separately from 




to the projects they required (as previously illustrated in Figure 13, Section 2.12). Permission 
to access projects on REDCap required two stages: The REDCap admin team created a user 
and then with my permission, ST would allow access for that user to the required projects.  
The EOI project and data storage were held on a different university server from the other 
REDCap projects. 
The required fields and branching for the feeding and medical questionnaires were discussed 
with ST. The questionnaires were setup on REDCap with fields designed to limit input errors. 
The web-based questionnaires underwent User Acceptance Testing (UAT) by three members 
of the research team see Figure 16. Once the final versions went live, the responses for each 
of the completed questionnaires were reviewed for content validity and reliability. In August 
2015 the data that had been collected were exported and reviewed by SLD (statistician) to 
check the quality that the system was working correctly to enable the data to be exported 
directly into Stata. Due to the iterative nature of this feasibility study, the data collected by 
the web-based and paper questionnaires was constantly reviewed together with feedback 
from participants. Where errors or inconsistencies were found appropriate changes were 






Figure 16: Process for piloting and launch of paper and web-based questionnaire.  
 Feeding and medical questionnaire data preparation 
For both the paper and web-based questionnaires, participants did not enter any personal 
details, their five-digit ID number was written on every page of the paper questionnaire by 
the research team prior to sending. Once the paper questionnaire was received in the post, 
the data were transferred verbatim onto the web-based version by me or a member of the 




The data captured on the REDCap system from the feeding and medical questionnaires was 
exported to Stata. Data were then cleaned by me, and throughout this process the original 
data were maintained with changes only made within Stata. All data cleaning and coding steps 
were recorded within Stata do files providing an audit trail. For closed questions, the cleaning 
of data largely involved examining the longitudinal data to remove discrepancies in the 
responses given by individual participants. For example, where a participant said that they 
had a medical condition known to be permanent in the initial questionnaire but failed to 
include it in a subsequent questionnaire this was changed. For the majority of questions 
where there were discrepancies, it was assumed that the initial questionnaire was correct.  
This avoided missing data.  For open questions common answers were coded and a standard 
coding framework was applied, this is described in the following section. When exporting the 
questionnaire data into Stata the variable names for many of the questions were too long and 
therefore new variable names needed to be created. A spreadsheet (Master Sheet) of all the 
variable names old and new were kept (see Appendix 22). 
Open Questions 
Data from free text and open responses to questions were coded to enable descriptive 
analysis. Depending on the question type, a standard coding framework was applied, this was 
important as some questions were repeated at different time points and could then be easily 
compared when looking at longitudinal data. The codes and the new variables that were made 
are in the Master Sheets Appendix 22 and 23. An example of the standard coding framework 
that was applied: there are a number of questions in the initial, seven month and 12-month 




given and for what infection with free text boxes for the responses. For consistency and to 
aid longitudinal analysis of antibiotic use, answers were coded for the antibiotic name and 
infection type across all the questionnaires. 
Thematic analysis with the use of direct quotes was used for some questions to accurately 
represent what the mothers were trying to portray. This was particularly pertinent to 
questions relating to feeding where responses were common to more than one participant. 
For example, in the 12-month questionnaire, question 2-7 in relation to breastfeeding “What 
were your reasons for stopping?”, the theme of “expressing being too time consuming” 
emerged. This was therefore made into a binary variable. More than one theme was 
sometimes applicable to a given response, therefore the use of binary variables allowed for 
each of these themes to be captured. Selected quotes are used in the results to illustrate. 
Quotes are also used to show unusual or unexpected responses which were actively sought 
out. All coding was completed by me to prevent any concerns with inter-rater reliability. 
Missing values 
Within the exported data there were two distinct types of “missing data”. Values that were 
missing because participants had bypassed those questions due to branching and values that 
were missing because no response had been supplied despite the question being relevant for 
the participant. During analysis if the true value for the missing data could be deduced this 
was inputted through Stata otherwise it remained as missing and the denominator for 




  Statistical Methods 
The analysis of the medical and feeding data were descriptive as this was a feasibility study 
the numbers of participants was too small for more analytical statistical methods. 
Frequencies were derived and given as a percentage. Where numerical values existed for 
example for birth weight and gestation interquartile ranges were calculated together with 
mean and standard deviations (if data followed a normal distribution) or median and 
interquartile ranges (where data did not follow a normal distribution).  
  Sample collection, Storage and Analysis 
The schedule for the collection of biological samples from participants is shown in Table 5 and 
the instructions that were provided to the families are in Appendix 17 and 18. The samples 
included DNA (from a mouth-swab) for HLA genotyping, stool for microbiome analysis, urine 
for Urine C-peptide and blood for measurement of autoantibodies and anti BSA antibodies. A 
maternal stool sample was also collected for maternal gut microbiome analysis. The initial 
baseline samples were collected as close to birth as possible, so sample packs were sent out 
to families as soon as they had been enrolled into the study. If a sample had been received 
within two months of the next time point, a further sample was not requested until the 
subsequent time point.   
Once collected, all samples were returned by post to the Diabetes and Metabolism Laboratory 
at Southmead Hospital. Once received, the samples were logged on the main database (the 
barcodes for the samples were entered into the database when the sample packs were sent 
out to the families). The barcodes were also then entered into the Sample database ready for 




for each of these sample types are described in the relevant sections (Section 2.16). Two 
studies were completed to refine the collection methodology for the collection of urine 
samples and for the collection of the stool samples. These studies are within Section 2.15 
Refinement of Collection Methodologies.  
The timings of the sample collection were initially designed to fit around the screening 
schedule recommended by the DSMIG (from the PCHR insert for babies born with DS third 
edition (DSMIG 2019b)). Annual thyroid screening is recommended from one year of age and 
the aim was to have blood samples taken at or around the same time to avoid participants 
having to attend additional appointments and ideally avoid them needing extra blood tests. 
The American Academy of Paediatrics recommends that a thyroid function test at six months 
of age and then every 12 months (Fergeson et al. 2009) but anecdotally this is poorly adhered 












Months of age 0* 
Baseline 
6 12 24 36 48 60 
Mouth swab for 
DNA  




X       
Stool for 
microbiome 
X X X X X X X 






X X X X X X X 
Urine for C-
peptide analysis 
X  X X X X X 
 
 Refinement of collection methodology 
Two small, internal feasibility studies were completed within this PhD. One was to establish 
the optimal method to preserve the integrity of gut microbiome samples during a national 
collection returned to the laboratory by post. The other was to determine whether the 
collection methods for the collection of urinary C-peptide from nappies provides a reliable 
Table 5: Schedule for sample collection during FADES.  
Footnote: *participants are recruited as close to birth as possible with a maximum age at recruitment of 









result comparable to standard testing on older people able to provide sample directly into 
the specimen tube.  
These internal feasibility studies are presented in this section in full together with results and 
discussion. The results and discussion are included here rather than Chapter 6 as they 
determine the overall methods that were used for the main study.  
  Feasibility study for the collection of gut microbiome samples 
This feasibility study has been published (Williams et al. 2019) so a brief description is given 
here. 
Introduction and aims,  
In FADES, parents were asked to collect a stool sample from their baby’s nappy and send it to 
the laboratory at Southmead by standard post. Faecal samples have been shown to be 
representative of the distal intestinal microbiome (Ley et al. 2005). In order to identify 
distinguishing features of the gut microbiome that vary between the participants and in 
different conditions (e.g. breastfed versus formula fed), accurate sampling methods were 
essential. Extracting fresh samples or freezing the stool sample immediately preserves the 
sample for gut microbiome analysis (Flores et al. 2015) but this was impractical and too 
expensive for this study which covers a large geographical area. The aim of this internal, 
feasibility study was to determine the optimal method to preserve the integrity of gut 





Initially, ten participants were recruited to participate in the study.  The participants were 
under the age of one year (six males and four females; age range six to 38 weeks) admitted 
to Bristol Royal Hospital for Children without diarrhoeal disease. Ethical approval was 
obtained from the South West Central Bristol Research Ethics Committee (14/SW/0030). 
Parents were asked to check their child’s nappy regularly and let the researchers know as 
soon as they identified their infant had a dirty (soiled) nappy to ensure samples were fresh.  
As shown in Figure 17, from a single stool (one “dirty” nappy) from each participant, samples 
were collected as follows: 1) a stool sample into an empty sterile tube (plain tube), 2) a swab, 
both of which were immediately frozen on dry ice. Then samples were collected into 3) a plain 
tube 4) onto a swab and finally 5) into the OMNIgene•GUT stool stabilisation fluid. The 
OMNIgene•GUT kit (commercially available from DNA Genotek Inc. Ottawa, ON, Canada) 
consists of a tube of stabilisation liquid and a ball bearing. The faeces are placed into the tube 
lid which is designed to break up the faeces and the ball homogenises the sample when it is 
shaken. Samples 3) -5) were posted to the Diabetes and Metabolism Unit at Southmead 





Figure 17: Process for collecting stool samples from nappies for the feasibility study. From a 
single stool, samples were collected as follows: 1) into a plain sterile tube, 2) onto a swab, 
both of which were immediately frozen, 3) into a plain tube and 4) onto a swab, both of which 
were sent to the laboratory through the post and 5) a sample into the OMNIgene•GUT 
stabilisation fluid which was also sent in the post. 
 
All samples returned in the post (ambient conditions) arrived within three days of sampling. 
On arrival, the samples were immediately frozen at -80⁰C. Samples (n=48) were shipped 
frozen by courier to The Alkek Center for Metagenomics and Microbiome Research (CMMR), 
at Baylor College of Medicine, Houston, Texas. There were nine participants who provided 
sufficient stool for all five sample types and one child who only provided sufficient sample for 
the OMNIgene Gut kit and two swabs (one at room temperature and one frozen).   
The  samples were subjected to extraction for 16S rRNA gene profiling using gene sequencing 
methods adapted from those developed for the Earth Microbiome Project (Caporaso et al. 
2011, Caporaso et al. 2012) and the NIH-Human Microbiome Project (Consortium 2012b, a) 
(Details of extraction and sequencing techniques can be found in the published paper 




16Sv4 rRNA gene sequences were clustered into operational taxonomic units (OTUs) at a 
similarity cut-off value of 97%. OTUs were mapped to a database (Edgar 2013, Quast et al. 
2013) containing only the 16S v4 region to determine taxonomies. A custom script 
constructed a rarefied OTU table for analyses of  taxonomic relative abundance, alpha-
diversity (number of OTUs - richness and Shannon’s diversity index), beta-diversity (including 
UniFrac) (Lozupone and Knight 2005), and phylogenetic trends. The ten most abundant Phyla, 
Classes, Order, Families and Genera observed in the 48 samples analysed are shown in 
(Appendix 24).  
Statistical Methods  
To assess the changes seen in diversity of the samples, comparisons were made of the number 
of OTUs which represent the array of species observed. To compare whether changes were 
related to the richness and evenness of the microbes within samples, the Shannon diversity 
index (Shannon index) was used. For each stool sample, the difference in the measurement 
(number of OTUs or Shannon index) between the frozen standard and each of the methods 
of sample collection were plotted against the mean of the two measurements (a Bland-
Altman (BA) plot) (Bland and Altman 1986). This test was used because we wished to measure 
the agreement between the frozen standard and the practical sample collection alternatives. 
The differences and the means were unrelated and therefore 95% limits of agreement could 
be calculated (mean difference +/- 2 standard deviations of the difference) and added to the 
plot.  This gave the range of disagreement between the frozen standard and each of the 
sampling methods (Bland and Altman 1986).   
The relative abundance of each of the four major phyla (Actinobacteria, Bacteroidetes, 




genera (Acinetobacter, Bifidobacterium, Enterobacter, Esherichia_Shigella, Lactobacillus, 
Peptoclostridium, Staphylococcus, Streptococcus, Subdoligranulum and Veillonella) were 
calculated and plotted on a stacked bar chart (Microsoft Excel) to allow a visual comparison. 
Limits of agreement were calculated and used to compare the abundance of each of the four 
main phlya between the frozen standard and the other sampling methods. The same analysis 
was also completed for Enterobacter, Escherichia Shigella, Bifidobacterium, Streptococcus, 
Staphylococcus, Veillonella, Lactobacillus and Rothia (Williams et al. 2019). These are all 
genera which were present in the samples and in the microbiota have been associated with 
T1D auto-antibody seropositivity, breastfeeding or other dietary components (Vatanen et al. 
2016). 
Results 
Recruitment: The initial recruitment target was for ten participants. One of the infants 
recruited did not produce an adequate stool volume to test all sampling methods (sufficient 
sample was available only for three tests; the Genotek method and frozen/posted swab.  
Analysis of initial profiling (Appendix 24) showed that one child had a significant Clostridium 
infection and the samples were removed from further analysis. The BA analysis is therefore 
presented on data from eight infants (six males and two females; age range 6 to 38 weeks) 
with five different sampling methods.   
Impact of sampling method on community diversity: The BA analysis of the observed OTUs 
(Table 6, Figure 18a) showed the OMNIgene•GUT kit to have the narrowest limits of 
agreement (-9.55, 10.55) with the frozen standard. The limits of agreement for the samples 




were similar to each other as expected (-16.13, 26.38 and -16.95, 29.95), and showed less 
agreement than the OMNIgene•GUT kit. The frozen swab compared to the frozen standard 
showed less agreement than would be expected (-35.49, 28.24) due to a single outlier. 
The BA analysis comparing the Shannon index results (Table 6, Figure 18b) showed that for all 
methods, the limits of agreement were narrow suggesting that Shannon index is not affected 
by collection method or by being exposed to ambient temperature. The closest agreement 
with the frozen standard was seen in the samples which were collected using a swab and 
frozen immediately (-0.85,0.93). For samples taken and exposed to ambient conditions in the 
post the OMNIgene•GUT kit showed the closest agreement to the frozen standard method (-
0.96, 1.0), with the plain post and swab post samples showing the least agreement as seen 
with analysis of OTUs (-1.1, 1.59 and -0.99, 1.42) 
 
 Methodology compared to Frozen standard 




























Table 6: Bland Altman analysis of OTU and Shannon index for the four different methods of 






Figure 18a) and b):  BA plots of observed OTUs a) and Shannon index b) for the four different 
methods of sample collection compared to the frozen standard of immediate freezing. 






Impact of sampling methods on community composition: As would be expected when 
samples are subjected to different conditions during sampling and transport, the relative 
abundance of the phyla changed as the conditions either encouraged the proliferation or 
suppressed the growth of microbes. The results presented are for the four phyla which were 
the most abundant within the infant gut microbiome, these are Firmicutes, Proteobacteria, 
Actinobacteria and Bacteroidetes. Figure 19 a) shows the variation in the relative abundance 
of different Phyla between individuals. Each of these infants appears to have a distinct gut 
microbiome. For five of the participants (ID 11, 14, 15, 18 and 19) the profile seen in the 
samples collected using the OMNIgene•GUT kit resembles the frozen standard sample 
method of collecting into a plain tube and freezing immediately. There has been an 
overgrowth of Proteobacteria within the samples exposed to ambient temperatures with a 














Figure 19 a) Relative abundance of the four main phyla for each sampling method (immediate freezing in a plain sterile tube (frozen), immediate 
freezing on a swab (swab frozen), using the OMNIgene•GUT kit (OMNIgene•GUT), collecting into a plain sterile tube in the post (plain post) and 
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Sample methods and participant identification
Genus
Acinetobacter Bifidobacterium Enterobacter Escherichia_Shigella Lactobacillus Peptoclostridium




The limits of agreement (Appendix 25) for the relative abundance of Firmicutes and 
Proteobacteria showed the OMNIgene•GUT kit and the frozen swab to show the closest 
agreement with the frozen standard method. The plain tube and the swab sent in the post 
showed that changes had occurred in the abundances of these phyla.  
The BA plots for Acinetobacteria (Appendix 25) show that the growth of Acinetobacteria is 
relatively unaffected by collecting samples into a plain tube or swab and transporting in 
ambient conditions than from using the OMNIgene•GUT kit. The frozen swab samples 
showed a large disagreement from the frozen standard method which is unexpected. The 
agreement in the amount of Bacteroidetes seen between the frozen standard and the other 
sampling methods was comparable for all apart from the OMNIgene•GUT kit (Appendix 25). 
This had a single outlier affecting the result, if this were to be removed, all of the sampling 
methods would show a similar agreement with the frozen standard method. 
The variation in the relative abundance of the different genera within the gut microbiome is 
much greater between individual infants than it is between the sampling methods (Figure 19b 
and Appendix 24). The method of collection and exposure to ambient temperatures does 
affect, to a variable degree, the growth or suppression of different genera (Williams et al. 
2019) (Appendix 26).  Bifidobacterium and Lactobacillus are both linked to autoimmunity and 
are affected by feeding methods and therefore are particularly relevant for the collection of 
samples for FADES.  For Enterobacter, Staphylococcus and lactobacillus the samples exposed 
to ambient temperatures showed a distinct abundance of these bacteria from the frozen 
standard (Appendix 26). The closest agreement with the frozen standard was between the 




(Appendix 26) the limits of agreement were similar to those observed for the phyla 
Actinobacteria as Bifidobacterium is a member of the Actinobacteria phylum and the 
differences seen in both are due to differences in growth of Bifidobacterium between the 
sampling methods. 
Discussion of the feasibility study for the collection of gut microbiome samples 
We have shown that there is variation in microbiome results from four different collection 
methods compared with the frozen standard of immediate freezing. This study demonstrates 
that the OMNIgene•GUT kit preserves samples taken from nappies and exposed to ambient 
temperatures. Parents were asked to collect the samples and found the method 
straightforward (data collected by questionnaire). The OMNIgene•GUT kit can be considered 
the best option for distance sample collection in general population studies and this method 
was added to the FADES protocol through Amendment 5 August 2016.  
Although parents were asked to check the baby’s nappy regularly, we do not know how fresh 
the stool samples were although they were all likely to have been collected within 2 hours of 
having been passed.  Samples sent through the post took three days to arrive in the 
laboratory. Sample collection at home for population-based studies may result in samples 
being exposed to ambient temperatures for longer periods of time although our laboratory 
protocols try to overcome this by asking participants to post samples on Monday or Tuesday 
to arrive in the laboratory before the weekend. The OMNIgene•GUT kit has recently been 
shown to preserve samples at ambient temperatures for up to 60 days (Hill et al. 2016, Song 




This is the first methodological study defining the method of choice for infants less than one 
year of age.  Although a relatively small study, all sampling methods were consistent, each 
method was tested within all eight participants samples and the genus data demonstrated 
large inter-individual variation. The infants analysed in this study appeared to each have 
distinctive microbiomes. 
The amount of faecal material that it is possible to collect from nappies depends on the baby’s 
age and feeding methods. Very liquid stools are rapidly absorbed into the nappy. For each of 
the methods described in this paper very little faecal matter was required. A previous study 
to compare collection methods from young children and the elderly also showed the 
OMNIgene•GUT to perform well at ambient temperatures for children with a median age of 
2 years old (Hill et al. 2016) and for collection of samples from adults (Choo, Leong, and Rogers 
2015).  
Previous studies comparing sampling and storage methods for microbiome samples have 
used measures of dissimilarity and correlation such as Bray-Curtis, Wilcoxon signed rank test, 
paired DESeq test, Man-Whitney-Wilcoxon test and Kruskal-Wallis test (Hill et al. 2016, 
Dominianni et al. 2014, Anderson et al. 2016) these show degrees of association between the 
sampling methods rather than an agreement. In this study, we conducted a Bland Altman 
analysis allowing analysis of agreement between each collection method with the frozen 
standard, this is a novel (but more appropriate) application of this statistical method for 
comparison of microbiome methodologies. 
This study as with others, shows that for all collection methods there is a change in the gut 




overgrowth of Proteobacteria and a relative reduction in abundance of Firmicutes in those 
samples exposed to ambient conditions. However, it also demonstrates that the 
OMNIgene•GUT kit preserves the samples with the least change to the diversity of the species 
seen (number of OTUs) or the richness and evenness of the samples (Shannon index).  
This approach is now being used to collect all gut microbiome samples from FADES 
participants (Amendment 5 in August 2016) and other cohorts from the general population.  
  Feasibility study for the collection of urinary c- peptide samples from nappies 
Introduction and aims 
Collecting urine samples from infants is usually undertaken as a “clean catch” whereby the 
nappy is removed, and the urine is caught into a sterile pot as it is passed. Alternative methods 
include an adhesive bag which can cause skin irritation or by catheter insertion although this 
is invasive and carries the risk of introducing infection. An alternative method is to place 
sterile cotton wool in the nappy onto which any urine that is passed is captured. Although this 
latter method is perhaps less reliable for microbiological samples where the urine needs to 
be uncontaminated it is used for biochemical analysis of urine samples and has been shown 
to be an effective approach (Fell et al. 1997, Ahmad et al. 1991, Smith and Taylor 1992).  
In the FADES protocol, the recommendation was for parents to collect the urine sample for 
C-peptide by either trying to catch a urine sample in a pot (clean catch), or by placing cotton 
wool in their child’s nappy and once they have urinated into the nappy removing the cotton 
wool and squeezing the urine out. Fibres in the cotton wool balls may absorb some proteins 
making the measurement of proteinuria by this method unreliable (Fell et al. 1997, Smith and 




(Ahmad et al. 1991). This has been reported when measuring proteins of a higher molecular 
weight than urine C-peptide (molecular weight is 3600 Daltons) (Fell et al. 1997). This internal 
feasibility study was to determine the reliability of this method when measuring urine C -
peptide.  
Method  
A pilot study was set up with 21 adult participants and five babies (neither adults or babies 
had Diabetes or DS). The adult participants were asked to provide two urine samples. One 
sample was collected into a sterile pot on waking and before having anything to eat or drink. 
This was then placed in their fridge until they had collected the second sample.  They then 
ate a breakfast and collected a further urine sample into a second pot two hours after the 
meal. Pre and post prandial samples were requested in order to provide a range of urine C-
peptide levels. Both the samples were transferred to the laboratory within 2 hours. For each 
urine sample, half was put straight into a boric acid containing collection tube in the usual 
way. The other half of the urine sample was poured onto cotton wool balls, and then the urine 
collected back off the cotton wool balls after a couple of minutes. This was done by squeezing 
excess fluid into a sterile pot and pipetting into a normal urine collection tube containing boric 
acid. 
For the samples collected from babies, the urine was collected using a clean catch method 
(the optimal method) pouring half of the urine collected into a boric acid tube and pouring 
the other half, back onto cotton wool placed in the baby’s nappy. After an hour in the nappy, 




All samples were labelled with an anonymised barcode and no personal data were recorded 
so samples could not be linked to the donor. The only information recorded was whether the 
donor was an adult or baby and for the adults whether the sample was pre or post prandial. 
The samples were frozen and sent by courier to the Biochemistry Department, Royal Devon 
and Exeter Hospital (Exeter, UK) where they were analysed. Electrochemiluminescence 
immunoassay was used to measure urine C-peptide as previously described (McDonald et al. 
2009). A BA analysis was completed for the adult samples to show agreement between the 
two collection methods (Bland and Altman 1986).   
Results  
For the adult pre-prandial samples, the average difference in the UCPCR measurement 
between the clean catch method and cotton wool method was -0.122 nmol/mmol with the 
95% limits of agreement being between -1.405 and 1.162 nmol/mmol. The majority of the 
participants appeared to have reasonable agreement when visually inspecting the BA plot 
(Figure 20) but there were four participants for whom the agreement was less with three 





Figure 20: BA plot showing the differences and averages in the pre-prandial UCPCR between 
the clean catch and cotton wool methods.  
Footnote: The dashed line shows the average difference with the shaded area representing the 95% limits of 
agreement 
 
The BA analysis for that adult post-prandial samples shows an average difference in clean-
catch UCPCR to cotton-wool UCPCR of -0.038 nmol/mmol the 95% limits of agreement were 
-1.267 to 1.190 nmol/mmol. Overall the BA plot (Figure 21) shows that most samples show 
close agreement but that for three participants with two outside of the 95% limits of 
agreement. There was one participant who had high UCPCR measurements, but the 
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Figure 21: BA plot showing the differences and averages in the post - prandial UCPCR between 
the clean catch and cotton wool methods.  
Footnote: The dashed line shows the average difference with the shaded area representing the 95% limits of 
agreement 
 
The number of samples from babies was too small for statistical analysis but the values are 
presented in Table 7. 
Baby Clean Catch UCPCR 
(nmol/mmol) 
Cotton Wool UCPCR 
(nmol/mmol) 
1 5.02 5.24 
2 6.89 6.36 
3 3.12 5.79 
4 0.29 0.31 
5 3.3 2.16 
 
Table 7: UCPCR measurements from samples from five babies. For each baby a single urine 
was tested following clean catch and having been exposed to cotton wool placed in a nappy. 
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Discussion of the feasibility study for the collection of urinary C-peptide samples from nappies 
Papers have suggested that the fibres in the cotton wool balls may absorb some proteins 
making the measurement of proteinuria by this method unreliable (Smith and Taylor 1992) 
and that this may also be affected by the contact time of the urine on the nappy (Smith and 
Taylor 1992) however this has been when measuring proteins of a higher molecular weight 
than urine C-peptide (molecular weight is 3600 daltons (Chowta et al. 2010)). Our small 
internal feasibility study demonstrated that differences are seen in UCPCR with different 
sampling methods. The BA plots suggest that for the majority of the participants the 
agreement between the methods was close. However, for those participants where the 
differences were outside of the limits of agreement this may have implications for research 
studies relying on this method. Studies look for evidence of remaining beta cell function 
measure very small amounts of urine C-peptide (with detectable UCPCR of ≥0.03nmol/L, 
minimal less than 0.2 nmol/mmol) at these very low levels the effects of the collection 
method might alter results. The participants who were outside of the limits of agreement did 
not show consistent under-measurement with the cotton wool method as might be expected. 
The reason why these differences were observed was unclear. This internal feasibility study 
was small and the number of samples from babies that we were able to collect was restricted. 
Therefore, no conclusion can be drawn from the samples collected in nappies and this would 
need to be repeated with a larger group of babies.  
Overall this study showed that both collection methods would be acceptable for this cohort 




However, if unexpected results are obtained, it would be advisable to ask for a repeat clean 
catch urine sample particularly when looking at low levels of urinary C-peptide.   
 
  Sample collection and laboratory methods for FADES 
The following sections describe the sample collection methods for DNA, urine C-peptide and 
gut microbiome for the participants. The processing, storage and initial testing of the samples.  
 DNA Sample collection and analysis 
DNA samples were collected by parents at home using the mouths-swab kit that was sent to 
them in the post together with the other sample kits and prepaid packaging. DNA samples 
were collected once in the initial sample collection; this was requested at recruitment. This 
was returned in the standard post to the Diabetes and Metabolism Unit at Southmead 
Hospital, Bristol, UK using the prepaid packaging together with the other samples (the full 
instructions for this are given in Appendix 17 and 18). Once the samples arrived in the 
laboratory they were logged in the main database and sample database and were frozen and 
stored at -20⁰C. The samples were defrosted for DNA extraction and HLA genotyping.  
DNA extraction and HLA genotyping  
DNA extraction was completed by GM and SCK and the samples were genotyped using the 
methods described by Gillespie et al (Gillespie et al. 2000). The HLA genotypes for the study 
population were compared with previously published populations for DS, DS and diabetes and 




 Stool Sample collection  
Stool samples were collected for gut microbiome from the baby close to birth and then 
longitudinally around six months of age, one year and then annually. Maternal stool samples 
were also collected at the same time as the baby’s initial sample collection. The maternal 
sample was collected following Amendment 1 (30th March 2015), this was added as the 
maternal gut microbiome is a key determinant of the infant’s microbiome (Ferretti et al. 
2018). Stool samples were collected at home by the families and then returned together with 
the other samples in the pre-paid package. Parents were asked to collect two samples from a 
single stool one using a swab as described below and one using the OMNIgene GUT collection 
tube. The two methods were used in order to maintain a standard collection method (i.e. 
swab) throughout the cohort despite the addition OMNIgene GUT collection tube methods 
(Amendment 5 (4th August 2016)). This amendment followed from the internal feasibility 
study (Williams et al. 2019).  
Parents were asked to collect the sample as soon as they noticed that their baby had 
defecated. They used a BDTM CultureSwabTM, rotating the swab within the stool in order to 
cover the heads of the swab. A spatula provided in the kit was then used to collect a sample 
from the same stool which could be placed into the OMNIgene GUT collection tube. This was 
placed in the return packaging together with the swab. Once the samples arrived, they were 
logged and stored at -80⁰C.  
Stool samples are batched ready for analysis once a significant proportion of the children have 




the differences which are seen between those who develop autoimmunity and those who do 
not, start to be identifiable (Giongo et al. 2011).  
 Urine Sample Collection 
Urine samples for Urine C-peptide were collected shortly after recruitment (initial/ baseline 
sample), at onr year and then annually. A sample was not requested at six months as it was 
unlikely that any significant change in Urine C-peptide from the baseline sample would be 
noted before at least one year of age. Parents were asked to collect a sample after a feed, 
they were given the option of collecting a sample as a ‘clean catch’ or placing cotton wool 
into the nappy to absorb the urine and collect it this way. These two methods were compared 
in the internal feasibility study. The urine sample was then transferred into a sample tube 
containing boric acid, packaged and returned with the other samples. A study by McDonald 
et al showed that UCPCR was not altered when urine samples in boric acid were stored at 
room temperature for up to three days (McDonald et al. 2009). Once samples arrived in the 
laboratory, they were aliquoted and stored at -800C.  
Following Amendment 7 (25th July 2017) parents were asked to document how long after the 
feed the sample was taken. As discussed in the feasibility study Section 2.15.2 and in Chapter 
6 Section 6.5, there is not a standard method for collecting samples for urine C-peptide in this 
age group. It is not possible to give a standard feed and babies cannot void on demand but 
urine C-peptide creatinine ratio replaces the mixed meal tolerance test in this study (Besser 




Measuring Urine C-peptide  
Samples were shipped frozen by courier to the Biochemistry Department, Royal Devon and 
Exeter Hospital (Exeter, UK) where the urine C-peptide analysis was completed. An 
Electrochemiluminescence immunoassay was used to measure urine C-peptide as previously 
described (McDonald et al. 2009).  The threshold of UCPCR ≥0.37nmol/mmol was used to 
describe significant endogenous insulin secretion in this study. Besser et al found that a 120-
minute post evening meal UCPCR correlated significantly with a 90 minute stimulated serum 
C-peptide result in children. A threshold of UCPCR ≥0.37nmol/mmol was highly specific for 
significant endogenous secretion (Besser et al. 2011). Although this was a small study, there 
are no standard cut-offs for UCPCR in children. UCPCR values were also plotted against the 
adult thresholds for detectable but minimal UCPCR of ≥0.03nmol/L and for intermediate 
insulin secretion 0.2 nmol/mmol (the cut off for intermediate insulin secretion (Oram et al. 
2014). 
  Blood  
The initial blood sample was collected as close to birth as possible, so once the participant 
had been recruited the parents were contacted via email to find out when they were next due 
to see a healthcare professional. The details of the relevant healthcare professional were 
provided or had to be determined and a request was made to them by GW to help facilitate 
the sample collection. The blood samples were taken by a variety of people, health visitors, 
GP practice nurses (at the time of immunisation), phlebotomist (in clinics and occasionally 
organised by the families themselves), neonatologists, community paediatricians, 




blood sample pack provided with them to the appointment. The pack contained pre-labelled 
tubes, instructions and all necessary equipment for a heel or finger prick sample. Some 
parents and families collected the annual samples themselves at home, this was mostly 
families who themselves had clinical experience. The Sarstedt Microvette tube that was 
provided for the sample allowed 300µl of blood to be collected. Two tubes were provided 
although only one tube was requested both tubes were filled for some participants when the 
blood was easy to collect. The blood sample collected was given to the family to post in the 
prepaid packaging. There was no involvement of local hospital NHS laboratories.  
Once the blood sample arrived in the laboratory, if the sample was less than ~20µL it was not 
separated but was frozen whole at -800C. Larger samples were spun down using the 
Microfuge at a maximum speed of 13.3 revolutions per minute for fifteen minutes. The serum 
was pipetted off into 500µL Starstedt tube, with an O-ring lid. The tube was labelled, and the 
serum volume recorded. The sample together with the remaining blood clot was then frozen 
and stored at -800C. 
 Analysing the blood samples for anti-bovine serum albumin antibody (BSA)  
Blood samples collected up until the 1st September 2017 were tested for anti-BSA antibodies 
by SG. These samples came from 53 participants, 30 of whom had longitudinal samples. A 
control group of 18 children under the age of two years from the BOX study were used 
(Bingley and Gale 1989, Kozhakhmetova et al. 2018).  
The laboratory methods for the anti-BSA Antibody Dissociation Enhanced Lanthanide 
Fluoroimmunoassay (DELFIA) were provided by and with permission from SG prior to 




was labelled using an Eu-N1 ITC chelate, with an aromatic isothiocyanato group as the reactive 
arm. To each well, 28.8ng/ml of labelled BSA (approximately 95,000 Europium (Eu) counts) 
was added in 25µl 50 mmol/l Tris 0.9% NaCl <0.5% Tween Buffer (DELFIA Assay Buffer). 
Glycine-blocked Protein A Sepharose was used to precipitate bound immunocomplexes. 
Following a centrifuge-based wash system (six times), bound Eu counts were counted on 
a Victor plate reader after the addition of DELFIA Enhancement Solution (Perkin Elmer). 
Samples were measured against a standard curve, constructed using dilutions of an anti-BSA 
antibody positive serum, obtained from a FDR, in an anti-BSA antibody negative serum from 
a healthy volunteer. Quality control sera with varying antibody titres to anti-BSA antibodies 
were also selected. Results were indexed by subtracting the cpm of the negative control and 
dividing by the positive control minus the negative control. The positive threshold was set at 
the 90th percentile of 228 healthy school children (Bingley et al. 1993) (113 Male, 115 Female 
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Chapter 3 Qualitative Study: What factors influence recruitment to a 
birth cohort of infants with Down’s syndrome? 
 Overview of Chapter 3 
This chapter presents the qualitative study that was completed to understand the potential 
barriers to recruitment for the FADES study. Data pertaining to the qualitative study has been 
published in an international peer reviewed journal (Williams et al. 2018). However, the 
present chapter fully describes the methods and evaluates the findings in the wider context 
of the thesis.  
 Introduction  
Birth cohorts targeting DS or other genetic conditions are rare. However, prospective cohort 
studies are essential for understanding the natural history of these conditions. Recruiting any 
family with a new-born into a research study is challenging, but the potential ‘setback’ of a 
diagnosis of DS compounds the difficulty. The majority of diagnoses are made at birth, or 
shortly afterwards (Morris and Alberman 2009): around 92% of prenatal diagnoses lead to a 
termination (Morris and Alberman 2009). As described previously babies with DS have 
associated conditions often diagnosed in the neonatal period (Roizen and Patterson 2003), 
these may have a significant impact on the baby, family and early bonding opportunities. 
Studies exploring how parents cope and adapt to receiving the diagnosis of DS, have described 
the increased stress compared to parents of a typical newborn (Van Riper 2007). Some 
families will respond with shock and upset whilst others will positively thrive (Van Riper 2007, 




recruitment during the feasibility phase and to inform future birth cohorts recruiting 
chromosomal/genetic anomalies or complex neonatal conditions.  
Qualitative methods in comparison to quantitative methods allow in-depth social inquiry 
enabling the researcher to gain a better understanding of the participant’s perspectives and 
experiences. It is interpretivist rather than positivist which is important in a context such as 
this where the diagnosis of DS is relatively rare, an individual’s reality of being a parent of a 
child with DS varies and there is little available prior research into recruiting this population. 
There are multiple qualitative analytic methods including grounded theory (Glaser 1992), 
interpretative phenomological analysis (Smith and Osborn 2004) and narrative analysis 
(Riessman 1993). However, thematic analysis was used in this study because it allows 
theoretical flexibility whilst being methodologically sound.  Thematic analysis enables the 
data set to be organised into themes, a theme encompasses something important in relation 
to the research question and may show a response that has a degree of commonality between 
participants and a pattern of ideas or meaning.  
Thematic analysis can be inductive or deductive. Inductive is data driven and described as a 
‘bottom-up’ approach (Patton 1990) whereas deductive analysis is ‘top-down’ and is usually 
associated more with the researcher’s topics of interest.and / or guided by pre-conceived 
theoretical framework.  Although taking a deductive approach leads to less rich evaluation of 
the data it provides more detail in the desired area. Analysis occurs at different “levels”, 
semantic being the most basic with latent analysis starting to uncover ideas, 
conceptualisations and ideologies (Braun, Clarke, and Terry 2014). The interviews in this study 




analysis allowed an understanding of how their opinions were formed. This method 
acknowledges the influence of the researcher’s theoretical and epistemological position 
(Braun, Clarke, and Terry 2014) this will be discussed in relation to this study in the discussion 
at the end of this chapter (Section 3.5.1.1).  
 Methods 
A copy of the study protocol is in Appendix 4. 
 Participants 
A purposive sampling strategy was used to recruit paediatricians, research nurses and family 
support workers. This strategy enabled participant selection based on their experience in 
supporting and caring for infants with DS and their families, during the months after birth, or 
recruiting new parents to research studies. This study was advertised amongst members of 
the Down’s Syndrome Medical Interest Group (DSMIG). Family support workers and charity 
workers from the Down’s Syndrome Association (DSA) and Down’s Syndrome Scotland (DSS) 
were approached via contacts already known to the FADES team.  FADES local collaborators, 
community paediatricians, neonatologists and research nurses were also invited to take part.  
Of the 18 interviewees; two-thirds were clinical (nine paediatricians and three research 
nurses) and a third were family support workers. Of those interviewed, five had a child with 
DS. Further demographics are not given as the relatively small professional community that 





A topic guide for the interviews was developed and informed by a literature review of parental 
adjustment to the diagnosis of DS and recruitment issues for neonatal studies. The guide 
included items which explored the interviewee’s experience of working with families having 
a child with DS and their views on recruiting this group into research studies (Appendix 5).  In 
keeping with the iterative nature of qualitative methods, the topic guide was revised 
following initial interviews.  In addition, the topic guide questions were tailored to the 
profession or background of the interviewee. For example, clinicians were asked “What are 
your particular areas of interest / specialism?”. The data were collected by GW through 
conducting semi structured telephone interviews with the participants. Recruitment ended 
when the interviews were no longer revealing any new information and data saturation had 
been reached. The interviews were between twenty-five minutes to one-hour duration.  
Ethical approval 
The qualitative study was approved by the South West Central Bristol Research Ethics 
Committee (14/SW/0030). 
 Analysis 
Interviews were digitally audio recorded and transcribed verbatim by a university approved 
transcription service. Thematic analysis was then undertaken following the guidelines 
stipulated by Braun & Clarke (Braun, Clarke, and Terry 2014).  Thematic analysis is described 
as a flexible and useful research tool which can potentially provide a rich and detailed, yet 
complex account of data (Braun, Clarke, and Terry 2014). The interview dataset was managed 




and AS familiarising themselves with the dataset by reading and re-reading the transcripts. A 
sub-sample of transcripts (two consultants, one research nurse and one support worker) were 
then open coded independently by GW and AS.  The initial codes were reviewed by AS and 
GW and disparities in codes were discussed until consensus was achieved. New codes were 
identified prior to coding the complete dataset.  In the process of coding the dataset further 
refinement to codes were made before a definitive coding framework was established. Once 
the definitive framework was agreed GW coded all the transcripts in Nvivo V.10. 
The final coding frame included the following codes: respondent’s role and experience, 
communication, comorbidity and health, social and developmental needs, diagnosis, family 
needs and guidance, family response and reaction, recruitment, feeding experience and 
opinion, general research, potential factors impacting on engagement, study promotion and 
study protocol, study specific opinions, and timeline. Descriptive summaries of codes were 
reviewed by GW and AS which led to the development of mind maps and the identification of 


















 Findings  
It was clear from the interview data that parents’ motivation to enrol their new baby with DS 
into a birth cohort study depends on the family context, the parents’ background, the health 
of the baby, and on the focus of the research being undertaken. These contextual factors 
contributed to forming the two main themes emerging from the dataset; these are ‘Family 
context’ and ‘Research factors’. In addition,’ Interactions’ emerged as an overarching theme 
which crosses both other main themes and was associated with parents’ extent of motivation 
to engage in research and engaging with health professionals. So thematic analysis led to the 
identification of three key themes; 1. ‘Family context’, 2. ‘Interactions’, and 3. ‘Research 
factors’.  
 
1. ‘Family context’ included the sub themes; 1.1’Family demographics’, 1.2‘Family 
attitudes and values’ and 1.3‘Child health status’.  
2. ’Interactions’ included the following sub-themes; 2.1‘Communication with parents’ 
and 2.2‘Recruitment approach’ 






1. Family context 
1.1 Family demographics 
Demographic factors such as the educational background, socio-economic status, ethnicity 
and the beliefs of families were described by health professionals to be potential barriers to 
engaging in research.  
 
“The group of families that I work with in……, a lot of the time it’s getting bread on the table 
and food and a roof over their head, and with immigration and a lot of social issues. Housing 
and immigration are very big issues for families where I work…. I think the more educated 
parents are more likely to consider it. I think a lot of the families that I work with come from 
cultures and communities where participation in research is almost unknown” (Community 
paediatrician)  
 
“Certainly, we have some families who live in incredibly deprived circumstances and life 
being what it is these are also often the ones who may not be English first language speakers, 
so they may have difficulties” (Community paediatrician) 
 
1.2 Family attitudes and values 
Health professionals suggested that some parents are more likely to consent to a study 





“Having a fairly altruistic view of what's happening. That's what made me think about this 
mum. Because a mum being diagnosed with a Down's syndrome baby at 20 weeks is a bit of 
a shock; to be recruited at that time, and agree, and wasn't going to have that baby 
terminated. Yes, that type of stance gets selective, doesn't it? But that sort of a mum; a mum 
that says, "This baby has Down's syndrome. so, what?" (Research nurse who also runs a 
support group) 
 
Altruism also featured as a big motivator for parents in taking part in research such that 
families wanted to give something back for the benefit of other families: 
 
“Very few parents don’t come back to me when I talk about a study saying, “Well even if it 
doesn’t help my child if it helps with other babies in the future”, then they want to do that. A 
lot of parents are altruistic from that point of view” (Paediatrician / Neonatologist) 
 
“I think a lot of families just want to help, you know, they want to help any families that may 
be coming up in the future, and again it’s usually the more positive people that want to do 
that, and the confident ones I suppose.” (Family support worker who runs a support group) 
 
There was a degree of concern about exacerbating any anxieties for families by inviting them 





“I think maybe they might be concerned that you might be asking questions that might 
unearth some things that they’re not ready to address.” (Research nurse) 
 
“Also the wish that the child is the same as everybody else and they don’t want  
them to be medicalised at all” (Community paediatrician) 
 
One health professional described parents falling into one of two groups: those that are 
either very involved or not psychologically prepared. 
 
“Well in a way you have got more extremes there because you will have those, “I have got 
a child with a disability. I want to do everything I can for them or for others” and they are 
more likely to agree. Equally, “This is a shock to me. I am not used to this. I don’t know what 
I am doing. There is so much to learn. There is so much to get my head around. I can’t take 
that on board as well”. (Research nurse) 
 
1.3 Child health status  
A significant factor for parents considering participation in a research study is their child’s 
health. Around fifty percent of infants with DS have congenital heart disease (Roizen and 




which becomes a parental and clinical priority. Clinicians emphasised that although an 
important consideration, it should not preclude research engagement. 
 
“With 54% of kids being born with some kind of cardiac condition, they may be the ones that 
are still in hospital further down the line, or kids who may have some kind of gut malformation 
will still be in the hospital for longer. For those parents, it may be that they haven’t really come 
to terms or thought about the Down’s syndrome. It’s really more the getting the health issues 
seen to”. (Family support worker) 
 
“You are involved with so many things when the baby is first born. You have got your health 
visitor, your specialist health visitor, your midwife and then you have got your paediatrician, 
your dietician, your physiotherapist if you are lucky and your speech therapist if you are 
extremely lucky and portage. The eye clinic, the ear, nose and throat clinic, the general clinic, 
there is everything as well as trying to do your normal stuff like your normal baby clinic. 
You sometimes think, “this baby is not mine everybody else has got a share.” I suppose you 
can get quite overwhelmed with the amount of other people being involved with your baby 
and you might just think, “No, I can’t cope with any more at the moment” (Family support 
worker and mother of a child with DS) 
 
“Our children are often having heart operations in that early stage….that’s the major, major 
thing isn’t it? 




Respondent: They’re just trying to keep them alive.” (Family support worker and mother of 
a child with DS) 
2. Interactions 
2.1 Communicating with parents 
Health professionals emphasised the importance of effective communication when sharing 
the diagnosis of DS and recruiting families. Engaging parents in a study requires the 
involvement of someone with an established trust and rapport with that family. The 
interviewees identified these people as doctors, allied health care professionals, support 
workers and other parents. 
 
“I guess there are multiple ways. The impact of the parent groups cannot be underestimated, 
as I've just said. So, through the Down's Syndrome Association, local parent groups, and 
making them aware. Then, of course, people who have regular contact with the families ... if 
you've got somebody who the parent trusts introducing the idea of the research, they're more 
likely to be receptive to it, and think, "Yes, that sounds like a genuine thing that we should 
consider."(Community paediatrician) 
 
Poor communication around the time of diagnosis and when discussing the outcomes for 
children with DS makes a lasting impression on families. This may affect future relations with 





“I mean if you’ve had a bad experience, and the whole thing about being told about your 
child’s diagnosis, well it’s always going to be a difficult memory, I would imagine, but I do think 
whether or not people are going to want to engage with their clinicians in research has got to 
be affected by the way that their relationship started off. I’m sure it’s related.” (Family support 
worker and mother) 
 
Explanations given for inadequate communication with parents were: lack of time, 
inappropriate timing, language barriers and the limited ability of some families to read and 
understand participant information sheets. 
 
“I was with a speech therapist yesterday and she said that you're so busy and you're trying to 
get things right, but actually you say the wrong things because of your busyness. You know 
that these parents are going to remember exactly what you say years later…” (Family support 
worker, mother and health visitor)  
 
“the length and the complexity makes probably the biggest difference and also we never 
actually check how well parents can read …I think sometimes their ability to read and 






2.2 Recruitment Approach 
Interviewees discussed different recruitment methods, most preferring face to face but also 
acknowledging the roles of social media, websites and invitation letters. Interviewees 
regarded the communication network between families (local parent baby groups and DS 
specific social media groups) as an important way to disseminate information regarding 
research.  
 
“But if you had a paediatrician that you didn’t feel was specifically interested and engaged 
with your child, particularly one of those who talks over the child like they don’t exist or 
something then you are probably not going to be engaged with it…Whereas you might 
actually take it on board from a support group, your local Down’s Syndrome group, other 
parents, even social media.” (Family support worker and mother) 
 
When a family might be most receptive to being approached for research recruitment varies. 
Each family has their own experience and response to having a new baby with DS. Participants 
suggested that greater awareness of timelines might help researchers interact with the 
families. For example, families who received an antenatal diagnosis of DS deciding to continue 
with the pregnancy may be more receptive to participating in research early. 
 
“I think the adjustments again varies. And I think, to be perfectly honest some of those with a 
prenatal diagnosis probably get there quicker. Because if they are say, maybe finding out at 
18/20 weeks or something by the time the baby actually arrives, a lot of them now – 




feeling part of it And I think some of them probably would get on board quicker than those 
people who don’t have a pre-natal diagnosis, you know, have to start from scratch and getting 
their heads around it.” (Family support worker and mother child with DS) 
 
The importance of parental bonding with their new baby and recovering from birth means 
that many felt there should be a period before introducing the idea of a study. How long this 
period should be was unclear but could be guided by the response of the parents and the 
expertise of the staff caring for them. 
 
“I think the most important is to try make sure that mum, parents have some time with the 
child before you actually rush in and upset everything” (Consultant neonatologist) 
 
“I think in a sense, you kind of have to let the SCBU staff judge it, perhaps, because I’m really 
not sure when would be… I think that you could capture that sense that certainly a lot of dads 
seem to have of, “We’ve got to do something about it; we need to find out absolutely 
everything there is,” and that might be an opportunity. 
But on the other hand, I suspect that you’ve also got to ensure that all that normal bonding 
stuff is happening as well, and that the whole talking to people about being a part of a 
research study when they’re still getting their heads around questions like, “Can I love this 





I would be guided by what the staff that are looking after the babies are saying, or if you’re in 
touch with support groups, what they’re telling you as well, because we do get quite early 
contact from families sometimes.”  (Family support worker and parent) 
 
The timing of recruitment will depend on aspects of the diagnosis.  One community 
paediatrician referred to parents who were unwilling to engage with them until the results of 
the karyotype had been given. 
 
“What I know is that practically speaking when it is an unexpected diagnosis however much 
you tell them you are certain that is Down’s syndrome or as certain as you can be a lot of 
families will say, “Okay we will wait for the blood test result thank you very much. Come back 
and have a conversation with us in three days’ time or whenever we have got the karyotype 
back.” Very often clinically we have to do that. Some families won’t agree to have an 
echocardiogram until they have got the blood test result back because we might have made 
a mistake and the baby wouldn’t need it. I think with some you won’t really be able to get any 
further until you have got that result back.” (Community paediatrician)  
 
3. Research Factors 
3.1 Burden 
For any parent with a new baby, life can be chaotic. Thus, involving them in research 




challenges which parents of a DS baby may have and how research might accommodate 
these. 
 
“Well it is the time – both the time taken to do it but also the timeframe and how it fits around 
where they are … if it is invasive tests or something that having the flexibility to fit that around 
what they are already doing, if they are already doing lots of hospital visits and things like 
that. So yes I think that is the biggest barriers …sometimes it is things like childcare for other 
children because they are quite happy to go along with the child with Down’s Syndrome and 
participate in something. But if it is supported…” (Family support worker) 
 
“It depends on how onerous it is for them. Things that involve a lot of hospital visits are not 
good. Things that involve lots of blood tests are not great for families with children. There are 
those sorts of practical obstacles, “We would like to do it, but we don’t think we can cope with 
all the demands made of us.” (Community paediatrician) 
 
Some health professionals felt that being part of a research study may be a supportive 
experience helping parents at a difficult time. 
 
“Sometimes they probably just need someone who is there special for them that they can talk 




back to them …That is where the research nurse can come in and do the extra. “You are special 
to me and I am going to help you.” (Research nurse)  
 
3.2 Gatekeeping 
Before eligible families are even approached there were several barriers highlighted by the 
interviewees. Institutional approvals are required and once approved, “recruiters” place 
restrictions on whom they will target either consciously or subconsciously. To be able to 
contact all potential families and minimise gatekeeping both, health services and voluntary 
organisations / charities should be used for recruitment: 
 
“I do think there is something to be said about a sort of two-pronged approach. … within the 
hospitals and SCBU staff, there is this kind of gate-keeping thing going on. … people have to 
find us via the DSA website; despite the fact we’ve left bits and bobs that tends to be the way 
people find us. So part of me worries that there is a bit of overzealous gate-keeping going on 
sometimes.….” (Family support worker and parent) 
 
Many of the interviewees were concerned about asking families to be involved in  
studies where blood tests need to be taken. One however described how this might 
be misguided gatekeeping. 
 
“I think people are much, much, much more willing to have blood tests done on 




them being worried about an extra blood test at six months, I think that's probably more in 
my mind than it is in theirs.” (Community paediatrician) 
 
Some of the paediatricians described how all eligible participants should be informed about 
research that they could be involved in. 
 
“Generally, parents are very keen to be offered it even if, and I always stress that they  
don’t have to take part at the end of the day, but it’s important to offer it to all parents  
even if they don’t want to.” (Paediatrician / Neonatologist) 
 
“I haven’t had any very negative experiences of people just saying, “How dare you approach 
me about research, I don’t want to do it.” Even they if they say no it is usually, “I am really 
sorry I can’t help you.” (Community paediatrician) 
 
3.3 Logistics 
Opportunities to interact with families and recruit into studies may be infrequent. Some 
babies will have a period in a neonatal unit and this was described as a good time to introduce 
research. Those with cardiac and bowel problems may have multiple appointments but this 
was perceived as a more unsettled time when parents may not be able to think about 





“They may be in the special care unit for an extended period of time in which case the neonatal 
consultant would be, you know, most suitable to do that.” (Community paediatrician)  
 
“I think one of the biggest factors that I would say from our point of view certainly is the health 
of the child. I mean most of them these days are having surgery if they need it at three to six 
months. And probably depending on what you are looking for, you are probably not going to 
get as many of them engaged until you have got through that post-op bit if you know what I 
mean. Because they have got a lot of hospital visits and check-ups and everything… So, I think 
they are probably less likely to engage until they have got through that surgery bit.” (Family 
support worker and mother) 
 
If a baby with DS has no additional medical issues the community paediatrician follow-up 
appointments may vary. Most health trusts adhere to current guidelines: following up at three 
and six months then annually until five years. 
 
“The problem you will have is that everywhere does it differently. Some places like us: the baby 
is born and then they become the responsibility of a Community Paediatrician. Some areas: 
the hospital doctors keep them until one or two, and so it’s very hard to know which group of 
doctors to approach. You have to find out, in each area, how they manage children with 






“Having made the initial contact postnatally hopefully we normally get them back at three 
months. Then in the first year we will see them a couple more times. Up to the age of five we 
routinely see them every six months. Once they have got to five and they are in school we see 
them every year unless there is anything going on medically which requires us to see them 
more often, which sometimes there is but very often there isn’t” (Community paediatrician) 
 
Finally, there was some consensus that three months may be a good age to approach families. 
Parents were described as having “got over” the new-born period and adjusted or adapted to 
the diagnosis of DS. This is also the time when paediatricians are seeing the babies for their 
follow up appointments in the community. Some however felt that families were not ready 
until a year or even two years if they had a bad experience at the time of diagnosis. 
 
“If you don’t get them in the new-born period then I think there is a sort of sense in which 
perhaps you wait until they come back to hospital for the first visit. In our case it would be at 
three months, but clearly other areas might have different policies. By then I think that is as 
good a time as any to do it. From then on I think you could do it at any time, but there is no 
problem with doing it at three months” (Community paediatrician) 
 
“I don’t think there is any general rule. We get those who are ringing when the child is probably 
two or three days old and they are there and ready. They are full of life of this new life and 




it can be years before they really… I have got friends now with young adults the same age as 
my daughter who still haven’t really come to terms with it all 25 years later”. (Family support 
worker) 
 
“I wouldn't have contacted her just after the baby was born. I've left her alone. I haven't made 
any contact whatsoever for two-and-a-half months, so the baby is nearly three months now. 
That was when I felt it was appropriate to make the contact…… 
….. Well, no, not really. I think it just with working with disability for such a long time, and 
knowing that time is needed, really.” (Research nurse) 
 
 Discussion of Chapter 3 
This qualitative study aimed to understand factors involved in recruiting new families to 
birth cohort studies of babies with DS, to optimise recruitment to the FADES study. The main 
findings suggest that successful recruitment requires a variety of approaches. Although 
parents often have a good relationship with their medical team and like being recruited by 
this traditional route, trust can be marred by difficult experiences at diagnosis and poor 
communication. Health professionals may act as gatekeepers and alternative routes may 
circumvent this. Using social media, websites and parent groups were suggested as 
alternative trusted sources. Understanding the dynamics around the time of diagnosis and 
following months helps in planning study logistics. Making the timings of recruitment and 




Interviewees did not discuss how patient and public involvement (PPI) could inform this type 
of research however PPI advice was sought for FADES.  
This study has benefitted from the variety of opinions gained, particularly those of affected 
parents. The interviewees recruited included a diverse group providing a wide range of 
perspectives and all demonstrated great candour in their responses. The family support 
workers receive training in family support, but this is unlikely to include research 
recruitment. Thus, the responses they gave in relation to research likely represent their own 
experiences and opinions. The paediatricians were all members of the DSMIG or involved in 
FADES which may have caused bias. However, this group has a wealth of experience with 
DS families and research.  
Discussion of reflexivity  
It was important to be aware of reflexivity throughout this study. Reflexivity takes into 
account the researchers’ demographic background, professional role, beliefs and 
experiences that may consciously or unconsciously influence the study. This influence may 
affect the manner in which the study is conducted, the participant responses, interpretation 
of data and the final conclusions made from the research (Sword 1999). As Berger wrote in 
his article (Berger 2015) reflexivity: 
 “means turning of the researcher lens back onto oneself to recognize and take 
responsibility for one’s own situatedness within the research and the effect that it 
may have on the setting and people being studied, questions being asked, data being 




A positive bias towards research may have been introduced as the interviews were 
conducted by myself a paediatric registrar and CI of FADES. Thus, the researchers’ 
background, training and own experience of working with families of children with DS 
should be acknowledged. My epistemological position will undoubtedly have shaped 
emerging themes. Working with researchers who were not part of the FADES research team 
and had not previously worked with families of a child with DS meant that my position and 
views were challenged and as such reduced the potential for bias. 
 
Context of interviews 
Interviews were conducted by telephone rather than face to face, enabling participation 
from a geographically wide area. Although occasionally viewed as inferior to face to face 
interviews, Sturges et al (Sturges and Hanrahan 2004) found no significant differences and 
suggested there may be notable benefits; particularly allowing participants a degree of 
anonymity which may have increased the candour of our participant’s responses. 
Previous studies 
Previously published research involving infants with DS is limited and details regarding 
recruitment is lacking. An HTA study exploring the feasibility of recruiting one to eleven year 
olds with DS into an otitis media, treatment study, interviewed clinicians and parents 
regarding recruitment. (Fortnum et al. 2014). Their conclusions were similar: any research 
needs to account for both the shared experiences of parents with a baby with DS and the 
variety of personal experiences. They also commented on timings noting that when a family 




explored and more novel recruitment methods may allow some of the variation in personal 
perspectives and timings to be navigated.  
Specific Issues in recruiting a cohort of infants with DS 
This study has explored recruitment issues that are pertinent both to the recruitment of 
typical new-borns and those with DS (these include family demographics, family attitudes and 
values and research factors). The issues which are more specific to the recruitment of a birth 

















Sub theme Factors relating to DS Effect  
Family attitudes and 
values 
Increased stress compared to a parent of a 
typical newborn. 






Child Health Status Associated medical conditions including 
congenital heart disease and 
gastrointestinal disorders.  
These conditions can be potentially life 





Communication at the time of sharing the 
diagnosis of DS with the families 
 






Interaction with many different 
organisations including medical, charitable 
and the voluntary sector.  
Affects who establishes 





Diagnosis of DS is frequently unexpected. 
Time to adjust to diagnosis varies.  
Timing  
Burden Children with DS often have multiple 
hospital appointments. 
Flexibility and timing  
Logistics Health of the child. 
Timing of medical treatment for cardiac or 
bowel abnormalities.  
Variations in when these babies have 
follow-up appointments and with whom. 
Flexibility and timing  
 





Conclusion of qualitative study 
This qualitative study provides insight into the issues surrounding recruitment of babies with 
DS. Recruitment should include the use of clinicians and alternative methods including, 
social media, parent groups, charities and websites. From the knowledge provided by those 
interviewed, families will have different experiences in the first few months of their child’s 
life depending on whether they had an antenatal diagnosis, how they adapt and adjust to 
the diagnosis, related medical conditions and the support they receive. This information 
helped develop the FADES protocol which has the flexibility to allow families and their 
















Chapter 4 Establishing the FADES cohort 
 Overview of Chapter 4 
In this chapter, the processes involved in setting up the cohort are summarised. The time 
taken to gain approvals and the ease or difficulties experienced in establishing a national 
cohort study are described. The results of the feasibility of the study are given in terms of 
whether they met the feasibility objectives (these objectives are described in more detail in 
the relevant sections; recruitment, sample collection, questionnaires and retention of 
participants). These objectives were analysed over a three-year period from September 2014 
until September 2017. The initial protocol had described that recruitment would be assessed 
over two years, but initial recruitment was very slow. An amendment was submitted to 
change recruitment methods and the assessment period was therefore extended to three 
years.  
 Setting up the study 
The study recruited participants from across the United Kingdom. The need to recruit babies 
as close to birth as possible and before eight months of age with a relatively rare condition 
required a wide geographical area. The study was therefore designed so that wherever a 
potential participant was identified within the UK, NHS Trust Research and Development (R 
and D) permissions would already be in place. This allowed participants to be consented 
immediately into the study (the processes are explained in more detail in Chapter 2). The 
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Figure 23: Timeline for setting up the study. 





 Approvals for FADES in England 
In total, R & D permissions were sought from 318 primary and secondary care sites in England. 
Of these 68% approved, 17% abandoned the study and the remaining 15% neither approved 
or abandoned the study (25 of these sites never acknowledged receiving a valid SSI 
submission, and 23 validated the SSI submission but did not go on to complete local checks). 
Table 9 shows the time to approve or abandon the study. Of note, one site gave permission 
on the 2nd July 2014 and then withdrew from the study on the 19th September 2014 (they 
have been counted in the numbers that granted permission). Furthermore, Figure 24 
illustrates that the majority of sites had approved the study within two months.  
 
Time to: Number of sites Median (IQR) days 
Valid *SSI submission received 293 5 (5, 5) 
SSI submission validated 293 6 (6, 8) 
Complete local checks 270 15 (13, 25) 
NHS permission 216 18 (13, 26) 
Abandon Study 54 18 (9, 48) 
 
Table 9: Median time to approve or abandon the study in England. 
Footnote: All dates were calculated from the 15th May 2014, the date that the first site, University Hospitals 
Bristol NHS Foundation Trust received the submission. 
*Site Specific Information form (SSI)  
 
To achieve this number of approvals, multiple emails, responses to queries and resubmission 
of forms were required. Points raised by some of the sites are illustrated in Table 10. Attempts 
were made to try and persuade sites to give approval. Some sites which initially abandoned 




particularly true for sites where potential participants had seen the study advertised on the 
internet or social media and were keen to be enrolled but where the site had not approved 
the study. In these cases, the relevant site was contacted to advise them that there was a 
family in their area who wanted to join but site approval was needed. Similarly, some sites 




Figure 24: Dates of approvals for NHS sites in England. In total 216 sites gave approval the 






























Points raised by sites during the 
approvals process 
Illustrative quote 
Concerns over funding “….. failure to meet this benchmark will affect the 
funding our site receives …… alternative choice to 
reject your study on the CSP system…..” 
Concerns regarding study setup  “Is this a secure website and will their data be 
protected and their ID anonymised?” 
Requesting changes to study 
protocol  
“The group suggests that clause 4 of the Consent 
form should also include informing community 
Paediatricians as these usually lead in the care of 
the child” 
 
“The group suggested the study title should say 
‘Feeding and autoimmunity in children with Downs 
Syndrome Evaluation Study’” 
Concerns regarding the collection of 
blood samples  
“What if the blood clots?” 
 
“Phlebotomy for small children involves 3 or 4 
members of staff – a phlebotomist, someone to 
support the arm, a play specialist and admin 
support…I do not wish to appear unhelpful, but I 
consider that more thought was needed into these 
procedures and issues at the planning stage.” 
No concerns “I needed to make a couple of checks that relied on 
other people, however they did not reply so I am 
going ahead with this and have attached the signed 
documents” 
 
“I am a Trials Manager at…...  I’ve had a read 
through the study documents and protocol and it 
seems there is very little, if any, involvement locally 
so I just wanted to check I hadn’t missed 
anything.  Are you only requesting R&D approval in 
case a family is recruited from our Trust who may 
need to have their heel/ finger prick blood test 
done here?” 
 Table 10: Points and concerns raised by sites during the approvals process. 





 Approval for FADES in Scotland  
Permission was obtained from 12 of the 14 health boards in Scotland. NHS Orkney and NHS 
Western Isles did not give approval and no reasons were given for this. The median time to 
approval (from 15th May 2014) was 20 days (IQR 11, 41) (this was based on approval dates 
from eleven sites, the date was missing for NHS Ayrshire and Aran).  
 Approval for FADES in Wales 
Permission was given from four of the seven Welsh Health Boards; Betsi Cadwaladr University 
Health Board, Powys Teaching Health Board, Hywel Dda University Health Board and Cwm Taf 
Health Board. The median time to approval from these sites was 19 days (IQR 17, 117) but it 
is worth noting that it took over 13 months to get approval from Cwm Taf Health Board. 
Aneurin Bevan Health board requested approval from local GP practices, and paediatric clinics 
to ensure they were happy to provide services. These local approvals were not sought due to 
time constraints and therefore approval from this health board was not gained. Abertawe Bro 
Morgannwg University Health Board did not receive an SSI despite it going through NISCHR 
and therefore did not approve the study. Cardiff and Vale University Health Board sent emails 
clarifying whether a local PI would be needed, they agreed a local PI was not required 
(following emails with Paediatric haematologist) but an approval was not subsequently 
received. 
 Approvals for FADES in Northern Ireland 
Permission was gained from three out of the five Health and Social Care Trusts (the sixth HSCT 




Social Care Trust, South Eastern Health and Social Care Trust and Western Health and Social 
Care Trust gave permission. Median time to approval was 132 days (IQR 128, 168).  Northern 
Health and Social Care Trust required a local PI, a local PI was not identified, and approval was 
not given. Belfast Health and Social Care Trust did not approve the study and no reason was 
given.  
 Study website and email  
No technical difficulties were experienced with participants accessing the EOI registration 
form via the study webpage (NIHR Bristol BRU 2016). Emails from families, local collaborators 
and the research team were managed through the study email account (fades-
study@bristol.ac.uk) and were checked at least twice weekly. The ease of communication via 
email allowed issues relating to consent or sample collection to be dealt with quickly and 
efficiently.   
 Feasibility outcomes:  
 Summary of Feasibility Results 
Table 11 summarises the feasibility results in relation to the feasibility objectives. More 







Feasibility Objective Target Results Confidence interval Achieved  
Rate of recruitment 100 infants per year 23 per year  No 
Collection of mouth 
swab / DNA 
75% to return initial sample before age 8 months 77.1% (54/70) 
median age of 5 months (IQR 4.0, 7.5) 
(65.5, 86.3) % Yes 
90% to be suitable for analysis 98.1% (52/53) (90.0, 100.0) % Yes 
Collection of urine 
samples 
75% to return initial sample before age 8 months 77.1% (54/70) 
median age 5 months (IQR 3.9, 7.5) 
(65.5, 86.3) % Yes 
75% to return 12-month sample before age 14-
months 
61.5% (32/52*) 
median age 12.7 months (IQR 12.3, 14.1) 
(47.1, 74.7) % No 
90% to be suitable for analysis 99.1% (108/109) (95.0, 100.0) % Yes 
Collection of stool 
samples 
75% to return initial sample before age 8 months 72.9% (51/70) 
median age 5 months (3.9, 7.5) 
(60.9, 82.8) % Almost achieved 
75% to return 12-month sample before age 14-
months 
60.4% (32/53**)  
median age 12.7 months (12.3, 13.5) 
(46.0, 73.5) % No 
90% to be suitable for analysis Not yet tested so unknown***   Unknown 
Collection of blood 
samples 
75% to return initial sample before age 8 months 65.7% (46/70) 
median age 5.7 months (4.3, 8.5) 
(53.4, 76.7) %  
 
No 
75% to return 12-month sample before age 14-
months 
53.8% (28/52****) 
median age 12.8 months (12.4, 14.8) 
(39.4, 67.8) % No 
90% to be suitable for analysis 88.5% (92/104) (80.7, 93.9) % No (nearly) 
Medical and Feeding 
questionnaires 
75% to complete initial questionnaire 87.1% (61/70) (77.0, 93.9) % Yes 
75% to complete 12-month questionnaire 74.1% (40/54) (60.3, 85.0) % No 
60% of participants to opt to use the online 
questionnaire rather than the paper questionnaire 
82% (58/70) (72.0, 90.8) % Yes  




Footnote: *16 participants were under the age of 12 months, two had provided samples after the age of ten months. **16 participants were below the age of 12 months; one 
had provided the six-month sample after the age of ten months. *** but feasibility study to determine the optimal method suggests that the samples will work****16 participants 




 Recruitment  
The feasibility of recruitment was assessed against the following feasibility objectives  
Rate of recruitment:  
Objective: to assess the rate of recruitment, with an initial target of 100 participants per year 
over a two-year period (this represents 20% of the DS families who are in contact with the 
Down’s Syndrome Association (DSA) per year); 
By September 2017, 70 families had consented to the study. The overall recruitment rate for 
the study was 23 participants per year over three years. This objective was assessed over 
three years (September 2014 to September 2017) as recruitment in the first six months was 
slow and recruitment methods were changed in March 2015 (Amendment 1 see Chapter 2 
Section 2.9). The recruitment rate increased from 1.5 participants a month in the first year up 
to 2.2 participants a month in the last year. The recruitment rate has remained below the 
feasibility target. 
EOIs were completed by 100 people as shown in Table 12 between 1st September 2014 and 
the 1st September 2017. Of these, 11 were ineligible as their babies were too old (over the 
age of 8 months), one could not take part as they lived in the United States and one potential 
participant was ineligible because the child was in care and no longer with the birth mother. 
Of those that were too old to take part, many expressed how important they felt the study 
was. EOIs were completed by two sets of parents after they had received a prenatal diagnosis 
of DS for their baby and prior to their baby’s birth. Both families were emailed to thank them 
for their interest and advised that the study team would be back in touch with them once 




other did not and no further contact was made. Reminders were sent to all (n=17) of those 
who were eligible and did not go on to consent after completing an EOI. The reasons why 
parents decided to take part or not were explored in the participant/ non-participant 
questionnaires (see Section 4.3.3). One local collaborator informed the study team that a 
potential participant who had completed an EOI did not go on to consent as the baby required 
cardiac surgery.   
 
Number of EOIs 
completed  
Number of EOI completed 
by potential participants 
that were eligible 
Number of participants consented  
100 87 70 
  
Table 12: Number of people registering an interest in the study and the number who went on 
to consent. 
Footnote: Expression of Interest (EOI) 
 
Recruitment Methods 
Objective: to consider the feasibility of novel recruitment methods, including recruitment 
through websites and social media.  
Initial recruitment strategies solely via ‘flyers’ in new parent packs sent out by the DSA or 
given out by the DSS resulted in slow recruitment with only five participants recruited in the 
first six months. Alternative methodologies were instigated, and a large number of 




substantial amendment (Amendment 1) to allow local collaborators to actively recruit and 
consent participants was approved in March 2015. Figure 25 illustrates recruitment rates in 
context of the dates when promotional activities took place. 
The time between completing an EOI form and consenting was a median of 13 days (IQR 7, 
21). For many participants, reminders had to be sent to ask whether they had received the 
consent forms and if they were still interested and this often prompted them to consent. No 
families contacted the research team with questions regarding the study and no major 
concerns were raised by parents regarding the protocol prior to consenting. For those 
recruited by local collaborators consent forms were sometimes received prior to the EOI 
being completed. In these situations, the participants were unable to be fully enrolled into 
the study. For four participants consented by local collaborators, consent forms were received 
but the EOI was never completed and the participants were therefore not included in the 
study.  
Parents were asked on the EOI “How did you hear about the study?” and were given options 
as well as a free text box for “other”. This question was added to the EOI September 2015 
(Amendment 4); participants who had registered with the study prior to this date were 
emailed to ask how they had heard about the study. Figure 26 shows the method of 
recruitment for the 70 participants who consented to the study. Recruitment from online 
sources (the combination of recruitment from the DSA website and social media) accounted 
for over half of the families. Recruitment by local collaborators did not begin until May 2015 










Figure 25: Recruitment of participants and promotional activities from September 2014 – September 2017. 
Footnote: Down’s Syndrome Medical Interest Group (DSMIG), Facebook (FB), Down’s Syndrome Association (DSA), Royal College of Paediatrics and Child Health 






Figure 26: Recruitment Methods: proportion of participants who heard about the study from 
different recruitment sources. 
Footnote: Down’s Syndrome Association (DSA), Down’s Syndrome Scotland (DSS) 
 
Geographical distribution of participants 
Participants were recruited from England, Scotland, Wales and Northern Ireland as illustrated 
in Figure 27. There is clustering of participants in some geographical areas and the reasons 
for this are explored in the Discussion Section 4.9 at the end of this chapter. The only problem 
encountered with web recruitment was that consent forms were occasionally incorrectly 
completed (in these cases the families were asked to complete another form correctly).  
Community 
paediatrician, 15.7 %
Neonatal doctor, 17.1 %
Research nurse, 7.1 %
Social media, 17.1 %
DSA website, 28.6 %
Flyer , 5.7 %
Not known, 2.9 %
DSS, 2.9 %
Friend, 1.4 %




There was variation in the success of recruitment by different local collaborators and sites. 
Just under half of our participants 46% were recruited from 32 sites who only recruited one 
participant. Two or three participants were recruited from each of eight sites, several of which 
had research nurses involved in identifying and recruiting participants. There were three sites 
who recruited multiple participants. Queen Alexandra’s Hospital, Portsmouth Hospitals NHS 
Foundation Trust recruited eight participants all through one enthusiastic neonatologist, 
Gloucestershire Royal Hospital NHS Foundation Trust recruited six participants through a very 
active research nurse and Norfolk and Norwich University Hospital NHS foundation trust 
recruited five participants. Recruitment at Norfolk and Norwich University Hospital NHS 
foundation trust had occurred after GW was invited to speak at the CRN East teleconference 
and promoted the study there, the study was then advertised amongst the CRN East 






Figure 27: Geographical spread of participants recruited to FADES.  






 Motivations and barriers to joining the study 
Objective: to understand the reasons why participants consented to take part in the study.  
Engagement questionnaires (completed by active participants) were completed by 89%, 25 
out of 28 that had been sent the questionnaires. Non-participant questionnaires (completed 
by families who had registered an interest in the study but who did not then go on to take 
part) were completed by 31%, eight of the 26 families who had been sent the non-participant 
questionnaire.  
Engagement (Participant) questionnaire responses 
Participants were asked in the engagement questionnaire “What initially interested you in 
the FADES study?”, the responses to the question are summarised in Table 13. Half of the 
participants described altruistic reasons for participating. They also talked about the 
importance of research and how their own interests and experiences influenced their desire 














responses were not 
exclusive to only 








 32% (8/25) “Interested in outcome, I think it is important to 
participate in research” 




children in the 
future with DS 
52% (13/25) “Helping other families with Children with DS” 
“Wanting to help other people if possible, in the future” 
 
Contributing and 
being pro active 
36% (9/25) “We found out in pregnancy that ..had DS and were keen 
to be as proactive as possible” 
“We always try and participate in any research that will 
help with the DS community” 
Feeding 12% (3/25) “The new knowledge that can be produced to help 
people with DS and my own interest in the role of 
nutrition in health” 
“As it was about feeding issues in DS, we have had lots 
of issues in the early days” 
Related to their own 
child’s diagnosis and 
issues 
16% (4/25) “My child was born with DS” 
“My son has feeding difficulties 
Parents own job / 
interests/experience 
12% (3/25) “I work in health and appreciate the value of research” 
“Being a scientist myself it was an opportunity to 
directly help with research that could benefit my 
daughter with Down’s and future children” 
 
Table 13: Participant’s responses to “What initially interested you in the FADES study?” open 
responses were summarised into themes with illustrative quotes.  
 
The responses to the question “Why did you decide to take part in the FADES study?” were 
similar but revealed some further information as shown in Table 14. This included the ease of 
participating in this particular study due to its design and the potential for participating in 




Theme (the responses 
were not exclusive to 






Contributing and being 
proactive 
36% (9/25) “I find research interesting. I’m happy and proud 
that … and I do something which will help people with 
DS. Also, it was something positive that we could do 
while coming to terms with the diagnosis” 
“We always try and participate in any research that 
will help the DS community” 
Ease and suitability 20% (5/25) “It’s an easy, non-invasive, research study which will 
help future generations” 
“Seemed very professional, could be done from 
home with ease”   
Helping the community 
and children in the 
future with DS 
68% (17/25) “Anything to help children and parents in the future” 
“Great progress in caring for people with DS has been 
made in recent years. Our son will benefit from this, 
but it has been made possible by the research and 
volunteers that have gone before him. We wanted to 
contribute to this and hope for even more 
improvements in the future.” 
Health screening and 
benefit to their 
individual child 
20% (5/25) “felt that it could bring benefits for my child or 
others” 
“I view it as additional health screening for my 
daughter ... My daughter will benefit from research 
that others have done previously so it is only fair that 
we contribute to future research.” 
Feeding  8% (2/25) “Might help prevent what happened to our baby 
happening with others. She developed NEC after 
being given formula in NICU.  Also, so better advice 
can be given to new parents regarding feeding” 
“I have had a very successful exclusive breast-feeding 
experience with my daughter and wanted to be part 
of the study to show it can be done. I received lots of 
negative comments early on that said she wouldn't.  
Also want more the study to benefit future families” 
Table 14: Participant’s responses to “Why did you decide to take part in the FADES study?” 




In response to “How would you recommend we improve the information that is provided 
about the study?” 44% (11/25) responded positively about the information that is provided. 
One participant responded, “It’s perfect” another “It was rather clear to me and I’m not 
English”. Three participants commented that they liked the newsletters. Those who made 
recommendations suggested providing more information on the timings of the sample 
collection and the ease of collecting the samples. A couple of responses commented on the 
importance of having information that is easy to understand. One participant wanted to see 
more information on the scientific background and rationale for the study. Some participants 
had been unaware of the website or had not accessed it, and one participant said that they 
had had difficulty with the link to the online questionnaire.  
Tables 15 and 16 show the opinions on the study website of those that took part with the 
majority finding the website attractive and not difficult to understand, although it is of note 
that a third found it only ‘somewhat’ attractive and two participants found the website ‘a 
little’ or ‘somewhat’ difficult to understand.  
 
What did you think about the attractiveness of the study website? 
Responses Number of respondents 
Not at all attractive 0%  
Somewhat attractive 33.3% (8/24) 
Quite attractive 58.3% (14/24) 
Very attractive 8.3% (2/24) 
 
Table 15: Participant’s opinions on the attractiveness of the study website as rated on a Likert 
scale 




How difficult did you find the study website to understand? 
Responses Number of respondents 
Very difficult to Understand 0% 
Somewhat difficult to understand 4.2% (1/24)  
A little difficult to understand 4.2% (1/24) 
Not at all difficult to understand 91.7% (22/24) 
Table 16: Participant’s opinions on the comprehensibility of the study website as rated on a 
Likert scale.  
Footnote: *missing data for one respondent on this question 
 
Participants were asked “What improvements to the study do you think we could make to 
encourage families to take part?”. As with the previous question, some participants 
commented that they felt no change was needed. Comments were made regarding issues 
around sample collection by seven participants, some highlighting that the need for blood 
samples may put some potential participants off. One parent suggested producing a credit 
card sized information leaflet that could be given/shown to health professionals when blood 
samples collection was needed. Another suggested that a doctor should go through the 
sample kit to demonstrate how to collect the samples. Further advertising of the study 
through social media was recommended by five participants and one participant suggested 
having an information sharing day to promote the study.  
The following comment was made in the “any further comments” by one parent: “Our 
hospital had a lead research promoter consultant who just happened to be doing his rounds 
on the first morning …child’s name…was in NICU. He said as we knew about …child’s name… 
diagnosis he felt he could mention the study to us but if we hadn't known he probably wouldn't 




and signed up as interested, we might not have followed it up as we were in the throes of new 
baby land. I wonder how parents who find out after their child is born are approached?” 
This comment illustrates potential gatekeeping that may occur. 
Non-participant questionnaire responses 
In response to why they were first interested in the study, six had said that they were 
interested in doing it to help with research for their own child or for people in the future. Two 
specifically said that they had been drawn to the study due to the area that this study was 
exploring.  
Table 17 shows the reasons why people felt unable to participate or continue in the study, 
the most common reason being that families simply did not get around to it despite intending 












Options given for “Why did you feel unable to 
participate or continue in the study?” 
(respondents could tick all that applied to them)  
Number of respondents 
Our baby was too unwell 0% 
We meant to take part but did not get around to it 37.5% (3/8) 
We decided not to take part because of the time that 
the study would involve 
12.5% (1/8) 
 




We did not want to take the blood samples 12.5% (1/8)* 
We were worried about completing the questionnaires 12.5% (1/8)  
Other 37.5% (3/8) ** 
 
Table 17: Reasons for not taking part in the study given by non-participants 
Footnote: *this was not the same respondent who answered that they did not want to take the stool, urine and 
mouth-swab. This respondent added to the other/comments box “My son had been badly jaundiced after birth 
and was having bloods drawn twice daily from his feet. When they squeezed the foot to collect blood, the older 
holes would open up. Couldn't bear to choose to have more blood taken from him when it wasn't necessary” 
**two said that they were told that their child was too old, one said that their doctor had not wanted to take 
the bloods as he had had trouble getting enough for routine blood sample.  
 
What did you think about the attractiveness of the study website? 
Responses Number of respondents 
Not at all attractive 0 
Somewhat attractive 28.5% (2/7) 
Quite attractive 57.1% (4/7) 
Very attractive 14.3% (1/7) 
Table 18: Non-participant’s opinions on the attractiveness of the study website as rated on a 
Likert scale 
 
In response to the question “How difficult did you find the study website to understand?” 




the response “Not at all difficult to understand” apart from one respondent who did not 
complete this question.  
When asked “How would you recommend we improve the information that is provided about 
the study?” only one person made a recommendation and that was “make it clear upfront 
about the level of commitment required”. In response to the question “What improvements 
in the study do you think we could make to encourage families to take part?” two respondents 
suggested involving more health professionals (local community paediatricians and health 
visitors). Three asked if there was any way to make the sampling easier but did not have a 
recommendation for how to do this and one suggested that parents should be able to choose 
when to take part in the study.  
 Sample collection from participants  
In this section, assessment of the feasibility objectives for the collection of samples from the 
participants is given. The feasibility of collecting each of the sample types, DNA, urine, stool 
and blood are assessed separately. The validity of the methods for the sample collection for 
urine C-peptide and gut microbiome was presented in Chapter 2 Section 2.15. 
Objective: to assess the ability of families to collect all the samples within the desired timeline, 
determined by the percentage of participants who return the requested samples in the time 
requested.  
The collection methodology would be deemed feasible if; 
• at least 75% of participants provide the requested initial samples before eight 




• at least 75% of participants provide the requested 12-month samples before 14 
months of age; and 
• at least 50% of participants to provide all samples up to the age of five years.  
• at least 90% of samples provided are adequate for analysis;  
As part of the feasibility assessment any issues or problems that occurred with sample 
collection were recorded. Families fell into different groups and which became clear through 
email correspondence when reminding them about samples. Below is a summary of those 
groups.  
• Families who provided all samples in a timely fashion without any issues. 
• Families who wanted to provide the samples but struggled with finding the time to 
collect them, needed reminders sent and occasionally lost the sample packs. Usually 
these families did eventually provide the samples. 
• Families who had intended to take the samples but were daunted by the sample pack 
when it arrived, some managed to collect some of the samples but not all. These 
families tended to either fail to provide samples despite lots of messages to say they 
were going to or provided the initial samples but none or only sporadic samples after 
this.  
• Families who always wanted to be in the study but had never really wanted to collect 
samples and didn’t. These families usually did not respond to reminders or gave 
reasons as to why it would not be possible to collect the samples. 
There were also families whose children had periods of poor health when there was a gap 
when they were unable (either due to lack of time or clinical reasons) to provide samples. Of 




provided samples during this time (presumably when the clinical staff were helping) but when 
he was discharged the family no longer collected samples. 
Feasibility of collecting mouth-swab samples 
Mouth-swab / DNA samples were received for 77.1% (54/70) of participants at a median age 
of five months (IQR 4.0, 7.5). This is above the feasibility target of 75% of initial samples to be 
received by eight months. The median age at which the samples were received is within 
target. DNA samples were only collected once. 
DNA was extracted from 53 mouth-swab samples to date (see Chapter 2 Section 2.16.1.1) 
providing a mean concentration of 0.051µg/µl of DNA (range 0.003µg/µl to 0.142µg/µl)). The 
concentration of the samples was adequate for HLA testing but 9.4% (5/53) had a low 
concentration, of equal to or less than 0.01µg/µl and this level would limit what further 
genetic testing might be possible. Overall 98.1% (52/53) of samples were adequate for 
analysis which is over the feasibility target and HLA class II genotyping was completed on 52 
samples. Although one sample had a detectable concentration of DNA, it was too weak for 
testing even after whole genome amplification. An additional sample will be requested from 
this child. 
There were no issues raised by the participants regarding the collection of the DNA samples. 
Although the reasons for not returning a sample were unknown for the majority, two samples 
were reported lost in the post and further samples were not returned from these participants. 
There were also two samples for which the lysis buffer had leaked out of the bottle because 
the lid had not been secured properly after sampling, one of which could be used, the other 




Feasibility of collecting urine samples 
Table 19 shows that the target of 75% for initial urine samples was achieved but not at 12-
months. The median ages and IQR showed the samples were provided by the families close 
to the requested age. At least one urine sample was provided by 77.1% (54/70) of 
participants. Longitudinal samples at repeat time points were provided by 45.7% (32/70). This 
is below the target of 50% but only a proportion of the 70 participants will have been old 
enough to provide samples at subsequent time points. 
 Initial 12 months 24 months 
Number of samples 
received* 
77.1% (54/70) 61.5% (32/52) *¹ 57.1% (20/35) *² 
Median age at which 
samples taken in months 
(IQR in months) 
5 (3.9, 7.5) 12.7 (12.3, 14.1) 
 
24.9 (24.6, 26.4) 
Table 19: Number of urine samples received at the requested time points and median age of 
the children at the time of sampling 
Footnote: *The denominator for these is calculated from those that were the correct age for sampling at each 
stage i.e. from those that had been requested to collect a sample (and those that had not already provided a 
sample within two months of that time point). *¹ 16 participants were under the age of 12 months, two had 
provided samples after the age of ten months. *² 35 participants were below the age of two years. 
 
To estimate a true reflection of post-prandial C-peptide secretion, information is also required 
regarding the timing of the sample in relation to feeds. Although the instructions provided to 
parents clearly stated that samples should be collected post feed, the actual timing of the 
sample post feeding, had not been requested initially. A request to collect this information 
was added to the sample sheet in Amendment 7 (July 2017). The time of last feed prior to the 
sample collection was available for 28.8% (30/109) of the samples (this includes three samples 




median time post feed was 45 minutes (IQR 30, 60). This included three samples collected 
first thing in the morning, twelve hours after the last feed. For one sample, the parent had 
written “a few hours after feed” rather than an exact time.  
The collection method used for urine collection to estimate C-peptide was recorded by 46% 
(49/106) of parents. The clean catch method was used for 36.7% (18/49) of these samples 
and 61.2% (30/49) used cotton wool (for one sample the parents said that they had used a 
combination of methods, and one sample leaked). Both methods obtained decent volumes 
for analysis (median 4mls). In total, 99% (108/109) samples were adequate, above the 
feasibility target of 90%.  
A few parents commented that sample collection was difficult using either method. With the 
cotton wool there were issues with trying to get an uncontaminated sample as often the 
babies would defecate at the same time. Parents also experienced issues with getting enough 
urine from the cotton wool as per the quotes from parents below 
“I got the stool one on Saturday and put it straight in the fridge, but the first set of cotton balls 
for the urine got pooed on, and I tried twice more on Sunday with flat cotton pads I had but 
only got a tiny drop out.  I don't know if she is dehydrated in the hot weather (the poo wasn't 
particularly hard this time) but the nappies aren't very heavy even first thing in the morning 
when I haven't put the cotton pads in.” 
“However, I'm really struggling to get a urine sample from child’s name. No luck yet with 
waiting poised with the specimen pot for him to pee. Cotton wool in his nappies hasn't worked 




Some parents commented that using the clean catch method became more difficult once 
their babies were older and more active. 
 Feasibility of collecting stool samples 
Whilst both the initial and 12-month stool sample collections did not meet the threshold for 
the feasibility study, the median ages when collected were acceptable as shown in Table 20. 
OMNIgene GUT stool sampling started after the feasibility project was completed in August 
2016. These samples were not considered in the feasibility assessment. In 74.3% (52/70) of 
cases at least one stool sample was received and longitudinal, repeat samples from 52.9% 
(37/70) which is above the set standard.  
 
 Initial 6 months 12 months 24 months 










Age at which samples 
taken in months  



















Table 20: Number of stool samples received at the requested time points, median age of child 
at the time of sampling and interquartile range.  
Footnote * OMNIgene GUT samples were only collected after Amendment 5 date August 2016, the ages at which 
these samples were collected were comparable to the ages at which the swabs were collected. ** Six 
participants were below the age of six months, 35 had provided the initial sample after the age of four months. 
***16 participants were below the age of 12 months, one had provided the six-month sample after the age of 
ten months. ****35 participants were below the age of two years 
 
Near recruitment, maternal samples were collected after Amendment 1, March 2015 so the 




stool samples from 60% of the participants and maternal stool samples collected using 
OMNIgene GUT from 24.3% of participants.  
Repeat samples were requested for five samples. One sample taken into the OMNIgene GUT 
kit had separated into two layers and would not mix for an unknown reason, a further sample 
was therefore requested. Three samples were lost in the post and one sample was ‘eaten by 
a pet’. A few parents overfilled the OMNIgene GUT kit tube. Once received in the laboratory, 
the samples were frozen at – 80⁰C for future analysis. 
There were no major issues highlighted by the parents with collecting the stool samples either 
using swab method or OMNIgene GUT kit. Any issues expressed were around the child being 
constipated or having loose stool rather than problems with the kit as illustrated in the quotes 
below: 
“The thing I'm struggling with is a stool sample. Child’s name is teething at the moment and 
so her stools are particularly loose and just get absorbed into the nappy. I'm going to start 
weaning a bit early...starting tomorrow. So hopefully that will help a bit...she may just be 
constipated initially. I hope I'm not holding things up!” 
“so far child’s name has only had his bowels open twice a week with the help of lactulose. 
Usually catches us out in the middle of the night or whilst we are out.” 
Feasibility of Collecting Blood Samples 
Blood sample returns did not achieve the feasibility target as demonstrated in Table 21 and 
the reasons for this are discussed in detail in the discussion (Section 4.11.4). At least one blood 




time points were provided by 47.1% (33/70) of participants, which is below the target. Median 
ages were acceptable although the upper limits of the IQR were over the target. Not all of the 
participants will have been old enough to provide longitudinal samples.  
 












Median age at 
which samples 
taken in months 









Table 21: Number of blood samples received at the requested time points and median age of 
the children at the time of sampling. 
Footnote :*Six participants were below the age of 6 months and 32 had provided their initial sample after the 
age of 4 months. **16 participants were below the age of 12 months and two had provided samples after the 
age of ten months. ***35 participants were below the age of two years.  
 
Serum volumes (approximately half of the whole blood volume) greater than 30µl can be used 
for testing a panel of autoantibodies associated with T1D, thyroid and coeliac disease. Below 
this volume samples can be used for limited testing. The estimated mean sample volume was 
107.5µl with 82.6% (86/104) of samples having a volume greater than 30 µl. Nine samples 
were less than 1µl, these were frozen whole and stored. Twenty-six blood samples were 
recorded as haemolysed and one sample had been incorrectly collected into an EDTA tube. 
Whilst these samples are suitable for antibody testing and thus do not affect the feasibility of 
this study, they might prove less useful in future studies. Of the samples received 88.5% 




Analysis of anti-BSA antibodies was therefore performed on samples from 53 participants (30 
with longitudinal samples (see Chapter 6 Section 6.4 ).  
 
Figure 28: Sample volumes by collection time point, showing median and interquartile range. 
Outliers are also shown. 
 
Repeat samples were requested only where it was felt appropriate to do so, for example when 
a parent emailed to say that it had been difficult to collect the sample and that they were 
happy to try again. Repeat samples were collected from seven participants, four due to 
difficulties obtaining the samples and three where the samples had been lost in the post.  
The timing of blood sampling was challenging as the babies and children did not have blood 
tests taken at predictable time points. Parents were emailed to ask when their next 




sites were unwilling to assist with sample collection. However, many sites were extremely 
helpful and had no issues with facilitating blood sample collection at their appointment.  The 
list below summarise the routes via which participants had their bloods collected (GW 
collected five of the samples where the participants lived locally): 
• families arranged the blood sample themselves with the health professional that they 
were seeing, or booked to have bloods taken by a phlebotomist or by their practice 
nurse at the GP without involving the research team; 
• as previously described, families informed us of the date when they were due to see 
a health professional, and we then contacted the health professional and requested 
their assistance with collecting the blood sample (this usually required several phone 
calls and emails).  Most were happy to help, but some cited a variety of reasons for 
not taking the samples including, that they would not have enough blood for the 
patient’s routine samples, that they would not have sufficient time, that they were 
not setup for collecting blood samples, or that they were unclear about how they 
would be reimbursed;   
• local collaborators helped either by arranging the samples or by research nurses 
meeting the participants at their appointments and collecting the samples; and 
• parents took the samples themselves or the samples were taken by a family member 
who had clinical training (this only accounted for three participants, several families 
had tried to take the samples themselves but were unsuccessful).  
 
Some participants and health care professionals experienced issues with the blood collection 




and a larger outer tube. Initially there were issues with samples leaking out of the inner tube, 
which was partly resolved by changing the way in which the tubes were prepared before 
sending them to the participants, with the small tube being sent already capped.  
 Retention of participants 
The feasibility of retaining participants within the cohort so that longitudinal questionnaire 
data and samples could be obtained was assessed by the following feasibility objective. 
Objective: The feasibility of retaining participants in the study, which in parallel also 
determines the overall acceptability of the study was set by the following objective: 
 
1. for compliance with the study protocol up until the age of five years old with a target 
of retaining at least 50% of participants.  
 
The target of maintaining participants in this longitudinal study was set at five years. For the 
purpose of this thesis however, retention of participants has been assessed up until 
September 2017 (none of the participants were aged over five years old at this stage). Of the 
70 participants who were recruited within the three-year period there were six participants 
who did not complete any questionnaires or provide any samples at any time point. These 
included the very first participant enrolled onto the study, with no reason being given as to 
why they did not take part. The paediatrician of one child who was very unwell in the new-
born period with cardiac complications in a paediatric intensive care unit, had advised that 
they would not be likely to be actively taking part in the study. Two parents emailed to say 




commit the time. For the other two participants, despite reminders and phone conversations 
they did not take part and no reason was given.  
Retention of participants at a year was judged by those who were inactive, partially active 
(completing any of the requested questionnaires or samples at a year) or fully active 
(completing all requested samples and questionnaires). Table 22 shows over half of the 
participants who had ever been active in the study remained fully active and a further ~36% 
remained partially active. At two years 60.7% of the children (who were of the correct age) 
were fully active and therefore at that point on target to meet the feasibility objective of at 
least 50% remaining compliant with the study protocol. Figure 29 is a flow diagram showing 
the activity of the participants over the three years. 
Compliance with Study  At 12 months At 24 months 
Fully active  
 
53.3% (24/45*) 60.7% (17/28**) 
Partially Active  
 
35.5% (16/45) 17.8% (5/28) 
Inactive 
 
11.1% (5/45) 21.4% (6/28) 
Table 22: Compliance of participants with study protocol at 12 months and 24 months. Where 
‘fully active’ is completing all requested samples and questionnaires, ‘partially active’ is 
completing any of the requested questionnaires or samples and ‘inactive’ is not completed 
any questionnaires or samples beyond the previous timepoint. 
Footnote:*six participants never completed any initial samples or questionnaires and have not been counted in 
this assessment. A further 19 participants were below the age of 12 months on the 1st September 2017. **36 





Figure 29: Flow diagram showing activity of participants over three years from September 
2014 to September 2017.  
Footnote * fully active meant that they were completing all of the requested questionnaires and samples. 
**Partially active meant that they continued to complete some of the questionnaires and/or samples.  
 
100 Expressions of 
interest completed
70 Consented
45 participants age ≥12months 
on 1st Sept 2017
24 Fully Active* 
28 participants were ≥24 months 
on the 1st September 2017
17  Fully Active 
6 Inactive 








 Medical and feeding questionnaires 
The feasibility for using the medical and feeding questionnaire was assessed, based on the 
following criteria. 
Objective: to assess the ability of the online questionnaires and paper questionnaires to collect 
the required data; 
• for at least 75% of participants to complete initial, seven and 12-month questionnaires;  
• for at least 60% of participants to opt to use the online questionnaire rather than the 
paper questionnaire;  
• for at least 50% of participants to complete the annual questionnaires up until the age 
of five years; and  
• for the data produced to be valid and easily converted into a form, which is ready for 
analysis.  
 
Table 23 shows that the feasibility target of 75% completion rate is being exceeded for the 
initial and 7-month questionnaires. Of nine participants who did not complete the initial 
questionnaire, six were inactive throughout the study and the remaining three completed the 
questionnaires after the cut-off date of 1st September 2017 (two had only enrolled within 
days of this cut-off).  For the 12-month questionnaire, one family did not complete the 
questionnaire until after this deadline. If they had contributed in time, a completion of ~76% 
would have been achieved. Of note, 15 participants completed the initial and 7-month 
questionnaires contemporaneously given mean age of recruitment. Two participants 




questionnaires at more than one time point completed them in temporal order, so the 








Number of completed 
questionnaires 
87.1% (61/70) 84.4% (54/64)* 74.1% (40/54) ** 
Age of child at time of 
completion in weeks 
Median (IQR) 
20 (13 - 29) 31 (29 - 34) 52 (51 – 55) 
 Table 23: Number of completed questionnaires and actual age of child at the time of 
completion. 
Footnote: *six participants were below the age of seven months. **16 participants were below the age of 12 
months 
 
Online questionnaires were requested by 80% (56/70) of participants in their EOI form. Due 
to an administrative error, four participants who requested a paper questionnaire were sent 
the online link and completed the questionnaires online. Paper questionnaires were sent out 
when online questionnaires had not been completed to prompt a response or if a participant 
was struggling to complete the online questionnaire. In total 82% of the initial questionnaires 
were completed online which is above the feasibility target.  
Importantly, the most frequent issue with the online questionnaires arose from there being 
no ‘save and come back’ feature within the web-based questionnaire, so the questionnaire 
had to be completed in one sitting. Therefore, some questionnaires were received online that 




The data obtained were easily exported into Excel files and into Stata (as described in Chapter 
2). An issue experienced with exporting the data was that many of the variable names were 
too long for Stata and new variable names had to be created. Several errors were identified 
during assessment of the data which were related to the branching of the questions. For some 
participants, they were incorrectly branched away from questions that they should have 
answered. These errors are described in more detail in Chapter 5.   
The results of the secondary objectives are given in Chapter 5 “Analysis of Medical and 
Feeding Questionnaires” and in Chapter 6 “Initial analysis of Clinical Samples from FADES 
cohort”. 
 Discussion of Chapter 4  
In this section the results presented in this chapter will be discussed particularly in relation to 
the feasibility of the study. A feasibility study should address the important overarching 
question as to whether the planned protocol will successfully lead to the collection of the 
desired data. Importantly this study successfully recruited participants from across the UK 
who completed all requested longitudinal questionnaires and provided all the desired 
samples. Although recruitment was below target, 70 participants were recruited which makes 
this one of the largest cohorts of babies with DS in the UK. The study met the feasibility targets 
for the collection and analysis of DNA (mouth-swab samples) and collection and analysis of 
initial urine samples for urine C-peptide. The target was almost met for the collection of stool 
samples for microbiome and despite not achieving the feasibility target, collected blood 
samples from 66% of participants, 89% of which were suitable for analysis. The retention of 




previous cohorts of babies with DS. The paper by Orsmond et al describes “the distinctive 
features of a feasibility study” (Orsmond and Cohn 2015).  The table in Appendix 27 
summarises this study in relation to these. 
The study protocol evolved and adapted over the three years in which feasibility was 
assessed. This is particularly true in relation to recruitment methodology. Assessing feasibility 
has its own inherent issues, by setting a date at which feasibility will be assessed, some 
participants were counted as not having completed a questionnaire or a sample which may 
then arrive the next day. In a study designed for flexibility, built in delay of a few weeks or 
even months is pragmatic but in terms of achieving feasibility targets may not be acceptable.  
Setting up a UK wide cohort of babies with DS was feasible but required considerable time 
and effort to complete all the required processes and obtain all the necessary permission. The 
individual aspects of the study design and set up are discussed in the sections below with the 
strengths and weaknesses highlighted.   
 Discussion of Study Set-up 
Ideally a feasibility study should include a focus group or steering committee with patient or 
participant representatives (in this study new parents of children with DS). Not having a pre-
arranged focus group for this study could be considered a weakness but this was not possible 
due to time constraints within the PhD program. The study was however designed with 
consultation from professionals and families through the DSA, DSS and a local DS group.  
The eligibility criteria led to the recruitment of appropriate participants which was a strength. 




families who needed to adjust to their baby’s diagnosis and where necessary urgent medical 
needs to be addressed.  
Ethics and R and D  
Rigorous governance is necessary to ensure that research is ethical and valid. The processes 
required in order to initiate this study were slow and prohibitive and this has similarly been 
noted in other studies (Thompson and France 2010, Snooks et al. 2012, Elwyn et al. 2005). It 
took six months from completing the initial Portfolio Adoption Form to receiving the first NHS 
site approval and then a further three months for sufficient NHS sites to be in place to start 
recruitment. Despite these delays however, 68% of the 318 primary and secondary care sites 
across the UK gave permission for the study which is testament to the study design.  
With this breadth of national sites, as soon as a baby was identified or self-identified by 
parents, they could be enrolled immediately wherever they were born in the UK. By gaining 
permissions across the UK ahead of recruitment, delays as a result of lack of permissions were 
minimised. Although this involved a significant amount of time, effort and multiple emails 
only a couple of participants were born in areas where permission was not already in place.  
Amendments 
Amendments during the three years improved the study and corrected omissions in the 
original protocol which were revealed during the study. For example, Amendment 1 which 
allowed local collaborators to recruit helped increase recruitment rates. Amendment 7 in 
which the sample sheets were changed to obtain information on the timing of feeds in 
relation to the collection of urine samples for urine C-peptide helped interpretation of data. 




approvals from ethics and local R and D sites. It may have been advisable to have included 
more flexibility into the original ethics and R and D forms as suggested by Hagen et al. in the 
quote below. 
“We suggest that a Formal Feasibility Study should allow investigators to improve the conduct 
of the trial based on what they learn as it is implemented. Investigators should include in the 
original study design their explicit intention to change the patient assessment process if 
required, and have these changes preapproved as part of the initial submission for scientific 
and ethical review.” (Hagen et al. 2011) 
Site Approval  
The concerns raised by sites unwilling to be involved varied and highlighted that internal 
processes were not standardised from one NHS trust to another. Full reviews of the study 
akin to an ethics committee meeting were undertaken by some sites whereas at other sites it 
was more of an administrative exercise. Some of these issues may be improved for future 
studies with the changes made by the introduction of HRA approvals (Salman et al. 2014, HRA 
2019).  
NIHR Support 
Help and support was provided from the NIHR CSP team in disseminating information about 
the study to all of the primary and secondary care trusts and in completing the complex steps 
described in Chapter 2 Methods. Having access to CSP was the most valuable resource for this 
study and without it, involving so many sites across the UK would have been impossible (CSP 




Unfortunately, it was not always clear what help was available from the NIHR Portfolio as it 
appeared to differ from one clinical network to another. This was also true between different 
NHS trusts some offering the support of research nurses to help with recruitment and blood 
sampling while others did not. This was partly due to available resources in the different trusts 
but also to the way that sites managed their accruals. This variation between networks has 
also been noted in other studies (Stock et al. 2016). 
Approval from Scotland, Wales and Northern Ireland 
Approval from the devolved nations again varied greatly, gaining approval from the Scottish 
Health Boards was straightforward and worked smoothly through the central NHS Research 
Scotland Coordinating Centre (NRS CC). For Wales each of the seven Health Boards had to be 
contacted separately and they had different requirements with regards to the need for 
named clinicians responsible for the study. There were delays in getting permission in 
Northern Ireland as they were themselves unclear of the best way to proceed with such a 
study covering many sites and it took some time to decide whether they would accept a single 
SSI.  
 Study Website and email 
The study website and email system proved invaluable with the study covering a wide 
geographical area and participants being able to self-identify.  The use of websites in research 
studies provides easily accessible information for participants and other research sites. In this 
study, the website enabled participants and researchers to download the participant 
information sheet and to register their interest in the study. Other studies have included 




confidential information (Paul, Seib, and Prescott 2005). Feedback on the attractiveness and 
understanding level of the website from the Engagement (Participant) / Non-participant 
questionnaires was positive as discussed in more detail (Section 4.3.3). Expanding the website 
to include more information for families, links to study newsletters and further information 
for local collaborators would be beneficial. Despite the internet being increasingly available it 
must be recognised that some families are unable to access a study website and this will 
introduce selection bias (Paul, Seib, and Prescott 2005, Topolovec-Vranic and Natarajan 
2016). Due to the relatively small number of participants, email enabled easy contact 
between families, local collaborators and the research team who could respond quickly to 
any queries.  
 Study Database 
The study database had many useful features whilst being secure and complying with ethical 
requirements for confidentiality. The database was a strength of this study and essential 
when collecting longitudinal data thus ensuring protocol adherence. The information 
collected on the database was also key to assessing whether feasibility targets were met.      
 Recruitment 
The study achieved a recruitment rate of 23 participants/year, far fewer than the 100 
participants/year target. However, on reflection we consider recruitment as successful as 
between 2014 and 2017, seventy families had consented to the study making this one of the 




study. Although 11 children were too old to take part, 100 families completed EOIs showing 
the level of interest in the study.  
Initial recruitment was very slow. The strategies involved having flyers describing the study in 
the DSA parent packs and through DSS support workers. However, following further 
discussions with the DSA, not all of these packs were going directly to new families. A 
proportion go to maternity hospitals to give out in the event of a new baby with DS being 
born. Some of the packs go to people who have come across the DSA when trawling for 
information, but this may be friends or other family members rather than parents themselves. 
The DSA provided information on the demographics of those who decide to become members 
of the DSA, if the babies are under a year of age when their parent’s become members a new 
pack is sent out to them. For the year end 2012, only three packs were sent out to parents 
before they had their baby (i.e. prenatal diagnosis). For those parents who had a baby under 
the age of six months, 196 packs were sent out, 167 of these babies were under three months 
of age. The number of packs sent did reduce during the three years (2014 -2017). This may 
have been due to parents accessing more information through the internet likely making 
flyers less useful in future studies. 
The recruitment rate more than doubled after the amendment (Amendment 1) to allow local 
collaborators to recruit and with an increase in activity on social media (0.9 participants a 
month increased to 2.3 participants a month). Although this increase cannot be purely 
attributed to the involvement of local collaborators, very active local collaborators 




The barriers to recruitment that were experienced during this PhD and the actions taken to 
try and overcome these are summarised in the table below: 
Barriers to recruitment  Action 
Flyer provided in DSA new parent pack and 
through the DSS only reached a limited 
number of families. 
Amendment to allow local collaborators 
(neonatologists, community paediatricians, 
research nurses) to recruit participants. 
Initial recruitment methods only 
approached those families who were 
information seeking or whose children were 
actively being managed by medical 
professionals. 
Recruitment via social media and websites.  
Lack of local collaborators at all sites Increased recruitment of local collaborators 
through the DSMIG, presentations given by 
GW at CRN meetings.  
Attrition of collaborators and maintaining 
profile of study 
Quarterly newsletters and regular updates.   
 
Table 24: Barriers to recruitment and remedial actions. 
 Recruitment methods 
The feasibility objective for recruitment methods was met. Participants were recruited 
successfully through a variety of recruitment methods. Recruitment via social media and the 
DSA website accounted for 46% of the participants which was comparable to the 40% 
recruited via local collaborators but they were only able to recruit from March 2015 when the 




 Strengths and weaknesses of recruitment methods 
Recruitment via flyers, website and social media where participants self-identified had many 
advantages including allowing recruitment of participants from a wide geographical area and 
those who were born where there was no active local collaborator recruiting.  
 Recruitment via websites and social media 
Recruitment via websites and social media took a median of almost two weeks from the time 
of EOI completion to consent and often required reminders to be sent by the team in Bristol. 
Web recruitment led to the need for some re-consenting, due to incorrectly filled forms. It 
should be remembered however that consent form errors happen in studies where 
participants are recruited directly (Smith, Moore, and Tunstall-Pedoe 1997). Consent forms 
completed with local collaborators were promptly filled and returned. However, reminders 
then had to be sent to complete the EOIs so that all the necessary participant details were 
obtained. System updates and repairs had little to no impact on overall recruitment. 
When participants self-identify through the internet and social media, selection bias naturally 
occurs as demographic factors influence use and understanding of these media. A study by 
Topolovec-Vranic et al. (Topolovec-Vranic and Natarajan 2016) suggested that this method of 
recruitment leads to participants with a higher educational level and higher socioeconomic 
status when compared to studies recruiting via more traditional routes. The same study also 
commented that social media was a good way to recruit difficult to reach populations, 
particularly participants with specific conditions. By using both internet and traditional 




qualitative research study, health professionals sometimes take on gatekeeping roles limiting 
which families are approached for research (Chapter 3). 
 Local collaborators 
Local collaborators increased recruitment considerably. The role of the local collaborator at 
different sites varied. Some sites approved the study as “no local collaborator”, some named 
me as their “Principal Investigator” and others had a named local principal investigator. The 
status of the site did not reflect the activity. For example, some had a local PI by name, but 
the PI did not actively recruit. Local collaborators were recruited through the DSMIG, CRNs 
and R & D at some sites (where recruitment was low) tried to engage local collaborators. 
Some active collaborators not only recruited participants but also informed colleagues at 
other sites who in turn became local collaborators. GW was invited to talk at CRN meetings 
to recruit more local collaborators (NIHR CRN Eastern research champions meeting and NIHR 
CRN Kent, Surrey and Sussex).   
Due to the use of the coordinated system for gaining NHS permission (CSP) and variations in 
the approval processes at each of the sites, information on whether a local collaborator 
existed could not be established with ease. This was a weakness in the study setup and caused 
issues when sometimes neither the site’s R&D team nor the FADES research team knew if 
there was a local collaborator. Importantly if local collaborators had been included in the 
initial protocol, it may have been slower to set up the study due to the rules around 
generic/single SSIs. The research activities would not have been considered as all taking place 




Geographical distribution of participants and local collaborators 
The distribution of the participants recruited reflects local activity, areas which had the 
highest recruitment rates were those with very active local collaborators. The reasons why 
some collaborators were more successful than others are unclear. Many babies with DS are 
admitted to neonatal units where trust and rapport is gained between the clinician and the 
parents as found in the qualitative research study. This is different for community 
paediatricians where they may only briefly meet the family post-delivery and might not see 
them again until the baby is a few months old. The schedule for following up with a 
community paediatrician varies across NHS Trusts and not all families meet their community 
paediatrician until their first outpatient appointment. Interestingly though, the study 
managed to recruit more community paediatricians as local collaborators than 
neonatologists, this was largely due to the study’s link with the DSMIG.  
  Motivations and Barriers to joining the Study 
Most of participants who were actively participating in the study completed the engagement 
questionnaire (89%) to explore why they joined the study and their opinion on the study. Not 
unexpectedly, only eight of the 26 non-participants with contact details (31%) completed the 
non–participant questionnaire exploring why they did not take part and their opinion on the 
study. These questionnaires only provided limited information, we know nothing of families 
who saw the study but did not complete an EOI or who were approached by local 
collaborators but declined involvement. However, it is a strength of the study that some non-




Engagement (Participant) questionnaire 
The engagement (participant) questionnaire showed that half of the families took part for 
altruistic reasons as noted in other studies (Fortnum et al. 2014, Caldwell, Butow, and Craig 
2003). Parents also wanted to be proactive: by taking part in research it gave them a way to 
contribute and one parent said that it gave them something positive to do whilst “coming to 
terms with the diagnosis”. The topic of feeding was of interest to some families. It is a strength 
of the study respondents found the study professional and that it appeared “easy and non-
invasive”. Previous studies (Caldwell, Butow, and Craig 2003, Nabulsi, Khalil, and Makhoul 
2011) have suggested that families are more likely to engage in studies that would provide 
additional medical input for their child. A fifth of the participants thought the study would 
provide additional health screening and would be of benefit to their individual child.  
Overall comments about FADES were very positive, stating that the information provided is 
clear and easy to understand. Participants suggestions for improvement were mostly around 
information on sample collection and this is an area for future development. The 
recommendation for improving recruitment was to increase presence on social media. One 
participant highlighted the potential issue of gatekeeping by clinicians.  
Non-participant questionnaire 
As the questionnaire was only completed by eight families, these findings can only be 
regarded as suggestive and conclusions should not be drawn. As for the engagement 
questionnaire, initial interest in the study was due to altruistic reasons or to potential benefit 
for their own child. The reason why many did not go on to actively participate was because 




this is a very busy time for families coping with a new baby who may have complex medical 
needs, adjusting to a new diagnosis and having multiple appointments (Van Riper 2007, 
Fortnum et al. 2014). However only one family said that they did not take part due to the time 
commitment which reflects that families did not see the study as overly burdensome. One 
family indicated an unwillingness to take stool, urine and mouth-swab samples and another 
were against taking blood samples. Collecting samples was not a barrier for most families 
although other families may not have completed an EOI because the collection of biological 
samples was unacceptable. An unwillingness by a clinician to take samples of sufficient 
volume was interesting as a perhaps surprising reason for one family not taking part.  
Non-participants also found the website ‘quite’ attractive and easy to understand. 
Recommendations from this group had included providing clearer information on the level of 
commitment required, involving more health professionals in recruitment and three had 
asked about making the sampling easier. Overall these questionnaires suggest improvements 
could be made to the information provided about collecting the samples and the website 
could be enhanced with advice from web designers. 
  Sample Collection from Participants 
Overall sample collection was successful, meeting the feasibility target for DNA samples, 
initial urine samples and nearly meeting the target for initial stool samples. Initial blood 
samples were collected for 65% of participants and over half of all 12 month requested 
samples were provided. The median ages at which samples were provided all met the targets 
with IQRs which were relatively narrow. Although the proportion of samples received were 




There had been many questions raised during the initial approvals stage of the study as to 
whether families would be able or willing to provide these samples. It was suggested that the 
study was overly burdensome. 
There were some issues with samples getting lost in the post, standard post (Royal Mail) was 
used and the samples were not tracked. This method was convenient for participants and cost 
effective but loss of samples enroute was a risk.  
 Mouth-swab samples 
The feasibility target was exceeded for the collection of mouth-swab samples and the median 
age of the baby at the time of collecting the sample was acceptable although for this particular 
sample, age is not crucial. Collecting mouth-swab samples is relatively simple and non-
invasive and the only issue was lysis buffer leaking when the lid was not tightly secured for a 
couple of samples. The concentration of DNA that was extracted from the samples was 
adequate and 98% of samples were analysed successfully for HLA Class II genotyping.  
 Urine Samples 
The target was met for the collection of the initial urine samples but not for the 12-month 
samples. It is challenging to collect a clean catch urine sample from a 12-month old as they 
become more mobile but are not toilet trained. For urine C-peptide analysis, longitudinal 
samples are of importance; 46% of participants provided longitudinal samples and as 16 
participants were under the age of 12 months, it suggests that at least half of participants 




Ideally for valid urinary C-peptide results, the collection needs to be a timed sample following 
a set meal: the mixed meal tolerance test (MMT) (Greenbaum et al. 2008). However, it is not 
possible to get a small child to void on demand or even to guarantee that they will take a fixed 
volume of feed and thus even in experimental immune-modulation trials, MMTs are not used 
under seven years of age. However, information on when samples were collected in relation 
to the time of the last feed does allow some comparisons of post-prandial urinary C-peptide 
measurements. Instructions were provided to parents advising them to collect urine samples 
post feed, but they were not required to record the time post feed until an amendment was 
added to change this (Amendment 7 July 2017). Time post feed was available for just under a 
third of participants. This is a limitation of the study. Besser et al measured UCPCR in children 
following an evening meal but the children had a median age of 14 years (IQR 11 – 16 years 
range 5 -19 years) (Besser et al. 2011). There have not been any studies measuring C-peptide 
in younger children which provide a normal range for a post prandial C-peptide.  
Parents tried both suggested collection methods with a slight preference for the cotton wool 
method over the clean catch method. From the emails and comments received from the 
families, both methods had positives and negatives. Both methods provided good urine 
volumes and 99% of samples were adequate for analysis. However as discussed in Chapter 2 
Section 2.15.2, there may be differences in the results related to using cotton wool and when 
the UCPCR result obtained is very low this should be repeated with a clean catch sample to 




  Stool Samples  
The number of initial stool samples collected was close to the feasibility target and 
longitudinal samples were collected by over half of participants. The gut microbiome changes 
during infancy becoming more stable and established around the age of three years 
(Yatsunenko et al. 2012, Lozupone et al. 2012). When considering why children with DS might 
be at increased risk of autoimmunity one hypothesis is that their gut microbiome may be 
different. This difference might be due to early feeding, infections and/or use of antibiotics. 
This can only be assessed when longitudinal stool samples can be linked to feeding and 
medical data. As the composition of the neonatal gut microbiome is also determined by the 
maternal gut microbiome, maternal stool samples were collected and 60% of mother’s 
provided samples. Ideally these samples should be collected immediately at the time of birth 
as the mother’s gut microbiome will alter with time but this is an inherent limitation of this 
study.      
Once the pilot study for the OMNIgene GUT kit had been completed samples were collected 
using both methods.  There were no major issues highlighted for either method and for future 
studies the OMNIgene GUT kit would be recommended.  
  Blood Samples 
The feasibility target for the collection of blood samples was not achieved.  To have at least 
one sample from over 70% of participants nevertheless suggests a degree of success. Of the 
samples received, over 88% were suitable for analysis of anti-BSA antibodies.  
Collecting blood samples from babies and young children is always challenging and can be 




challenges, they tend to have puffy hands and feet and can be peripherally poorly perfused. 
Some children also have cutis marmorata, livedo reticularis and acrocyanosis which are 
vascular cutaneous manifestations seen in DS which make visualising veins difficult (Madan, 
Williams, and Lear 2006). The volumes of blood that were collected in this study were not 
large, but over 80% of the samples obtained resulted in serum volumes of greater than 30µl 
and a mean sample volume of over 100µl. It might be thought that as the children got older, 
it would be easier to get a larger blood sample.  Surprisingly, when volumes collected were 
compared for the different ages at sample collection they were similar. Repeat samples were 
requested if inadequate or if lost in the post only where parents had suggested that they were 
happy to do so.  
Coordinating the collection of the bloods samples was very time consuming, although the 
design was for the samples to be done at the same time as a routine local appointment, the 
health professional needed to be contacted. The recommendation from the DSMIG is for 
children with DS to have thyroid function checked annually (TSH annually and TFTs every two 
years) (DSMIG 2019a). Protocols vary across trusts and it is sometimes unclear who organises 
this screening test. Certainly, in some areas of the country there are dedicated clinics for 
children with DS usually run by community paediatricians but usually these are in densely 
populated cities. Even where thyroid function is checked annually, it is not always collected 
close to the child’s birthday. The study team contacted families close to the participants’ 
birthdays to arrange the sample collection, but appointment dates were sometimes several 
months off. In these cases, the families were advised that the sample could wait, but this 




for other interventions for example cardiac surgery which provided opportunities for blood 
collection.  
The advantages of this proposed setup was that it avoided participants having to attend 
additional appointments solely for the study. It enabled participants to be recruited from a 
wide geographical area as dedicated trained research staff were not required. This also 
reduced costs in setting up and paying for clinic space or phlebotomy services. The 
disadvantages were that it was not possible to time the sample collection and a degree of 
flexibility was required. Written instructions were provided but there were a couple of errors 
with the use of the bottles which if used incorrectly leaked.   
  Retention of participants 
The majority of active participants are engaged and committed. For the children who had 
reached the age of two by September 2017, just over 60% of participants were fully active 
having provided all of the requested samples and completed all of the questionnaires and 
nearly 80% of participants were either fully or partially active (still completing some samples 
and/or questionnaires at two years of age). Higher attrition levels have been observed in 
other studies (Golding and Birmingham 2009, Zook et al. 2010, CDSS 2018). This study 
requires significant family input within many cases, very little contact with the research team 
hence the online newsletters were employed to improve engagement.  
Assessing the feasibility target of retaining 50% of participants until five years of age will be 
assessed in 2020 but from these data there appears to be a fall out of around 20% over two 
years. As discussed, some information as to why participants were unable to continue in the 




intended to take part, they then felt unable to commit the time. There were also some 
participants who became seriously unwell and therefore the families no longer engaged. 
Many of the families in this study had self-identified, finding the study through their own 
research on websites and social media. This suggests that these are already very proactive 
parents who are less likely to drop out. A quarterly newsletter is sent out to all the current 
participants and local collaborators, it includes updates on the study progress, useful 
information about aspects of the study such as the sample collection and parents send in 
photos and news of their children (see Appendix 28). These newsletters have had positive 
feedback from participants and has been a good way of keeping families engaged, other 
studies have also found newsletters have helped with retention of participants (Abshire et al. 
2017). 
  Medical and Feeding Questionnaires 
The target of 75% for completing the initial and seven-month questionnaires was exceeded 
and for the 12-month questionnaire, it was almost achieved. These are long and thorough 
questionnaires; the ethics committee had raised a concern that they would be too 
burdensome for the participants. Mothers however, filled in the questionnaire promptly and 
in detail, providing significant extra information in the free text boxes. The detail provided in 
these suggests that at least for some of the respondents, response fatigue was not an issue. 
Birth cohorts of babies with DS are unusual and it is important for families to have the 
opportunity to tell their individual stories and share their experience of the care that they 





  Questionnaire Design 
The use of a web-based questionnaire allowing completion wherever internet access was 
available by phone, tablet or computer was a definite strength with 82% of participants 
completing questionnaires online. Many issues that frequently occur with paper 
questionnaires were removed; for instance, participants losing paper versions before they are 
completed, completing the paper questionnaire but not getting around to posting it. There 
were also no postage costs. As previously described, branching on the web-based 
questionnaire meant that the mothers saw only the relevant sections making it quicker and 
easier to complete. Compared with face to face or telephone interviews there is no risk of 
interviewer bias. Interviewer bias can be reduced with training but is often subtle and 
interviewers are unaware that they are being encouraging or positive, negative or 
interrupting. Mothers may have felt able to answer more freely as online questionnaires offer 
relative anonymity. There are frequently feelings of guilt around whether a mother can 
breastfeed or if they have decided not to breastfeed (Hegney, Fallon, and O’Brien 2008, 
Thomson, Ebisch-Burton, and Flacking 2015); being able to answer questions regarding early 
feeding without the presence of an interviewer may have provided more open responses and 
reduced social desirability bias (Bowling 2005). Using web-based questionnaires increases 
data completeness and removes input errors as the data could be transferred directly into 
Stata.  
The strength of the questionnaires is that they are longitudinal and prospective. The initial 
questionnaire asks the mother to recall a significant amount about their baby’s initial feeds. 




be present in the data collection for early feeding. One could hypothesise that mothers coping 
with very young babies, often sleep deprived with the additional worries of an often-
unexpected diagnosis for their baby may be poor historians. However, mothers said that 
receiving the diagnosis caused them to remember every detail of those early days of their 
baby’s life. Although the seven-month and 12-month questionnaires both asked about the 
preceding six months, the recall bias for these questionnaires is minimal with median age at 
completion being seven months and 12 months respectively.  
Open questions with space for participants to provide free text aimed to reduce researcher 
bias and allow new knowledge to be gained. Closed questions with limited responses made it 
easier to compare the answers given by different participants with fewer confused or 
irrelevant responses given. 
  Overall feasibility of data collection 
Overall the study successfully collected the desired samples and data. The information 
provided to participants including the sample instruction sheets were comprehensible. 
Although members of the research team did not meet the families directly, this must be 
inferred by the number of usable samples that were returned and lack of calls or emails to 
the team suggesting the contrary. The SOPs for the handling of data and samples worked with 
no adverse events. Initial testing of samples is complete and these results are given in Chapter 
6. The study team had the skills and capacity to manage the study. The lessons learnt in setting 



















Chapter 5  Analysis of Medical and feeding questionnaires 
 Overview of Chapter 5 
This chapter provides data from the medical and feeding questionnaires. The ability to use 
these results to characterise the cohort is used to help determine feasibility. The results 
describe the demographics, medical conditions, infections and antibiotic usage, early feeding 
and weaning some comparisons are made with the general population.  
 Results of Medical and feeding questionnaires 
The ability of questionnaires to obtain the required data was assessed by: 
Objective: The ability to characterise the cohort in relation to; 
• ethnicity, maternal age, socio-economic background 
• medical conditions related to a diagnosis of Down’s syndrome 
• to determine the numbers and types of infections experienced during early life and 
antibiotic usage; 
• to describe early feeding and weaning in the cohort; 
The characterisation of the cohort was undertaken in order to determine whether the cohort 
was representative of the general population of children with DS. In the following analyses, 
data from the initial, seven-month and 12-month questionnaire were used. Data from the 24 
and 36-month questionnaires were not analysed as the number of families reaching these 
time points are insufficient for meaningful results. Descriptions are given for the 61 




 Maternal Characteristics 
Table 25 shows that within the study population, over 80% of mothers were at least 30 years 
old with the majority being at least age 35 years. Mothers were largely white British, married 
/ in a civil partnership or living together. At 12 months, half of mothers were in active 
employment or on paid maternity leave. Although seven mothers had returned to work by 
the time their child was seven months, the majority did not return until their baby was over 
the age of nine months.  
Background Characteristics  
Maternal age (years) at time 
of completing initial 
questionnaire 
20 to 24  8.2%   (5/61) 
25 to 29 9.8%  (6/61) 
30 to 34 24.6% (15/61) 
 35 to 39 37.7% (23/61) 
 40 or over  19.7% (12/61) 
Mother’s marital status Living together 27.9% (17/61) 
 Married or in a civil partnership 65.6% (40/61) 
 Single 4.9% (3/61) 
 Widowed, divorced or separated 1.6% (1/61) 
Mother’s ethnic group Other 3.3% (2/61) 
 White British 86.9% (53/61) 
 White Irish 4.9% (3/61) 
 White Other 4.9% (3/61) 
Maternal employment status 
at 7-months 
In active employment 13.2% (7/53) 
On paid maternity leave 64.2%  (34/53) 
 On unpaid maternity leave 3.8%  (2/53) 
 No 18.9%  (10/53) 
Maternal employment status 
at 12-months 
In active employment 45.0% (18/40) 
On paid maternity leave 5.0% (2/40) 
On unpaid maternity leave 15.0% (6/40) 
 No 35.0%  (14/40) 
Age of child when mum 
returned to work 
6 months, less than 9 months 11.1% (2/18) 
9 months or older 88.9%  (16/18) 




 Participant characteristics and birth details 
This sub-section describes the perinatal history, birth details and any admission to Special 
Care Baby Unit (SCBU). Parents informed the study that their child had a diagnosis of DS. 
Genetic information regarding the full karyotype was not obtained. No notification was 
received from doctors or allied health professionals that the karyotype had altered the 
diagnosis, but this was not explicitly asked of them.  
The median age of completion of the seven-month questionnaire was 7.2 months and 12 
months for the 12-month questionnaire; the IQR for both questionnaires is relatively narrow 
as shown in Chapter 4 Table 22. Of the 61 participants, 54.1% were female (33/61). 
Table 26 shows that a quarter of the participants were diagnosed antenatally with Down’s 
Syndrome. Over half were born via a normal vaginal delivery with a mean birthweight of 3kg. 
Most of the babies were born in consultant or midwife led hospital units, three were delivered 
at home. The median gestation was slightly early at 38 weeks but still within the definition of 
“Term”. Thirteen babies who were born pre-term (gestations of between 32 and 37 weeks). 
One baby had a sibling with DS, but no other family history of DS was given. Two participants 
were non-identical twins (not with each other), with siblings who did not have DS. The median 
length of hospital stay after birth was five days.  
Only 72.3% (34/47) of participants had the correct ‘DS insert’ in their Red book, the personal 
child health record that is given to every baby. The ‘DS insert’ contains the correct growth 
charts for babies and children with DS, this is important to ensure that they are growing as 




Some babies required prolonged stays in hospital following birth. Parents were asked about 
hospital admissions between questionnaire time points (see Appendix 29). 
Birth History     
First baby  
 
31.2% (19/61) 
Prenatal diagnosis of DS  24.6% (15/61) 
Twin Birth  
 
3.3% (2/61) 
Type of delivery Normal Vaginal delivery 63.3% (38/60) 
 C-Section 28.3% (17/60) 
 Forceps 3.3% (2/60) 
 Ventouse 5.0% (3/60) 
Gestation (weeks) 
 
Median 38 (IQR 37 – 39) 
Pre-term 32-37 weeks  21.3%  (13/61) 
Birthweight Birthweight Mean 3.0kg (0.5 SD) 
Location of birth At home 5.0% (3/59) 
 In hospital (consultant led) 49.2%  (29/59) 
 In hospital (midwife led) 42.4% (25/59) 
 Birth centre (midwife led) 3.4% (2/59) 
Length of initial hospital stay (hours) Median 120 (IQR 72 – 216) 
 
Table 26: Birth Details 
Footnote: C-section (Caesarean Section) 
 
Table 27 shows that over half of the participants were admitted to SCBU for a median 
admission duration of two weeks. About a third were admitted due to problems related to 










Admitted to SCBU 55.7% (34/61) 
Admitted to SCBU due to problems with feeding  29.4%  (10/34) 
Admitted to SCBU for any other reason*  70.6% (24/34) 
Hypoxia / respiratory distress / PPHN 50.0% (17/34) 
Jaundice 20.6% (7/34) 
Cardiac / cardiac monitoring 11.8%  (4/34) 
Infection 11.8% (4/34) 
Prematurity 8.8% (3/34) 
Polycythaemia 5.9%  (2/34) 
Other 20.6% (7/34) 
Number of different reasons given for admission 
to SCBU (excluding feeding as a reason) 
  
1 41.7%  (10/24) 
2 37.5% (9/24) 
3 16.7%  (4/24) 
4 4.2%  (1/24) 
Length of SCBU stay (weeks) Median 2 (IQR 2 – 4)  
Table 27: Admissions to Special Care Baby Unit 
Footnote: SCBU (Special Care Baby Unit), Persistent Pulmonary Hypertension (PPHN) 
*Due to the branching of the questions relating to SCBU, once the parents answered “Yes” to “After the birth, 
were you told that your baby needed to go to special care because of problems specifically with feeding?”, they 
were then branched away so that they could not also answer “Yes” to “Was your baby put into special care for 
any other reason?”. Some babies may therefore have had feeding and other issues which are not represented 
here. 
 
 Medical conditions and input of professionals 
This section includes the assessment of the presence of medical conditions associated with 
DS, including cardiac defects and details of other common conditions in the study population. 




Over half of the participants in the study were diagnosed with a cardiac condition with about 
10% having more than one cardiac diagnosis as shown in Table 28. The most common defects 
were atrioventricular septal defect, atrial septal defect and ventricular septal defect.  
Cardiac  
Diagnosed with a heart condition  61%  (37/61) 
Atrioventricular septal defect  13.1% (8/61) 
Atrial septal defect  13.1% (8/61) 
Ventricular septal defect 13.1% (8/61) 
Patent ductus arteriosus  9.8% (6/61) 
Patent foramen ovale  6.6% (4/61) 
Unspecified hole in the heart 4.9% (3/61) 
Tetralogy of Fallot 3.3% (2/61) 
Aberrant right subclavian artery 1.6% (1/61) 
Bicuspid aortic valve 1.6%  (1/61) 
Pulmonary hypertension 1.6% (1/61) 















Table 28: Cardiac conditions 
Table 29 shows medical diagnoses that are either known to occur more frequently in DS or 
which have been coded from free text and frequencies given where there was commonality 
between participants. The most commonly reported diagnosis was reflux. Other significant 
conditions reported were Transient Abnormal Myelopoiesis in three participants and gut 
abnormalities, Hirschsprung’s and Duodenal atresia in four participants. Other diagnoses 
mentioned by families included for example glue ear, undescended testes, eczema, 
nystagmus and craniosynostosis. None of the participants were reported to have developed 
diabetes or coeliac disease in any of the questionnaires. Of the two hypothyroid children, one 




blood samples were tested as part of this study for autoantibodies to thyroid peroxidase and 
were negative suggesting that their hypothyroidism was not due to autoimmunity.  
Medical diagnoses Initial 
questionnaire  
New diagnosis 
(from 7-month or 
12-month 
questionnaire) 
Total number  
Hirschsprungs*** 3.3% (2/61)  3.3% (2/61) 
Hypothyroid  n/a**  3.3 % (2/61)  3.3% (2/61) 
Transient abnormal* 
myelopoesis 
4.9% (3/61)  4.9% (3/61) 
Duodenal atresia*** 3.3% (2/61)  3.3% (2/61) 
Reflux* 8.2% (5/61) 3.3% (2/61) 13.1% (8/61) 
Cow’s milk protein* 
allergy age <3months 
 3.3% (2/61) 3.3% (2/61) 
Chest / Bronchiolitis*  4.9% (3/61) 4.9% (3/61) 
Laryngomalacia*  3.3% (2/61) 3.3% (2/61) 
Sleep apnoea*  4.9% (3/61) 4.9% (3/61) 
Number of other 
medical conditions not 
listed in the conditions 
above  
0   65.6% (40/61) 
1   26.2% (16/61) 
2   4.9% (3/61) 
3   1.6% (1/61) 
5   1.6% (1/61)  
0    77.8% (42/54) 
1    18.5% (10/54) 
2    1.9% (1/54) 
4     1.9% (1/54) 
 
Table 29: Medical diagnoses excluding cardiac. 
Footnote: Missing values have been counted as “no” as some diagnosis have been created from free text 
and therefore the denominator for these was 61 already. (Percentages were manually calculated where the 
denominator needed to be changed).  
*New variables were created for diagnoses which were coded from free text and frequencies have been 
given where there was commonality between participants (see master sheet of new variables in Appendix) 
**Participants were not asked in the initial questionnaire about autoimmune conditions as autoimmunity 
at birth is rare but were asked in the subsequent questionnaires.  
***The initial questionnaire specifically asked about duodenal atresia and Hirschsprung disease, as there 
is an increased risk of having these malformations in babies with DS. 
 
The variety of health professionals involved in a child with DS’s care is shown in Table 30. 
Although nearly 80% reported having a community paediatrician before seven months of age, 




cardiologist and over half had a speech and language therapist involved in their care by 12 
months. The other professional who played a role in the care of many of the participants was 
a physiotherapist. 
Specialists involved in baby’s care 0 – 7 months 7-12 months 
Community Paediatrician 79.6% (43/54) 25% (10/40) 
Cardiologist 61.1% (33/54) 57.5% (23/40) 
Speech and Language Therapist (SALT) 44.4% (24/54) 57.5% (23/40) 
Dietician 24.1% (13/54) 25% (10/40) 
Gastroenterologist 7.4% (4/54) 12.5% (5/40) 
Endocrinologist 3.7% (2/54) 12.5% (5/40) 
   
Other (from open question) 55.6% (30/54) 60.0% (24/40) 
Physiotherapist 42.6% (23/54) 40.0% (16/40) 
Portage / Early Years Teacher 11.1% (6/54) 12.5% (5/40) 
Ophthalmology 9.3% (5/54) 10.0% (4/40) 
Occupational Therapist 9.3% (5/54 17.5% (7/40) 
Community Nurse / Health Visitor / 
Paediatric Nurse 
7.4% (4/54) 2.5% (1/40) 
Audiologist 3.7% (2/54) 2.5% (1/40) 
Cranio-facial / Head Specialist 3.7% (2/54) 2.5% (1/40) 
Ear Nose and Throat Doctor  3.7% (2/54) 5.0% (2/40) 
Haematologist / Oncologist 3.7% (2/54) 5.0% (2/40) 
Surgeons 3.7% (2/54) 2.5% (1/40) 
Allergist 1.9% (1/54)  
Psychotherapist 1.9% (1/54)  
Hepatologist 1.9% (1/54)  
Stoma Nurse 1.9% (1/54)  
Paediatrician / Neonatologist  10.0% (4/40) 
Respiratory Consultant   5.0% (2/40) 
   
Table 30: Specialists involved in child’s care 
Footnote: The data in this table is taken from the 7-month and 12-month questionnaires. This question is not 





Table 31 shows the proportions of participants experiencing common childhood conditions. 
Half of the babies aged nine to 12 months had chest problems and this was a common issue 
at younger ages too. Gut problems including vomiting, diarrhoea and constipation were 
commonly experienced, with constipation reported by 35% to 48% of participants from age 
three to 12 months. Poor weight gain during the first month of life was reported by 23 
participants; although this appeared to have improved for many by seven months, it became 
a more frequent issue again between the ages of 9-12 months. It is important to note that all 
study participants required hospital admissions prior to their first birthday. 
Common condition by age   
 Age 0 – 1 
month  
Age 1- 3 
months 












24.1% (13/54) 20.0%  
(8/40) 
50.0% (20/40) 
Constipation 11.5%  
(7/61) 
19.7% (12/61) 48.2% (26/54) 35.0% (14/40) 35.0% (14/40) 
















































Not gaining enough 
weight 








Gaining too much 
weight 








Something else 14.8% (9/61) 13.1 (8/61) 11.1% (6/54) 2.5% (1/40) 15.0% (6/40) 




 Antibiotic use and infections 
In this section, data on maternal use of antibiotics during pregnancy, labour, early feeding 
and infancy are explored. Data on the frequency of antibiotic use in infancy and the infections 
for which antibiotics were given are also presented. The antibiotics and the types of infections 
were coded from open questions. 
Table 32 shows that 18% of mothers received antibiotics during pregnancy, 7% during labour 
and nearly 15% whilst breastfeeding (during the first three months of their baby’s life). From 
open responses, urinary tract infections were the most common infection for which mothers 
received antibiotics during pregnancy. Urinary tract infection was one of the indications given 
by the mothers for antibiotics during the time that they were breastfeeding. Other infections 













Maternal infections and antibiotic use  
Antibiotics given in first trimester 4.9% (3/61) 
Antibiotics given in second trimester 8.2% (5/61) 
Antibiotics given in third trimester 6.6% (4/61) 
Number of trimesters in which antibiotics were given   
None 82.0% (50/61) 
One trimester 16.4% (10/61) 
Two trimesters 1.64% (1/61) 
Antibiotics given during labour    
Yes  6.7% (4/60) 
No  88.3% (53/60) 
Not known 5.0   (3/60) 
Antibiotics when breastfeeding    
Yes 14.5% (8/55*) 
No  76.3% (42/55) 
Not applicable as formula fed 12.7 % (7/55) 
Not known 1.8 % (1/55) 
Table 32: Maternal antibiotic use during pregnancy, labour and breastfeeding 
Footnote: the details of the types of antibiotics given are in the Appendix 23 and 29. No mother said that they 
were taking antibiotics whilst breastfeeding their baby over the age of 3 months. *55 is the number of mother’s 
who ever breastfed or gave expressed breastmilk to their baby (see Section 5.2.5). 
 
The proportion of children receiving any antibiotics during the first year of life is shown in 
Table 33. Nearly 70% of children received antibiotics during the first 12 months with around 
half during the first few months of life. Infections for which antibiotics were required were 
given most often in the neonatal period and before the age of one month and then later in 
infancy after seven months. There were children who received multiple courses of antibiotics 
during the first year of life (Multiple courses of antibiotics were counted if parents said that 
antibiotics were given at more than one time point (further detail is given in Appendix 29). 





Infant antibiotic use  
Ever received antibiotics  68.9% (42/60) 
Antibiotics age 0-3 months 45.9%  (28/61) 
Antibiotics age 3-7 months* 32.8%  (20/61) 
Antibiotics age 7-9 months 22.5% (9/40) 
Antibiotics age 9-12 months 47.5% (19/40) 
Table 33: Infant antibiotic use by age 
Footnote: For three participants their parents could not remember at which age they received antibiotics. * this 
number may be overrepresented - the question in the 7 month questionnaire was simply worded “My baby was 
aged 3 months plus when they were taking antibiotics”. To see information on the number of antibiotic courses 
given between questionnaires see Appendix 29 
  
Suspected sepsis in the neonatal period was the most common indication for antibiotic 
treatment before the age of three months (18% (11/61)), followed by chest infections (6.6% 
(4/61)). Two babies were given antibiotics for umbilical infections and one for necrotizing 
enterocolitis. Chest infections including bronchiolitis was a frequent indication throughout 
infancy with 40% (16/40) of study participants being given antibiotics between the ages of 
nine and twelve months. Further details on the types of infections can be seen in Appendix 
29 but other indications given for study participants to receive antibiotics during infancy 
included conjunctivitis, urinary tract infections, cellulitis, line infections, suspected meningitis 
and viral infections. Some babies were also given antibiotics as prophylaxis during surgery, 
chemotherapy and to prevent urinary tract infections.  
 Initial feeding after birth 
This section summarises the initial feeds received after birth, maternal experiences of support 




Table 34 shows that half of the mothers in the study had breastfed a previous child. Despite 
all attending antenatal check-ups for the study baby, they did not all attend sessions on 
feeding babies. Most of the mothers who had received a prenatal diagnosis of DS were told 
that babies with DS experience feeding problems but only a minority of these received any 
specific advice. 
Prenatal Feeding Information 
Breastfed a previous child  73.2 %  (30/41*) 
Attended antenatal check-ups  100 %  (61/61) 
Attended a session which included talk on 
feeding babies  
30 %  (18/60) 
Told about specific problems related to feeding 
a baby with DS (if prenatal diagnosis)  
86.7 %   (13/15**) 
Received specific advice antenatally about help 
with breastfeeding a baby with DS   
20.0 %  (3/15**) 
Table 34: Prenatal feeding information 
Footnote: *42 mothers had an older child (missing data on breastfeeding for one). **15 mothers had received 
a prenatal diagnosis for their baby. 
 
The problems that babies with DS have with feeding that were described to mothers included 
baby’s low tone, the size of tongue, difficulty of latching baby on to nipple, being tired or 
getting tired when feeding, taking longer to establish feeding, issues with baby coordinating 
suck and the potential complication of other medical diagnosis. One mother mentioned that 
she was told babies with DS could breast feed and a couple of the mothers said that they had 
been informed about the potential of using other feeding methods. Below are quotes from 
the questionnaire data to illustrate the information given to mothers in response to the 




you told about any specific difficulties related to feeding a baby with Down's syndrome? What 
were you told?’ 
“The paediatrician explained it may be difficult to breastfeed and we may need to consider 
other forms of feeding due to a possible weak suck” 
“Due to low muscle tone and size of tongue, breast feeding could be tricky.  My midwife said 
that because I had breast fed before I would have a confidence that the baby would feed off 
and there was no reason breast feeding wouldn’t work.” 
For specific information on who discussed feeding with the mothers antenatally and who gave 
specific advice regarding breastfeeding a baby with DS please see Appendix 29. 
Table 35 shows the details of the babies first feeds after birth. The majority of mothers had 
skin to skin contact with their baby within 24 hours after birth. The majority of mothers 
initially breastfed their baby (for information on who helped putting the baby to the breast 
whilst in hospital and who helped with breastfeeding see Appendix 29). Feeding problems 
that were experienced in the hospital or birthing centre by the majority of mothers, included 
those commonly associated with babies with DS. Although low tone is one of the explanations 
frequently given as a cause for feeding difficulties in babies with DS only one parent described 









Ever breastfed or received expressed breast milk 90.2 %  (55/61) 
Had skin to skin contact within 24hrs of birth – Yes 78.3 %  (47/60) 
Maternal health problems after birth that affected feeding 6.6 % (4/61) 
Received help with breastfeeding within first few days – yes 66.7 % (40/60) 
How soon after birth was baby put to the breast within a few minutes 25.5 % (14/55) 
 <30 min  30.9 % (17/55) 
 30 min to 1 hr 16.4 % (9/55) 
 >1 hr - 8 hrs 5.5 % (3/55) 
 >8 hrs – 24 hrs 5.5 % (3/55) 
 > 24 hrs later 16.4 % (9/55) 
Experienced problems when feeding their baby in the hospital, birth 
centre or unit  
77.5 % (45/58*) 
Common problems with feeding**  Poor latch 44.4 %  (20/45) 
 Medical issue 31.1 % (14/45) 
 Jaundice 31.1 % (14/45) 
 Tired / lethargic 28.9 %  (13/45) 
 Maternal reason 8.9 %  (4/45) 
 Tongue size/ position 6.7 % (3/45) 
 Low tone 2.2 % (1/45) 
Reported that they received enough help with feeding in hospital / birth 
centre  
82.8 % (48/58) 
Table 35: First feeds 
Footnote:* Three babies were home births ** These problems were coded from open responses. 
 
The quotes below from the open question: ‘Were there any problems feeding your baby while 
you were in the hospital, birth centre or unit? What problems were there?’ illustrate some of 
these issues and the experiences of the mothers. 
 “X would not take anything from the breast and was very sleepy so had an NG tube put in.” 
“A feeding tube was inserted straight away, which prevented me from breast feeding. It also 




“baby continually pushing tongue out and could not latch on. Decided to try the bottle which 
she took immediately so did not try breast again and was not questioned by staff” 
When describing problems many mentioned the need for expressing, NG tube feeding or the 
use of bottles.  
At least half of the participants who completed the initial questionnaire required NG tube 
feeding as shown in Table 36, and the proportion may be higher due to the problems with the 
branching of the questionnaire. Of the babies who were admitted to SCBU, all were NG tube 
fed. Nearly 40% of the babies required NG tube feeds in SCBU due to issues with feeding the 
remainder due to medical co-morbidities (36.9% due to multiple medical indications).  The 
milk that was given down the NG tube was mostly expressed breastmilk or a mixture of 
expressed breast milk and infant formula. Over half of the participants (61.3%) required NG 
tube feeds for less than two weeks. Nearly a third of the participants had feeds stopped at 











Feeding in SCBU and NG tube Feeds 
SCBU admission affected ability of mother to feed baby as she 
would have liked 
67.7 % (23/34) 
Shown how to express milk in SCBU 85.3 % (29/34) 
Felt supported to express milk in SCBU 90.0 % (27/30) 
Had NG tube feeds 100 % (31/31*) 
Required NG tube feeds due to problems with feeding 38.7 % (12/31) 
Medical reason for NG tube 
feeds** 
Prematurity 10.5 %  (2/19) 
Dehydration / hydration 10.5 %  (2/19) 
 Ventilation 10.5 %  (2/19) 
 Respiratory problems 42.1 %  (8/19) 
 Jaundice / polycythaemia 21.1 % (4/19) 
 Vomiting or surgical abdomen 21.1 % (4/19) 
Number of medical reasons 
given for NG tube feed 
1 63.2 % (12/19) 
2 21.1 % (4/19) 
 3 10.5 % (2/19) 
 4 5.3% (1/19) 
Length of time NG tube fed 0 < 3 days 16.1 % (5/31) 
 3 < 7 days 19.4 % (6/31) 
 1 < 2 weeks 25.8 %  (8/31) 
 2 < 4 weeks 19.4 %  (6/31) 
 1 – 2 months 16.1 %  (5/31) 
 >2months 3.2 % (1/31) 
Type of NG tube feeds 
given 
Only expressed breast milk 32.3 % (10/31) 
Only infant formula 6.5 % (2/31) 
 Expressed breast milk and infant 
formula 
61.3 % (19/31) 
Feeds stopped and IV fluids given – yes  32.4 % (11/34) 
Length of time on IV fluids 0 – 3 days 22.2 %  (2/9) 
 3 < 7 days 44.4 %  (4/9) 
 7 days – 1 month 33.3 %  (3/9) 
Table 36: Feeding in SCBU and NG tube feeds. 
 
Footnote: Intra- venous fluids (IV fluids). 
*Due to an issue with branching, only participants who had answered “yes” to “After the birth were you told 
that your baby needed to go to special care because of problems specifically with feeding?” or “yes” to “Was 
your baby put into special care for any other reason?” were able to answer the question regarding NG tube 
feeds. Furthermore, people who had answered yes to being admitted to SCBU but then answered not applicable 
to could not express or did not want to express were also unable to answer the question regarding NG tube 
feeds. This applied to three people. Where they were branched away, people have been counted as missing, so 
the denominator is 31. 





Of 61 participants, 39 (63.9%) continued breastfeeding for over six weeks (Table 37) (this 
included babies who received infant formula as well as breastmilk).  Over the age of six 
months, this had decreased to 54.2% (32/59) participants still breastfeeding.  
The prevalence of exclusive breastfeeding in the study population at six weeks was 21.3% 
(13/61). By six months of age, less than 4% of participants were exclusively breast feeding 
(2/54). Although five participants said that they had only introduced formula over the age of 
six months, two of those had started solids between the ages of five to six months and one 
said that they had given a drink other than milk at the age of six months. Using data from the 
initial and 7-month questionnaires, the median age at which formula was introduced was five 
days (IQR 1, 21 days). Recommendations are that cow’s milk should not be given as a drink 
until 12 months of age but can be mixed in food prior to this; the median age for starting 
cow’s milk in the study population was 11 months so below the recommended age. 
Whilst the seven-month questionnaire elicited a response from all mothers that going back 
to work had not influenced infant feeding (n=7), by 12 months three felt it did. However, by 









Types of feeds / Stopping breastfeeding 
Age stopped breastfeeding  
6 weeks or less 40.7% (11/27*) 
>6 weeks to 4 months 25.9% (7/27) 
>4 months to 6 months 11.1% (3/27) 
>6 months 22.2% (6/27) 
Age started formula feeds  
6 weeks or less 77.2% (44/57**) 
>6 weeks to 4 months 5.3% (3/57) 
>4 months to 6 months 8.8% (5/57) 
>6 months 8.8% (5/57) 
Age when given a non – milk drink (weeks)  Median 26 (IQR 20 - 28)  
Age at which first given cow’s milk 
(months) 
Median 11 (IQR 7-12) 
 
Table 37: Age at which participants stopped breastfeeding (including using expressed 
breastmilk and mixed feeding) and/or were introduced to other types of milk feeds or drinks. 
Non-milk drinks included any drink other than milk including water (which would be fine) and 
juices which would not be recommended. 
Footnote: *this denominator is the number of women who had stopped breastfeeding by the data cut off date. 
Some babies would still have been receiving breastmilk at the cut-off date for data analysis. Some would also 
have been still mixed feeding both breastmilk and formula. **this denominator is the number of participants 
who had started formula by September 2017.  
 
Just over half of the participants had problems with feeding after discharge from hospital as 
can be seen in Table 38. The most common problems experienced were with babies being 
lethargic or failing to thrive. Three of the mothers mentioned that their babies were 
readmitted to hospital due to issues relating to poor feeding. The majority did receive advice 








General Feeding and feeding after discharge from hospital / birth centre 
Problems with feeding baby after discharge from hospital / birth 
centre 
53.6% (30/56) 
Problems with feeding after discharge*  
 Lethargy 21.3% (13/61) 
 Poor weight gain / weight loss 16.4% (10/61) 
 Low tone 1.6%  (1/61) 
 Latch 8.2% (5/61) 
 Medical 4.9% (3/61) 
 Jaundice 4.9%  (3/61) 
 Reflux 4.9% (3/61) 
Received help or information with feeding problems after discharge 84.4% (27/32**) 
Aware of the benefits of breastfeeding for their baby – yes 91.8% (56/61) 
Knowledge of specific health benefits of breastfeeding*   
 Immune system / protection against 
infections 
85.3% (52/61) 
 Nutritional value / Natural / Vitamins 31.2%  (19/61) 
 For bonding and comfort 29.5% (18/61) 
 Oro – motor development 23.0% (14/61) 
 Good for digestion 19.7%   (12/61) 
 Healthy weight / preventing obesity 16.4% (10/61) 
 Allergies 13.1% (8/61) 
 General health 6.6%  (4/61) 
 Brain development 6.6% (4/61) 
 Constipation 4.9% (3/61) 
 Diabetes prevention 4.9% (3/61) 
 Gut flora 4.9% (3/61) 
 Sudden Infant Death Syndrome 3.3% (2/61) 
 Other 4.9% (3/61) 
Table 38: General Feeding and feeding after discharge from hospital / birth centre 
Footnote *coded from open responses. **This denominator comes from the 30 participants who experienced 






The quotes below illustrate the information that the mothers provided in the questionnaire 
regarding the problems they experienced: ‘Since you left the hospital, birth centre or unit 
have you had any problems with feeding your baby? What problems were there?”  
“She slept a lot and had to be woken to feed. She was slow to gain weight at first.  Once we 
got rid of the nipple shields which I introduced to help establish breastfeeding (and I believe 
helped initially) as I was advised that it helped babies with DS latch on, she gained more 
weight”  
 
“About 2 days after getting her home, child’s name stopped feeding and I was worried that 
she was becoming dehydrated.  She was also very sleepy and had to be woken up for feeds.  
This was quite frightening as we had not been told to expect this.  I used to need to strip her 
off to feed and make my hands cold so that she would wake up.  I was scared she was going 
to die to be honest, it was awful.   We were told to top up feed her with a bottle, we did this 
with expressed breast milk, and she gained weight well.” 
 
Over half of the mothers said that they would have liked to have breastfed for longer as shown 
in Table 39. The reasons for stopping breastfeeding included inadequate breastmilk supply, 









Stopping breastfeeding and 
problems with feeding 
Initial Q  7 month Q 12 month Q 
Maternal opinion on how long they breastfed* 
Breastfed for as long as they 
intended 
37.8% (14/37) 17.4% (4/23) 20.0% (4/20) 
Breastfed for longer than they 
intended 
8.1% (3/37) 13.0% (3/23) 15.0% (3/20) 
Would have liked to breastfeed 
longer. 
54.1% (20/37) 69.6% (16/23) 65.0% (13/20) 
Reasons for stopping breastfeeding** 
 Inadequate breastmilk supply 30% (6/20) 13.0% (7/54) 5.0% (2/40) 
 Problems expressing milk 25% (5/20) 5.6% (3/54) 10.0% (4/40) 
 Excessive time expressing milk 25% (5/20) 1.9% (1/54) 5.0% (2/40) 
 Baby losing weight 20% (4/20) 3.7% (2/54) 5.0% (2/40) 
 Maternal medical problem 15% (3/20) 3.7% (2/54) 2.5% (1/40) 
 Lethargy 5% (1/20) 1.9% (1/54)  
 Weaning by choice n/a 7.4% (4/54) 7.5% (3/40) 
 Other   5.6% (3/54) 10.0% (4/40) 
Feeding problems since completing the previous 
questionnaire (including breast, bottle and / or giving 
solids)** 
41.5% (22/53) 47.5% (19/40) 
 Swallowing difficulties / gagging / reflux 14.8% (8/54) 15.0% (6/40) 
 Difficulties managing bottles 9.3% (5/54)  
 Feeding position 9.3% (5/54)  
 Constipation 7.4% (4/54)  
 Gastro – intestinal problems with solids 
(constipation / flatus / vomiting) 
5.6% (3/54)  
 Difficulty / slow weaning onto solids  15.0% (6/40) 
 Medical  12.5% (5/40) 
 Allergy  5.0% (2/40) 
 Other 7.4% (4/54) 7.5% (3/40) 
Received help or found information 
to help with these feeding 
problems*** 
 81.8% (18/22) 73.7% (14/19) 
Table 39: Stopping breastfeeding and general problems with feeding including breastfeeding, 
bottle feeding and giving solids.  
Footnote: *The denominator of 37 for the initial questionnaire is greater than the number who said they had 
stopped breastfeeding. It may have also been answered by some mothers who were giving expressed breastmilk 
rather than feeding directly from the breast. ** Coded from open responses. ***Further details on the sources 





The quotes below from the questionnaire illustrate the reasons mothers gave for stopping 
breastfeeding ‘Have you stopped breastfeeding (no longer give your baby any expressed milk 
or put your baby to your breast)? What were your reasons for stopping?’ (the same question 
was asked in the initial, 7-month and 12-month questionnaires.   
“Significant weight loss in early days, poor latch, inadequate milk being taken by baby, 
readmission to hospital for tube feeding, introduction of bottle feeding in hospital, milk supply 
subsequently drying up due to baby being put on bottle and use of pumps further made milk 
supply deteriorate.” 
“Baby fell asleep too much at the breast to feed properly. It was too time consuming and 
stressful to keep expressing.” 
The feeding problems experienced or reported changed as the babies got older as shown in 
Table 39. Both in the 7-month and 12-month questionnaire, problems with swallowing and 
reflux were found, but problems with positioning and managing bottles were more common 
at a younger age. These are illustrated in the quotes below from the 7-month questionnaire 
(Have you had any problems with feeding your baby (including breastfeeding, bottle feeding 
and / or giving your baby solids) since the time you filled in the previous questionnaire? Please 
specify)  
“engaging interest in solid food, then getting her to swallow, 'chew' and eat solid food. Made 
more difficult because so hard to find practical comfortable feeding seating arrangement with 




“Child’s name has an unsafe swallow and is on a continual feed of 20ml hour via ng tube” 
(from 7-month questionnaire)  
“was told when in intensive care unit that child’s name likely had chronic aspiration, therefore 
she was nil by mouth until January and slowly starting purees while awaiting videofluroscopy 
in February. Child’s name had been breastfed and I did not have enough supply for her needs, 
so she is currently on a mix of expressed breastmilk and formula via ng tube.  Also, I add 
formula to the EBM to make it more calorific due to weight loss when sick.  Child’s name is still 
being treated as cow’s milk protein allergy, I do not consume any dairy and the formula she 
receives is a mix of neocate and infatrini peptisorb” (from 12-month questionnaire) 
Mothers were asked “What would have helped you breastfeed longer?” the answers 
included, not introducing bottles as early, not needing to express, being at home and having 
more specific support. Below are quotes from the initial, 7-month and 12-month 
questionnaires in response to this question. Some mothers also used this question to explain 
that they did breastfeed. 
“Knowing as I do now that it's common to have feeding problems with Down syndrome. More 
specific breastfeeding support.” (from initial questionnaire) 
“My infections couldn't have been helped, however I feel I was forced to give Child’s name a 
bottle when she was only a day old as the midwife was unwilling to entertain my concerns 
about the bottle meaning that she would never take the breast. I had wanted to give the milk 
by syringe or cup to give her a chance to keep trying the breast, but I was shot down and 




“I just became too sick unwell but at the same time I fed longer than I thought I would. Thanks 
to the support I received.” (from 12-month questionnaire) 
“She lost 6% of her birth weight by day 9 and the NICU home midwife suggested we move 
onto top up. I think that was the pinch point. If I had said no, let’s try harder to feed from the 
breast it might have established itself. But she had just been discharged from hospital and I 
was so reluctant to go back. You really have the threat of readmission hanging over you. I also 
had a three-year-old to look after so couldn't spend hours sat feeding her or encouraging her 
to feed. I would have loved to feed her myself. It is my biggest sadness but there were too 
many other variables at play. I am pleased I was able to exclusively breast feed her though for 
well over 4 months.” (from 12-month questionnaire)  
 Weaning 
In this section, results are given regarding the age at which participants were weaned onto 
solids, the reasons for starting solids at that age and issues that they encountered with 
weaning. Information is given on ingredients that parents excluded from their child’s diets 
and the reason for this. Table 40 shows that just over half of the babies in the study who had 
been weaned onto solids by 1st September 2017 were weaned prior to or just up to the 
recommended age of 6 months. Of those who had started weaning by September 2017, 81.3% 







Weaning onto solid feeds 
Age when started weaning onto solid feeds   
4 months or less 5.7% (3/53*) 
5 months or less 20.7% (11/53) 
6 months or less 52.8%  (28/53) 
7 months or less 94.3% (50/53) 
More than 9 months 100.0% (53/53) 
 
Table 40: Age at which weaned onto solids.    
Footnote: Results are cumulative *53 had started solid feeds by September 2017  
The reasons for weaning are given in Table 41, the most common reasons being; the advice 
of health professionals, previous experience with another baby and having read or seen 
information which advised starting solids. Advice on which types of solid feed should be given 
to their baby was received by 80 % (40/50). Further details on sources of advice that the 
mothers used and what types of feeds the babies had been given at different ages can be 












Reason for starting solid feeds 7-month Q 12-month Q 
Advice of health professional 50.0% (27/54) 72.5% (29/40) 
Previous experience (with another baby) 51.5% (28/54) 42.5% (17/40) 
Read leaflets / seen information that advised 
me to  
24.1% (13/54) 27.5% (11/40) 
Baby was not satisfied with milk 13.0% (7/54) 5.0% (2/40) 
Baby was able to sit up and hold food in hand 11.1% (6/54) 12.5% (5/40) 
Start4Life 3.7% (2/54) 7.5% (3/40) 
Baby was not gaining enough weight 3.7% (2/54) 7.5% (3/40) 
Baby was waking up during the night 5.6% (3/54) 7.5% (3/40) 
Advice of friend or relative -  5% (2/40) 
Other 20.4% (11/54) 10.0% (4/40) 
Followed standard advice* 7.4% (4/54)  
Parental choice* 5.6% (3/54)  
Number of different reasons given for 
starting solids 
  
None 7.4% (4/54)  
1 31.5% (17/54) 40.0% (16/40) 
2 40.7% (22/54) 32.5% (13/40) 
3 14.8% (8/54) 22.5% (9/40) 
4 3.7% (2/54) 2.5% (1/40) 
6 1.9% (1/54) 2.5% (1/40) 
Table 41: Reasons for starting solid feeds. 
Footnote: *coded from free text where there was a commonality between the answers given by different 
participants 
 
Table 42 shows that of those who were able to answer the question, less than half had issues 
with introducing solids and the most frequent issues were around the baby not taking certain 
foods or being disinterested. From the open question, issues around the mechanisms of 







Issues with weaning onto solids 
Issues introducing solids – yes 41.2% (14/34*) 
Issues with starting solid feeds 
Baby would not take certain solids 20.6% (7/34) 
Baby was disinterested in food 11.8% (4/34) 
Baby prefers to drink food 11.8% (4/34) 
Baby would not take solids 8.8% (3/34) 
Baby vomiting 8.8% (3/34) 
Baby does not like to eat with a 
spoon 
2.9% (1/34) 
Other** 23.5% (8/34) 
Swallow / gagging 11.8% (4/34) 
Texture 11.8% (4/34) 
Slow to wean / other 11.8% (4/34) 
Number of difficulties with starting solids  
1 8.8% (3/34)  
2 5.9% (2/34)  
3 8.8% (3/34)  
4 11.8% (4/34)  
5 5.9% (2/34)  
Table 42: Issues with weaning onto solids 
Footnote: *There was a branching issue with this question so that people who answered “no” to “Did you get 
any information about when to start giving solids foods to your baby?” could not then go on to answer questions 
about issues with weaning onto solids. ** these were coded from open questions and have been included where 
there is a commonality. 
Issues with the branching of the questionnaire meant that six of the mothers were branched away from the 
questions on issues experienced with weaning their babies 
 
Table 43 shows that of the participants who were able to answer this question, half avoided 
including certain ingredients in their children’s diet. The reasons given for excluding or 
restricting these foods was largely due to standard guidelines around healthy eating and also 
standard recommendations for young infants. Some parents gave specific reasons around DS 




“Too much salt in any diet is bad leading to problems later in life.  Too much added sugar is 
bad for teeth, and weight.  Down’s Syndrome has an increased risk of heart problems, weight 
gain and diabetes.”   
“I don't eat gluten myself and have read about some of the problems children with DS have 
with gluten. I do plan to trial her on it when she is older.   Sugar-the negative effects of sugar 
on health   Table salt-again don't think this is very good but do add a small amount of sea salt.  
Dairy- Has butter most days. I have read that can increase mucous production, butter is the 
most digestible and as she is quite congested have avoided so far but I will introduce more 
soon” 
Restricting diet / omitting ingredients 
Avoids some solid foods with particular 
ingredients 
50.0% (17/34*) 
Foods which are avoided   
Refined sugar / sugar 26.5% (9/34) 
Salt 14.7% (5/34) 
Animal milk/ cow’s milk 11.8% (4/34) 
Honey 11.8% (4/34) 
Soya 8.8% (3/34) 
Gluten 8.8% (3/34) 
Egg 5.9% (2/34) 
Fish 5.9% (2/34) 
Nuts 5.9% (2/34) 
Other 11.8% (4/34) 
Table 43: Ingredients omitted from participant’s diets.  
Footnote: *As with Table 40, six participants were branched away from this question.  
 Comparison of Study Cohort and General population 
The results of the medical and feeding questionnaires in this chapter are descriptive as the 




to the general population in the UK. The tables below summarise some of the key findings 
and have been presented together with data from previously published literature on the 
general population. Comparisons will be explored further in the discussion section at the end 
of this chapter.  
Table 44 shows a summary of the background characteristics for the mothers (refer to Table 
23 for more detailed results). This table shows that mothers in the study were older, the 
majority of mothers were white British, and this was slightly greater than the proportion of 
mothers in the population for England. A larger proportion of mothers in the study were 




Average age of mothers  30.4 years*¹ 
 
Majority over the 
age of 35 (57.4%) 
Ethnicity 83% White*2 87% White British 
Marital Status of mother.  
(proportion of mothers who 
were married, in a civil 






Maternal Employment status 
(proportion employed or on 
paid maternity leave) 
66% *4 50%*5 
Table 44: Background characteristics of mothers in the study shown beside data from the 
general population 
Footnote: *¹(ONS 2016), *2 Proportion of mothers classed as White in a study of 600,000 mothers in England 
(Heslehurst et al. 2010). *3(ONS 2016). *4 (ONS 2017) *5 (ONS 2017). 
 
The summary birth statistics for the general population are shown for comparison together 
with those of the participants in Table 45 (refer to Table 26 for more detailed results). The 




general population as were the proportion of home births (although numbers were very 
small). The mean birthweight for the babies in the study is also comparable to that of the 
general population of babies with DS (Morris et al. 2015).  
 General Population FADES Participants  
Type of Delivery   
normal vaginal delivery  59%* 63%  
C section 28%* 28% 
Home Births  2%*1 5% 
Pre-term births  8%*2 (<37 weeks) 21% (<37 weeks) 
Median gestation 38 weeks  
Birth weight 
 
3.5 kg  Mean 3.0 kg (0.5 SD) 
Admitted to SCBU 14%*3 56% 
Table 45: Birth details and SCBU admissions for the study population shown beside data from 
the general population.  
Footnote: * (NHS Digital 2017). *1 (ONS 2015). *2 (NHS Digital 2017). *3 (RCPCH 2018) 
 
A selection of the more common conditions found in children with DS are shown in Table 46. 
The prevalence of congenital heart disease, duodenal atresia/stenosis, Hirschsprung’s disease 
and transient abnormal myelopoiesis within the study population are similar to those 









Table 46: Medical conditions for the study population shown beside data from the general 
population and the general population of children with DS  
Footnote:*(BINOCAR 2013). **Of note this includes babies with DS (Craig 2006). *** This includes those with DS 
who make up approximately 30% of those with a diagnosis of duodenal stenosis atresia (Eovaldi and Cohen 
2018). ****From a study in the North of England (Best et al. 2012).  
*1 (Freeman et al. 1998, Roizen and Patterson 2003). *2 Of those with congenital heart disease. *3 (Freeman et 
al. 2009) *4 The frequency of transient abnormal myelopoiesis in the general DS population is unknown as it can 
be a silent condition and will not be picked up unless a full blood count and film are done. The estimated rate 
however is 4% to 10% of babies with DS (Yumura-Yagi et al. 1992). 
 
Early feeding and breastfeeding statistics for the general population and for FADES 
participants are given in Table 47. This table shows that at all time points the proportion of 
babies within the study who were either breastfeeding (including those who received 
formula) or exclusively breastfeeding were higher (or in one case comparable) to those 










0.5 – 0.9%* 40 – 60%*1  60%  
AVSDs 0.2 – 0.3 per 1000 live 
births** 
30 – 40%*1 22%*2 
Duodenal atresia / 
stenosis 
1 in 5000 to 10000 live 
births*** 
1-5%*3 3% 
Hirschspungs Disease  1.6 per 10000 live 
births**** 
1-3%*3  3% 
Transient abnormal 
myelopoesis 







Skin to skin contact within 24 
hours after birth  
88% 78% 
Initial breastfeeding rates 81%*2 90% 
Prevalence of breastfeeding at 
6 weeks*3 
55% 64% 
Prevalence of breastfeeding at 
6 months 
34% 54%  
Exclusive breastfeeding rates at 
6 weeks 
23%  21% 
Exclusive breastfeeding rates at 
6 months 
1%  4%  
Table 47: Breastfeeding rates for FADES and the general population. 
Footnote:*1 IFS 2010 (McAndrew et al. 2012). *2 UK rates for initial breastfeeding (babies who were breastfed 
even if just on one occasion or if received expressed breastmilk). *3 prevalence of breastfeeding (which includes 
mixed feeding) in the general UK population at 6 weeks. 
 
 Discussion of Chapter 5: Medical and Feeding Questionnaires 
The feasibility of the medical and feeding questionnaires were addressed in Chapter 4. This 
Chapter determines the secondary objectives of characterising the cohort and exploring the 
medical and feeding data. This was to establish whether the cohort is representative of the 
general population of children with DS. Also, whether the questionnaire data revealed 
information regarding the factors involved in the development of autoimmunity that they 
were designed to explore. These are discussed in detail in the following sections.  
 Cohort characteristics 
Overall the results suggest that the FADES study population is representative of the overall 





Mothers were of a similar age and ethnicity to other mothers, although a higher proportion 
were married, in civil partnerships or living together. But fewer mothers were in employment. 
The majority were at least 35 years old when they completed the initial questionnaire. This is 
similar but slightly older than a previous research study in 2007/8 which found an average 
age for mothers of babies with DS of 34.4 years (Morris and Alberman 2009). This might 
simply reflect selection bias, with older mothers who have decided to go ahead with a 
pregnancy (a quarter of the babies in the study were diagnosed antenatally, higher than the 
11% of live births of children with DS in England and Wales according to the NDSCR (Morris 
and Springett 2014b) then self-identifying and finding the study themselves. The average age 
of all mothers in England and Wales in 2016 was 30.4 years (ONS 2016). The majority of the 
mothers were white British similar to a recent national study which also showed over 80% of 
mothers in England are white British (Heslehurst, Rankin et al 2010).  Interestingly only 60.6% 
of babies born in England and Wales in 2016 were classified White British by their mother. A 
larger proportion of these mothers were likely to have been White British but the father 
having differing ethnicity. A weakness of this study was that only parents who were English 
speaking were able to join the study inevitably leading to selection bias. The ONS report 2016, 
reported that 84% of babies in England and Wales were born to parents in marriage, civil 
partnership or living together (ONS 2016): the FADES population has even higher levels. 
Parents in stable relationships may feel better able to engage in research. Information on 
maternal employment status was collected as an indication of socio-economic and 
educational background. Compared to mothers in the general population in England, fewer 




decisions regarding when or if to return to work may have been based on different factors to 
mothers in the general population. Very little can therefore be concluded from this question; 
the aim would have been better achieved by asking more detail regarding educational 
background instead (age left school, university education, qualifications).  
Participant characteristics and birth details 
Just over half of the participants were female (54%). The percentage of babies in the cohort 
delivered by spontaneous vaginal delivery or C section were similar to the 59.4% of 
spontaneous deliveries and 27.8% of C-section deliveries in England between 2016 and 2017 
(NHS Digital 2017). The mode of delivery is of interest as the incidence of autoimmune 
conditions particularly T1D is higher in those born via C-section compared with the vaginal 
route (Norris et al. 2003).  This difference may be due to the microbiota of babies born via C 
section being different from that of babies born vaginally (Stewart et al. 2018). As the 
proportion of babies born via C-section in the study is similar to the general population 
however, this is unlikely to contribute to any increased risk of autoimmune diabetes. 
The proportion of preterm births (<37weeks) was relatively high in the study population 
compared to the 7.9 % of babies born at <37 weeks in England (NHS Digital 2017). None of 
the babies in the study were very or extremely preterm. The median gestation of 38 weeks 
within the study cohort fits with the modal gestation reported by Morris et al. of 38 weeks for 
babies with DS (Morris et al. 2015). Up to 38 weeks gestation the birth weight for babies with 
DS is similar to that of other babies but by 40 weeks new-borns with DS are smaller. The 
median birth weight from 37- 42 weeks gestation for boys with DS is 2.97 kg and for girls 




The karyotype for the babies in the cohort was not requested which might be considered a 
weakness. FADES potentially might include children with mosaic Down’s syndrome who can 
be phenotypically milder although this is rare: one to three children in every 100 children 
diagnosed as having DS have the Mosaic form (Devlin and Morrison 2004). This is unlikely to 
skew any conclusions. Two children with DS had a non-DS twin. Attempts were made to allow 
the twin siblings without DS to enter the study as controls. Although the parents were willing, 
ethics approval was not given.    
The median length of hospital stay after birth was five days, often reflecting the amount of 
time it took to establish feeds but also the time to confirm the diagnosis of DS and check for 
other associated conditions. This is an important period for the families to adjust to the 
diagnosis. The range of time babies stayed in hospital was very wide with some babies going 
home 13 hours post-delivery and others not going home for several months due to medical 
problems. 
Of concern is the observation that over a quarter of the mothers reported that they were not 
given the correct ‘DS insert’ in their Personal Child Health Record (‘Red’ book). This insert 
provides families and health professionals with important information about children with 
DS. It contains the correct growth charts for babies with DS (DSMIG 2019b, RCPCH 2019). 
Healthy babies with DS gain weight and grow more slowly than other children and it is 
important to understand this so that expectations are managed, and parents are given the 
correct advice about their baby’s feeding. If a baby with DS is plotted on a standard growth 




may be told that she needs to supplement feeds, start formula feeds if she is breastfeeding 
or even that her baby needs admission to hospital. 
 Medical  
SCBU admissions    
Over half of the babies in the cohort were admitted to SCBU with approximately a third being 
due to problems with feeding and two thirds with medical complications. The most common 
reason for SCBU admission was respiratory problems other causes being jaundice, cardiac 
conditions/monitoring and infection. The degree to which the diagnosis of DS was a factor in 
the decision to admit the baby to SCBU is unknown. Having a period when their baby was in 
SCBU will have been helpful for some parents with additional support but for others it may 
have affected their autonomy particularly around decisions for infant feeding. 
Medical conditions  
The FADES cohort is similar to children with DS in general in terms of associated medical 
conditions. Within FADES, 61% of babies had congenital heart disease which aligns with 
around 40% to 60% of children with DS having a heart condition (Freeman et al. 1998, Roizen 
and Patterson 2003). AVSD is the most common defect seen (30%) in children with DS and 
accounted for 20% of the cardiac defects seen in the cohort ((Roizen and Patterson 2003, 
Freeman et al. 1998). Other medical conditions in the cohort included Hirchsprung’s disease, 
duodenal atresia, transient abnormal myelopoesis, hypothyroidism and sleep apnoea. These 
are all conditions known to be associated with DS; duodenal atresia/ stenosis is found in one 
to five percent of children with DS, one to three percent have Hirschsprung disease (Freeman 




it may be a silent condition (unless a full blood count is done), it is estimated that the rate is 
around four to 10% of babies with DS (Yumura-Yagi et al. 1992). Other conditions that were 
reported are relatively common amongst all newborns. Reflux was the most frequent 
condition with 13% of the cohort reporting that their child has reflux however as described 
by Hyman et al there are many common neonatal and childhood gastrointestinal disorders 
which might be mis-labelled as reflux (Hyman et al. 2006).  
Having a representative sample of Trisomy 21 associated comorbidities is important as 
feeding is necessarily tied up with co-morbidity and this study focused significantly on the 
baby’s ability to feed, the method by which they are fed and the types and quantities of feeds 
that were given.   
This study was established to focus on the development of autoimmunity but no clinical 
diagnoses of coeliac disease or T1D were made in the study population during the period 
analysed. There were two children with hypothyroidism but neither child had antibodies 
suggesting the cause of hypothyroidism was not autoimmunity. Karlsson et al concluded that 
although autoimmune thyroid disease was common in people with DS over the age of eight, 
the causes of hypothyroidism before this age was not clear but maybe due to thyroid 
hypoplasia or dyshormonogenesis (Karlsson et al. 1998).  
It was surprising that all participants required admission to hospital prior to their first 
birthday. Although acknowledging that children with DS have frequent infections and may 
have conditions which require surgical intervention, this universal re-admission highlights the 
severity of the condition. Hilton et al found that most hospital admissions for infants with DS 




al. 2007, Hilton et al. 1999). When parents were asked about common childhood conditions, 
chest and respiratory issues were frequent with half of the babies aged between nine and 12 
months reporting a problem. Gut problems and weight gain were also common in all age 
groups up to 12 months. Moore et al previously reported that functional and structural 
abnormalities within the gastro-intestinal tract are common in children with DS (Moore 
2008).   
Delivery of care and input of professionals 
Parents were asked about the professionals that were involved in their babys’ care and the 
responses that were given show the wide variety of clinical specialties that may be involved. 
This review of clinical involvement has not been reported elsewhere but is important to 
inform plans for service provision for future families in the UK. It indicates that some families 
will be coping with multiple appointments.  This should be and was considered when asking 
families to join a research study such as this one. 
The professionals most commonly involved were community paediatricians, cardiologists, 
physiotherapists, speech and language therapists and dieticians. It would be interesting to 
compare the input of the allied health professionals between geographical regions, as from 
discussions with some of the charities, there is a suggestion that the availability of support is 
inequitable. The input or perceived input (as this is completed by parents not the 
professionals or from notes) of the community paediatricians was striking, 80% of families 
said that a community paediatrician was involved in their child’s care up until the age of seven 
months but only a quarter thought that they were involved once their child was 12 months 




DS which suggests that children with DS are seen every three months in the first year of life 
by a lead paediatrician (with expertise in DS) and at least a minimum of once every year 
subsequently to that (RCPCH & DSMIG 2015). The lead paediatrician would in most areas be 
the community paediatrician and it is concerning that only quarter of parents reported a 
community paediatrician was involved in their child’s care. Community paediatricians suggest 
that this confusion may arise where children are seen in multi-disciplinary settings where the 
face to face input may come mainly from the allied health professionals with the community 
paediatrician oversight (personal communication).  
 Antibiotic use and infections 
Maternal use of antibiotics 
Maternal infections during pregnancy, labour and breastfeeding and use of antibiotics were 
all asked about. This may lead to changes in the gut microbiota of the baby by altering the 
maternal microbiome which is vertically transmitted to the baby. Antibiotics given to the 
mother whilst breastfeeding may also alter the microbiome of the breastmilk which in turn 
alters the baby’s microbiome. Only four mothers were given antibiotics in the last trimester 
but 18% received them at some point during their pregnancy and four received antibiotics 
whilst in labour. During pregnancy the type of infection itself may impact on the microbiome 
especially if they are gut or urogenital infections; some mothers reported having mastitis 
which again may alter the microbiome of the breastmilk. As the numbers are small it would 
be impossible to present any significant findings in relation to infant microbiome and 
maternal antibiotic use however, it is important that the study demonstrates this information 




Infant antibiotic use 
The majority of infants in the study had received antibiotics during the first 12 months of life 
(70%); but this is no higher than the rates of antibiotic use in a similarly aged general 
population. The rates for antibiotic use are poorly reported, but are around 70% for children 
in the pre-school age group and 65% in the first year of life in the general UK paediatric 
population (Rossignoli, Clavenna, and Bonati 2007, Schneider-Lindner et al. 2010). Given the 
known immune defects and propensity for respiratory infections it might be expected that 
antibiotic use might be higher in Downs syndrome. It might be of more relevance that at least 
a third of the children received multiple courses of antibiotics. 
 Feeding  
Exclusive breastfeeding amongst the babies with DS at six months is comparable to that seen 
in the general population (4% vs 1%). Apart from exclusive breastfeeding at six weeks when 
prevalence was similar (21% of babies with DS versus 23% in the general population) 
breastfeeding (exclusive or combination feeding) amongst the study participants were higher 
at all time points than levels reported in the general population. This was surprising and does 
not support the hypothesis that low tone and oro-motor issues associated with DS preclude 
normal breastfeeding. This is an important and encouraging message for families, midwives 
advising them and other healthcare professionals.  We need to change the current message 
which seems frequently heard (from the questionnaire results) that baby may be unable to 
breastfeed. This will be achieved by making this message a salient feature of a breast-feeding 
paper from this study.  Another relevant finding in relation to the study hypothesis was that 




feeds were introduced by 52% of mothers by a week of age in the IFS and 75% by six weeks. 
Similarly, in this cohort just over three-quarters had been started on formula feeds by the age 
of six weeks. As discussed in Chapter 1 (Section 1.5.3) the introduction of cow’s milk protein 
in formula feeds leads to the production of anti–BSA antibodies. These antibodies have been 
associated with autoimmune conditions (Karjalainen et al. 1992, Atkinson et al. 1993). Linking 
the data from the feeding questionnaires and medical questionnaires with the results of the 
bloods samples as the cohort grows will enable this association to be investigated. 
From the high proportion of mothers in the study who initially breastfed their baby, many of 
these mothers intended to breastfeed. Due to the wording of the questionnaire, it was not 
possible to distinguish between those who directly breastfed or those who gave expressed 
breastmilk, and this would be important to include in future questionnaires. Overall, over half 
of the mothers were still breastfeeding over the age of six months (including babies who 
combination fed with breastmilk and infant formula) which is a very positive message for 
families. This is higher than for the general population for whom prevalence of breastfeeding 
is 34% at six months.  
The feeding questionnaire also demonstrated a high proportion of babies with DS are NG tube 
fed at some point. Prevalence on NG tube feeding rates in the general population and in the 
typical DS population are poorly reported. Lewis et al reported that 40% of DS babies in their 
study had been NG tube fed during the neonatal period (Lewis and Kritzinger 2004) which was 
less than in FADES. A third of those in the study whose baby was NG tube fed continued to 
give exclusively expressed breastmilk. Many of the babies were fed using expressed 




including bottle. This allowed mothers to “exclusively” breastfeed, but some mothers found 
this to be “stressful” and “time consuming”. Over 60% of the babies who were NG tube fed 
received a combination of expressed breast milk and formula down the NG tube. This meant 
that these mothers were able to continue their supply of breastmilk and had the potential to 
breast feed in combination with receiving NG tube top ups or breastfeed once the NG tube 
was removed.  
Any advice that is given to mothers on feeding a baby with DS based on the findings of this 
study would need to include the message that babies with DS can be exclusively breastfed or 
receive a combination of breast and formula feeds, but due to the challenges with feeding 
some may need to include expressed breastmilk and alternative feeding methods. Providing 
mothers with access to tailored support and advice specifically around expressing should be 
included, as should information on NG tube feeding. This would need to be sensitively 
presented so that the information is supportive and informative but not overwhelming.  
The higher rates of breastfeeding in the study compared to the general population may be 
due to selection bias. Mothers who have chosen to take part in the study may already have a 
specific interest in infant feeding and therefore may be better informed regarding the advice 
to exclusively breastfeed until 6 months of age. In the UK the higher breastfeeding rates are 
seen in those mothers who are over 30 years of age (87%) (McAndrew et al. 2012) which may 
also explain the higher rate of initial breastfeeding in FADES. 
Barriers to breastfeeding    
There are two main breastfeeding barriers for mothers of babies with DS. The first being 




require surgical intervention. The other is oro-motor difficulties described in previous 
publications and reported by some mothers in FADES (Desai 1997, Kumin and Bahr 1999). 
Mothers reported being advised about the difficulties babies with DS may have with feeding, 
but they were not told any specific advice on how to help with this. It was positive that one 
mother had been told that there was no reason why breastfeeding would not work. However, 
this study provides more accurate and optimistic information for future mothers. Of all the 
mothers (those with a prenatal diagnosis and those without) only a third had attended an 
antenatal session on feeding. As many of the issues experienced by the mothers in the study 
such as difficulties with latching and positioning are common to babies with and without DS, 
even generic feeding advice would have been helpful.  
The majority of mothers in the study had skin to skin contact with their baby in the first 24 
hours after birth as recommended as close to birth as possible to help with establishing 
breastfeeding. It is suggested to benefit both mother and baby although the evidence is weak 
(Moore et al. 2016) and is mostly for immediate skin to skin contact. The proportion of 
mothers with a baby with DS who had skin to skin contact within the first 24 hours was less 
than the proportion seen in the general population likely due to questions over the baby’s 
diagnosis. When mothers of older children with DS talk about their experience of the 
immediate postnatal period, they wish that their baby had been treated the same way as any 
other baby and emphasise the importance of having time to bond, this includes time having 
skin to skin contact (McAndrew et al. 2012, Moore et al. 2016).    
The majority did experience problems with feeding after birth. The problems were those 




associated with babies with DS. Of those who experienced problems, poor latch was given as 
the most common issue and this has previously been described (Desai 1997, Kumin and Bahr 
1999). There was a high proportion with medical conditions as previously discussed, a third 
also commented that they had problems with feeding due to jaundice. This is more complex 
as it was difficult to discern whether the jaundice caused feeding difficulties, or the feeding 
difficulties contributed to the jaundice. Babies with jaundice tend to be more lethargic and if 
their jaundice is significant, they need interventions including spending periods of time under 
a UV light which may interrupt feeding. Lethargy was reported by almost 30% of the mothers 
for their baby and this continued to be a problem for mothers after discharge. Being more 
lethargic has been reported previously in babies with DS and unfortunately it is a vicious circle 
with a baby who feeds less often or for only a short period getting less nutrition and therefore 
becoming sleepier. Strategies for mothers to manage feeds for these babies is an area for 
future research. Although large or protruding tongues and low tone can be an issue for 
feeding babies with DS, the tongue size/position was only mentioned by three mothers and 
low tone by one mother during this immediate post-natal period.  
The proportion of mothers with feeding problems after discharge reduced to just over half, 
but this is higher than in the general population (around 30% (McAndrew et al. 2012)). 
Lethargy was the most commonly reported problem with far fewer citing poor latch as an 
issue once they had gone home. It may be that many more babies had already started using 
alternative feeding methods including bottle feeds once they had been discharged. 
Importantly, 16% of the mothers said that poor weight gain or weight loss was an issue. 
Weight loss is a common problem for many babies at this age (with or without the diagnosis 




syndrome specific growth chart. With over a quarter of the mothers saying that their red book 
did not contain this chart it is of concern that these babies may in fact have had normal weight 
gain for a DS baby but have been incorrectly plotted on the wrong chart. It was positive to see 
that most mothers (84%) did receive help or information regarding their feeding problems.  
Facilitators to breastfeeding 
Most mothers had breastfed a previous child which increases the likelihood of subsequent 
breastfeeding success (McAndrew et al. 2012). Over 90% of the mothers said they were aware 
of the benefits of breastfeeding to the immune system including protection against infection. 
Having the ability to proactively do something to help or benefit their child would have been 
a motivator for many of these mothers to breastfeed. Almost a quarter were aware of the 
benefits to oro-motor development but interestingly only 6% mentioned cognitive / IQ 
development which is the benefit with the most consistent evidence (Quigley et al. 2012, 
Heikkilä et al. 2011, Kramer et al. 2008). Children with DS have variable degrees of learning 
difficulties and the any potential improvement to cognitive function might well encourage 
mothers to breastfeed.  
Amongst the mothers who breastfed, over half had put their baby to the breast within half 
an hour of the baby’s birth. The support received by mothers during the postnatal period in 
the hospital, birth centre or unit was sufficient according to over 80% of the mothers. This will 
have had a positive impact on the number of mothers who then went on to successfully 
breastfeed and this is a credit to all the midwives and breastfeeding supporters who helped 




 Special Care and NG Tube feeds 
As previously discussed, over half of FADES babies were admitted to SCBU and all admitted 
were given NG tube feeds. In around 40% of babies issues with feeding were responsible for 
NG placement and for most of these participants this was also the reason why these babies 
were admitted to SCBU. Almost 70% of the mothers said that having their baby in SCBU had 
affected their ability to feed the way they would have liked. This is an area which requires 
further investigation to identify if some admissions might be prevented with more 
specialised/tailored support and input on the postnatal ward. Some hospitals will only have 
one or two babies born a year with DS, some of these babies may be automatically admitted 
to SCBU due to increased levels of anxiety around the other potential complications and 
associated conditions. In terms of oro-motor skill development it is important that babies 
have the chance to feed orally early on, this is postulated to be important for the development 
of oral skills, tolerance of tastes and textures and is also important for social development 
(Mason, Harris, and Blissett 2005). Most of the babies required NG tube feeds for less than 
two weeks but a third also required feeds to be stopped altogether at some point and were 
put onto IV fluids.  
NG tube feeding was required for some babies due to dehydration, jaundice, polycythaemia 
and vomiting. Although classified as a ‘medical’ reason, inability to feed may have contributed 
or caused these issues. The other ‘medical’ reasons, prematurity, being on a ventilator, 
respiratory problems and abdominal issues requiring surgery are all standard reasons for any 




 Stopping Breastfeeding 
The findings in relation to stopping breast feeding varied between the questionnaires. At each 
consecutive time point, the data included babies who were older at the time breast feeding 
stopped. As found in the general population (McAndrew et al. 2012) over half of mothers 
would have liked to have breastfed for longer but over 40% breastfed for as long as they 
intended or even for longer than originally intended (initial questionnaire). The wording of 
the question may have affected the responses. Those who had low initial expectations of their 
ability or their baby’s ability to breastfeed may have been exceeded the duration of 
breastfeeding that they initially anticipated but with opportunity would still have liked to 
breastfeed longer. By the 12-month questionnaire the proportion who ‘would have liked to 
have breastfed for longer’ increased to 65%. This may represent an increase in knowledge 
(through DS groups and social media) that some babies with DS can breastfeed and the 
development of feelings of guilt which are common for many mothers. The proportion who 
breastfed for longer than intended also increased slightly to 15%. This might be due to the 
group including babies who stopped feeding at an older age.  
The reasons given for stopping breastfeeding were similar to the IFS (McAndrew et al. 2012) 
with inadequate breastmilk supply and weight loss being common. There were however a 
large proportion who mentioned issues surrounding expressing milk. This highlights again the 
need for mothers who are expressing to receive tailored support. Mothers were asked “What 
would have helped you breastfeed longer” the responses indicated that mothers 
understandably wanted ‘normality’, they wanted their babies to be well, to not require bottle 




many of the babies, every effort should be made to listen to the family’s desires and assist 
where possible. Some mothers used this question to voice their frustration at alternative 
feeding methods being introduced as they perceived too early or against their wishes. The 
feeling from a few mothers was that NG tube feeds and/or bottle feeds reduced the chances 
of their baby subsequently breastfeeding. 
 Weaning - Introducing Solids 
Timing of weaning onto solid feeds and the introduced to cow’s milk is of interest due to the 
potential link with the development of autoimmunity. Except for specialised formulas, infant 
formula contains cow’s milk protein. The timing of initiating cow’s milk (as opposed to infant 
formula) was asked but this was in relation to nutritional guidelines which advise that cow’s 
milk should not be introduced until 12 months of age (World Health Organization 2009). 
Cow’s milk was introduced early (median 11 months). 
The WHO guidelines are that babies should not be weaned onto solid food before six months 
of age (World Health Organization 2009). This advice is consistent with the advice to 
exclusively breast feed until six months of age. Amongst the study participants over 50% were 
weaned onto solids prior to 6 months of age. In the general UK population in 2010, three 
quarters of mother had introduced solids by five months of age (McAndrew et al. 2012). This 
is much higher than the 21% of the study population. The most common reasons given by 
mothers for starting solids was on the advice of a health professional or from previous 
experience. From the responses given, the advice to start solids was based on the baby being 
developmentally ready rather than due to concerns over weight gain. The early introduction 




as discussed in Chapter 1 (Section 1.4.6) (Norris et al. 2003). There is also thought to be a 
protective factor in mother’s breastfeeding whilst introducing gluten (Sollid 2002, Akobeng 
et al. 2006)  
Mothers were asked about feeding problems in the 7-month and 12-month questionnaires 
which include the period when babies are weaned onto solid feeds. They were also asked 
specifically about issues introducing solids. More mothers experienced problems with 
introducing solid feeds than in the general population, with 41.2% having problems compared 
to 11% in the IFS (McAndrew et al. 2012). In both questionnaires, mothers mentioned 
problems with swallowing, gagging and reflux, issues known to affect young children with DS 
(Kumin and Bahr 1999). Other problems associated with oro-motor issues were difficulty 
managing bottle, problems with feeding position and difficulty or slow weaning onto solids. 
The numbers were not high for any of these issues showing that although there is 
commonality with some of the problems experienced, they will not affect all or even most 
babies. Some mothers said in relation to weaning in the 12-month questionnaire that their 
babies fed well with no problems, one saying that their child was no different weaning than 
her other “typical“ children. Support should be available where necessary to provide advice 
on positioning those babies with hypotonia, and suitable food textures for those with 
swallowing difficulties. As discussed earlier many of the babies had input from speech and 
language therapists and occupational therapists.  
Half of the mothers did avoid giving certain foods to their infants but the reasons for doing so 




 Overall ability to characterisation study participants 
The data gained from the questionnaires was complete and informative. It revealed the 
desired information regarding ethnicity and maternal age. It was a weakness of the 
questionnaire design that the socio-economic background information was minimal, and this 
could be improved. The medical information was detailed with parents provided extra 
information in the free text boxes. Analysis of this data confirmed that FADES is 
representative of the general population of children with DS.  
Parents provided details regarding the infections and antibiotic use, some of which was 
incomplete due to parent’s inability to recall all of the information but did show that 
infections and antibiotic use was considerable in this population. 
The feeding data was detailed and revealed new knowledge regarding this population. A 
weakness of the web-based questionnaire design study was that due to the branching of a 
few questions, some information was lost.  From the questionnaires it was possible to deduce 
the ages and dates at which the babies were introduced to formula feeds, solids and the age 
at which breast feeding stopped. Similarly, ages at which the babies had infections and 
antibiotics could be determined. This was key to the aims of the overall study with the ability 
to link dates to the samples provided and explore whether feeding, infections and antibiotic 

























Chapter 6 Initial analysis of Clinical Samples from the FADES Cohort  
 Overview of Chapter 6  
In this chapter, results for the initial sample analysis are given for DNA, urine and blood 
samples. For the mouth swab samples DNA was extracted and HLA class II genotyping was 
completed. The FADES data is presented together with previously published populations of 
children with DS, children with DS and diabetes, healthy controls and children with T1D (from 
the Diabetes and metabolism team (Aitken et al. 2013)). The urine samples were tested for 
urine C-peptide/creatinine ratios (UCPCR) and the blood samples were tested for anti- bovine 
serum albumin (BSA) antibodies. For methods used in these analyses see Chapter 2 Methods 
Sections 2.16 and 2.17.   
 DNA samples: Analysis of HLA genotype 
HLA genotyping was completed for 52 participants. The HLA genotypes were compared to 
previously published populations (Aitken et al. 2013) As shown in Table 48, six percent had 
the highest risk diplotype for autoimmune diabetes (DR4-DQ8/DR3-DQ2). As expected, this 
was less than the population with Down’s Syndrome and Diabetes (17%) or Type 1 diabetes 
alone. Moderate risk haplotypes were present in 27% of the study participants (15% DR4-DQ8 
and 12% DR3-DQ2). The proportion of participants with no risk haplotypes was comparable 
to the DS control population and the healthy control population. Overall, the study population 



















N=  52 222 97  621 194 
DR4-DQ8/DR3-
DQ2 
High risk (%) 
 6  2  17  3  38 
DR4-DQ8/X (%)  15  12  24  13  40 
DR3-DQ2/X (%)  12  22  32 27  17 
X/X (%)  67  64  27  57  5 
 
Table 48: HLA genotype. HLA risk genotypes of FADES participants, Down’s syndrome control 
population, Down’s syndrome and Diabetes, Healthy controls and population with Type 1 
diabetes (control populations are described in (Aitken et al. 2013))  
Footnote : *HLA DRB1*04-DQB1*0302/HLA DRB1*03-DQB1*0201, HLA DRB1*04-DQB1*0302/X and HLA 
DRB1*03-DQB1*0201/X are described as DR4-DQ8/DR3-DQ2, DR4-DQ8/X and DR3-DQ2/X respectively where X 
is not HLA DRB1*02-DQB1*0602 (DR2-DQ6) 
 
 Urine Samples: Analysis of Urine C-peptide 
The urine, C-peptide creatinine ratio (UCPCR) was measured in 108 samples from 54 
participants, 32 of whom had provided longitudinal samples. UCPCR measurements would 
not normally be done on children unless there was evidence of diabetes or an abnormal 
glucose tolerance test. UCPCR is a measurement of endogenous insulin secretion and is 
normally measured following a meal stimulus. As discussed in Chapter 2 Methods (Section 
2.16.3.1) the timing of the urine sample in relation to feeds is important for interpretation. 
Figure 30 shows the UCPCR threshold of 0.37nmol/mmol which was suggested by Besser et 
al as the threshold for significant endogenous insulin secretion in children (Besser et al. 2011). 
There were a proportion of children in FADES with low UCPCR levels (See Appendix 30): four 
samples with detectable but minimal UCPCR of ≥0.03nmol/mmol but less than 0.2 




undetectable UCPCR. These thresholds for minimal and detectable UCPCR are based on an 
adult population rather than a paediatric population. The minimal and undetectable samples 
were from 14 participants, none of whom had a diagnosis of diabetes and therefore were 
unlikely to have such low C-peptide levels although there is a dearth of data on C-peptide 
levels in infancy. This raises an issue regarding protocol compliance and their results were 
examined closely. Of the 14 participants with low C-peptide levels, there were six participants 
who had samples which were undetectable on the last available sample. The others (n=8) had 
at least one sample in which UCPCR was measured as at least intermediate insulin secretion. 
Interpretation of these results is explored further in the Discussion at the end of this chapter 
but there was non-compliance with the protocol in relation to the timing of sampling post 
feeds which will affect results. Of note, 38.5% (5/13) of those with an undetectable UCPCR 





Figure 30: Urine C-peptide Creatinine Ratio (UCPCR nmol/mmol) levels in samples from 
participants N=54, followed longitudinally (total samples tested N=109). The dashed line 
represents the threshold for significant endogenous insulin secretion in children of 






 Blood Samples: Analysis of Anti BSA Antibodies. 
Analysis of anti-BSA antibodies was completed on serum samples from 53 participants, 30 of 
whom had longitudinal samples. A control group of 18 samples from children aged under two 
years from the BOX study were also analysed (males n=9, median age 1.6 years (IQR 1.3, 
1.8years)). Anti-BSA antibodies were found to be positive in 58.5% (31/53) of the FADES 
participants tested. As seen in Figure 31, there was a distinct group of participants who had 









Figure 31: Anti BSA antibodies in the FADES cohort and BOX (Barts Oxford study) under 2 
control population. The threshold for positivity 0.33 Indexed Units was determined using 244 
healthy schoolchildren (90th centile) (see Chapter 2 methods). 
 
Figure 32 shows that anti- BSA antibodies developed with age as would be expected with the 
introduction of formula feeds and solids containing cow’s milk protein.   























Figure 32: Anti-BSA antibodies in FADES participants from Baseline (<6 months) to 3 years. 
The threshold for positivity: 0.33 Indexed Units was determined using 244 healthy 
schoolchildren (90th centile). 
 
The development of anti BSA antibodies with the introduction of feeds is shown in Figure 33. 
As the numbers of samples within some of the groups for age at which formula was 
introduced were small no clear trends can be ascertained. There were two samples provided 
by the same participant prior to any formula being introduced and these show that this 
participant was still negative for anti BSA antibodies at a year. Conversely there were also 
participants who had formula introduced before six weeks of age but who remained anti-BSA 
antibody negative at a year.   
































Figure 33: Anti BSA antibody positivity in relation to age and age at which formula was 
introduced.  
 
Footnote: For two samples there was no feeding data (two different participants) available one was negative 
0.29 Indexed Units for BSA the other was positive 0.42 Indexed Units.  
 
 Discussion of Chapter 6: Sample analysis  
Overall the study showed the ability for parents to collect their own child’s samples (DNA, 




standard mail.  The pilot studies for the collection of urine and stool samples provided validity 
for some of the collection methods used. 
The sample analysis showed that the DNA samples collected were adequate for analysis of 
HLA genotype, urine samples were adequate for measurement of urine C-peptide and blood 
samples were suitable for analysis of Anti-BSA antibodies.  
As the number of samples included  was small, the findings were descriptive and not 
statistically analysed  but showed that the FADES population had similar HLA class II risk 
profile to a previously published DS control population (Aitken et al. 2013). Aitken also shows 
that DS with diabetes have less HLA risk than those with T1DM without DS (Aitken et al. 2013).  
Interpreting the results of the urine C-peptide measurement is challenging. Urine C-peptide 
is usually measured post prandially, with urine collected two hours after a standard mixed 
meal (Greenbaum et al. 2008). As previously mentioned, it is not possible to time exactly 
when a baby will pass urine following a feed and although it may be possible to provide a 
fixed feed volume consumption is not guaranteed. There are also no reference ranges for very 
young babies. The results showed 14 participants who had a sample with minimal or 
undetectable urine C-peptide which would be expected in someone with diabetes who has 
inadequate insulin production due to beta cell destruction. None of these babies had been 
diagnosed with diabetes and many went on to have further samples which did show evidence 
of detectable urine C-peptide.  It is more likely that these results were due to samples being 
collected when the babies were fasted and had had a long period post feed. Another 
explanation might be that the samples were collected onto cotton wool (It is a weakness of 




small number of participants). Repeat ‘clean catch’ samples could be collected to confirm the 
results. The initial instructions had advised parents to collect the urine samples after a feed 
but had not asked for this time to be recorded on the sample sheet. An amendment was put 
in place, but the timing of the urine sample was still not consistently recorded and where it 
was recorded sometimes revealed the long period between feed and sample. The addition of 
information regarding the timing of the urine sample post feeds will help to improve this but 
was a weakness of the study. Nearly 40% of those who had an undetectable urine C-peptide 
were under the age of 6 months and levels at this age may be very low or drop considerably 
faster after a meal. Renal immaturity at this age may also account for reduced clearance of C-
peptide via the kidney.  Comparison with data from non-DS infants will be carried out in future 
to help explain the C-peptide results.   
The methods used for the collection and transport of the blood samples was shown to be 
adequate and the analysis shows that most samples were suitable for testing. Importantly the 
results could be linked to longitudinal feeding data. One of the questions that the cohort was 
designed to answer in the future is whether the early introduction of cow’s milk protein in 
the form of formula feeds correlates with increased risk of autoimmunity. The development 
of anti BSA antibodies is a marker of the immune system having been exposed to cow’s milk 
protein and has been associated with the development of autoimmunity (Karjalainen et al. 
1992, Atkinson et al. 1993). The analysis showed that there was a group who were positive 
for anti-BSA antibodies and a group who were not. Numbers were small and therefore it is 
not possible to draw any significant conclusions but it shows the feasibility of the collection, 
transport, storage and lab methods. The proportion of participants who were positive 




of babies who are exclusively breastfed beyond this stage is around 1% in the general 
population and 4% in this cohort. However, when the feeding data were looked at in more 
detail, it showed some participants who had formula introduced early remained anti BSA 
antibody negative even at a year of age. These differences are most likely to be due to 
inherent differences in the participant’s immune responses. They may also be related to level 
of exposure; some babies may have received only a few formula feeds whilst breastfeeding 
was established. However, Juvonen et al. suggested that development of anti-BSA antibodies 
was related to timing of exposure to formula rather than duration of exposure (Juvonen et al. 
1999). Mothers who breastfeed and also consume dairy products will still pass some cow’s 
milk protein to their baby and therefore the feeding data regarding exposure to cow’s milk 
protein is not complete as mothers were not asked as to their own diet and exclusion of dairy. 
Participants were able to collect stool samples at home and send them in the standard post. 
The stool samples have not yet been tested (currently stored frozen at -800C) so it is not 
possible to comment on how usable the samples are, but the methods have been tested in 
the feasibility study (Chapter 2 section 2.15). 
The study continues to collect a bank of data on early feeding, medical conditions and 
infections for these children which can be linked to longitudinal samples. As the cohort 
progresses it is expected that Type 1 diabetes and other autoimmune conditions will be 
diagnosed in participants or that antibodies associated with such conditions will develop and 
be detectable. It will then be interesting to determine whether these participants are those 
with the higher risk HLA genotype although earlier data suggests this association is not strong 




that have been collected from these participants adds to the completeness of this cohort. 
Urine samples maybe used in the future not only for urine C-peptide measurement but also 
potentially for looking at the metabolome of these participants. Future testing of the blood 
samples for auto antibodies and linking this data with the results of the feeding and medical 
questionnaires and other sample analysis will allow exploration of the factors involved in the 
























Chapter 7 Final Discussion and Future Direction 
 Overview of Chapter 7 
This chapter summarises the principal findings in relation to the feasibility and secondary 
objectives. Strengths and weaknesses of FADES are discussed, as well as recommendations 
made for future national birth cohort studies of a relatively rare conditions. The final sections 
describe future directions and conclusions.  
 Principal Findings  
The establishment of the only UK wide birth cohort of babies with DS to prospectively study 
early feeding and the development of autoimmunity in children with DS has been achieved. 
FADES forged successful collaborations with all major DS charities in the UK including the DSA, 
DSS and DHG, as well as with clinicians in the DSMIG. The cohort continues recruitment until 
2020, and follow up until 2022, with over ninety participants to date. I have detailed 
information on early feeding, medical conditions, infections and antibiotic use during the first 
few years of life in children with DS. The input of professionals from a range of specialties in 
the care of these babies has been described. A bank of longitudinal samples were collected 
including DNA, urine for C-peptide and future metabolomics, stool for gut microbiome and 
blood samples for autoantibodies and other biomarkers.  
The study was presented at the DSMIG meetings, the Royal College of Paediatrics and Child 
Health Conference and at the World Down’s Syndrome Congress 2018. The Study team held 
a dedicated symposium at the World Down’s Syndrome Congress where delegates included 




A confidentiality agreement has been signed between members of the FADES team and a 
pharmaceutical company based in Norway (Pharmasum) who have developed a DRYK1A 
Kinase inhibitor, (DRYK1A also known as mini-brain in Drosophila flies).  DRYK1A is found in 
the DS critical region on chromosome 21, is over-expressed and may be important in 
dementia and diabetes (Dirice et al. 2016, Nguyen et al. 2018).  
My initial PPI work supporting the establishment of a birth cohort of children with DS was 
confirmed as important by families, clinicians and researchers. My paper describing 
challenges in recruiting babies with DS concluded that a flexible approach to recruitment is 
required whilst fully supporting alternative modes of engagement, including social media, 
parent groups, charities and websites. Over half of the FADES participants were recruited 
using these alternate routes. I confirmed that using the internet for recruitment is both a 
practical and successful solution for low risk studies looking at a relatively rare conditions over 
a large geographical area. In addition, providing web-based questionnaires was popular with 
participants with the majority of families completing the questionnaires online. This method 
proved convenient and practical for parents and the study team alike.  
Analysis of questionnaires demonstrated that the desired key questions in relation to factors 
which have been hypothesised to be involved in autoimmunity were addressed. These 
included; mode of birth delivery, feeding and the introduction of formula feeds, introduction 
of solid feeds likely to contain gluten, antibiotic use and infections. Although no formal 
statistical comparison could be made, there were no clear differences seen in any of these 
areas when frequencies were compared to the non-DS, general population. A key finding from 




guidelines. This may require significant perseverance from the mother and supportive 
professionals, as establishing breastfeeding was challenging for some. This was often due to 
oro-motor difficulties and significant medical needs, but the take home message from this 
study is that mothers who wish to breastfeed should be encouraged and supported to do so 
as success is possible.   
The feasibility studies for the collection of urine and stool samples (see Chapter 2 Section 
2.15) provided validity for the sampling methods used. The paper describing the optimal 
collection methodology for long distance gut microbiome sampling (Williams et al. 2019) 
should prove invaluable for future studies covering a wide geographical area. Overall, FADES 
demonstrated the ability for participants to collect their own child’s samples (DNA, urine and 
stool) and for these to provide adequate material and quality for analysis after return to the 
laboratory by standard mail. HLA genotyping shows that the study population are 
representative with a risk profile similar to that of a previously published DS control 
population (Chapter 6 Section 6.2). Analysis of anti BSA antibodies demonstrated the 
development of antibodies with the introduction of formula feeds, although this was not 
entirely consistent for all participants. The differences seen are likely to relate to a variation 
in individual’s immune system. Continued analysis of additional samples is ongoing. 
Describing these findings in relation to the development of autoimmunity in these 
participants will be possible once autoantibody testing has been completed.   
Thabane et al (Thabane et al. 2010) described the four potential outcomes of a pilot/ 
feasibility study as: 1) Stop - not feasible and therefore not to continue with the main study. 




without adjusting the protocol but would need to continue to monitor closely. 4) Continue – 
no modifications required, and the study can continue with the current protocol. This study 
falls under ‘feasible with modifications’ but these modifications are minor and easily 
achieved, although recruitment rates are still under those originally envisaged. Many aspects 
of the study design were successful and will remain including the use of web recruitment and 
online questionnaires. Sample collection methods have been shown to work but could be 
optimised further. The lessons learnt during this study which might inform a future cohort 
study are discussed below (Section 7.4). Improvements to the protocol and future directions 
for the study are also discussed in more detail (Section 7.5).   
This study provides the springboard for future research. It has generated a bank of data and 
samples from which the associations between early life factors and the development of 
autoimmunity can be explored. Antibody testing needs to be completed in order to determine 
the number of autoantibody positive participants. The number of participants required to 
calculate statistical power for findings in relation to; feeding practices, differences in 
microbiome or antibiotic use, and infections could then be calculated and used to inform a 
major grant application.   
 Strengths and Weaknesses 
The retention of participants was the main strength of this longitudinal cohort study. Over 
half of the participants provided all of the requested samples and questionnaires over two 
years. Attrition is a major issue for longitudinal cohort studies particularly those involving 
paediatric patients (Zook et al. 2010, Golding and Birmingham 2009). There are many 




this study including, reminders, newsletters and regular email contact (Golding and 
Birmingham 2009, Marmor et al. 1991, Morton et al. 2014). 
The main weakness of this study was the ability to recruit enough participants within the time 
period. However, compared to other cohorts involving young babies with DS who were 
followed prospectively, this is now a notably large cohort and continues to grow. A sample 
size calculation was not made for this study as the use of sample size calculations for feasibility 
studies is inappropriate (Lancaster, Dodd, and Williamson 2004, Arain et al. 2010, Thabane et 
al. 2010). Thus descriptive results using proportions and confidence intervals were 
acceptable. A true feasibility study should come before a ‘main study’ however, as this is an 
important cohort and recruitment will always be the main stumbling block, the current 
participants will remain whilst the study continues recruiting further participants. It would 
also be unethical to remove families from a low risk, longitudinal study such as this in which 
they have invested much time and effort.      
The methods for assessing the feasibility of the study were robust with clear feasibility 
objectives (Eldridge, Chan, et al. 2016, Lancaster, Dodd, and Williamson 2004). This included 
a qualitative study providing important and deeper understanding of the issues that were 
being faced by families in relation to recruitment. A previously published study also explored 
the issues around recruiting children with DS into research but did not specifically look at 
recruiting very young babies (Fortnum et al. 2014). FADES did not include a dedicated 
longitudinal PPI advisory group which was a weakness but throughout the study there was 




charities. For initial PPI, a local parent support group (BADSS) was also consulted on the 
protocol, the participant-facing information and questionnaires. 
The families recruited were representative of the general population of children with DS with 
similar numbers of children having associated conditions including cardiac abnormalities as 
reported in other series. The eligibility criteria were broad and did not exclude any medical 
conditions. A further strength is that the study was UK wide rather than specific to a regional 
population reducing selection bias. Those who could not speak English were excluded and this 
may have had altered feeding results with cultural differences in early feeding (Griffiths, Tate, 
and Dezateux 2005). Translating all study documentation however was not possible for the 
multiple languages represented in UK. The majority of mothers in the study were white, this 
is similar to the proportion seen in other national studies. It is acknowledged that feeding 
practices amongst different ethnicities varies with mothers who are white having lower 
breastfeeding rates than other ethnic groups according to the Millennium Cohort Study 
(Griffiths, Tate, and Dezateux 2005). The Millennium cohort also highlighted that partner’s 
ethnicity influences breastfeeding rates but partners ethnicity was not obtained and this can 
be amended for the study going forward. Further information on the socio-economic status 
of the parents would also have provided valuable information particularly educational 
background as breastfeeding rates are lower amongst those without academic qualifications 
again this will be amended.  
Ideally as a ‘birth cohort’, recruitment should occur prenatally allowing questionnaires to be 
completed without recall bias and samples completed at the time of birth for both mother 




mother as it is the vertical transmission of microbiota at the time of birth which is of interest. 
However as previously described for many parents the diagnosis of DS is unexpected (Hedov, 
Wikblad, and Annerén 2002, Van Riper 2007). Samples analysed during a longitudinal cohort 
study should ideally be collected from a control group which can be tested at the same time. 
However, it is unlikely that ethical or parental approval would have been obtained for 
collecting multiple biological samples from ‘healthy babies’.   
It was not possible to collect preserved whole blood samples for detailed immune cell analysis 
from the babies as had been proposed in the original protocol. As described, obtaining 
adequate samples for antibody analysis already provided challenges. It was clearly a weakness 
of the study as alterations in the T cell population are likely to play a significant role in the 
development of autoimmunity in this population. It might be possible to obtain a greater 
volume of blood once the babies are older. Ethical approval was obtained, and families were 
consented to use the day five blood spot that is collected from every baby as part of the new 
born blood spot screening program (England 2018 ). This would mean that even if babies are 
recruited at an older age, a very early sample would be available for testing. Dried blood spots 
can be used to tested for auto-antibodies. Unfortunately, although FADES had ethics 
approval, the newborn screening laboratories were not prepared to provide such sample. 
Although in the past the blood spots had been used for research, this has recently been under 
consultation. 
Other cohorts of children with DS have focused on the child’s development or on very disease 
specific conditions (Bloemers et al. 2007, Carr 1988, CDSS 2018). FADES in comparison, is 




It has achieved this through the qualitative work and through the free text boxes that were 
available to parents throughout their questionnaire sessions contributing to its value.  
 
 Researcher Impact 
Throughout the study has been influenced by my own position as a paediatric doctor 
specialising in paediatric diabetes and endocrinology. I have worked with families and 
children with DS prior to my PhD studies both acutely in hospital and in the community. My 
medical position helped with understanding some of the complications and medical needs of 
the children after birth but from a very clinical perspective. This was important for the 
planning and set-up of the study and enabled me to answer questions from sites, 
collaborators and when talking to parents. However, my understanding of the personal 
journey that parents go through has developed and grown through this study and has been a 
valuable lesson for both my research and clinical career. 
Initial hypothesis in relation to feeding were influenced by my prior experience particularly 
around the difficulties that some DS babies have with feeding, but it was important to 
recognise that as a clinician I was seeing those babies with difficulties more than those 
without (reflexivity was discussed separately in Chapter 3 with respect to the qualitative 
study).  
It would be of value to the study to develop a dedicated PPI group which includes families 
already enrolled in the study as this would reduce some of the inherent biases that exist as a 




importance for such a group to review the results of the feeding data and when producing 
information leaflets for feeding recommendations.  
 
 Lessons learnt for future studies 
From this study the following recommendation can be made when planning the development 
of future national, rare disease cohorts. Early involvement and engagement of all 
stakeholders is key. For a condition such as DS, diagnosed around the time of birth this should 
include the neonatal networks, parent organisations, community paediatricians, national 
charities and medical interest groups.  A focus group including stakeholders and, in this case, 
new parents of children with DS can provide important insights when designing a study 
protocol, the participation information leaflets, consent form and overall support for the 
study. This is crucial to successful approvals processes and may potentially engage local 
collaborators earlier. Applying qualitative research methodologies to understand potential 
barriers and motivations for families to engage should occur prior to or early after study 
onset. Qualitative research can focus on various aspects which would benefit a study, 
providing a deeper understanding of parental perspectives which can aid recruitment and 
retention. Such an approach can highlight aspects of the study which might be unacceptable 
and logistical challenges that might not have been previously considered by the research 
team.     
The time taken to gain R and D approvals across the UK prior to the start of the study was 
considerable but did reduce delays for the participants. For future studies, it may be 




those sites. For those self–identifying through web recruitment in sites with no local 
collaborator this may however cause a delay. The process for gaining approvals across 
multiple sites has now changed to HRA which has been designed to be quicker (HRA. 2019). 
Therefore, aiming to obtain approvals at all sites may still be optimal. 
Adopting the emerging technologies becoming available to research studies helps provide 
ease of access, accuracy and security. Participants will increasingly expect to be able to 
undertake research online at their convenience, as illustrated by most participants opting to 
complete the web-based questionnaire rather than the paper version. Therefore, I would 
recommend that study information ‘sheets’ be provided on websites. Consequently, potential 
participants should be able to identify themselves via an online form and questionnaires 
should become web-based. Availability of email access to the research team means that 
issues can be dealt with promptly and participants and researchers can develop a relationship 
during an otherwise non-participant facing study. 
This study proves that parents can collect DNA, urine and stool samples from their babies 
independently at home and return them in the standard post. For large cohort studies this is 
convenient and reduces costs. The feasibility study for the collection of stool samples showed 
that the OMNIgene•GUT kit was the optimal method for preserving the samples whilst being 
posted in the standard post. For the collection of urine samples for urine C-peptide, a clean 
catch method is the most reliable system. Collection onto cotton wool could be used where 
parents are struggling, but if the UCPCR is very low, a repeat clean catch sample should be 
obtained. It is important that information is collected on the timing of feeds prior to the 




The recommendations from families were that more information should be provided 
regarding the sample collection. The use of online videos to demonstrate how samples are 
collected are being used in other studies and have received positive feedback (personal 
communication from the BOX study). Timing of blood samples and methods for collecting 
them continues to prove problematic. The use of research nurses who can meet participants 
at their appointments and collect the blood sample is the ideal; but may not be possible at all 
sites. Involving local collaborators and the clinical research networks as much as possible 
facilitates blood sample collection and discussions should be held with them early during the 
study set-up. 
 Future Directions and Unanswered questions 
Why people with DS are at increased risk of autoimmunity still needs to be established. 
Autoimmune conditions are more common with a three-fold increased risk of diabetes 
(Bergholdt et al. 2006), ten-fold increased risk of coeliac disease and four-fold increased risk 
of thyroid disease compared to the general population (Karlsson et al. 1998, Bonamico et al. 
2001). It is acknowledged that people with DS have variations in their immune system which 
leads to an increased number of infections, autoimmune conditions and haematological 
malignancies (Øster and Nielsen 1975, Kusters et al. 2009).They have an altered T cell 
population and T cell function is impaired, (Kusters et al. 2009). In addition, the histological 
appearance of the thymus which essentially acts as an immune system regulator in early life, 
in people with DS is different. The thymus is important in the development of the immune 
system: T regulatory cells (Tregs) expressing FOXP3 come from the thymus and suppress the 




Tregs but their function is impaired. These alterations in the immune system are the most 
likely cause of the increased risk of autoimmunity. However, there are some confounding 
factors including the increased number of infections seen in people with DS and antibiotic use 
which may alter microbiota which in turn, may affect the developing immune system. A 
complex web therefore needs to be explored and untangled. 
There may also be a genetic explanation. A recent paper by Johnson et al looking at neonatal 
diabetes and DS has supported previous publications which show that autoimmune TID can 
occur early (before six months of age) in babies with DS and may not be HLA mediated 
(Johnson et al. 2019). Those with TID and DS do not have the prevalence of the high risk HLA 
diplotype DR3/DR4 as seen in people with TID alone. The authors conclude that T1D in people 
with DS includes instances where T1D is linked to an HLA risk genotype and those which are 
not. Other genes described in Chapter 1 (Section 1.4.3) which are located on chromosome 21 
are candidates for a causal link. These include Ubiquitin associated and SH3 domain 
containing A (UBASH3A) gene, autoimmune regulator (AIRE) and the cluster of genes which 
includes four interferon receptors (IFNAR1, IFNAR2, IFNGR2 and IL10RB). These have all been 
implicated in T1D and other autoimmune conditions independently of DS and the 
mechanisms by which they affect the development of autoimmunity have been explored. 
Studies specifically examining the expression of AIRE in people with DS have revealed 
compelling arguments for its role. Mutations in AIRE lead to APECED which as previously 
described has overlaps with conditions seen in DS. The expression of AIRE within the thymus 
of people with DS has been shown to be reduced (Lima et al. 2011). It plays an important role 
by regulating the transcription of genes encoding antigens allowing the development of self-




with a reduced expression of AIRE (Giménez-Barcons et al. 2014). Testing the FADES cohort 
for mutations within these candidate genes and analysing these together with auto-antibody 
data will provide further evidence for any potential links. 
The role of the gut microbiome in autoimmune disease is becoming established with 
publications suggesting those with autoimmune conditions have a less diverse gut 
microbiome (Giongo et al. 2011, Kostic et al. 2015). A recent study of the longitudinal gut 
microbiome in children participating in TEDDY Study, showed that the developing gut 
microbiome undergoes three distinct phases of microbiome progression: a developmental 
phase (months 3 to 14), a transitional phase (months 15 to 30), and a stable phase (months 
31 to 46) (Stewart et al. 2018). Receipt of breast milk, either exclusive or partial, was the most 
significant factor associated with the microbiome structure. It will therefore be important to 
link any microbiome data from this study with feeding data. Longitudinal stool samples have 
been collected but are yet to be tested, there are no other studies which have looked at the 
microbiota of those with DS nor related them to outcomes of relevance.  
In order to recruit a cohort of sufficient size to answer some of these questions, FADES will 
probably need to be established internationally. In some countries, unlike the situation in the 
UK, there are national registers of children with DS making identification of potential 
participants much easier (Bergholdt et al. 2006).  Professor E. Molloy (Trinity College Dublin) 
is establishing such a register in the Republic of Ireland and we are collaborating with her to 
establish FADES there. The amendment for this expansion has been approved through the 
HRA we are now awaiting local approval in Ireland. Up until January 2019, the number of 




the referendum in May 2018 to repeal the Eighth Amendment. However, due to cultural and 
religious beliefs in Ireland many women may still not consider screening for DS and 
termination of pregnancy would not be an acceptable option for them. The number of babies 
born in Ireland with DS is therefore still likely to be higher than in the UK despite the smaller 
overall population. Within the UK, the study will continue to involve new local collaborators 
with a particular focus on the neonatal networks. 
This feasibility study has raised some important questions and highlighted potential 
opportunities for interventions in relation to early tube feeding in children with DS. A high 
proportion of babies required NG tube feeding but it is important to determine why, whether 
this practice is the same in all regions and if any recommendations or changes could be made 
in relation to this. In order to be able to develop guidelines for feeding babies with DS, some 
of the more detailed questions from the FADES questionnaires, including those around who 
provided feeding support in the hospital, birth centre and after discharge home can be 
investigated in more detail. 
Another area for future development and potential improvement is in the screening 
guidelines for autoimmune conditions in the DS population. FADES will likely provide useful 
information on the age at which organ specific antibodies first develop. This is particularly 
pertinent for coeliac disease which can cause significant problems with abdominal 
symptomatology and thriving but is often diagnosed late (Csizmadia et al. 2000, Bonamico et 
al. 2001). There are new guidelines being developed for coeliac screening in DS which are 
likely to include HLA genotyping to help stratify risk of coeliac disease and guide screening. 




with coeliac disease lack DQ2 and DQ8), it is important that the role of the HLA genotype for 
coeliac disease is also confirmed for those with DS as screening and diagnostic testing may be 
different in this population as it is with T1DM (Wouters et al. 2009). FADES is perfectly 
positioned to answer this type of clinical question.   
The cohort has collected questionnaire data and samples that could also be used for 
previously unrecognised research avenues in DS. A potential area of interest is to look at the 
developing longitudinal metabolome of the children in the cohort (Caracausi et al. 2018). 
Caracausi et al have suggested differences in the metabolomic profiles of children with DS 
compared to a control population identifying differences in metabolites related to 
mitochondrial metabolism. It has been postulated that there is a metabolic explanation for 
the intellectual impairment seen in people with DS. If this was confirmed it might lead to 
potential therapeutic targets.  
The points below summarise the next steps this and future studies would need to take to test 
the hypotheses discussed in this PhD: 
• Ongoing recruitment and establishment of the study in Ireland.  
• Testing of T1D auto-antibodies, thyroid antibodies and TTG antibodies to determine 
the natural history and development of autoimmunity (specifically Type 1 diabetes, 
coeliac disease and thyroid disease) amongst the cohort. 
• Relate the development of antibodies to HLA genotype, feeding and medical data, 
infections and antibiotic usage. 
• Test for mutations within candidate genes on Chromosome 21 and relate these 




• Analyse gut microbiome samples from the cohort to characterise the gut microbiome 
of infants with DS and to determine if the gut microbiome is altered in those who go 
on to develop autoimmunity.  
 Conclusion 
The ongoing study of the development of autoimmunity in children with DS may inform us as 
to the factors that influence the maturation of the immune system. Whether alterations in 
the gut microbiome, differences in feeding practices, infections or use of antibiotics play a 
significant role in the increased risk of autoimmunity in these children remains to be 
determined. Due to the complex and variable medical, social and educational challenges for 
many people with DS, understanding the natural history and pathophysiological evolution of 
these issues is essential to develop future therapeutic options and support for these people 
and their families. FADES is a unique UK wide cohort which continues to expand our 
knowledge of children with DS, their families and the associated medical conditions which 
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Appendix 1: Common autoimmune conditions and associated HLA genotypes 
and autoantibodies 
 
Condition HLA risk genotype Antibodies 
T1D DRB1*03 - DQA1*0501 – DQB1 0201 
(DR3-DQ2)  and DRB1*04 – DQA1*0301 





CD DQ2 and DQ8 tTG 
Anti-gliadin antibody 
EMA 










Appendix 2: FADES Protocol 
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NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE 
NUTRITION THEME 
Feeding and Autoimmunity in Down’s syndrome Evaluation Study (FADES) 
PROTOCOL 
Aim: To develop a family acceptable study protocol and establish the feasibility of creating a 
national cohort of infants with Down’s syndrome (DS) to study the associations between early 
infant feeding, infections and the development of autoimmunity in Down’s syndrome. 
Setting: This study has beenset up as a partnership between the NIHR, Bristol Biomedical 
Research Unit in Nutrition, The University of Bristol, School of Clinical Sciences, Diabetes 
Research Group, Imperial College London, Department of Medicine, the Down’s Syndrome 
Medical Interest Group, the Down’s Syndrome Association and Down’s Syndrome Scotland. The 
study is being extended to the Republic of Ireland with the support of Down’s Syndrome Ireland 
Fiona McGrane (research nurse) and Professor E Molloy Trinity College Dublin.  
Summary: Children with Down’s Syndrome (DS) have increased risk of autoimmune conditions 




coeliac disease (which causes malabsorption). In DS, autoimmunity is likely to be related to lifelong 
inherent defects in the immune system.  The increased risk of diabetes-related autoimmunity is 
despite a reduced prevalence of the usual HLA haplotypes commonly associated with type 1 
diabetes. Infant feeding practice has been linked to diabetes and coeliac risk with some evidence 
that prolonged breastfeeding is protective.  We hypothesise that in infants with DS, already at 
increased risk, early feeding practices may be related to the development of autoimmunity. 
Children with DS are more floppy and therefore have difficulties with breastfeeding leading to the 
rapid introduction of formula feeds which contain modified cow’s milk protein.  
We aim to create a cohort of infants with DS recruited through the Down’s Syndrome Association 
(DSA), Down’s Syndrome Scotland (DSS), Down’s Syndrome Ireland (DSI), community 
paediatricians and neonatologists to study the association between early infant feeding, infections 
and the development of autoimmunity. We initially anticipated that we would recruit 100 patients 
per year.  
Parents are asked to complete questionnaires at baseline detailing family history, birth history, 
weight, medical problems and early feeding. They have further feeding questionnaires to complete 
at 7 months and 12 months, and medical questionnaires annually. Samples arecollected at baseline 
including faeces to store from mother and baby a brushing from the infants cheek for genotyping 
(looking at their DNA), a blood sample from the baby to look at development of auto-antibody 
production (antibodies which act against their own cells), and a urine specimen to detect 
development of diabetes. Further stool, urine and blood samples are collected at 6 and 12 months 
and once a year thereafter. The study is currently funded to run until January 2022 and participants 
will continue to complete annual questionnaires and samples around the time of their birthday 
until this date. 




There has also been a small pilot study (Phase 1) to assess the stool collection kit that we are now 
using in the main study (Phase 2). The kit that we are using in the main study is a new kit designed 
to preserve stool samples. We wanted to compare the new kit with the standard stool collection 
method to see if it is better at keeping samples fresh for analysis in the laboratory. The protocol 
for the pilot study can be found in appendix 1.  
Phase 2 Recruitment: Is across the UK and the Republic of Ireland recruiting families with 
newborns with Trisomy 21 from as near to birth as possible. The Down’s Syndrome Association 
(DSA) and Down’s Syndrome Scotland (DSS) with whom we are collaborating on this project, 
assess they are able to contact around 500 new mothers with a child born with Down’s syndrome 
a year (Information supplied by Sheila Heslam: Policy Manager DSA and Sarah Van Putten: Family 
Support Service Manager DSS). With a relatively conservative estimate of 20% interest in this study 
we therefore thought that we would be able to recruit 100 patients per year. Interested community 
paediatricians, neonatologists and research nurses also help with recruitment and display flyers for 
the study in community clinics and neonatal units. The DSA and Down’s Syndrome Ireland  
provide links to the FADES study via their website and social media links. We are recruiting 
participants until January 2020. 
Background: Children with Down’s Syndrome (DS) have increased risk of thyroid, pancreatic2 
and coeliac3 autoimmunity likely related to lifelong defects in intrinsic immunity4.  Furthermore, 
the increased risk of pancreatic autoimmunity is associated with an earlier age of diabetes 
presentation suggesting an accelerated or exaggerated process in the autoimmune destruction of 
islet β cells5 6. We have documented this increased risk of diabetes-related autoimmunity despite a 
significantly reduced prevalence of the classical DR3/4 genotype in those with DS getting type 1 







HLA high risk genotypes in healthy controls, Down’s syndrome (DS), Down’s syndrome  
and diabetes (DS+T1D) and type 1 diabetes(T1D) 
A recent study in DS may be pertinent documenting a liability to elevated circulating T regulatory 
cells expressing FOXP3 but associated with a reduced T-cell inhibitory ability8. Uibo et al identified 
a similar picture with regards to FOXP3 expression in a cohort of patients positive for classical 
GADA or IA-2 antibodies regardless of clinical status9.  In another study from the same group 
undertaken in mucosal biopsies of patients with coeliac or coeliac disease with diabetes, a picture 
of increased CD4 positive cells at the site of inflammation was associated with greatly increased 
FOXP3 positive Tregs10. 
Infant feeding practice has been linked to diabetes and coeliac disease risk with some evidence that 




























The frequency of T1D - associated HLA    
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be through an abnormal immune response to Bovine Serum Albumin (BSA) present in cow’s milk 
derived formula feeds. In animal studies and children developing diabetes, there is evidence of 
abnormally high titres to BSA not present in control groups13. A study by Atkinson and colleagues 
confirmed increased levels of anti-BSA antibodies in those with and at risk of autoimmune diabetes 
as well as those with other autoimmune conditions. In this study however it was shown that T 
cells in autoimmune diabetes are not activated against BSA peptides. They concluded that  “Anti-
BSA antibodies may reflect a general defect in the process of immunologic tolerance associated 
with a predisposition to autoimmunity rather than immunity specific to beta cells”14.  
 We have identified that children with DS and especially DS and diabetes have a greatly increased 
prevalence of low affinity antibodies to BSA15. In theory this may be related to an increased gut 
permeability and immature immune system associated with trisomy 21.  We hypothesise that in 
infants with DS, already at increased risk of autoimmunity, early feeding practices such as 
a rapid introduction of modified cow’s milk protein possibly related to a reduced ability to 
breast feed due to hypotonia16 that classically accompanies DS, is related to the 
development of autoimmunity. A recent study in Scandinavia suggested that dietary 
manipulation to prevent early exposure to complex cow’s milk protein in non-DS, but at risk 
infants might impact upon the development of autoimmunity.17  Whilst infant milk feeding practice 
may associate with an increased risk of diabetes, it is also possible that weaning practice with 
regards to gluten containing cereals may also be of importance. There is evidence that the 
development of islet autoimmunity in non-DS children may be related to an early introduction of 
gluten-containing cereal feeds possibly influenced by early gastro-intestinal infections18-20. One 
further avenue by which early feeding practices may influence autoimmunity of gut and pancreas 
is through the microbial population present in the intestine, the so-called ‘gut microbiome’.  There 
have been well documented differences in this microbiome recorded both in those developing 




development of the gut microbiome has been linked to early infant feeding practices such breast 
versus cow’s milk feeding and time of weaning24. Resident gut microflora are known to contribute 
to immune function and homeostasis. At the epidemiological level, children born by Caesarian 
section are at greater risk of T1D25 indicating that early exposure to maternal bacteria may be 
protective. Furthermore NOD mice, kept in non-germ free conditions are relatively protected 
from diabetes.  Increased gastrointestinal permeability or a “leaky gut” has been associated with 
the risk of developing T1D and other autoimmune conditions. For example individuals with, or at 
increased risk, of T1D26 have been shown to have abnormal intestinal permeability to the sugars 
mannitol and lactulose27, upregulation of the gut permeability modulator zonulin28 and mucosal 
alterations on electron microscopy (Secondulfo et al. 2004). In the Biobreeding rat model of T1D 
there are distinct bacterial populations resident in diabetes prone and resistant strains and oral 
transfer of Lactobacillus johnsonii  strain 6.2 from the resistant to susceptible strains transfers 
resistance29 30.  In the NOD mouse, it has been shown that interaction of intestinal microbes with 
the innate immune system is a critical factor in T1D predisposition31. Most recently in humans, 
differences in diversity of the gut microbiome have been identified in those who develop type 1 
diabetes, compared with non-autoimmune prone individuals21.  
Overall the rationale of this study is to study factors known to be important in autoimmunity in 
the general population, in a population known to be at increased risk of organ specific 
autoimmunity, namely children with Down’s syndrome. The research design allows longitudinal 
follow-up of the natural history of feeding regimes, the appearance of antibodies to BSA and 







Phase 1: Was  a pilot study to evaluate the performance of the DNA Genotek Stool Collection 
Kit compared to a standard stool self collection kit. The methodology for Phase 1 can be found 
in Appendix 1. 
 
Phase 2:  
  
Recruitment: 
When a parent is told either antenatally or after birth that their baby has a diagnosis of Down’s 
syndrome they are provided with the details of The Down’s Syndrome Association (DSA) and/or 
Down’s Syndrome Scotland (DSS) and/or Down’s Syndrome Ireland (DSI) as a source of 
information and support. DSA and DSI send out new parent information packs to all families who 
request them and the DSS make contact with families who request their input. The DSA and DSI 
have agreed to send out a flyer with their ‘New Parent Packs’ with simple details about the study. 
DSS have also agreed to mail out our flyers to all families with a baby under 8 months of age with 
whom they have contact, and will also take the flyer with them on the home visits they make to 
new parents. They will also have information about the study posted on the DSA, DSI and DSS 
websites on their research pages and through Blogs. The DSA has also created a link via their 
Facebook page and Twitter feed to our webpage. The study flyer and the information on the 
website will include a web address by which parents can register an interest in taking part and 
download a more detailed information sheet. In areas where there are interested community 
paediatricians and neonatologists who will act as local collaborators potentially eligible families will 
also be identified by their community paediatrician or neonatologist or research nurse who will 
provide them with details of the study, how to register. Community paediatricians, neonatologists 
and research nurses who are local collaborators will be able to support them through the study. 




research team, either email or telephone. We  then send them 2 copies of the consent form in the 
post, with a copy of the information sheet we  then contact them after at least 48 hours in order 
for them to have a chance to ask any questions and discuss any concerns. If happy to proceed we 
ask them to sign both consent forms, one to post back to us in the stamped addressed envelope 
provided and one for them to keep for their own records. Where there is a community 
paediatrician, neonatologist or research nurse acting as a local collaborator the information sheet 
and consent forms may be provided by them and they may consent the participant.  
Once a participant has been consented we write to their GP and community paediatrician to 
inform them that they are in the study. We also write to inform the mother’s GP.  
 
Inclusion Criteria: 
• Babies recruited antenatally or in the first 8 months of life born with Down’s syndrome (3 




• Babies with Down's Syndrome who have a child protection plan or who are no longer with 
birth mother. 
• Babies with Down's syndrome over 8 months of age 
• Babies with Down's syndrome in whom the parents do not speak English. The study is  
recruiting families who are trying to cope with a difficult diagnosis and may wish to have 
conversations with the research staff to establish what the implications of recruitment 
would involve for them. Participants are also be required to fill out 7 questionnaires over 
5 years which are in English. 
 
Period of Enrolment 
Infants are  ideally  enrolled in the antenatal or early postnatal period (maximum age 8months) and 
are being  followed up until January 2022. We will be recruiting participants until January 2020.. 




old, those recruited in 2015 until they are 6years old and then for each additional year they will be 
followed for one year less (see table below) 
Year of birth / 
recruitment 
Follow up period 
2019 2 years 
2018 3 years 
2017 4 years 
2016 5 years 
2015 6 years 
2014 7 years 
 
Data collection:  
 
Overview: We are collecting a variety of data from each participant and their family. There are 
questionnaires that the family can either complete online or in a paper version. In addition are 
seeking consent from the baby’s parents to access stored blood spots taken on day 5 of life (as 
part of the Newborn Screening Programme) to look at baseline levels of autoimmunity. There are 
a series of samples that we ask parents to help us take during the study. These  include samples of 
DNA from a brushing of the inside of the baby’s cheek, blood, urine and stool specimens to be 
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Fig 1. Timeline for sample collection. (*at recruitment) 
 
1. Baseline: Once parents have consented for their baby to take part in the study we send them 
out a pack which will include the instructions of how to log on to the online questionnaire (if 
they requested a paper version of the questionnaire this will be sent out in this pack). Parents 
are asked to fill in some details about their own medical history, family history, details of birth 
history, weight, related medical problems such as congenital cardiac disease and any history of 
infections. The initial questionnaire also include feeding questions exploring parental 
expectations and barriers to breast feeding,  introduction of modified cow’s milk feeding if 
applicable and any other problems with early feeding.  
Having gained consent from the parent we will also access the baby’s day 5 blood spot (Guthrie 






(a) A stool specimen from infant to the laboratory for storage for later evalaution of stool 
microbiome. This will be a sample collected from the baby’s nappy by the parents.  
A stool specimen from the mother to the laboratory for storage for later evaluation of 
stool microbiome. The mother is asked to take a swab from a piece of soiled toilet 
paper. 
(b) A swab from infant’s buccal mucosa for DNA extraction for HLA genotyping. - The 
parents are provided with a swab for taking a painless brushing from the inside of the 
baby’s cheek.  
(c) Urine specimen for urinary ‘C’ peptide analysis. Parents are provided with  sterile 
cotton wool which can be placed in the nappy to collect urine on after a feed. Or if the 
parents prefer they can catch the urine in the pot. We advise that either the nappy is 
taken off prior to the feed or the cotton wool is placed in the nappy just prior to a feed 




(d) A heel prick blood test for analysis of auto-antibody production (approx 0.5ml blood) 
and immune cell analysis at Imperial College (0.5ml) collected by a health professional 
at a routine health check as detailed above. 
 
2. Month 6 - 7: At 7 months parents are asked to fill in a further feeding questionnaire regarding 
length of time of breast feeding alone, timing of cow’s milk introduction, type, quantity 
consumed per 24 hours, and time of weaning with which ‘solid food’ products. The 
questionnaire also explores the medical history of the infant including, primary and secondary 
care consultations/admissions, indication for consultation and use of antibiotics in first 6 
months and for what indications. 
 
Samples: At 6 months parents are asked to send: 
 
(a) A stool specimen from infant to the laboratory for for gut microbiome analysis. 
(b) A heel prick blood test for analysis of auto-antibody production. Having observed the 
initial blood test parents should be able to do this blood test at home if happy to do so. 
 
3. Month 12: A further feeding and medical history questionnaire is requested for life events 
between 7-12 months. 
 
Samples: Parents are asked to send: 
(a) A stool specimen from infant to the laboratory for gut microbiome analysis. 
(b) A fingerprick blood test for analysis of auto-antibody production. At this age the blood test 
can be taken from a finger prick by the parents or alternatively at the time of routine thyroid 
disease screening. 
(c) Urine for urinary ‘C’ peptide analysis 
 
 
4. Once a year around the time of the child’s birthday up until January 2022   
 





Samples: Every year parents are asked to send: 
(a) A stool specimen from infant to the laboratory for gut microbiome analysis. 
(b) A finger prick blood test for analysis of auto-antibody production. 




Apart from the initial blood test, samples can be collected by the parents at home. We  send them 
out a pack which contains instructions for taking all the samples (brushing from the baby’s cheek, 
blood, stool and urine) as well as the equipment for taking it. The parents can take the initial 
brushing from the baby’s cheek and collect the  urine and stool samples at home 
After birth, all babies have a number of routine health checks carried out by health professionals 
including their midwife, GP, GP practice nurse and for babies with Down syndrome, they will also 
have an appointment with a paediatrician. With consent from the families, we contact one of the 
key health professionals with which they are having their routine appointments to ask if they can 
assist with the first blood test. We  also provide the parents with a factsheet that can be shown to 
the health professional, outlining the study, and basic requirements for  blood sampling. Where 
there is a local collaborator for the FADES study, the initial blood test may be organised by them 
to coincide with one of their appointments. They may also help with coordinating the future blood 
tests.Once this initial blood test has been taken with the parents observing, the heel prick blood 
test at 6months can be done by the parents at home if they are happy to do so. The finger prick 
blood tests at a year and annually after that can also be done by the parents at home although we 
provide advice on the alternative of having these samples taken at the same time as their routine 
clinical yearly samples taken for thyroid disease screening. Once the samples have been taken they 




We also provide the necessary pre-paid packaging so that parents can post the samples back to us 
at the University of Bristol’s Learning and Research Centre at Southmead. The packaging ensures 
that the samples do not deteriorate during transportation and all samples are labelled with the 
participant’s ID number so that traceability is maintained. Any samples that need to be sent out to 
other laboratories for analysis are sent from Southmead using university approved couriers. This 
will include blood for immune cell analysis by Prof Irene Roberts at Imperial College, urine will 
be sent to Exeter for analysis of urinary C peptide and the stool will be sent for microbiome 
analysis. All samples will be used, stored and disposed of in accordance with The Human Tissue 
Act 2004. 
 
If the questionnaires are not completed or samples are not sent back we initially email the family 
if they have previously expressed that they are happy to be contacted by email, or send a reminder 
letter out to the family 2 weeks after the date that we sent out the pack. If we still have no response 
from the family after a further 2 weeks we email or phone them to discuss whether they need a 
new pack, or if they would prefer to send us only some of the samples or whether they wish to 
withdraw from the study. 
   
Laboratory methods:  
A dedicated password protected Access database has generated to hold patient data. A separate 
database has been generated for laboratory data. The databases are linked by an ID number only 




1. HLA class II analysis 
DNA samples will be genotyped for all HLA class II HLA DRB1 and DQB1 haplotypes 
by polymerase chain reaction using a well established PCR-SSP method (Gillespie et al. 






2. Urinary C Peptide analysis 
Urine samples will be sent from the Learning and Research Centre at Southmead to Dr 
Timothy Macdonald for analysis of urinary c peptide using university approved couriers. 
The samples will be labelled with the participant’s ID to ensure traceability is maintained. 
 
3. Autoantibody analysis 
Serum from all individuals recruited will be tested for islet autoantibodies to insulin, GAD, 
IA-2 and ZnT8R/W using established standardized radioimmunoassays with 125I or 35S 
labeled antigens (Long et al. Diabetes 2012).  Anti-BSA antibody analysis will also be 
determined by radioimmunoassay. Thyroid and gut autoimmunity will be analysed by 
testing for antibodies to tissue transglutaminase (Tg) as previously published (Williams AJ, 
Norcross AJ, Lock RJ, Unsworth DJ, Gale EA, Bingley PJ. Diabetes Care. 2001 
Mar;24(3):504-9). Antibodies to thyroid peroxidase (TPO) will be measured using a 
radioimmunoassay kit purchased from RSR Limited, Cardiff UK.  I125 labelled TPO will 
be incubated with patient sera and calibrators.  Antigen-antibody complexes will then 
precipitated using solid phase protein A and centrifugation.  Unbound labelled TPO will 
be removed by aspiration and the remaining pellet measured in a gamma counter.  
Percentage binding is calculated as the pellet count divided by total count multiplied by 
100.  A calibration curve is produced using the calibrator data allowing patient TPO 
autoantibody levels to be determined.  Antibodies to gastric H+/K+ ATPase 4A subunit 
antibodies will be measured using a method recently described (Development of a novel 
autoantibody assay for autoimmune gastritis in type 1 diabetic individuals. (Wenzlau JM, 
Gardner TJ, Frisch LM, Davidson HW, Hutton JC. Diabetes Metab Res Rev. 2011 
Nov;27(8):887-90. doi: 10.1002/dmrr.1267. This analysis will be done at the Learning and 
Research Centre at Southmead. 




Blood samples will be sent from the Learning and Research Centre at Southmead to Irene 
Roberts using university approved couriers. The samples will be labelled with the 
participants ID to ensure traceability is maintained. EDTA blood samples would be red 
cell- and granulocyte-depleted by density gradient centrifugation and mononuclear cells 
isolated for: (i.) immunophenotyping by multiparameter flow cytometry (BD Fortessa) 
using a panel of B-cell (CD19, CD10, CD27, IgM, IgD) and T-cell (CD4, CD8, CD45RO, 
CD62L/CCR7, CD25/cFoxP3, V24/v11) antigens; and (ii) RNA extraction to assess 
expression of lineage-associated genes by flow-sorted B cells. 
5. Gut microbiome  
We have run a pilot study (Phase1) to evaluate the performance of the DNA Genotek 
Stool Collection Kit compared to a standard stool self collection kit. See Appendix 1 for 
the pilot study protocol.. 
Parents collect small samples of stool from their babies nappies using a swab and will 
transfer it into containers which will be provided. Maternal stool samples will be collected 
by swabing a piece of soiled toilet paper and transferring into the provided container. The 
gut bacterial DNA will be extracted and sent for analysis in a laboratory with expereince 
in microbiome analysis. All samples sent out by the research team will be anonymous and 
linked only to the patient by a four digit number.  
Feasibility study objectives 
As this is a feasibility study there are a number of objectives that we will use to assess the 





The feasibility of our recruitment methods will be determined by the number of participants that 
we are able to consent to the study, our target is 100 participants a year recruiting over a 2 year 
period (20% of the DS families who are in contact with the DSA) 
The acceptability and feasibility of web recruitment will be explored. Potential participants are 
asked to complete an online registration/ expression of interest form, from this the participant 
information sheets and consent forms are sent out to them in the post (the exception are those 
recruited and consented by local collaborators). We will keep a record of any problems that occur 
which prevent or delay participants being recruited as a result of the online system. 
Qualitative telephone interviews with community paediatricians, neonatologists, research nurses, 
other relevant healthcare professionals and family support workers from charities such as the DSA 
and DSS will be used to explore the barriers and motivations to families with new babies with DS 
in taking part in research. We will also be asking them about the feasibility and acceptability of the 
FADES protocol (appendix 3) 
Questionnaires 
Online and paper questionnaires are completed at initial recruitment, 7 months, a year and annually 
until January 2022. The feasibility and acceptability of the questionnaires will be determined by the 
percentage of participants that complete the questionnaires as well as by the quality of the data. 
We are aiming for 75 % of recruited participants to complete initial questionnaires, the 
questionnaires at 7 months and to be completing questionnaires at a year. We aim for 50% to 
complete the and annual questionnaires up until the age of 5 years.  
The feasibility and accepatbility of using online questionnaires will be determined by the number 
of participants who choose to use the online versions. We hope that over 60% of participants will 




form which is ready for analysis. A record of any problems that occur which prevent or delay 
participants completion of the online questionnaire and any issues that are raised by participants 
in relation to the online or paper questionnaires will be recorded. 
Sample collection 
Families are asked to collect a number of samples at home which they post back to us. The 
feasibility of the sample collection is being assesed in several ways: 
The method for collection of urinary c peptide using cotton wool was established in a small pilot 
study prior to the start of the FADES study. 
Phase 1 (appendix 1) is being used to establish whether gut microbiome samples are preserved 
whilst being sent in the post.   
The feasibility and acceptability of collecting all the samples within the desired timeline will be 
determined by the percentage of participants who return the requested samples. We hope that 
75% of participants will provide the requested initial samples before 8 months of age. Of the 
samples provided 90% of samples should be adequate for analysis. For many participants they will 
not need to collect samples at 7 months because of the age at recruitment therefore acceptability 
and feasibility will be determined by the percentage of participants who return the requested 
samples at 12 months. Our target would be for 75% of participants to provide the requested 12 
month samples before 14 months of age. The aim will be for 50% of participants to provide all 
samples up to the age of 5 years. 
In order to determine the acceptability and feasibility of the study we will also be recording any 
issues or problems that occur with sample collection at home. Blood samples can be collected by 
health professionals during participants routine health appointments we will record any issues that 




Retention of participants 
The acceptability and feasibility of the study will be determined by the number of participants who 
reamain active in the study up until the age of 5 years old with a traget of retaining 50% of 
participants.  
Patient and Family Involvement (PPI 
The DSA, DSI andDSS are parent/member led charities with whom we are collaborating with on 
this study. They have had input into the study design as well as advising us on the wording of the 
information sheets, consent forms and questionnaires.  
Conflict Of Interest: None of the researchers have any affiliations or involvement in any 
organisation or entity with any financial interest or non-financial interest which would impact on 
this study.  
Monitoring and Audit: The University of Bristol has a Service Level Agreement in place with a 
local NHS Trust (UH Bristol). As part of this, UH Bristol will undertake maonitoring of research 
projects where University of Bristol is fulfilling the responsibilities of a research sponsor. A 
minimum of 10% of UoB projects will be monitored.  
All study related documents will be made available on request for monitioring and audit by UH 
Bristol and the relevant Research Ethics Committee. 
Safety Reporting: For safety reporting procedures we will follow the UH Bristol Research 
Adverse Event Policy 
Indemnity: This is a University of Bristol sponsored research study. The University of Bristol has 
arranged Public Liability insurance to cover the legal liability of the Univeersity as Research 
Sponsor in the eventuality of harm to a research participant arising from management of the 




cover the legal liability of the University, for harm to participants arising from the design of the 
research, where the research protocol was designed by the University. The University of Bristol’s 
Public Liability insurance policy provides an indemnity to our employees for their potential liability 
for harm to participants during the conduct of the research. 
Ethics and R & D Approvals: The study will be carried out subject to Research Ethics 
Committee (REC) approval and Research and Development (R&D) approval from the relevant 
NHS Trusts. 
Research Governance Statement: This study will be sponsored by the University of Bristol and 
conducted in accordance with the Research Governance Framework for Health and Social Care 
and Good Clinical Practice. 
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NIHR Bristol Nutrition Biomedical Research Unit 
 
 
Pilot Study Design – University Hospitals Bristol 
OBJECTIVE 
 
This pilot study will evaluate the performance of the DNA Genotek Stool Collection Kit (OMR 
200) for use in the FADES study. The DNA Genotek Stool Collection Kits to be evaluated in this 
pilot study will be prototypes still under development and thus will require participants to 
strictly follow the collection instructions provided. The DNA Genotek Stool Collection Kit will 






10 Participants will be recruited from patients admitted to Bristol Royal Hospital for Children 
for non-infectious causes (likely infants being admitted for elective surgery).  We will provide 
flyers to parents of babies under 1 year of age who are admitted to the Bristol Royal Hospital 
for Children. If they are interested, we will give them a study information sheet. If they are 
happy to proceed, we will meet them on the ward to answer any questions, complete the 




Samples will be collected by parents on the ward from their baby’s nappy. The samples need 




nappy” (i.e. from the same stool). In order to acquire a ‘fresh’ stool we will ask parents to 
check their baby’s nappy regularly within one hour after a feed as babies tend to have a 
pronounced gastro-colic reflex. We will arrange to be on the ward the day that the sample is 
collected so that we can freeze one of the samples immediately and package the other 
samples for posting.  
 
The first sample from the nappy will be collected using the DNA Genotek stool collection kit 
(OMR 200) (“Tube 1”) which will be sent in the post. The second and third samples will be 
collected using the standard stool self-collection kit without stabilization liquid; “Tube 2” 
which we will send in the post with “Tube 1” in order to compare to the DNA Genotek Stool 
Collection Kit. “Tube 3” we will freeze immediately (the current accepted method for 
collecting stool for gut microbiome).  
 
Prior to collection the tubes will be labelled as Tube 1, Tube 2 and Tube 3 appropriately. A 
unique identifier will be assigned to each tube and each tube will be weighed (to be used as 
baseline to determine amount of sample collected post-collection).  
 
The parents of the ten participants will each be provided with the required materials for 
sample collection as described in Section 3 Study Materials. The parents of the 10 
participants, will each collect stool samples from one “dirty” nappy. A small amount of the 
stool will be put into each of the three provided tubes following the appropriate provided 
Collection Instructions. Tube 1 will be the DNA Genotek Stool Collection kit (OMR 200 tube 
contains mixing bead and stabilization liquid) Tube 2 and Tube 3 will be the standard stool 
collection kit without stabilization liquid. 
 
The parents will then be asked to complete the questionnaire in Appendix 2 which asks how 
easy they found the collection kit to use. 
 
Once the sample has been collected  
 
Tube 1(Genotek sample kit): - we will package with Tube 2 and send to the Diabetes and 
Metabolism Unit at Southmead Hospital. These samples will be in standard packaging and 
labelled so as to maintain traceability. It is anticipated that shipping will comprise ambient 
temperature conditions for 4 -5 days.  
 
Tube 2(Standard collection kit): - we will package with tube 1 and send to the Diabetes and 
Metabolism Unit at Southmead hospital. 
 
Tube 3 (Standard sample kit): - we will put on dry ice (-78.5°C) and transport to the Diabetes 










On arrival at the Diabetes and Metabolism Unit the tubes will be weighed and sample weights 
determined based on matched baseline values measured pre-collection, the samples will then 
all be placed in the freezer at -80⁰C until DNA extraction.  
 
Three aliquots (0.25mL each) of each sample will be removed and DNA extracted using the 
MoBio PowerFecal DNA Isolation Kit or MoBio PowerSoil DNA Isolation Kit, following 
manufacturer’s instructions, specifically: 
• Vortex the DNA Genotek tubes containing sample and stabilization liquid to 
ensure homogenization 
• Remove 0.25mL of stool sample mixed with stabilization liquid from Tube 1 
(“DNA Genotek kit”) or 0.25g of stool sample from Tube 2 (no stabilization 
liquid) and add to the Dry Bead Tube as described in Step 1 of the Experienced 
User Protocol for the PowerFecal kit, or add to the PowerBead Tubes as 
described in Step 1 of the Experienced User Protocol for the PowerSoil kit. 
Continue with the remainder of the protocol. 
Each purified DNA sample will be tested for the following endpoints: 
• DNA concentration (using fluorescence) 
• High molecular weight DNA using agarose gel electrophoresis 
• Microbiome stability assessed using Denaturing Gradient Gel Electrophoresis 





Each participant will be provided with the following materials for collection:  
• Tube 1: One DNA Genotek Stool Collection Kit (tube containing the DNA Genotek 
stabilization liquid and a collection tool) (provided by DNA Genotek) 
• Collection Instructions for Tube 1 (in Appendix 1) 
• Tube 2 and 3: Two empty tubes and collectors as the standard stool collection kit. 
• Collection Instruction for Tube 2 and 3  
• A rack to hold tubes during collection  




Ten (10) donors will each provide three tubes each containing a small amount of stool sample 
for a total of 30 samples. Each sample will be extracted in triplicate for a total of 90 extracted 







 Study Endpoints 
 
Questionnaire results from DNA Genotek Collection Kit and standard stool collection kit  
Sample weight 
DNA concentration (using fluorescence) 
High molecular weight DNA measured using agarose gel electrophoresis 
Microbiome stability assessed using Denaturing Gradient Gel Electrophoresis (DGGE) and/or 












Warnings and precautions: 
• FOR EXTERNAL USE ONLY. 
• Do NOT remove the yellow tube top from the tube. 
• Do NOT spill the stabilizing liquid in the tube. 
• Wash with water if liquid comes in contact with eyes 
   or skin. Do NOT ingest. 
• If fecal sample is liquid or donor has diarrhea wait 
   until the next bowel movement to collect the sample. 
• Small items may pose a choking hazard. 
 
 
Step Procedure   
1 As soon as you are aware that your baby has passed a stool (done a poo) in their 
nappy remove the nappy. We want the stool to be as fresh as possible when the 
sample is collected. 
2  Unscrew ONLY the purple cap from the collection 






Do not remove the yellow cap       




               
For the first sample Tube 1 use the stick to collect a 




Transfer the stool (poo) sample into the yellow tube 
top. Repeat until the sample reaches the top and fills it 
completely  
                              




Scrape horizontally across the tube top to level the 
sample and remove any excess. Discard the stick. 
Wipe the exterior of the tube and top with the toilet 






Screw the purple cap back onto the yellow top tube 
until tightly closed  




Shake the sealed tube as hard and fast as possible in a 
back and forth motion for a minimum of 30 seconds. 
8 
 
The stool (poo) sample will be mixed with the 
stabilizing liquid in the tube. Not all particles will 
dissolve. 
IMPORTANT: Keep shaking if large particles remain 
as shown in Fig. A  
9  Proceed with the collection of the sample into Tube 2. Open the tube and use the 
scoop to pick up some stool from the nappy put the cap back on including the scoop. 
10 Repeat step 9 with Tube 3  
11 Give all 3 tubes to the member of the research team who will be present on the ward 
together with a completed questionnaire. 
 
Australian Sponsor: Emergo Australia, Level 20, Tower II, Darling Park, 201 Sussex Street, Sydney, NSW 2000 Australia 
OMNIgene•GUT is for research use only, not for use in diagnostic procedures. 
 
®OMNIgene is a registered trademark of DNA Genotek Inc. 
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APPENDIX 2: Questionnaire for the DNA Genotek Stool Collection Kit – Tube 1 
 
 
1. How old was your baby (in weeks) at the time of stool collection?  
2. Using this Bristol Stool Chart, please circle the Type (1-7) which most closely resembles 





3. When collecting the sample into Tube 1  how did you find  transfer of the sample into 
the yellow top : (please circle all that apply) 
a. How many collections (step 3) or transfers were required to fill the top of the 




iv. More than 3 
 
4. Regarding the overall collection experience: 
b. Were the components provided in the kit for tube 1 sufficient to collect and 
transport samples in a comfortable manner?   Yes / No 
 





ii. I would remove from the kit: 
______________________________________________ 
iii. I would change the kit by: 
______________________________________________ 
 
c. Were the collection instructions easy to follow?   Yes / No 
 
d. Was enough detail provided in the instructions for a first-time donor?   Yes / No 
 
e. Were you overwhelmed by the number of collection steps?   Yes / No 
 
f. Would you consider your collection successful?   Yes / No 
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SYNOPSIS 
 
Title Feeding and Autoimmunity in Down’s Syndrome Evaluation 
Study 







Objectives The overall aim of the research is to establish the feasibility of 
creating a national cohort of infants with Down’s syndrome (DS) 
to study the associations between early infant feeding, 
infections and the development of autoimmunity in DS. 
  
The objectives are: 
 
To explore the views and opinions of healthcare professionals 
and support workers about their experience of working with 
parents of new babies with DS (babies under the age of 8 
months). 
 
To explore the views and opinions of healthcare professionals 
and support workers about research in this population. 
 
To explore the views and opinions of healthcare professionals 
and support workers about potential barriers to families taking 
part in research and how these may be overcome. 
 
To explore the views and opinions of healthcare professionals 
and support workers about potential motivations to families 
taking part in research. 
 
To explore healthcare professionals and support workers 
experience of the FADES study and its acceptability for families 
that they work with. 
 
To explore the views and opinions of healthcare professionals 
and family support workers on how recruitment in the FADES 
study might be improved. 
 
To establish the feasibility of creating a national cohort of 
infants with DS to study the associations between early infant 
feeding, infections and the development of autoimmunity in DS 
Study 
Configuration 
The study will consist of approximately 15-20 interviews with 
community paediatricians, neonatologists, research nurses, 
other relevant healthcare professionals and family support 
workers from charities such as the Down’s Syndrome 
Association and Down’s Syndrome Scotland. Each participant 
will undergo one telephone interview lasting for approximately 
an hour. Interviews will take place over a 6 week period, at a 
time convenient to the participant. 
Sample size 
estimate 
It is anticipated that approximately 15-20 healthcare 
professionals and support workers who work with parents of 






It is anticipated that a total of 15-20 interviews will take place.  
Eligibility criteria • Community paediatricians, neonatologists, research nurses 
and other relevant healthcare professionals with experience 




• Family support workers from charities such as the DSA and 




Community paediatricians, neonatologists, research nurses, 
other relevant healthcare professionals and family support 
workers from charities such as the DSA and DSS with experience 
in working with parents of new babies with DS will be invited to 
take part in a telephone interview with the researcher at a time 
that would be convenient to them. 
 
The telephone interviews will last about an hour and will be 
digitally audio recorded. Interviews will be conducted 
individually, with one researcher and one participant. 
 
The interviews will focus on a range of aspects relating to their 
experience of working with parents with a new baby with DS. 
We want to explore their overall experience and explore the 
pressures that families are under at this time and the concerns 
that parents have. We want to explore the opinion and views of 
the health care professionals and support workers on the 
acceptability to families of taking part in research during the 
first few months with their baby. We want to find out if they are 
aware of potential barriers to families taking part in research 
and how these may be overcome and also what might motivate 
parents to want to engage in research. 
We also want to explore their opinions on the FADES study, 
specifically its acceptability for families and how recruitment 
might be improved. We will provide participants with copies of 
the FADES flyer, protocol and participant information sheet 
prior to the telephone interviews. 
Duration of 
study 
Intended Start date: September 2015 
 
It is anticipated that the interviews will take place over a 6 week 
period, thus recruitment and data collection will run until 





Following recruitment, ie. asking to participate and providing 
consent, participants will only be involved for the duration of 
their interview. This is expected to last about one hour.  
 
Some participants may already be local collaborators for the 
FADES study and would therefore continue in this role after the 
interviews have taken place.   
Randomisation 
and blinding 
Randomisation will not take place. Healthcare professionals and 
support workers will be asked to participate in the research 




As qualitative research, there will not be quantifiable outcomes. 
The key outcomes of the research are to understand the 
barriers and possible motivations for families with a young baby 
with DS taking part in research. 
Statistical 
methods 
Qualitative data will be collected during this research, and 
statistical analysis will therefore not be required. Interview data 
will be digitally audio recorded, transcribed and analysed 







STUDY BACKGROUND INFORMATION AND RATIONALE 
We aim to create a cohort of infants with DS recruited through the Down’s Syndrome 
Association (DSA), Down’s Syndrome Scotland (DSS), community paediatricians and 
neonatologists to study the association between early infant feeding, infections and 
the development of autoimmunity. We initially anticipated that we would recruit 100 





Children with Down’s Syndrome (DS) have increased risk of autoimmune conditions 
where the body’s immune system attacks its own cells, such as thyroid problems, 
diabetes and coeliac disease (which causes malabsorption). In DS, autoimmunity is 
likely to be related to lifelong inherent defects in the immune system.  The increased 
risk of diabetes-related autoimmunity is despite a reduced prevalence of the usual 
HLA haplotypes commonly associated with type 1 diabetes. Infant feeding practice 
has been linked to diabetes and coeliac risk with some evidence that prolonged 
breastfeeding is protective.  We hypothesise that in infants with DS, already at 
increased risk, early feeding practices may be related to the development of 
autoimmunity. Children with DS are more floppy and therefore have difficulties with 
breastfeeding leading to the rapid introduction of formula feeds which contain 
modified cow’s milk protein.  
 
Parents are asked to complete questionnaires at baseline detailing family history, 
birth history, weight, medical problems and early feeding. They have further feeding 
questionnaires to complete at 7 months and 12 months, and medical questionnaires 
annually until the age of 5 years. Samples are collected at baseline including faeces to 
store from mother and baby, a brushing from the infants cheek for genotyping 
(looking at their DNA), a blood sample from the baby to look at development of auto-
antibody production (antibodies which act against their own cells), and a urine 
specimen to detect development of diabetes. Further stool, urine and blood samples 





This study is a feasibility study and therefore we need to understand whether 
recruiting families and asking them to participate in such a study is acceptable and 
feasible. The proposed research will use the experiences of those that work with these 
families; community paediatricians, neonatologists, and family support workers from 
the DSA and DSS to understand the potential barriers and motivations for families to 
take part in research shortly after their baby has been born[1, 2]. We want to explore 
the pressures that families are under at this time and the concerns that parents 
have[3, 4]. We want to explore the opinion and views of the health care professionals 
and support workers on the acceptability to families of taking part in research during 
the first few months with their baby. We want to find out if they are aware of 
potential barriers to families taking part in research and how these may be overcome 
and also what might motivate parents to want to engage in research.  
 
We would also like their opinion on the FADES study its acceptability for families and 
how recruitment might be improved. We will provide participants with copies of the 
FADES flyer, protocol and participant information sheet prior to the telephone 
interviews 
The primary aim is to establish the feasibility of creating a national cohort of infants 
with DS to study the associations between early infant feeding, infections and the 










The primary objectives are: 
To explore the views and opinions of healthcare professionals and family support 
workers about their experience of working with parents of new babies with DS (babies 
under the age of 8 months). 
 
• To explore the views and opinions of healthcare professionals and family 
support workers about research in this population. 
• To explore the views and opinions of healthcare professionals and family 
support workers about potential barriers to families taking part in research 
and how these may be overcome. 
• To explore the views and opinions of healthcare professionals and family 
support workers about potential motivations to families taking part in 
research. 
• To explore healthcare professionals and family support workers experience of 
the FADES study and its acceptability for families that they work with. 
• To explore the views and opinions of healthcare professionals and family 
support workers on how recruitment in the FADES study might be improved. 
• To establish the feasibility of creating a national cohort of infants with DS to 
study the associations between early infant feeding, infections and the 









The study will consist of approximately 15-20 telephone interviews with community 
paediatricians, neonatologists, research nurses, other relevant healthcare 
professionals and family support workers from charities such as the Down’s Syndrome 
Association and Downs Syndrome Scotland who have experience in working with 
these families. Each participant will undergo one interview lasting for approximately 
an hour. Interviews will take place over a 6 week period at a time that will be 
convenient to the participant. 
Primary endpoint 
As qualitative research, there will not be quantifiable outcomes. The key endpoint of 
the research is to have gained an understanding of the barriers and motivations for 
families with new babies  with Down’s syndrome to taking part in research. The key 
outcomes of the research are to use this knowledge to establish the acceptability and 
feasibility of FADES.  
 




Randomisation will not take place. Healthcare professionals and support workers will 
be asked to participate in the research following a purposive sampling strategy. 
As this is not an intervention study, blinding is not necessary. 
 
STUDY MANAGEMENT 
The Chief Investigator has overall responsibility for the study and shall oversee all 
study management. There is not a Trial Steering Committee for this research, as this 
is a small qualitative study. 
 
The data custodian will be the Chief Investigator. 
 
DURATION OF THE STUDY AND PARTICIPANT INVOLVEMENT 
It is anticipated that the interviews will take place over a 6 week period, thus 
recruitment and data collection will run until November 2015.  
Following recruitment, ie asking to participate and providing consent, participants will 
only be involved for the duration of their interview. This is expected to last about an 
hour. 
Some participants may already be local collaborators for the FADES study and would 





End of the study 
The end of the study for each participant will be following their interview. Following 
recruitment, the participants will only speak with the researcher on one occasion; for 
the interview. Those who are already local collaborators for the FADES study will 
continue in this role after the interviews have taken place.   
 
SELECTION AND WITHDRAWAL OF PARTICIPANTS 
The target population will be community paediatricians, neonatologists, other 
relevant healthcare professionals and family support workers from charities such as 
the Down’s Syndrome Association and Down’s Syndrome Scotland who have 
experience in working with families of babies with Down’s syndrome in the first few 
months of life. Participants will be recruited through the local collaborators that we 
already have helping with the study, through the Down’s Syndrome Medical Interest 
Group and through contacts with the charities including the DSA and DSS. We will 
email participant information sheets to our local collaborators and to members of the 
DSMIG and to family support workers through the charities to find out who would be 
interested in taking part. We will then send out consent forms to those that have 





Participants will be recruited using a purposive sampling method. 
Consent forms and information sheets will not be available printed in other 
languages. Participants must have a sufficient understanding of the English language 
to participate. 
It will be explained to the potential participant that participating in the research is 
entirely voluntary and that all data will be anonymised and treated as confidential. 
They can withdraw at any time but attempts will be made to avoid this occurrence. In 
the event of their withdrawal it will be explained that their data collected so far 
cannot be erased and we will seek consent to use the data in the final analyses where 
appropriate. 
 
Removal of participants from the research 
Participants would be removed from the study if they request to withdraw their 
participation. However if a participant indicates a wish to withdraw attempts will be 
made to persuade the participant to at least permit primary outcome data to be 
collected, ensuring that enough data are recorded to support the planned analysis. 
Participants will not be accepted as lost to follow-up unless we receive no response 
from phone calls, emails and letters. Participants will be made aware (via the 
information sheet and consent form) that should they withdraw the data collected to 






After interested potential participants have been identified information about the 
research will be provided by the researcher, in the form of the Information Sheet and 
any questions the potential participants have about the research will be answered.  
 
Potential participants will be asked whether they are happy to provide a contact 
telephone number for the researcher. Their name and telephone number will be 
stored within the Bristol Nutrition BRU in a locked file and will not leave the Bristol 
Nutrition BRU. The researcher will ask whether the potential participant is interested 
in participating in the research, and if they are, a date for the interview will be set. 
When the researcher calls the participant on the date of the interview, the 
information sheet and consent form will be discussed in detail and signed. Again, 
participants will be informed that participation is voluntary, they can withdraw at any 
time and that all data will be anonymised and treated as confidential.  
 
If the potential participant states that he does not want to participate in the research 
when they are called by the researcher, then their name and telephone number will 





Consent will be taken over the phone, the researcher will discuss the information 
sheet (which will have been emailed or posted to the potential participant) with the 
participant over the phone and ask if they have any queries. Once they have had an 
opportunity to ask any questions if they are happy to take part the researcher will 
complete the consent form and consent will be recorded. (Consent over the phone 
has been used in previous qualitative studies NRES reference 13/NW/0228)  
 
Should there be any subsequent amendment to the final protocol, which might affect 
a participant’s participation in the research, continuing consent will be obtained using 
an amended consent form which will be signed by the participant.   
 
STUDY TREATMENT AND REGIMEN 
Once a participant has orally agreed to participate, an interview date will be arranged 
between the individual and the researcher. We will email and/or post copies of the 
FADES protocol, FADES flyer and FADES participant information sheet to the 
participant for them to view prior to the telephone interview as these will be 
discussed. 
 
The researcher will conduct the interview in a quiet, private location, where they will 





The interview will last for approximately an hour, and will be digitally audio recorded. 
Recordings will be transcribed using a University of Bristol approved transcription 
service who have signed a data protection agreement. All names and identifying 
information will be removed from the transcripts upon transcription. An ID will be 
allocated in order to identify whether the participant is a community paediatrician, 
neonatologist, another healthcare professional or a family support worker. Interviews 
will be conducted individually, with one researcher and one participant.  
 
Interviews will be semi-structured, and will cover the following topics. The interviews 
will focus on a range of aspects relating to their experience of working with new 
parents of children with Down’s syndrome. We want to find out their opinions on the 
barriers that these parents might have to taking part in research and also the possible 
motivations they may have. We also want to find out their opinion on the 
acceptability of the FADES study having viewed the flyer, protocol and participant 
information sheet. We want to know if they have any ideas or suggestions for 
improving  recruitment. 
 
Criteria for terminating research 






ANAYLSIS AND STATISTICS 
Qualitative data will be collected during this research, and statistical analysis will 
therefore not be required. Interviews will be digitally audio-taped and transcribed 
verbatim. Thematic analysis of the interview data will be conducted using a qualitative 
method, such as the Framework Approach (Ritchie and Spencer, 2002). Individuals 
will not be identified by name in the written transcript. A qualitative analysis 
computer program, such as NVivo (NVivo10, QSR International, 2012) will be used to 
assist with the analysis. 
 
ADVERSE EVENTS 
The research consists of participant interviews, following a standardised interview 
procedure. It is not anticipated that any adverse events will occur as a result of this 
research. However in the occurrence of adverse events, the event will be reported 
immediately to the Chief Investigator and necessary advisory boards. The event will 
be investigated, resolved where appropriate and a report written.  
 




Any participant who experiences an adverse event may be withdrawn from the study 
at the discretion of the Investigator. 
 
ETHICAL AND REGULATORY ASPECTS 
 
ETHICS COMMITTEE AND REGULATORY APPROVALS 
The research will not be initiated before the protocol, informed consent forms and 
participant information sheets have received approval from the Research Ethics 
Committee (REC). Should a protocol amendment be made that requires REC approval, 
the changes in the protocol will not be instituted until the amendment and revised 
informed consent forms and participant information sheets have been reviewed and 
received approval from the REC. A protocol amendment intended to eliminate an 
apparent immediate hazard to participants may be implemented immediately 
providing that the REC are notified as soon as possible and an approval is requested. 
Minor protocol amendments only for logistical or administrative changes may be 
implemented immediately; and the REC will be informed. 
 
The research will be conducted in accordance with the ethical principles that have 




Practice, and the Department of Health Research Governance Framework for Health 
and Social care, 2005. 
 
INFORMED CONSENT AND PARTICIPANT INFORMATION 
The process for obtaining participant informed consent will be in accordance with the 
REC guidance, and Good Clinical Practice (GCP) and any other regulatory 
requirements that might be introduced. A copy of the participant information sheet 
and consent form will be emailed or sent to the potential participant. Consent will be 
taken over the phone, the researcher will discuss the information sheet with the 
participant over the phone and ask if they have any queries. Once they have had an 
opportunity to ask any questions if they are happy to take part the researcher will 
complete the consent form and record consent.  
The participant will receive a copy of the signed and dated forms and the original will 
be retained in the Trial Master File.  
The decision regarding participation in the study is entirely voluntary. The investigator 
or their nominee shall emphasize to them that consent regarding study participation 
may be withdrawn at any time without penalty. No research-specific data collection 
will be carried out before informed consent has been obtained. 
 
The investigator will inform the participant of any relevant information that becomes 




wish to continue with the study. If applicable they will be asked to sign revised 
consent forms. 
If the Informed Consent Form is amended during the study, the investigator shall 
follow all applicable regulatory requirements pertaining to approval of the amended 




Case Report Forms  
Each participant will be assigned a unique identity code number, for use on Case 
Report Forms (CRFs), other research documents and the electronic database. The 
unique identity code number will consist of a CP for a community paediatrician, NT 
for a Neonatologist, RN for research nurse or an SW for a family support worker and 
for other health care professionals similar code numbers will be created. A unique 
letter ie. A is the first participant, B is the second, C is the third, within the community 
paediatrician, neonatologist or support worker’s interviews and a number eg. 001 for 
the first participant, 002 for the second, 003 for the third. Examples of the unique 
identity code include CP_A_001, NT_E_005, SW_G_007. Each participant will 
additionally be assigned a pseudo-name, for the purpose of transcription and analysis. 
This will correspond to the unique letter in their identity code, it will also correspond 




be Andrew, a community paediatrician (CP_A_001), Emma, a neonatologist 
(PA_E_005), Gemma, a support worker (ST_G_007). This system will ensure 
anonymity for the participants throughout analysis and dissemination of research 
findings. 
 
CRFs will be treated as confidential documents and held securely in accordance with 
regulations. The investigator will make a separate confidential record of the 
participant’s name, date of birth, contact details, and unique identity code number, 
to permit identification of all participants enrolled in the study, in accordance with 
regulatory requirements. 
 
CRFs shall be restricted to those personnel approved by the Chief Investigator and 
recorded on the ‘Trial Delegation Log.’ 
 
All paper forms shall be filled in using black ballpoint pen. Errors shall be lined out but 
not obliterated by using correction fluid and the correction inserted, initialled and 
dated. 
 




Source documents shall be filed at the investigator’s site and may include but are not 
limited to, consent forms and audio tapes. A CRF may also completely serve as its own 
source data. Only research staff shall have access to research documentation other 
than the regulatory requirements listed below. 
 
Direct access to source data / documents 
The CRF, and all source documents, shall be made available at all times for review by 
the Chief Investigator, Sponsor’s designee and inspection by relevant regulatory 
authorities.  
 
DATA PROTECTION  
All study staff and investigators will endeavour to protect the rights of the research 
participants to privacy and informed consent, and will adhere to the Data Protection 
Act, 1998. The CRF will only collect the minimum required information for the 
purposes of the research. CRFs will be held securely, in a locked room, and locked 
cabinet. Access to the information will be limited to the study staff and investigators 
and relevant regulatory authorities (see above).  
 
Computer held data including the study database and audio tapes will be held 




passwords (encrypted using a one way encryption method) Electronic data will be 
backed up regularly to both local and remote media in encrypted format. 
 
QUALITY ASSURANCE & AUDIT  
 
INSURANCE AND INDEMNITY 
The University of Bristol has arranged Public Liability insurance to cover the legal 
liability of the University as Research Sponsor in the eventuality of harm to a research 
participant arising from management of the research by the University. 
The University of Bristol holds Professional Negligence insurance to cover the legal 
liability of the University, for harm to participants arising from the design of the 
research, where the research protocol was designed by the University. 
 
The University of Bristol’s Public Liability insurance policy provides an indemnity to 
our employees for their potential liability for harm to participants during the conduct 






Research conduct will be subject to systems audit of the Trial Master File for inclusion 
of essential documents; permissions to conduct the research; Trial Delegation Log; 
CVs of research staff and training received; local document control procedures; 
consent procedures and recruitment logs; adherence to procedures defined in the 
protocol (e.g. inclusion / exclusion criteria, correct randomisation, timeliness of 
visits); adverse event recording and reporting; accountability of research materials 
and equipment calibration logs. 
 
RESEARCH DATA  
Monitoring of research data shall include confirmation of informed consent; source 
data verification; data storage and data transfer procedures; local quality control 
checks and procedures, back-up and disaster recovery of any local databases and 
validation of data manipulation. The Research Coordinator, or where required, a 
nominated designee, shall carry out monitoring of research data as an ongoing 
activity.  
Research data and evidence of monitoring and systems audits will be made available 
for inspection by REC as required. 
 




In compliance with the ICH/GCP guidelines, regulations and in accordance with the 
University of Bristol Research Code of Conduct, the Chief Investigator will maintain all 
records and documents regarding the conduct of the study. These will be retained for 
at least 7 years or for longer if required. If the responsible investigator is no longer 
able to maintain the study records, a second person will be nominated to take over 
this responsibility.  
 
The research documents held by the Chief Investigator on behalf of the Sponsor shall 
be finally archived at secure archive facilities at the University of Bristol.  This archive 
shall include all research databases and associated meta-data encryption codes. 
DISCONTINUATION OF THE RESEARCH BY THE SPONSOR  
The Sponsor reserves the right to discontinue this research at any time for failure to 
meet expected enrolment goals, for safety or any other administrative reasons. 
STATEMENT OF CONFIDENTIALITY  
Participant confidentiality will be further ensured by utilising identification code 
numbers to correspond to data in the computer files. 
Data generated as a result of this study will be available for inspection on request by 
the University of Bristol representatives, the REC, and regulatory authorities. 




Data collected during this research may contribute to peer reviewed publications in 
journals and presentations at conferences. All data will be anonymised, and 
participants will not be identified in any publications, reports or future grant 
applications. 
USER AND PUBLIC INVOLVEMENT 
User and public involvement has not been included in the design of the research to 
date, as there has yet to be an opportunity for this to occur.  
STUDY FINANCES 
Funding source  
NIHR Bristol Nutritional Biomedical Research Unit, University of Bristol. Participants 
will not be paid to participate in the research.  
SIGNATURES 
 
Signatories to Protocol: 
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Appendix 5: Qualitative Study Topic Guide 
 
NIHR BRISTOL NUTRITION BIOMEDICAL RESEARCH UNIT  
Questions / Topic Guide for Professionals Telephone Interviews 
 
Intro statement 
Hi I’m Georgina, I’m a paediatric registrar currently doing a clinical PhD looking at how early 
life influences may affect the development of Autoimmune conditions in children with Down’s 
syndrome. 
Thank you for talking to me I hope that from these telephone interviews I will get a better 
understanding of the motivations and barriers for new parents of babies with Down’s 
syndrome to taking part in research and particularly in the FADES study. Children with Down’s 
syndrome are a minority group in whom little research has been conducted, understanding 
why recruitment in this group is challenging will be important for anyone undertaking 
research in Down’s syndrome in the future. I am conducting these interviews with community 
paediatricians, support workers, neonatologists, research nurses and midwives. 
This will be a general conversation about families with children with Down’s syndrome and 
research as well as some more specific questions in relation to the FADES study (protocol, 




The interview should take about an hour - is now a good time for you? If you are pressed for 
time please let me know and I can adjust some of the questions accordingly. (grey questions 
are omitted in shortened version) 
Have you had the opportunity to read the participant information sheet? 
Do you have any questions or anything you would like me to clarify?    
I am now going to take consent, I will read through the consent form please let me know if 
you are happy for me to sign the consent form on your behalf? – Read through consent form 
and take consent. 
Do you have any questions before we start? 
We will be putting together a report based on what is said in the telephone interviews and to 
make this possible we would like to record what is said. We will of course treat this discussion 
as confidential, and will not use your real names anywhere in the transcripts or report. So I 
will just turn on the recorder on if that’s OK and then I will ask you again and record your 
answer…. 
(TURN ON RECORDER) 









If you don’t mind I will start with some questions about your background 
1. Please could you tell me a bit about your job? 
 
2. What are your particular areas of interest/ specialism? 
 
 
3. Tell me about your experience of working with families with Down’s syndrome? 
- Have you had any particular training in working with families with Down’s 
syndrome? 
- How long have you been working with children with Down’s syndrome and their 
families? 
 
4. How many families with a child with Down’s syndrome do you see each year? 
 
5. What are your first impressions when you meet a parent of a new baby with Down’s 
syndrome? – do you find for example that they are in usually in shock or coping well 
are they information seeking or in denial? 
 
6. What do your interactions with these families involve? 
 
7. How often would you see / follow up these families? 
 




8. Do you have any experience of participating in research with children with Down’s 
syndrome?  
- Please tell me about your experience of recruiting families. 
    
9. What do you think are the barriers for these families to participating in research in 
general? 
 
10. What motivations might families with Down’s syndrome have to taking part in 
research in general? 
 
11. How do you think parent’s experiences of when they first receive the diagnosis of 
Down’s syndrome might affect their engagement in research or interaction with the 
medical profession or researchers? 
- Does this change over time? 
We are trying to recruit families as close to birth as possible our maximum age for recruitment 
is 8 months  
12. Some parents may need time to adjust to the diagnosis that they have received, 
sometimes referred to as a period of “adaptation” – what is your experience of this?  
- when do you think parents might be the most amenable / accepting of the idea of 
joining a study? 
   
13. What would be the best ways do you think of letting new parents of a child with DS 
know about research and how to get involved?   




- What methods should be used for example face to face / invitation letters ? 
Thinking about barriers to research…. 
14. What pressures are families under at this time in these first few months?  
- Do they have multiple appointments to attend? – how do you think this might 
effect their participation?  
- Do they talk to you about other family pressures that may exist – siblings, marital 
relationships? – how do you think this might effect their participation?  - (feels a 
bit leading?) 
- Do they have many “hoops” to go through for example claiming disability benefits/ 
support? – how do you think this might effect their participation? 
- Do you feel these parents feel under a “burden of care”? – how do you think this 
might effect their participation? 
 
15. What sort of support do you find families are looking for? How might this relate to 
being part of a study?  
 
16. Are parents particularly protective of their baby with DS, more so than other parents 
during the newborn period? 
 
- Do you think this effects their participation in research? 
 
Thinking about motivations to research…. 
 




- Do you think they feel a responsibility towards other families and children with 
Down’s syndrome? 
- Does this change over time?  
- Are these families often looking for a “voice”? 
 
FADES specific questions 
18. How have you heard about the FADES study and how aware of it have you been? 
- Have any families spoken to you about the FADES study without you mentioning 
it to them? (if yes) please can you tell me what they said or why they were talking 
about it. 
- Have any colleagues spoken to you about the FADES study without you mentioning 
it to them? (if yes) please can you tell me what they said or why they were talking 
about it. 
 
19. Have you had an opportunity to look at the FADES protocol, flyer and participant 
information sheet? 
  
20. If you were a parent why might you join this study? 
  
21. What might stop you from joining this study? 
This study is looking at early life influences particularly feeding and how this might affect the 




22. What do you think are parent’s early experiences of feeding their newborn baby with 
DS? Do they have many concerns about feeding their baby?  
 
23. Some parents may feel that they would like, or would have liked increased support 
with feeding, is this something you hear from the parents that you meet? 
 
24. How do you think parents will view this area of research? 
 




26. What did you think about the FADES flyer? Do you think new families receiving 
information about Down’s syndrome would be engaged by seeing this flyer? 
 
27. Was there anything in the participant information sheet for parents that might 
concern families considering taking part in the study? 
The study involves participants completing questionnaires as close to birth as possible, at 6 
months, 12months and yearly thereafter.  
28. How do you think these families would feel about completing these questionnaires – 
what might encourage / motivate them? What might put them off?  
We also ask parents to collect a mouth swab sample, urine sample and stool sample close to 
birth. We as them for further stool sample at 6 months and a urine and stool sample at 12 
months and yearly thereafter until the age of 5 years. These samples are collected at home by 




29. How do you think these families would feel about collecting these samples – what 
might encourage / motivate them? What might put them off?  
We also ask for a blood sample close to birth at 6 months, 12months and yearly thereafter 
until the age of 5 years. We explain that they should not need any additional appointments in 
order to have these bloods collected that they can be done at the same time as their routine 
appointments 
30. How do you think these families would feel about collecting these samples – what 
might encourage / motivate them? What might put them off? 
  
31. Do you have any specific comments about anything else that you saw in the protocol 
that might affect recruitment to the study 
 
32. Do you have any comments about your experience of the FADES study? 
  
Closing 
Summarise back to them 
Thank you so much for the time you have taken for this interview and I would just like to 
reiterate that the recording is confidential and will be anonymised.  
Is there anything else you think would be helpful for me to know so that I can try and increase 
recruitment for the FADES study and establish the feasibility of conducting research in babies 










Appendix 6: REC Queries 
Query and comments from 
ethics committee 
 Changes made in response 
How would inclusion criteria be 
assessed? 
• Within the GP letter a paragraph was added to say 
“Children are excluded from the study if they are no 
longer with their birth mother or are subject to a child 
protection plan. We would be grateful if you could 
inform us if you become aware that this child is no 
longer eligible for this study” 
• The question “Are you the birth mother of this child?” 
was added to the consent form 
The PIS should be amended to 
emphasise that samples could 
be taken by health 
professionals at routine 
appointments, but that if 
parents wished to they could 
be shown how to take the 
samples themselves at home. 
• The wording was changed to make it clear that 
samples could be taken at routine appointments but 
that there is an option for collecting samples at home 
as well. 
The PIS should be amended to 
reflect the burdensome nature 
of the study - An estimate of 
• The estimated time to complete each of the 
questionnaires and a table of study procedures was 




the time to complete each 
questionnaire should be 
included in the PIS 
• It was highlighted that under the heading “what are 
the possible disadvantages and risks of taking part” 
on the PIS that there was a comment “We do 
understand that this is a considerable commitment in 
terms of being part of an on-going study as you will 
have additional papers and samples to be collected 
from your child that families with a child with Down’s 
syndrome do not normally have to do”  
Clarification on whether the 
storage and use of data and 
samples in future research is 
optional 
• The PIS was changed to explain that the storage and 
use of data and samples in future research is optional 
and [Yes] and [No] boxes were added to the relevant 
items on the Consent Forms for participants to 
indicate their agreement as appropriate. 
It was requested that a section 
be added to the PIS to explain 
how the samples would be 
analysed and what would 
happen to them at the end of 
the study 
• A section was added “what will happen to any 
samples provided?” it did not contain detailed 
explanation of the biochemical analytical methods, 
but it was explained that the study team would be 
happy to answer any questions parents had on the 
analysis prior to consent.   
• “What will happen to samples at the end of the 




The PIS for the stool collection 
feasibility (Phase 1 study) 
should be amended to explain 
why three samples are 
collected and the committee 
suggested an online instruction 
video be produced that could 
be viewed by participants. 
• The PIS was amended to explain the need for three 
samples. Genotek the company who produced the 
stool collection kit were emailed to see if they had an 
instruction video, but they did not. However a 
researcher would be present and part of the study 
was to test it’s ease of use. 
• For the main study (Phase 2) the instructions for 
collecting stool samples were simplified following 
discussion with the lab conducting the sample 
collection for the TEDDY study. 
It was requested that the PIS be 
amended to include a section 
on insurance arrangements for 
the Study 
• It was explained that the study was a low risk study 
and that it was not anticipated that any harm would 
come to participants. 
• A new section “What if something goes wrong?” was 
added to the PISs 
It was requested that the 
questionnaires should be proof 
read to ensure the branching 
and order of the questions was 
correct. 
• The questionnaires were renumbered and simplified. 
• Dr Sam Leary statistician proof read the 






Appendix 7: Confirmation of ethical approval 
  
NRES Committee South West - Central Bristol  
Bristol Research Ethics Committee Centre  
Whitefriars  
Level 3, Block B   
Lewin's Mead  





0117 342 1335  Facsimile: 0117 342 0445 23 April 2014  
  
Dr Georgina Williams  
PhD Studentship / Clinical Research Fellow  
Bristol Nutrition BRU  
Level 3, University Hospitals Bristol Education & Research Centre  
Upper Maudlin Street  
Bristol BS2 8AE  
  
  
Dear Dr Williams  
  
Study title:  Feeding and Autoimmunity in Down's syndrome 
Evaluation Study (FADES)  
REC reference:  14/SW/0030  




IRAS project ID:  130663  
  
Thank you for your letter of 24 March 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation.  
  
The further information has been considered on behalf of the Committee by the Chair.   
  
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details, unless you expressly withhold permission 
to do so.  Publication will be no earlier than three months from the date of this 
favourable opinion letter.  Should you wish to provide a substitute contact point, 
require further information, or wish to withhold permission to publish, please contact 
the REC Manager Mrs Naazneen Nathoo, nrescommittee.southwest-bristol@nhs.net.  
  
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below.  
Ethical review of research sites  
  




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see "Conditions of the favourable opinion" below).  
Conditions of the favourable opinion  
The favourable opinion is subject to the following conditions being met prior to the start of 
the study.  
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned.  
  
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements.  
  
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give permission 
for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with 





Sponsors are not required to notify the Committee of approvals from host organisations  
  
Registration of Clinical Trials  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees).    
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details 
as part of the annual progress reporting process.  
To ensure transparency in research, we strongly recommend that all research is 
registered but for non clinical trials this is not currently mandatory.  
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to 
be made. Guidance on where to register is provided within IRAS.   
   
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable).  
  
Approved documents  
The final list of documents reviewed and approved by the Committee is as follows:  




Document     Version     Date     
Advertisement   FADES Flyer v.1   18 November 
2013  
Advertisement   Pilot Study Flyer v.1   18 November 
2013  
Covering Letter      30 January 2014   
Evidence of insurance or indemnity   CT1704 insureconfirm.doc   03 December 
2013  
GP/Consultant Information Sheets   Factsheet for Health 
Professional v.1   
22 January 2014   
GP/Consultant Information Sheets   2   28 March 2014   
Investigator CV   (Academic Supervisor - Kathleen  
Gillespie)   
01 January 2014   
Investigator CV   (Academic Supervisor - Sam 
Leary)  
06 February 2014   
Investigator CV   (Chief Investigator - Dr Georgina  
Williams)   
28 January 2014   
Investigator CV   (Academic Supervisor - Julian  
Shield)   
02 December 
2013  
Other: Organisational Approval from DSS   1   10 January 2014   
Other: Organisational Approval from DSA   1   10 January 2014   




Other: Generic instructions   2   25 March 2014   
Participant Consent Form   2. Pilot   28 March 2014   
Participant Consent Form   2   28 March 2014   
Participant Information Sheet   2   24 March 2014   
Participant Information Sheet   2 Pilot study (stool collection)   28 March 2014   
Protocol   FADES v.1   20 January 2014   
Questionnaire: Initial   2  25 March 2014  
Questionnaire: Annual medical qn.   2   25 March 2014   
Questionnaire: 12mo feeding qn.   2   25 March 2014   
Questionnaire: 7 mo feeding Qn   2   25 March 2014   
REC application      24 January 2014   
Response to Request for Further 
Information  
covering ltr   24 March 2014   
Summary/Synopsis   Instructions for collecting Blood  
Samples   
    
  
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  




Reporting requirements  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The NRES website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures.  
Feedback  
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website.  
Further information is available at National Research Ethics Service website > After 
Review  
  
14/SW/0030                          Please quote this number on all correspondence  
  
We are pleased to welcome researchers and R & D staff at our NRES committee 





With the Committee’s best wishes for the success of this project.  
  
Yours sincerely  
Dr Pamela Cairns  Chair  
  
  
Enclosures:    “After ethical review – guidance for researchers” [SL-AR2]  
  
Copy to:    Dr Birgit Whitman  








Appendix 8: Scientific Review 
 
NIHR Biomedical Research Unit in Nutrition, Diet and Lifestyle 
Level 3, University Hospitals Bristol Education Centre 






t: 0117 342 1754 
 
Dear FADES Research Team,  
 
 




The FADES study was scientifically reviewed by the Professor Andy Ness and Professor Richard 
Martin on the 1st May 2013. As part of the scientific review of the study the following aspects 
were considered: 
 
Originality and importance of the work 
Scientific Reliability 
Is the research question is clearly defined and answered? 
Overall design of the study 
Are the participants adequately described and conditions defined? 
Are the methods adequately defined?  
 















Professor of Epidemiology  Professor of Clinical Epidemiology 
  
 
Appendix 9: DSA Organisational approval  
 
Prof JP Hamilton Shield 
Professor of Diabetes and Metabolic Endocrinology 
University Hospital  




Dear Prof Shield 
 
Feeding and Autoimmunity in Down’s syndrome – Evaluation Study (FADES) 
 
 
I am writing to confirm that the Down’s Syndrome Association is delighted to be able to 





We agree to send out the initial information about the study to families as they contact the 
DSA with our ‘new parent packs’, and we also agree to approve content of information sent 
out to those families. 
 

























 Would you like to take part in our study? 
 








NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE NUTRITION THEME 
What is the study about? The study will investigate early feeding in babies and 
children with Down’s Syndrome (DS). 
Who can take part? We are looking for new parents who have a baby under the age 
of 8 months. 
How will this benefit children with Down’s syndrome? We hope the study will help 
us understand why children with Down’s syndrome are more likely to experience 
problems with their hormones and their gut, help reduce this risk and lead to the 
development of new treatments to help with feeding.  
What will it involve? We will be asking parents to complete a questionnaire about 
their child’s feeding and health as a young baby and at 6 and 12 months. We will 
also ask about the child’s health yearly after this until the age of 5 years old.  
We would need to collect some samples from your baby soon after birth, at six and 
twelve months and yearly thereafter if possible until the age of 5 years. All 
questionnaires can be completed online (or paper versions if preferred) at home, 
and apart from the initial blood sample all samples can be taken at home, or during 
your baby’s routine health checks. You would not need any additional hospital 
attendances. We will provide pre-paid packaging so that all samples and 




The Study Team: Professor J Hamilton-Shield, Dr Kathleen Gillespie, and Dr 
Georgina Williams at University of Bristol and University Hospitals Bristol NHS 
Foundation Trust. We are collaborating with 
the Down’s Syndrome Association, Down’s 
Syndrome Scotland, Down’s Syndrome Ireland 
and Professor E Molloy Trinity College Dublin.  
What next? If you would like to take part in 
this study, or just want to know more please 
contact us: 
EMAIL: fades-study@bristol.ac.uk 
There is also our website: www.bristolnutritionbru.org.uk. Click on the 
‘FADES Study’ tab. 






Appendix 12: Participant Information Sheet  
NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE 
NUTRITION THEME 
 
Study Information Sheet 
 
Study title: Feeding and Autoimmunity in Down’s syndrome Evaluation Study (FADES) 
 
Dear Parent(s) 
Congratulations on the birth of your baby! 
Thank you for showing interest in our research study, and for asking for more information. 
 
We would like to follow up your baby’s early life looking at any feeding problems you might 
encounter, any infections your child has and whether these are associated with the 
development of conditions more common in children with Down’s syndrome. 
 
What is the purpose of the study? 
This study will look at early feeding in babies and children with Down’s Syndrome and see 




syndrome have of developing thyroid, coeliac disease (which causes gut problems) and 
diabetes. These are all known as autoimmune conditions.  
 
Do we have to take part in this study? 
The simple answer is no. If you do not wish to take part, it will in no way affect the care you 
and your child receives from any of your doctors. 
 
What will I be asked to do if I take part? 
You will be asked to fill in a questionnaire online (or a paper version depending on your 
preference) which mainly asks questions about your baby’s birth history, medical history and 
early feeding. It also contains some questions about your family history and briefly about your 
medical history. This initial questionnaire will take around 30 minutes to complete. There are 
further questionnaires about your baby’s medical history and feeding at six and twelve 
months these are shorter and will take around 20 minutes to complete. We will then send out 
an annual questionnaire each year (until January 2022) this is a short questionnaire about 
your child’s health, which takes about 10 minutes to complete. 
 
We would also like to collect a sample of stool (poo) from you (the mother) and from your 
baby, as well as urine from your baby at six and twelve months and yearly thereafter if 
possible. We will also ask you to use a special tiny brush, to brush the inside of your baby’s 




Every baby born in the UK has a small sample of blood taken from a heel prick as part of their 
new born screening and with your permission we will also analyse this spot of blood.  
Finally we would like to collect small samples of blood from your child using a special 
heel/finger prick sample collector which causes minimal discomfort. The first sample we will 
arrange to be done during one of your baby’s routine health checks. We would also like to 
collect bloods samples at six and twelve months and yearly thereafter we will advise you on 
how these can be taken at your child’s routine appointments with health care professionals, 
when your child would normally be having routine screening bloods. If however you would 
prefer to take these samples yourself at home once you have seen the first sample being 
taken we will advise you on how you could do this. All the samples can then be sent with any 
paper questionnaires back to Bristol in the supplied pre-paid packages. Your child should not 
need additional hospital attendances. 
 
We understand that this study involves considerable time and input from participants and if 
for any reason, you miss a sample/questionnaire we would still like your child to continue in 
the study as your contribution will still be important. 
Below is a chart showing the timeline for questionnaires and sample collection for your baby. 
 
Months of age 0 
Baseline 
7 12 Every year around the time of your 




Combined feeding and 
medical questionnaire 
X X X  
Medical questinnaire    X 
Mouth swab X    
Stool (poo) sample X X X X 
Urine sample X  X X 
Heel or finger prick blood 
sample.  
X X X X 
 
The study is currently running until 2022 we will therefore be asking you to complete 
questionnaires and provide samples around the time of your child’s birthday until 1st January 
2022. 
 
What will happen to the samples that are provided? 
We will be analysing your child’s samples to see if we can find any common findings which 
might explain why babies with Down’s Syndrome might develop autoimmune conditions. The 
mouth swab will be used to look at your baby’s genes (little packets of information within 
your cells) particularly those that we know may be associated with autoimmune conditions. 
We will look at your stool and your baby’s stool (poo) to see the natural bacteria that live 
within the gut. The urine sample will help us to know which babies may be developing 




they are in the study. The blood samples will be used to look for antibodies which are 
associated with autoimmune conditions.   
 
What are the possible disadvantages and risks of taking part? 
We do not believe there to be any risks. Your child might find the heel / finger prick tests a 
little uncomfortable but it only lasts a minute or so and there will only be seven of these over 
five years. We do understand that this is a considerable commitment in terms of being part 
of an on-going study as you will have additional papers to fill in and samples to be collected 
from your child that families with a child with Down’s syndrome do not normally have to do.  
 
What are the possible benefits in taking part? 
This study is designed to try and find out what difficulties babies and children with Down’s 
Syndrome have with feeding and infections. We want to reduce the risk of these problems 
and develop new treatments to help with feeding. We also hope we will increase our 
knowledge of why children with Down’s syndrome are at increased risk of developing 
problems with their hormones and gut known as “autoimmune conditions”. These include 
thyroid or coeliac disease and diabetes.  
Whilst our findings may not directly help your baby they will hopefully benefit children born 
with Down’s Syndrome in the future. From the findings of this study we hope that we will be 




also hope the study will enable us to provide parents and carers of children with Down’s 
syndrome with more information regarding feeding and autoimmune conditions. 
 
Will details on my child in this study be kept confidential? 
All data collected in this study will be maintained and stored in strict accordance with the data 
protection regulations. All information that is collected about you and your child during the 
course of the research will be kept strictly confidential. All members of the study team will 
have a duty of confidentiality to you and your child as research participants.  
We keep the information we collect about your child and the results from any samples 
collected separate from your child’s personal details and we can only link this information 
together with a secure code. Only authorised people working on the study will have access to 
your child’s information. 
 
With your consent we will inform your child’s GP and community paediatrician that your child 
is participating in the study and will send them a factsheet explaining what will be involved, 
we will also inform your GP. We will also contact key members of your child’s health care 
team with your consent to arrange blood sampling. They will not have access to any of the 
information that is collected about your child during the course of the research; we will only 
contact them if any of the results are significant for your child’s current or future health.  
 




We will keep the data and samples for 15years and then destroy them securely unless you 
have chosen to consent for the data and / or samples to be stored for use in future ethically 
approved studies in this area of research. If this is the case we will give you the option to be 
re-contacted in order that you can provide your consent again if you so wish to do so.   
 
Who is organizing and funding the research? 
The study is sponsored by the University of Bristol and is funded by the National Institute of 
Health Research, Bristol Biomedical Research Unit in Nutrition. The study is being conducted 
as part of a Clinical PhD in Child Health. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a research ethics 
committee to protect your safety, rights, well–being and dignity. This study has been 
reviewed and given a favourable opinion by the NRES committee (South West Central Bristol 
Research Ethics Committee). This study has also been reviewed by the executive board of the 
Bristol Biomedical Research Unit, the University of Bristol Research and Enterprise 
development team and the University Hospitals Bristol Research and Development team. 
 
What if something goes wrong? 
The researchers do not anticipate that taking part in this study could cause any harm to your 




Public Liability insurance. If you have a concern about any aspect of this study, you should ask 
to speak to the researchers who will do their best to answer your questions (contact details 
below). If you remain unhappy and wish to complain formally, you can do this by contacting 
the hospitals Patient Support and Complaints Team (contact details below). 
 
Will I be informed of the results of the study?  
If you would like to be updated regarding the progress of the study we can arrange to send 
you regular updates via email. At the end of the study we will provide you with a summary of 
the findings and copies of any publications that you would like to receive.  
 
What do I do now? 
Thank you for considering taking part in this research. We will contact you either by email or 
telephone depending on your preference and will answer any questions you may have. Once 
you have had an opportunity to ask any questions, if you are interested in your child taking 
part, please fill in the consent forms which we will send to you in the post with a copy of this 
information sheet. Keep one copy for your own records and send the other back to us in the 
stamped addressed envelope provided. 
 
If you have any questions regarding the study please call the FADES research team on +44 





If you have concerns about any aspect of the way you have been approached or treated during 
the course of this study you may wish to contact the hospital’s Patient Support and 
Complaints Team on 0117 342 3604, email pals@uhbristol.nhs.uk or write to Patient Support 
& Complaints Team, Trust Headquarters, University Hospitals Bristol, Marlborough Street, 
Bristol, BS1 3NU 
 
Professor J Hamilton-Shield, Dr Kathleen Gillespie and Dr Georgina Williams 
Bristol Biomedical Research CentreNutrition Theme 






Appendix 13: FADES Initial Questionnaire 
NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE 
NUTRITION THEME 




What is this questionnaire about? 
 
Thank you for taking part in this study. This questionnaire asks about the birth of your baby, 
your baby’s health, a little about the health of you and your family and your baby’s feeding.  
(This is the longest of the questionnaires that you will fill in, the questionnaire at 6 months 
and 12 months will be much shorter). 
 
How to fill in the paper questionnaire  
 
1.  Please fill in the questionnaire in black biro.  
 
2. Most questions on the following pages can be answered simply by putting a cross in the 







Sometimes you are asked to write in a number or the answer in your own words. Please 





3. Occasionally you may have more than one answer to a question. Please cross all the boxes 
next to the answers that apply to you if the instruction “Please cross one or more boxes” 
is printed. 
  
4. Usually after answering each question you go on to the next one unless a box you have 
crossed has an arrow next to it with an instruction to go to another question.  
 
Example:  
Yes  □ → Go to Q8  
No  □  
 
By following the instructions carefully you will miss out questions which do not apply, so 
the questionnaire will be shorter than it looks.  
 
5. If you cannot remember, do not know, or are unable to answer a particular question 
please put a cross in the box marked “do not know” or when there is an option to insert 
text please write in that you don’t know. 
 
6. If you would like to give any further information on any of your answers you can write this 
in at the end of the survey.  
 
7. If at any point you have any problems or difficulties with the questionnaire please do 
contact us and so that we can help you. (Contact details below)  
 
8. When you have finished, please post the questionnaire to us as soon as possible in the 
pre-paid envelope provided, even if you were not able to complete all of it.  
 
We are very grateful for your help. 
Contact: 
EMAIL: Georgina.Williams@bristol.ac.uk 
Tel: +44 (0)117 342 1755 
What is your identification number for this study? (Please do not put your 






If you no longer wish to take part in this study please cross the box below and 
return the questionnaire to us so we do not trouble you further. 






SECTION 1: The birth of your baby and your baby’s health  
First of all we would like to ask some general questions before finding out how you feed 
your baby. 
Q1.1. How old is your baby?  
Please write numbers in both boxes  
Write in how many whole weeks plus any additional days:  
 
□  and  □ 
Weeks   days 
 
 
Q1.2. Thinking about the birth of your baby, what kind of delivery did you have?  
 
Normal (vaginal) birth       □ 
A caesarean (through a cut in the abdomen)    □  
Delivery using forceps       □  
Delivery using vacuum cap on the baby’s head (ventouse) □ 
 
Q1.3. How many weeks pregnant were you when your baby was born?  
Please write numbers in both boxes if you are able to 
Write in how many whole weeks plus any additional days:  
□ and  □ 
Weeks   days 
  
 
Q1.4. How much did your baby weigh when he/she was born?   
 
Either in pounds and ounces:  
□  lb   □  oz 
  
Or in kilograms:  
□  Kg 
 
Q1.5 Where was your baby born?  
 
In hospital – in a midwife-led unit     □ → go to q1.6 
In hospital – in a consultant-led unit    □ → go to q1.6 




At home        □ → go to q1.7 




Q1.6 How long after the baby was born did you stay in the hospital, birth centre or unit?  
Please enter number in one box only. Please give an estimate if you are not sure. 
 
Either:  
How many hours did you spend in the hospital, birth centre or unit?  
□hours  
OR  
How many days did you spend in the hospital, birth centre or unit?  
□Days 
Q1.7a Is this your first baby?  
Yes  □ → go to Q1.8 
No   □ → go to Q1.7b 
 
Q1.7b Did you breastfeed any of your other children/child?  
 
Yes  □  
No  □ 
 
Q1.8 Is your baby one of twins, triplets or other multiple births?  
 
No      □ 
Yes, twin     □  
Yes, triplets or other multiple birth  □ 
 
 
Q1.9 Did you know prior to your baby’s birth that they had Down’s Syndrome? 
Yes  □  






Q1.10a Does anyone else in your immediate family have Down’s syndrome?  
Yes □  → go to Q1.10b 
No □  → go to Q1.11a 
 
Q1.10b Who in your family has Down’s syndrome? (you do not need to give names) please 
cross the box which corresponds with how are they related to your baby? Please cross one 
or more boxes. 
Mother  □ 
Father  □ 
Sibling  □ 
Grandparent □ 
Cousin  □ 
 
Q1.11a While you were pregnant did you have any antenatal check-ups?  
 
Yes  □ → Go to Q1.11b 
No  □ → Go to Q1.12 
Q1.11b At the check-ups did anyone discuss feeding your baby with you?  
 
Yes  □ → Go to Q1.11c  
No □→ Go to Q1.12 
 
Q1.11c. At the check-ups, who discussed feeding your baby with you?  
Please cross one or more boxes  
 
Doctor     □ 
Health visitor    □  
Midwife    □ 
Nurse     □ 
Peer supporter (a mum who has breastfed their own baby and been trained to give 
support to other mums) / Volunteer  □  








Q1.12 During this pregnancy did you attend any sessions that included talks or discussions 




Q1.13a If your baby was diagnosed with Down’s Syndrome before they were born, were 
you told about any specific difficulties related to feeding a baby with Down syndrome?  
 
Yes  □ → go to Q1.13b 
No  □ → go to Q1.14a 
 






Q1.14a During your pregnancy were you given any specific advice that would help with 
breastfeeding a baby with Down’s syndrome? 
 
Yes □ → go to question 1.14b 
No  □ → go to question 1.15 
Q1.14b Where did you get that advice from? 
Midwife    □ 
Down’s Syndrome Association  □ 
Down’s syndrome Scotland  □ 
GP     □ 












We are now going to ask you about infections that either you had during your pregnancy, 
or your baby has had since birth. We also ask about whether these infections required 
antibiotics, this gives us an indication of the level, number and type of infections. We know 
that babies with Down’s syndrome are more prone to getting certain infections. 
Q1.15a During your pregnancy did you have any infections requiring antibiotics? 
Yes □ → go to question 1.15b 
No □ → go to question 1.16 
 
Q1.15b During which stage of your pregnancy did you take antibiotics? Please cross one or 
more boxes if you required antibiotics during more than one stage of your pregnancy. 
  In the first trimester (first 3 months of pregnancy)  □   
If you remember which antibiotic did you take? Please enter name of antiobiotic or write “not 
known” if you don’t know. 
 
If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know. 







In the second trimester (between your 3rdth and 6th month of pregnancy)
 □  
If you remember which antibiotic did you take? Please enter name of antiobiotic or write “not 
known” if you don’t know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 








In the last trimester of your pregnancy (in the last 3 months of your pregnancy)  □  
If you remember which antibiotic did you take? Please enter name of antiobiotic or write “not 








 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know. 
 
 
Q1.16 Were you given antibiotics during labour because of a known risk of infection such 
as having a high temperature during labour or your waters breaking early? 
Yes   □  
No   □ 
I don’t know   □ 
 
 
Q1.17a If you have breastfed your baby, have you been on any antibiotics during the time 
you were breastfeeding? 
Yes      □ → go to question 1.17b 
No      □ → go to question 1.18 
I don’t know / I can’t remember   □ → go to question 1.18 
Not applicable as I have only fed my baby with formula milk  □→ go to question 1.18 
   
 
Q1.17b How old was your baby when you were on antibiotics and breastfeeding?  
 
I don’t know   □ 
Age 0-1 months □  
If you remember which antibiotic did you take? Please enter name of antiobiotic or write “not 







 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 




  Age 1-3months   □  
If you remember which antibiotic did you take? Please enter name of antiobiotic or write “not 
known” if you don’t know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know. 
 
 
Age 3months plus   □  
If you remember which antibiotic did you take? Please enter name of antiobiotic or write “not 
known” if you don’t know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 











Q1.18 Has your baby ever suffered from any of the following problems?  
Please cross one or more boxes. Please indicate at roughly what age (eg 0-1month, 1-
3months or more than 3 months old (3months plus) 














age 1-3months □ age 3months plus □ 




age 1-3months □ age 3months plus □ 




age 1-3months □ age 3months plus □ 




age 1-3months □ age 3months plus □ 













age 1-3months □ age 3months plus□ 




age 1-3months □ age 3months plus□ 




age 1-3months □ age 3months plus □ 
Something else (please 


















Q1.19a. Since your baby was born has he/she been given any antibiotics? 
Yes   □ → go to question 1.19b 
No   □ → go to question 1.20 










Q1.19b How many separate courses of antibiotics has your baby had since they were born? 
Please enter a number in the box below. 
□courses of antibiotics 
 
Q1.19c When was your child given antibiotics? Please cross one or more boxes  
 I don’t know  □ 
 
Age 0-1 months □  
If you remember which antibiotic did they take? Please enter name of antiobiotic or write 
“not known” if you don’t know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection).   
    
 
Age 1-3months  □  
If you remember which antibiotic did they take? Please enter name of antiobiotic or write 
“not known” if you don’t know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 











   
Age 3 months plus  □  
If you remember which antibiotic did they take?? Please enter name of antiobiotic or write 
“not known” if you don’t know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know. 
   
 
Q1.20 Does your baby have any of the following medical conditions:  
a) A heart condition?  




No  □ 
 
b) A problem with the gut known as duodenal atresia ? 
Yes  □ 









c) A condition known as Hirschsprungs (causing very bad constipation from birth)? 
Yes  □ 
No  □ 
 
d) Any other medical conditions? 





No  □ 
 
There are now some questions about your own health and other members of your child’s 
family 
Q1.21 Have you ever been diagnosed with any of the following conditions? Please cross one 
or more boxes 
Type 1 diabetes? (this does not refer to gestational diabetes which only develops 
during pregnancy or Type 2 diabetes)   □ 
An underactive thyroid gland known as hypothyroidism? □ 
An overactive thyroid gland known as hyperthyroidism?  □ 
Coeliac disease?      □ 
 
Q1.22 Has the father of your baby ever been diagnosed with any of the following 
conditions? Please cross one or more boxes 
Type 1 diabetes? (this does not refer to Type 2 diabetes) □ 
An underactive thyroid gland known as hypothyroidism? □ 
An overactive thyroid gland known as hyperthyroidism? □ 







Q1.23 If your baby has any siblings have any of them been diagnosed with any of the 
following conditions? Please cross one or more boxes 
Type 1 diabetes? (this does not refer to Type 2 diabetes) □ 
An underactive thyroid gland known as hypothyroidism? □ 
An overactive thyroid gland known as hyperthyroidism?  □ 
Coeliac disease?      □ 






SECTION 2: About your baby’s first feeds 
We are now going to ask some questions about your baby’s first feeds. We know that often 
babies with Down’s Syndrome have difficulties with both breast and bottle feeding and we 
are interested to hear about your experience.  
Please note that when we ask about ‘breastfeeding’ we also mean ‘giving your 
baby expressed breast milk’. 
Q2.1 Did you have skin-to-skin contact with your baby within the first 24 hours after he/she 
was born? (By skin-to-skin contact we mean you were holding the baby so that his/her bare 
skin was next to your bare skin.)  
 
Yes □   
No  □  
 
Q2.2 After the birth did you have any health problems that affected your ability to feed 
your baby the way you wanted to?  
 
Yes □  
No □ 
 
Q2.3a During the first few days, did anyone help you put your baby to the breast?  
 
Yes  □ → go to Q2.3b 
No  □ → go to Q2.4 
Q2.3b Who was this?  
Please cross one or more boxes  
 
Midwife    □ 
Midwifery Support Worker  □ 
Nurse      □  
Nursery Nurse     □ 
Healthcare assistant    □ 
Health visitor    □ 




Voluntary or charitable organisation  □  
Peer supporter (a mum who has breastfed themselves and been trained to give 
support to other mums)    □  
Breastfeeding support group   □  
Partner, friend or relative   □  




Q2.4 Have you ever breastfed your baby? (put them to your breast even if it was just once or 
ever given them expressed breast milk) 
 
Yes  □ → go to Q2.5 
No  □ → go to Q2.6a 
 
Q2.5. How soon after your baby was born did you first put him/her to the breast?  
Please cross one box only. If you can’t remember exactly please estimate which is the closest 
answer 
 
Immediately / within a few minutes   □ 
Within half an hour     □ 
More than ½ hour, up to 1 hour later □ 
More than 1 hour, up to 4 hours later   □ 
More than 4 hours, up to 8 hours later   □ 
More than 8 hours, up to 12 hours later   □ 
More than 12 hours, up to 24 hours later  □  
More than 24 hours later    □ 
Q2.6a Were there any problems feeding your baby while you were in the hospital, birth 
centre or unit?  
 
Yes      □ → go to Q2.6b 
No      □ → go to Q2.7 
Not applicable as I had a home birth □ → go to Q2.7 
 
 
Q2.6b What problems were there?  















Q2.6c Did anyone give you any help or support with this/these problems?  
 
Yes  □ → go to Q2.6d  
No  □ → go to Q2.7 
Q2.6d Who helped or supported you?  
Please cross one or more boxes  
 
Midwife      □  
Midwifery Support Worker    □ 
Nurse       □ 
Nursery Nurse      □ 
Healthcare assistant     □ 
Health visitor      □ 
Doctor / GP      □ 
Voluntary or charitable organisation   □  
Peer supporter (a mum who has breastfed themselves and been trained to give 
support to other mums)      □  
Breastfeeding support group    □ 
Partner, friend or relative    □ 






Q2.7 While you were in the hospital, birth centre or unit did you get enough help and 






Yes – received enough help   □  
No – would have liked more help  □ 
 Not applicable as I had a home birth □ 
 
Q2.8a After the birth were you told that your baby needed to go to special care because of 
problems specifically with feeding? 
 
Yes □ → go to Q2.9a 
No  □ → go to Q2.8b 
Q2.8b Was your baby put into special care for any other reason?  
 











Q2.9a For how long was your baby in special care?  
 
One day or less    □ → go to Q2.10 
Two or three days    □ → go to Q2.10 
Four days to one week    □ → go to Q2.10 
More than one week up to one month  □ → go to Q2.9b 
More than one month    □ → go to Q2.10b 
 
Q2.9b How many weeks in total was your baby in special care?  
If you are unsure please estimate  
□weeks 
 
Q2.10 Did having your baby in special care affect your ability to feed your baby the way you 
wanted to?  
 
Yes  □ 
No  □ 





Yes □ → go to Q2.11b 
No  □ → go to Q2.11b 
Not applicable to me (could not express or did not wish to express)  □ → go to 
Q2.13a 
 
Q2.11b Did you feel supported to express breast milk whilst in special care? 
Yes  □  
No  □ 
 
Q2.12a Did your baby need to be fed with a naso-gastric (NG) tube (a feeding tube which 
goes from the baby’s nose to the baby’s stomach)?  
 
Yes  □ → go to Q2.12b 








Q2.12b Was this solely because of problems with feeding or other medical conditions? 
  
Problems with Feeding     □ 








Q2.12c For how long did your baby need to be fed with an NG tube (please estimate if you 
are unsure) 
Either in days: □ 
OR  
In whole weeks plus any additional days:  
□ and  □ 
Weeks   days 
 






Only expressed breast milk   □ 
Only infant formula      □ 
Expressed Breast milk and infant formula □  
I don’t know       □ 
 
Q2.13a Were all feeds stopped at any point and your baby put onto fluids given into a vein 
ie intravenous (iv) fluids?  
 
Yes   □ → go to Q2.13b 
No   □ → go to Q2.15 
I don’t know □ → go to Q2.14 
 
Q2.13b How long was your baby on iv fluids? 
□ and  □ 
Weeks   days 
 
I don’t know  □ 
 
 
Q2.14 Were you given, or did your red book contain the specific Down’s Syndrome insert 
with growth charts for babies with Down’s Syndrome?  
 
Yes □  
No  □ 
 
We are now going to ask some questions about your experience of having your baby at 
home - either from the start because your baby was born at home or since leaving the 
hospital / birthing centre 
Q2.15 Was your baby born at home? 
 
Yes  □ → go to Q2.16  
No  □ → go to Q2.17 
 
Q2.16 Have you had any problems feeding your baby? 
 
Yes  □ → go to Q2.18 






Q2.17 Since you left the hospital, birth centre or unit have you had any problems with 
feeding your baby?  
 
Yes  □ → go to Q2.18  
No  □ → go to Section 3 question 3.1 
 
Q2.18 What problems were there?  











Q2.19a Did you get any help or information about this/these problems?  
 
Yes  □ → go to Q2.19b  




Q2.19b Where did you get this help or information?  
Please cross one or more boxes  
 
SureStart or Children’s Centre / Children’s Health Clinic  □ 
Voluntary or charitable organisation    □  
Peer supporter (a mum who has breastfed themselves  
and been trained to give support to other mums)  □ 
Down’s syndrome Association     □ 
Down’s syndrome Scotland    □ 
Breastfeeding support group     □ 
Partner, friend or relative     □ 
Start4Life       □ 
Books / leaflets / magazines     □ 
Television / radio      □ 
The internet / web based resources    □ 
Breastfeeding clinic      □ 
National Breastfeeding Helpline    □ 
Doctor / GP       □ 





Midwife       □ 
Nurse        □ 








SECTION 3: About the milk that you give your baby  
 
We are now going to ask some questions about the milk that you give your baby. We know 
that often babies with Down’s Syndrome have difficulties with both with breast and bottle 
feeding and we are interested to hear about your experience. The earlier sections were 
about your baby’s first feeds, we now want to ask some more questions about feeding in 
general. We apologise that some of the questions in this section may feel repetitive, this is 
so we can collect as much detailed information as possible. 
Please note that when we ask about ‘breastfeeding’ we also mean ‘giving your baby 
expressed breast milk’. 
 
Q3.1 Thinking about the milk that your baby has received over the last 7 days, has he/she 
had…  
Please cross one box only  
 
Only breast milk   □ → go to Q3.2 
Only infant formula   □ → go to Q3.3  
Breast milk and infant formula  □ → go to Q3.5 
Q3.2. Has your baby EVER been given infant formula, even if this was only once?  
 
Yes (even if only once)   □ → go to Q3.5 
No     □ → go to Q3.12 
Q3.3 Has your baby EVER fed from your breast, even if this was only once?  
 
Yes (even if only once)   □ → go to Q3.5  
No     □ → go to Q3.4 
Q3.4 Has your baby EVER been given expressed breast milk (via syringe, bottle or cup etc.)?  
 
Yes (even if only once)   □ → go to Q3.5  





Q3.5 Have you stopped breastfeeding (no longer give your baby any expressed milk or put 
your baby to your breast)? 
 
Yes □ → go to Q3.6  





Q3.6 How old was your baby when you stopped breast feeding? 
Please write the age in the appropriate box – Please estimate if you are not sure 
Either in days: □ 
OR  
In whole weeks plus any additional days:  
□ and  □ 
Weeks   days 
 
 
Q3.7  What were your reasons for stopping?  









Q3.8 Which of the following best describes how long you breastfed for?  
Please cross one box only  
 
I would have liked to breastfeed for longer  □ → go to Q3.9 
I breastfed for as long as I intended  □ → go to Q3.10 
I breastfed for longer than I intended  □ → go to Q3.10 
 
 
Q3.9 What would have helped you breastfeed for longer?  
















Q3.10 How old was your baby when he/she FIRST received infant formula?  
Please write the age in the appropriate box. Please estimate if you are not sure.  
Either in days: □ 
OR  
In whole weeks plus any additional days:  
□ and  □ 
Weeks   days 
 
 
Q3.11 Since your baby was born, how often has he/she been fed infant formula?  
If your pattern of using infant formula has varied please select the answer you feel comes 
closest to describing your situation.  
Please cross one box only  
 
All or almost all feeds   □  
About half of all feeds   □ 
One or two feeds a day    □ 
A few feeds a week, but not every day  □ 
A few feeds since they were born, but not every week □ 
Only once or twice since they were born □ 
Q3.12 Has your baby ever needed to have special milk which has been prescribed by a 
doctor or dietician?  
 




No  □  
 






Yes  □ → go to Q3.13b 
No  □ → go to Q3.14 
Q3.13b What health benefits, if any, are you aware of for the BABY?  




Q3.14 Is there anything else you would like to say about feeding your baby?  
 





No  □ 
 
Section 4: And finally… 








Q4.2 What age are you now?  
Please cross one box only  
Under 20  □  
20, up to 24  □  
25, up to 29  □ 
30, up to 34  □  
35, up to 39  □ 







Q4.3 Are you…  
 
Married or in a civil partnership   □ 
Living together     □ 
Single      □ 
Widowed, divorced or separated  □ 
Q4.4 What is your ethnic group?  
Please cross one box only  
 
White  
British     □ 
Irish     □ 






White and Black Caribbean □ 
White and Black African  □ 
White and Asian   □ 
Any other mixed background (Please cross and write in) □  
 
 
Asian or Asian British  
Indian     □ 
Pakistani    □ 
Bangladeshi    □ 





Black or Black British  
Caribbean    □ 
African     □ 





Chinese or Other ethnic group  
Chinese     □ 
















 / /  
Q4.6 Is there any further information that you would like to add? 





No  □ 
Was there anything you intended to go back and complete?  
Please check. 
Appendix 14: FADES 7 Month Questionnaire 
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7 month questionnaire 
 
What is the questionnaire about?  
 
Thank you for filling in the first questionnaire we sent you. This questionnaire asks some more 
questions about your baby’s health and feeding.  
 
If you no longer wish to take part in this study please cross the box below and return the 




Section 1: About your baby and their health 
 
Q1.1 How old is your baby?  
Please write numbers in both boxes  
Write in how many whole weeks plus any additional days:  
 
□ and  □ 




Q1.2 Some babies with Down’s syndrome have medical conditions which mean that they 
need to spend some of the first few weeks or months of their early life in hospital.  Please 
indicate how long your baby has spent in hospital?  
  
Less than a week     □ 
1week  – less than 4 weeks    □ 
1month – less than 2months    □
2 months – less than 3 months   □
3 months – less than 4 months  □ 
4 months  - less than 5 months  □ 
5 months  - less than 6 months  □ 






Q1.3 Which specialists are involved in your baby’s care? Please cross one or more boxes  
Paediatric cardiologist/ heart doctor  □ 
Paediatric gastroenterologist / gut doctor □ 
Paediatric Endocrinologist / hormone doctor  □ 
Paediatric dietician    □ 
Community Paediatrician   □ 
Speech and language therapist   □ 











Q1.4 Since completing the last questionnaire has your baby been diagnosed with any of the 
following: 
a. A heart condition? 






No  □ 
 
b. A condition known as Hirschsprungs? 
Yes  □ 
No  □  
  
c. Hypothyroidism requiring treatment?  
Yes, diagnosed age  less than 3 months   □ 3 months plus  □ 
  
No  □  
 
d. Type 1 diabetes requiring insulin? 






No  □  
 
e. Coeliac disease, for which your child has been put on a gluten free diet? 
Yes, diagnosed at age  less than 3 months   □ 3 months plus  □ 
No  □  
 
f. Any other medical conditions? 
Yes,  diagnosed age less than 3 months   □ 3 months plus  □ 













Q1.5 Has your baby ever suffered from any of the following problems?  
Please cross one or more boxes. Please indicate at roughly what age (eg.  0-3months, 
3months plus) 
a. Sickness or vomiting age less than 3months  
□ 
age 3months plus  □ 
b. Diarrhoea age less than 3months  
□ 
age 3months plus  □ 
c. Constipation age less than 3months 
□ 
age 3months plus  □ 
d. Chest problems / infection age less than 3months  
□ 
age 3months plus  □ 
e. Ear problems / infection age less than 3months  
□ 





f. Urinary tract infection age less than 3months  
□ 
age 3months plus  □ 
g. Colic / painful wind age less than 3months  
□ 
age 3months plus  □ 
h. Thrush age less than 3months  
□ 
age 3months plus  □ 
i. Not gaining enough 
weight 
age less than 3months  
□ 
age 3months plus  □ 
j. Gaining too much weight age less than 3months  
□ 
age 3months plus  □ 
k. Something else (please 




   age less than 3months  
□ 








Q1.6a Since completing the last questionnaire has your baby been given any antibiotics? 
Yes  □ → go to Q1.6b  
No  □ → go to section 2 
 
Q1.6b How many separate courses of antibiotics has your baby had since they were born?  
□courses 
 
Q1.6c When was your child given antibiotics?  





 I don’t know  □ 
 
   Age less than 3months □  
If known which antibiotic? Please enter name of antiobiotic or write “not known” if you don’t 
know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know.  
    
 
 
Age 3months plus □ 
If known which antibiotic? Please enter name of antiobiotic or write “not known” if you don’t 
know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 











Section 2: About the milk that you give your baby 
 
We are now going to ask some questions about the milk that you give your baby. We know 
that often babies with Down’s Syndrome have difficulties with both with breast and bottle 
feeding and we are interested to hear about your experience. 
Some of these questions are repeated from the initial questionnaire that you filled in but 
please fill them in again as this is so we can collect as much detailed information as possible. 
Please note that when we ask about ‘breastfeeding’ we also mean ‘giving your baby 
expressed breast milk’. 
Q2.1 Thinking about the milk that your baby has received over the last 7 days, has he/she 
had…  
 
Please cross one box only  
Only breast milk     □→ go to Q2.2  
Only infant formula / other milk   □→ go to Q2.3 
Breast milk and infant formula / other milk  □→ go to Q2.5 
Q2.2 Has your baby EVER been given any kind of milk other than breast milk, such as infant 
formula or cow’s milk (even if this was only once)?  
 
Yes (even if only once) □→ go to Q2.10
No     □→ go to Section 3 
 

Q2.3 Has you baby EVER fed from your breast, even if this was only once? 
 
Yes (even if only once) □→ go to Q2.5 
No     □    → go to Q2.4 
 
 
Q2.4 Has your baby EVER been given expressed breast milk (via syringe, bottle or cup etc)?  
 
Yes (even if only once)  □→ go to Q2.5 





Q2.5 Have you stopped breast feeding (no longer give your baby any expressed milk or put 
your baby to your breast)? 
 
Yes    □ → go to Q2.6




Q2.6 How old was your baby when you stopped breastfeeding?  
If you cannot remember exactly, please put in the approximate age.  
Write in how many whole weeks plus any additional days  
Please write numbers in both boxes  
  
 
□ and  □ 
Weeks   days 
 
 
Q2.7 What were your reasons for stopping breastfeeding?  













Q2.8 Which of the following best describes how long you breastfed for?  
Please cross one box only  
 
I would have liked to breastfeed for longer   □→ go to Q2.9  
I breastfed for as long as I intended   □→ go to Q2.10 
I breastfed for longer than I intended   □→ go to Q2.10 
 
Q2.9 What would have helped you breastfeed for longer?  















Q2.10 How often has your baby been given breast milk over the last 7 days on average?  
 
Not at all    □
Once a day   □
Twice a day    □
3-4 times a day   □
5-6 times a day   □
7-8 times a day   □
More than 8 times a day  □
 
Q2.11 Which of the following kinds of milk has your baby EVER been given, even if this was 
only once?  
Please cross one or more boxes  
 
Infant formula (or “first” milk)    □
Follow-on formula      □
Cow‟s milk       □





Q2.12 How old was your baby when he/she was FIRST given any kind of milk other than 
breast milk such as infant formula or cow’s milk?  
If you cannot remember exactly, please put in the approximate age.  
Please write in the age to the nearest whole week  
 







Q2.13 Excluding breast milk, which one of the following kinds of milk has your baby been 
given MOST OFTEN over the last 7 days?  
Please cross one box only  
 
Infant formula (or “first” milk)    □
Follow-on formula      □
Cow‟s milk       □





None of these      □→ go to Section 3  
 
 
Section 3: About other drinks and food that you may give to your baby 
Q3.1a Has your baby EVER had anything else to drink apart from milk such as water, fruit 
juice, squash or herbal drink?  
 
 
Yes (even if only occasionally) □→ go to Q3.1b  
No     □→ go to Q3.2a 
 
Q3.1b How old was your baby when he or she was FIRST given something apart from milk, 
such as water, fruit juice, squash or herbal drink?  
If you cannot remember exactly, please put in the approximate age.  
Please write number in the box to nearest whole week  
□ Weeks 
 
Q3.2a Has your baby ever had any solid foods such as cereal, rusks, baby rice, fruit, 
vegetables or any other kind of solid food?  
 
Yes  □→ go to Q3.2b 
No  □→ go to section 4  
 
Q3.2b How old was your baby when he/she first had any food apart from milk?  
If you cannot remember exactly, please put in the approximate age.  
Please write number in the box to nearest whole week  
□ Weeks 
 
Q3.3 Why did you start giving your baby solid foods?  
Please cross one or more boxes  
 
Doctor / health visitor / other health professional advised me to  □





Read leaflets / seen information that advised me to   □
Start4Life         □
Previous experience (with another baby)     □
Baby was not satisfied with milk      □
Baby was not gaining enough weight     □
Baby was waking up during the night     □
Baby able to sit up and hold food in hand     □





Q3.4 What was the FIRST solid food given to your baby?  
Please cross one box only  
 
Ready made baby food   □
Rusk       □
Baby rice     □
Fruit (home prepared)   □
Vegetables (home prepared)   □ 
Homemade food    □
Any other food (for example, yoghurt,  □
fromage frais or breakfast cereal) 
 
 
Q3.5 What sort of solid foods has your baby EVER had?  
Please cross one or more boxes  
 
Ready made baby food   □
Rusk       □
Baby rice      □
Fruit (home prepared)   □
Vegetables (home prepared)   □
Homemade foods    □
Any other food (for example, yoghurt,  □
fromage frais or breakfast cereal) 
 
 
Q3.6 What sort of solid foods did your baby eat yesterday?  
Please cross one or more boxes  
 
Ready made baby food    □
Homemade foods     □
Rusk       □
Baby rice      □





Vegetables (home prepared)   □
Homemade foods     □
Any other food (for example, yoghurt,  □
fromage frais or breakfast cereal)  
Didn’t have solids yesterday    □












If you answered Yes at Q3.7 or Q3.8 please go to Q3.9 
Otherwise go to Section 4 
 
Q3.9 Where did you get this information?  
Please cross one or more boxes  
 
SureStart or Children’s Centre / Children’s Health Clinic  □
Partner, friend or relative      □
Voluntary or charitable organisation     □
Peer supporter (a mum who has breastfed themselves  □
and been trained to give support to other mums)  
Breastfeeding support group     □
Start 4 Life        □
Books / leaflets / magazines      □
Television / radio       □
The internet / web based resources     □
Breastfeeding Clinic       □
National Breastfeeding Helpline     □
Doctor / GP        □
Health visitor        □
Midwife (including at antenatal sessions)    □
Nurse         □










Section 4: Help and information for you about feeding your baby 
 
Q4.1a Have you had any problems with feeding your baby (including breastfeeding, bottle 
feeding and/or giving you baby solids) since the time you filled in the previous 
questionnaire?  
 
Yes  □→ go to Q4.1b  
No  □→ go to section 5 
 
Q4.1b What problems have you had?  









Q4.1c Did you get any help or information about this/these problems?  
 
Yes  □→ go to Q4.1d 
No  □→ go to section 5 
 
Q4.1d Where did you get this help or information?  
Please cross one or more boxes  
 
SureStart or Children‟s Centre / Children‟s Health Clinic □
Partner, friend or relative     □
Voluntary or charitable organisation    □
Down’s Syndrome Association    □
Down’s Syndrome Scotland     □ 
Peer supporter (a mum who has breastfed themselves  □
and been trained to give support to other mums)  
Breastfeeding support group      □
Start 4 Life       □
Books / leaflets / magazines      □
Television / radio       □
The internet / web based resources    □
Breastfeeding Clinic       □
National Breastfeeding Helpline     □
Doctor / GP        □
Health visitor        □
Midwife (including at antenatal sessions)    □
Nurse         □







Section 5: About your plans for work  
 
Q5.1 Are you doing any paid work at the moment?  
 
Yes     □ → go to Q5.2 
On paid maternity leave  □ → go to Section 6
On unpaid maternity leave  □ → go to Section 6
No    □→ go to Section 6 
 
Q5.2 What age was your baby when you returned to work?  
 
1 month, less than 2 months  □
2 months, less than 3 months  □
3 months, less than 4 months  □
4 months, less than 5 months  □
5 months, less than 6 months  □
6 months, or older   □

Q5.3a Has your return to work affected the way in which you are feeding your baby at all?  
 
Yes  □→ go to Q5.3b 
No □→ go to Section 6 
 
 
Q5.3b How has this affected the way in which you feed your baby?  


























Section 6:   
 
Q6.1 Is there anything else you would like to say about feeding your baby?  
 








Q6.2 Is there anything else you would like to say about your baby’s health?  
 







No  □ 
Q6.3 Please give the date when you filled in this questionnaire  
 
DD/MM/YYYY 
 / / 
Q6.4 Is there any further information that you would like to add? 

















Was there anything you intended to go back and complete?  




Appendix 15: FADES 12 month questionnaire 
NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE NUTRITION 
THEME 
Feeding and Autoimmunity in Down’s syndrome Evaluation Study (FADES) 
12 month questionnaire 
 
What is the questionnaire about?  
 
Thank you for filling in the two previous questionnaires. This questionnaire asks some more 
questions about your baby’s health and feeding.  
 
 
Section 1: About your baby and their health 
 
Q1.1 How old is your baby?  
Please write numbers in both boxes  
Write in how many whole weeks plus any additional days:  
 
□ and  □ 
Weeks   days 
 
 
Q1.2 Some babies with Down’s syndrome have medical conditions which mean that they 
spend some weeks or months of their life in hospital.  
 
Please indicate since you last filled in the questionnaire when your baby was 7 months old, 
how long your baby has spent in hospital?  
  
Since my baby was 7 months old they have spent…. 
 
Less than a week    □ 
1week – less than 4 weeks   □ 
1month – less than 2months   □ 
2months – less than 3 months  □ 
3months – less than 4 months □ 
4months – less than 5 months □ 
5months – less than 6 months □ 
More than 6 months □ 





Q1.3a Has your baby been seen by any specialists since you last completed the 
questionnaire when your baby was 7 months old? (for example paediatric cardiologist / 
heart doctor, paediatric gastroenterologist/ gut specialist, community paediatrician etc)  
 
 
Yes  □ → go to Q1.3b 
No  □ → go to Q1.4 
 
 
Q1.3b Which specialists has your baby been under the care of since they were 7months old? 
Please cross one or more boxes 
Paediatric cardiologist/ heart doctor  □ 
Paediatric gastroenterologist / gut doctor □ 
Paediatric dietician    □ 
Community Paediatrician   □ 
Speech and language therapist  □ 





Q1.4 Since completing the last questionnaire has your baby been diagnosed with any of the 
following: 
a. A heart condition? 






No  □ 
 
b. Hypothyroidism requiring treatment?  
Yes, diagnosed age  7months - less than 9 months □       9-12 months plus □
  







c. Type 1 diabetes requiring insulin? 
Yes, diagnosed age  7months - less than 9 months □        9-12 months plus 
□ 
No  □  
 
 
d. Coeliac disease, for which your child has been put on a gluten free diet? 
Yes, diagnosed at age    7 months - less than 9 months □ 9-12 
months plus □ 
No  □  
 
 
e. Any other medical conditions? 
Yes, diagnosed age  7 months - less than 9 months □       9-12 months plus
  □  








No  □ 
 
Q1.5 Has your baby ever suffered from any of the following problems since you last 
completed the questionnaire at around 7months?  
Please cross one or more boxes. Please indicate at roughly what age (eg 7months – less than 
9 months, 9-12 months) 
a. Sickness or vomiting 7months, less than 9months  □ 9-12months  □ 
b. Diarrhoea 7months, less than 9months  □ 9-12months  □ 
c. Constipation 7months, less than 9months 
□ 
9-12months  □ 
d. Chest problems / 
infection 
7 months, less than 9months  □ 9-12months  □ 
e. Ear problems / infection 7 months, less than 9months  
□ 





f. Urinary tract infection 7 months, less than 9months  
□ 
9-12months  □ 
g. Colic / painful wind 7 months, less than 9months  
□ 
9-12months  □ 
h. Thrush 7 months, less than 9months  
□ 
9-12months  □ 
i. Not gaining enough 
weight 
7 months, less than 9months  
□ 
9-12months  □ 
j. Gaining too much weight 7months, less than 9months  
□ 
9-12months  □ 
k. Something else (please 
cross age and write in) 
 7 months, less than 9months  
□ 
9-12months  □ 
 
 
    l.  None of these  
□            
 
    
Q1.6a Since completing the last questionnaire has your baby been given any antibiotics? 
Yes  □ → go to Q1.6b  
No  □ → go to Q1.7 
 
Q1.6b How many separate courses of antibiotics has your baby had since they were 7 
months old?  
   □ 





 I don’t know     □ 
 
   Age 7months – less than 9months  □ 
If known which antibiotic? Please enter name of antiobiotic or write “not known” if you don’t 
know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know 
    
 
Age 9 months – less than 12months □  
If known which antibiotic? Please enter name of antiobiotic or write “not known” if you don’t 
know. 
 
 If you were told what infection you had please specify (eg. Chest infection, ear infection), or 
write “not known” if you don’t know. 
 
    
 









We are now going to ask some questions about the milk that you give your baby.  
 
Please note that when we ask about ‘breastfeeding’ we also mean ‘giving your baby 
expressed breast milk’. 
 
Some of these questions are repeated from the last questionnaire that you filled in but 






Q2.1a  Since completing the last questionnaire at around 7months  have you had any 
problems with feeding your baby?  
 
Yes  □ → go to Q2.1b  
No  □ → go to Q2.2  
 
 
Q2.1b  What problems have you had?  









Q2.1c Did you get any help or information about this/these feeding problem(s)?  
 





No  □ → go to Q2.2 
 
Q2.1d Where did you get this help or information?  
Please cross one or more boxes  
 
SureStart or Children’s Centre / Children’s Health Clinic  □ 
Partner, friend or relative      □ 
Voluntary or charitable organisation     □ 
Peer Supporter (a mum who has breastfed themselves  □ 
and been trained to give support to other mums)  
Breastfeeding support group      □ 
Start 4 Life        □ 
Books / leaflets / magazines      □ 
Television / radio       □ 
The internet / web based resources     □ 
Breastfeeding clinic       □ 
National Breastfeeding Helpline     □ 
Doctor / GP        □ 
Health visitor        □ 
Midwife (including at antenatal sessions)    □ 
Nurse         □ 








Q2.2 Thinking about the milk that your baby has received over the last 7 days, has he/she 
had…  
Please cross one box only  
 
Only breast milk    □ → go to Q2.3 
Only infant formula / other milk   □ → go to Q2.4 
Breast milk and infant formula / other milk  □ → go to Q2.5  
 
Q2.3 Has your baby EVER been given any kind of milk other than breast milk, such as infant 
formula or cow’s milk (even if this was only once)?  
 
Yes   □ → go to Q2.5  









Q2.4 Has your baby EVER fed from your breast or EVER been given expressed breast milk 
(via syringe, bottle or cup etc)?  
 
Yes (even if only once) □→ go to Q2.5 
No    □→ go to Q2.11 
 
Q2.5 Have you stopped breast feeding (no longer give your baby any expressed milk or put 
your baby to your breast)? 
 
Yes   □→ go to Q2.6
No   □→ go to Q2.10 
 
 
Q2.6 How old was your baby when he/she was LAST given breast milk or you put them to 
your breast?  
 
10 weeks or less      □ 
More than 10 weeks, up to 4 months   □ 
More than 4 months, up to 5 months   □ 
More than 5 months, up to 6 months  □ 
More than 6 months, up to 7 months  □ 
More than 7 months, up to 8 months   □ 
More than 8 months, up to 9 months   □ 
More than 9 months      □ 
 
Q2.7 What were your reasons for stopping breastfeeding?  










Q2.8  Which of the following best describes how long you breastfed for?  






I would have liked to breastfeed for longer  □ → go to Q2.9  
I breastfed for as long as I intended   □ → go to Q2.10 
I breastfed for longer than I intended   □ → go to Q2.10  
 
Q2.9 What would have helped you breastfeed for longer?  









Q2.10 On average how often has your baby been given breast milk over the last 7 days?  
 
Not at all    □ 
Once a day    □ 
Twice a day   □ 
3-4 times a day   □ 
5-6 times a day   □ 
7-8 times a day   □ 
More than 8 times a day  □ 
 
Q2.11  Which of the following kinds of milk has your baby EVER been given to drink, even if 
this was only once?  
Please cross one or more boxes  
 
Infant formula (or “first” milk)     □  
Follow-on formula (sometimes known as stage 2/3)  □  
Cow’s milk       □  






Q2.12 How old was your baby when he/she was first given ANY KIND OF MILK OTHER THAN 
BREAST MILK, such as infant formula or cow’s milk?  
 
10 weeks or less      □ 
More than 10 weeks, up to 4 months   □ 
More than 4 months, up to 5 months   □ 






More than 6 months, up to 7 months   □ 
More than 7 months, up to 8 months   □ 
More than 8 months, up to 9 months   □ 
More than 9 months      □ 
 
Q2.13  Excluding breast milk, which one of the following kinds of milk has your baby been 
given MOST OFTEN over the last 7 days?  
Please cross one box only  
 
Infant formula (or “first” milk)     □  
Follow-on formula       □ 
Cow‟s milk        □  






None of these      □ 
 
 
Q2.14a Has your baby ever been given any COW’S MILK? 
 
Yes  □ → go to Q2.14b  
No  □ → go to Q2.15 
 
 
Q2.14b how old was he/she when COW’S MILK was first given?  
If you cannot remember exactly, please put in the approximate age.  
Please write number in the box to nearest whole month  
□ Months 
Q2.15 Has your baby ever had any solid foods such as cereal, rusks, baby rice, fruit, 
vegetables or any other kind of solid food?  
 
Yes  □ → go to Q2.16 
No  □ → go to Section 3 
 
Q2.16 How old was your baby when he/she first had any food apart from milk?  





Please write number in the box to nearest whole week  
□ Weeks 
Q2.17  Why did you start giving your baby solid foods?  
Please cross one or more boxes  
 
Doctor / Health visitor / Other Health   □ 
Professional advised me to     □ 
Friend or relative advised me to    □ 
Read leaflets / seen information that advised me to □ 
Start4Life       □ 
Previous experience (with another baby)   □ 
Baby was not satisfied with milk    □ 
Baby was not gaining enough weight   □ 
Baby was waking up during the night   □ 
Baby able to sit up and hold food in hand   □ 







Q2.18  What was the FIRST solid food given to your baby?  
Please cross one box only  
Ready made baby food    □ 
Homemade foods     □ 
Rusk       □ 
Baby rice      □ 
Fruit (prepared at home)   □ 
Vegetables (prepared at home)  □ 
Any other food (for example, yoghurt,   
Fromage frais or breakfast cereal)  □ 
 
Q2.19  What sort of solid foods has your baby EVER had?  
Please cross one or more boxes  
Ready made baby food    □ 
Homemade foods     □ 
Rusk       □ 
Baby rice      □ 
Fruit (prepared at home)   □ 





Any other food (for example, yoghurt,    





Q2.20  What sort of solid foods did your baby eat yesterday?  
Please cross one or more boxes  
Ready made baby food    □ 
Homemade foods     □ 
Rusk       □ 
Baby rice      □ 
Fruit (prepared at home)   □ 
Vegetables (prepared at home)  □ 
Any other food (for example, yoghurt,  □ 
fromage frais or breakfast cereal)  
Didn’t have solids yesterday   □ 
 
Q2.21 Please estimate how often do you usually give your baby these particular TYPES of 
solid food?  
 





a day  












□ □ □ □ □ □ 
Rice or pasta  □ □ □ □ □ □ 
Bread  □ □ □ □ □ □ 




□ □ □ □ □ □ 
Butter/Margari
ne and other 
spreads  
□ □ □ □ □ □ 
Beef  □ □ □ □ □ □ 
Lamb  □ □ □ □ □ □ 
Pork (including 
ham)  
□ □ □ □ □ □ 
Chicken / other 
poultry  






□ □ □ □ □ □ 
Eggs  □ □ □ □ □ □ 
Beans, lentils, 
chickpeas  





□ □ □ □ □ □ 
Nuts (including 
ground nuts)  
□ □ □ □ □ □ 
Fruit  □ □ □ □ □ □ 
Vegetables  □ □ □ □ □ □ 
Cheese, 
yoghurt, 
fromage frais  
□ □ □ □ □ □ 
Puddings or 
desserts  




□ □ □ □ □ □ 
Crisps and corn 
snacks  
□ □ □ □ □ □ 
 
Q2.22  Did you get any information about when to start giving solid foods to your baby?  
 
Yes  □ 
No  □ 
 
Q2.23  Did you get any information about the types of solid foods to give your baby?  
 
Yes  □ 
No  □ 
If you answered Yes at Q2.22 or Q2.23 please go to Q2.24, otherwise go to Section 3 
Q2.24  Where did you get this information?  
Please cross one or more boxes  
 
SureStart or Children’s Centre / Children’s Health Clinic  □ 
Partner, friend or relative      □ 
Voluntary or charitable organisation     □ 
Peer Supporter (a mum who has breastfed themselves  □ 
and been trained to give support to other mums)  




Start 4 Life        □ 
Books / leaflets / magazines      □ 
Television / radio       □ 
The internet / web based resources    □ 
Breastfeeding clinic       □ 
National Breastfeeding Helpline     □ 
Doctor / GP        □ 
Health visitor        □ 
Midwife (including at antenatal sessions)    □ 
Nurse         □ 










Q2.25a Do you avoid giving your baby solid foods with particular ingredients?  
 
Yes  □ → go to Q2.25b  
No  □ → go to Q2.26  
 
Q2.25b Which ingredient(s) do you avoid giving your baby? Please write in below, if there 










Q2.25c Why do you avoid giving your baby this / these ingredient(s)? Please write in below 
indicating which ingredient you are referring to. 
 















Q2.26a Has it been difficult to introduce your baby to solid foods?  
 
Yes  □ → go to Q2.26b 
No  □ → go to Section 3  
 
Q2.26b In what way has it been difficult?  
Please cross one or more boxes  
 
Baby would not take solids    □  
Baby would only take certain solids  □ 
Baby was disinterested in food   □  
Baby prefers drinks to food    □ 
Baby vomiting     □  
Baby doesn’t like eating from a spoon  □  






Section 3: About your plans for work  
 
Q3.1 Are you doing any paid work at the moment?  
 
Yes     □ → go to Q3.2 
On paid maternity leave  □ → go to Section 4  
On unpaid maternity leave  □ → go to Section 4  
No     □ → go to Section 4 
 
Q3.2 What age was your baby when you returned to work?  
 
less than 3 months    □ 
3 months, less than 4 months  □ 
4 months, less than 5 months  □ 
5 months, less than 6 months  □ 
6 months, less than 9 months  □ 
9 months or older    □ 
Q3.3a Has your return to work affected the way in which you are feeding your baby at all?  
 
Yes  □ → go to Q3.3b 
No  □ → go to Section 4  
Q3.3b How has this affected the way in which you feed your baby?  




























Section 4:  
 
Q4.1 Is there anything else you would like to say about feeding your baby?  
 




No  □ 
Q4.2 Is there anything else you would like to say about your baby’s health?  
 








No  □ 




Q4.4  Is there any further information that you would like to add? 
















No  □ 
Was there anything you intended to go back and complete?  




Appendix 16: FADES Annual Questionnaire 
 
NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE 
NUTRITION THEME 
Feeding and Autoimmunity in Down’s syndrome Evaluation Study (FADES) 
 
Annual Medical Questionnaire 
 
Thank you for filling in the previous questionnaires. This questionnaire is only about your baby’s 
health and you will be asked to fill in a similar questionnaire every year around the time of your 
baby’s birthday, until they are 5 years old.  
 
 




Tel: +44 (0)117 342 1755 
What is your identification number for this study? (Please do not put your 






If you no longer wish to take part in this study please cross the box below and 
return the questionnaire to us so we do not trouble you further. 







Q1 How old is your child?  
Please write numbers in both boxes  
Write in how many months plus any additional weeks:  
□    and  □ 
Months   weeks 
 
Q2 Some children with Down’s syndrome have medical conditions which mean that they 
spend some weeks or months of their early life in hospital. 
 
Please estimate since you last filled in the questionnaire (which would have been around 
the time of their last birthday) how long your child has spent in hospital 
 
Less than a week     □ 
1 week – less than 4 weeks    □ 
1 month – less than 2months   □ 
2 months – less than 3 months   □ 
3 months – less than 4 months  □ 
4 months – less than 5 months  □ 
5 months – less than 6 months  □ 
More than 6 months □ 
      
 
Q3a Has your child been seen by any specialists since you last completed the questionnaire? 
(for example paediatric cardiologist / heart doctor, paediatric gastroenterologist/ gut 
specialist, community paediatrician etc)  
 
Yes  □ → go to Q3b 





















Q3b Which specialists has your child been under the care of in the last 6months? Please 
cross one or more boxes  
Paediatric cardiologist/ heart doctor  □ 
Paediatric gastroenterologist / gut doctor □ 
Paediatric dietician    □ 
Community Paediatrician   □ 
Speech and language therapist  □ 





Q4 Since completing the last questionnaire has your baby been diagnosed with any of the 
following: 
a. A heart condition? 




No  □  
 
b. Hypothyroidism requiring treatment?  
Yes  □   
No  □  
 
c. Type 1 diabetes requiring insulin? 
Yes  □ 









d. Coeliac disease, for which your child has been put on a gluten free diet? 
Yes  □ 








e. Any other medical conditions? 
Yes  □ Please specify 
 
 
No  □ 
 
 
Q5 Has your baby suffered from any of the following problems since you last completed the 
questionnaire?  
Please cross one or more boxes.  
 
Sickness or vomiting     □ 
Diarrhoea      □ 
Constipation     □ 
Chest problems / infection    □ 
Ear problems / infection    □ 
Urinary tract infection    □ 
Colic / painful wind     □ 
Thrush      □ 
Not gaining enough weight    □ 
Gaining too much weight    □ 






None of these    □ 
 






Yes □ → go to Q6b 




Q6b. How many separate courses of antibiotics has your baby had in the last year, since you 
completed the last questionnaire? Please estimate if you are unsure. 
□ 
Q7 Is there anything else you would like to say about your baby’s health?  












 / /  






























Appendix 17: Instructions for sample collection for DNA, Urine and Stool 
NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE 
NUTRITION THEME 
Feeding and Autoimmunity in Down’s syndrome 
Evaluation Study (FADES) 
 
Instructions for sample Collection 
Thank you for participating in this study. We appreciate that 
completing the questionnaires and collecting the samples will take 
time and we want to support you with this in any way we can. 
If you have any questions regarding either the questionnaires or 
collecting the samples please do not hesitate to contact us either by 
email fades-study@bristol.ac.uk or telephone 0117 342 1756. You 
may also find the answer you are looking for on our website 









 This pack contains: 
Kit for mouth swab collection    
   
 










2 x Kit for stool collection 
 
      
And a sheet for recording the date and time that your child’s samples 
were taken. 
The instructions for collecting the mouth swab, urine and stool 
samples are all within this booklet. The instructions and kit for 
collecting blood samples are in a separate booklet. 
We would be grateful if you could collect the samples as soon as you 
















5-6  Mouth Swab Instruction 




9-10 Stool Collection Instructions for baby’s sample 







Instructions for taking Mouth swabs 
 
Kit contents: Mouth swab, inner tube, outer mailing tube, outer Biohazard bag. You 




1. Stand inner tube up in the lid of the outer tube. The inner tube 





2. Rub the swab very gently on the inside of your baby’s cheeks and 






3. Put used swab into the inner tube (so that the foam end is 
submerged in the collection buffer) and cut off some of the stick, 
enough so that the swab will fit into the tube with the lid closed. 




4. Put the inner tube into the outer mailing tube (lid end up) and close 




5. Place in the zip lock biohazard bag and then into the prepaid 







INSTRUCTIONS FOR COLLCTING A URINE 
SAMPLE 
 
Kit contents:  Cotton wool bud packs x2, urine collection cup, gloves, 1 green top urine 





1. You can either “catch” your child’s urine in the cup provided or use 
the sterile cotton wool buds in the nappy to catch the urine. When 
your child is older and if they are out of nappies urine can be 
collected in the cup provided. 
 
2. If you have decided to catch your child’s urine please take off your 
baby’s nappy just prior to a feed and be ready to try and catch the 
first urine that your child does after their feed. If your child is out 
of nappies please catch the first urine after they have eaten. Please 
note the time of the feed / meal. 
 
3. Once you have caught the urine in the cup transfer it into the urine 
tube pictured below using the plastic pipette provided. The tube has 
some white powder in it which is meant to be there, so please do 





   
4. If you have decided to use the cotton wool to collect the urine in 
the nappy - immediately prior to your baby’s feed place 4 cotton 
wool balls in the nappy and fasten the nappy in the usual way. 
Please note the time of the feed 
 
5. Half an hour after your child’s feed check whether your baby has 
passed urine if they have, the cotton wool will be wet (if there is also 
poo on the cotton wool this will need to be discarded and try again 
at the next feed).Take the cotton wool out of the nappy and squeeze 
the urine from the cotton wool balls into the cup (you may wish to 
wear the gloves provided to do this), try to squeeze out as much as 
you can. Carefully transfer the urine from cup into the urine tube 
using the plastic pipette and push the lid on securely. The container 
has some white powder in it which is meant to be there, so please 
do not tip it out. 
 
6. Write the date and the time the sample was taken on the sheet 
provided. Please also note how long after the feed or meal the 
sample was collected. 
 
7. Put the green-topped container (with your child’s urine in) inside 
the sealable biohazard plastic bag that contains some absorbent 




8. Please post this either the same day with the other samples or, if 
the sample was taken in the evening you may post your sample the 
next morning if you keep it in the fridge or cool place overnight. 





INSTRUCTIONS FOR COLLECTING A STOOL 
SAMPLE (BABY) 
 
Kit contents: BD BBLTM CultureSwabTM EZ II Swab, gloves, zip lock 
biohazard bag. OMNIgene GUT collection tube and spatula.  
 
 
Please collect 2 samples from a single nappy (from the same poo) one 
into the tube with the purple lid according to the instructions and one 







Things to consider:  
• If the nappy is very wet from urine, do not collect a faecal (poo) 
sample from this nappy but wait until the next time your baby 
defecates.  
• Avoid collecting the faecal specimen from the edges.  
• Try to avoid scraping the nappy while collecting the sample 
 
 Procedure:  
1. Remove the nappy as soon as you are aware that your baby has 
defecated (done a poo). 
 
2. Pull/twist the BDTM CultureSwabTM from the covering tube by 
holding the swab by the purple cap. Set the tube aside at a 
reachable distance as you will need to re-use this. 
   
3. While wearing gloves collect the faecal (poo) specimen by gently 
rubbing the foam ends of the double swab in the faeces that is 
on the nappy in a circular motion until both swab heads are 





4. Return the used 
double head swab into 
the covering tube and push firmly closed. Please write your 
child’s name on the covering tube.  
  
5. Place swab in the plastic biohazard zip lock bag, this can then be 
put in the mailing envelope with the other samples that you have 
collected. 
 
6. DO NOT throw the nappy away as you need to collect another 






Step Procedure   
Avoid collecting too much sample so 
it is difficult to reintroduce the swab 
back into the tube. 
 
Warnings and precautions: 
• FOR EXTERNAL USE ONLY. 
• Do NOT remove the yellow tube top from the 
tube. 
• Do NOT spill the stabilizing liquid in the tube. 
• Wash with water if liquid comes in contact with 
eyes or skin. Do NOT ingest. 
• If stool sample is liquid or your baby has 
diarrhoea wait until the next bowel movement to 
collect     the sample. 





1 Having collected one sample from the nappy using the swab you now need to collect 
another sample from the SAME nappy (same poo) using the instructions below. 
2 
 
While holding the yellow tube top, unscrew ONLY the 
purple cap from the kit and set it aside for later use. 
IMPORTANT: Do not remove the yellow cap       
Do not spill the stabilization liquid in the tube 
3 
 





Transfer the stool (poo) sample into the yellow tube top. 
If there is enough poo repeat until the sample reaches 
the top and fills it completely, if not fill it as much as 
you can. 
                              
IMPORTANT: Try not to push the sample into the tube. 
  5 
 
Scrape horizontally across the tube top to level the 




Wipe the exterior of the tube and top with toilet paper 
or tissue as needed. 
6 
 
Screw the purple cap back onto the yellow top tube until 
tightly closed  




Shake the sealed tube as hard and fast as possible in a 
back and forth motion for a minimum of 30 seconds. 
8 
 
The stool (poo) sample will be mixed with the 
stabilizing liquid in the tube. Not all particles will 
dissolve. 
IMPORTANT: Keep shaking if large particles remain 





1. Place both the swab and the purple top tube (OMNIgene GUT 




in the mailing envelope with the other samples that you have 
collected. 
2. Mail the envelope as soon as you can or store at refrigerated 
temperature until you are able to post it – this should be as soon 
as possible to preserve the sample. 
 
 




Kit contents: BD BBLTM CultureSwabTM EZ II Swab, gloves, zip lock biohazard bag. Fe-col 








Please collect 2 samples from the same poo. One into the tube with 
the purple lid according to the instructions and one using the swab as 
per the instructions.  
Please read the instructions before collecting the samples.  
Things to consider:  
•  Avoid passing urine at the time of defecation.  
• Avoid collecting the fecal specimen from the edges.  
 
Procedure:  
1. Pull the cap from the double swab, by grabbing the red cap and 
pulling. Set aside at a reachable distance 










3. While wearing gloves collect the faecal (poo) specimen by gently 
rubbing the cotton end of the swab in the faeces  
 
that is on faeces collection device in a circular motion until both 
swab heads are covered with it. (See image below) 
 
 
4. Return the used double head swab into the capsule and seal. 
  
5. DO NOT flush the faeces (poo) away but collect a second sample 
following the instructions below. 
6. Place swab in plastic zip lock this can then be put in the mailing 
envelope once you have collected the other sample.  
Step Procedure  
 Having collected one sample using the swab you now need to collect another 
sample from the SAME poo using the instructions below. 
1. 
 
While holding the yellow tube top, unscrew ONLY 






IMPORTANT: Do not remove the yellow cap       
Do not spill the stabilization liquid in the tube 
2. 
 




Transfer the faecal sample into the yellow tube 
top. Repeat until the sample reaches the top and 
fills it completely. 
 




Scrape horizontally across the tube top to level the 
sample and remove any excess. Discard the stick. 
Wipe exterior of tube and top with toilet paper or 
tissue as needed. 
5. 
 
Screw the purple cap back onto the yellow tube top 






Shake the sealed tube as hard and fast as possible 




The faecal sample will be mixed with the stabilising 
liquid in the tube; not all particles will dissolve. 
 
IMPORTANT: Continue shaking if large particles 




• Place both the swab and the purple top tube (OMNIgene GUT 
tube) in the plastic biohazard zip lock bag. This can then be 
put in the mailing envelope with the other samples that you 
have collected. 
• Mail the envelope as soon as you can or store at refrigerated 
temperature until you are able to post it – this should be as 







Thank you very much for your help with this study. If you have any 
queries please contact Dr Georgina Williams on email: fades-





Appendix 18: Instructions for blood sample collection 
NIHR BRISTOL BIOMEDICAL RESEARCH CENTRE 
NUTRITION THEME 
Feeding and Autoimmunity in Down’s syndrome Evaluation 
Study (FADES) 
 
Instructions for sample Collection 
Thank you for participating in this study. We appreciate that 
completing the questionnaires and collecting the samples will take 
time and we want to support you with this in any way we can. 
If you have any questions regarding either the questionnaires or 
collecting the samples please do not hesitate to contact us either by 
email fades-study@bristol.ac.uk or telephone 0117 342 1756. You 






We will be in touch with you to help you to arrange having the blood 
test taken at the same time as one of your child’s routine health care 
appointments.  
Please take everything included within this pack including this 
instruction leaflet and your copy of the consent form to the 
appointment.  
 
This pack contains: 






And a sheet for recording the date and time that your child’s samples 
were taken. Please also note on this sheet whether the sample was 
from a heel prick / finger prick or from a vein (if taken at the same time 
as other routine blood tests) 
The instructions for collecting the blood samples are within this 
booklet. There is also a factsheet for health care professionals at the 
back of the booklet. 
We understand that you may not be able to collect the blood samples 
at the same time as the other samples.  
Once the blood sample has been taken it can be sent back separately 






Heel Prick Instructions For Parents and/or Health 
Professional 
The initial blood test should be taken by a health professional and 
we will contact you in order to help you with coordinating this with 
one of your baby’s routine health checks.  
 
We understand that it is not easy for a parent to watch blood being 
taken from their child but the discomfort only lasts a few minutes and 
your baby will be quickly comforted after by a cuddle with you.  
 
If having observed the initial sample you feel you would prefer to take 
the other samples (at 6months, a year and then annually) at home 
yourself please follow the instructions below:  
 
It is much easier to take the blood with two people, one to cuddle your 
baby and one to take the blood. 
 
1. Lay out the equipment so that you can reach it all easily - dry 
cotton wool, warm water (never place hot water near your 
baby), lancet (very small needle, we have provided you with a 






To prepare the blood collection tube you need to remove the 
small cap from the bottom of the tube but keep it close as you 
will need to put it back on at the end.  
 
2. There is evidence that the discomfort for your baby is reduced if 
you are able to have your baby next to your skin (skin to skin) 
whilst the blood is being taken. 
 
3. The person taking the blood should wash their hands with soap 
and water or alcohol gel.  
 
4. Wash your baby’s heel with warm water and dry. The person 
taking the blood should encircle your baby’s heel in their hand, 
they should not need to squeeze the foot or hold the foot tightly. 
 
5.  The blood is taken from the side of the heel (shaded areas on 







6. Prepare the safety lancet by twisting off the green tab at the end. 
Whilst holding the heel with one hand, place the lancet against 
the area where you want to take the blood and depress the top 
of the lancet. This may make your baby startle and cry but it is 







7. Wipe the first drop away with some dry cotton wool and then, 
holding the sample collection tube horizontally (with both ends 
open), place the thin end of the tube next to the next blood drop 
and start collecting. The blood should be sucked into the tube 
via capillary action. Once the tube starts to get full you  
may need to place the lid on the bigger end to prevent the blood 
from dripping out. You may need to gently squeeze and release 
the heel in order to keep the blood flowing but this can be done 





8. Please collect as much as you are able to, if possible into one 
tube if the heel keeps bleeding please then also use the spare 
tube (Sometimes it helps to wipe the heel with the cotton wool 
part way through collection, particularly if the blood spreads 
rather than going in the bottle). If the blood is no longer going 
into the tube from the bottom but the heel is still bleeding place 
the small cap on the bottom and allow the drops to go in from 
the top.  
 
9. Once you have finished collecting the blood first place the cap 
on the bottom  
 
 
…and then place the lid on the top of the bottle. Make sure it is 







 This tube can now be placed back in the outer tube. 
  
 
10. You may find that your baby’s heel stops bleeding after only a 
few drops, or they may continue bleeding even after you have 
filled the bottles. If their heel is still bleeding just gently press 
some dry cotton wool against their heel for a few seconds and it 





11. The used lancet can be placed in the clear plastic bag marked 
‘biohazard’  with the blood bottle these can both go into the 






















INSTRUCTIONS FOR COLLECTING A FINGER 
PRICK BLOOD SAMPLE  
(For babies over the age of 12 months only, babies younger than 12 
months should have a heel prick blood test) 
 
You may be taking this sample yourself at home or this maybe done 




it is not easy for a parent to take blood from their own child but the 
discomfort only lasts a few minutes and your child will be quickly 
comforted after by a cuddle with you. This will be much easier with 
two people, one to cuddle your child and one to take the blood. 
 
1. Lay out the equipment so that you can reach it all easily - dry 
cotton wool, warm water, lancet (very small needle, we have 
provided you with a spare lancet) and blood collecting tubes x2. 
 
To prepare the blood collection tube you need to remove the 
small cap from the bottom of the tube but keep it close as you 
will need to put it back on at the end.  
2. The person taking the blood should wash their hands with soap 
and water. 
 








4. Select one of the following (shaded)sites to puncture:  
 
5. Prepare the safety lancet and puncture the skin as shown:  
 
 
6. Discard the first drop of blood by blotting finger on the gauze 
swab. 
  
7. Collect the blood as shown below 
 
 
Twist the tab at the bottom until it separates 
from the lancet.  
Press the lancet very firmly against the finger to 
ensure a good puncture site and blood flow. You may 








To maintain good blood flow, hold arm downwards and you can gently 
massage your child’s hand.  
Avoid repeated strong pressure around the puncture site (milking) as 
this will be uncomfortable for your child and may spoil the sample. 
 
Please collect as much as you are able to, if possible into one tube if 
the finger keeps bleeding please then also use the spare tube. 
(Sometimes it helps to wipe the area with the cotton wool part way 
through collection if the blood spreads rather than going in the bottle). 
If the blood is no longer going into the tube from the bottom but the 
finger is still bleeding place the small cap on the bottom and allow the 
drops to go in from the top. 
 
10. Once you have finished collecting the blood first place the cap on 





and then place the lid on the top of the bottle. Make sure it is on 











11. You may find that your child’s finger stops bleeding after only a 
few drops, or they may continue bleeding even after you have filled 
the bottles. If their finger is still bleeding just gently press some dry 
cotton wool against their finger for a few seconds and it should stop.  
The used lancet can be placed in the clear plastic bag marked 
‘biohazard’ with the blood bottle these can both go into the prepaid 









Study Fact Sheet for Health Professionals 
 
Study title: Feeding and Autoimmunity in Down’s syndrome 
Evaluation Study (FADES) 
 
What is the aim of the FADES study? 
To develop a family acceptable study protocol and establish the 
feasibility of creating a national cohort of infants with Down’s 
syndrome (DS) to study the associations between early infant feeding, 
infections and the development of autoimmunity in Down’s 
syndrome. 
Who is responsible for this study? 
This study has been set up as a partnership between the NIHR, Bristol 
Biomedical Research Unit in Nutrition, The University of Bristol, School 




London, Department of Medicine, the Down’s Syndrome Association 
and Down’s Syndrome Scotland. 
What is the background to the study? 
Children with Down’s Syndrome (DS) have increased risk of 
autoimmune conditions including thyroid problems, diabetes and 
coeliac disease. In DS, autoimmunity is likely to be related to lifelong 
inherent defects in the immune system.  The risk of diabetes-related 
autoimmunity is increased despite a reduced prevalence of the usual 
HLA haplotypes commonly associated with type 1 diabetes. Infant 
feeding practice has been linked to diabetes and coeliac risk with some 
evidence that prolonged breastfeeding is protective.  We hypothesise 
that in infants with DS, already at increased risk, early feeding 
practices may be related to the development of autoimmunity. 
Children with DS have hypotonia and therefore have difficulties with 
breastfeeding leading to the rapid introduction of formula feeds which 
contain modified cow’s milk protein.  




Infants are recruited through the Down’s Syndrome Association (DSA) 
and Down’s Syndrome Scotland (DSS).  
What would be my involvement?  
During this study we will be collecting a variety of data from each 
participant and their family as shown in the table below, the majority 
of the samples will be collected by the parents at home and they have 
been given all the necessary instructions and equpiment. They will 
also complete the questionnaires at home.  We are asking if you could 
kindly assist with taking the blood samples when you see the 
participant for their routine health checks. The blood samples at 
12months and yearly thereafter can be taken at the same time as their 



















Months of age 0* 
Baseline 
6 12 Every year around the time  of 
the participant’s birthday until 
January 2022 
Day 5 blood 
spot for 
autoantibodies 





X X X  
Medical 
questinnaire 
   X 
Mouth swab for 
DNA extraction 
X    
Stool for 
microbiome 
X X X X 
Heel or finger 
prick blood 









All the necessary equipment for collecting the sample will be 



















How do I return the samples?  
The blood bottles have already been labelled with the participants 
unique identifier code. The parents have been provided with special 
pre-paid packaging in which they can return the samples too us.  
Will I be given the results of the tests? 
We will only contact the participant’s GP with the results of the tests 
if they are of clinical significance to the participant 
Will I be informed of the outcomes of the Study? 
If you are interested in the study and would like to be updated 
regarding its progress we can arrange to send you regular updates via 
email. At the end of the study we can provide you with a summary of 






Thank you for your help and support with this study!  
We hope that the outcomes of the study may benefit children born 
with DS in the future. From this study we hope to go on and do a 
further study to develop an intervention to help with feeding in babies 
born with DS. We also hope the study will increase our knowledge of 
autoimmune conditions and will provide increased information in this 






Appendix 19: Engagement/ Participant Questionnaire 








Thank you so much for your ongoing participation in the FADES study. We are trying to 
improve this study and also make recommendations for future research for babies with 
Down’s Syndrome.  
Why have I been contacted? 
We are contacting families who are currently participating in the FADES study as well as those 
who have shown an interest in the study but have not gone on to take part. We want to find 
out what initially interested them and either their experience of being part of the study or 
why they did not go on to enrol in the study. 
This will help us to improve the study and will help to inform future research with families 




What am I being asked to do? 
If you would like to help us please complete this short anonymous questionnaire online it 
should take less than 10 minutes to complete. If you would prefer a paper version of the 
questionnaire please let us know and we will send this to you together with a stamped 
addressed envelope. 
Thank you  
 
 




1.  How did you hear about the FADES Study? Please tick any that apply 
Through the Down’s Syndrome Association website    □ 
From the flyer in the Down’s Syndrome Association New Parent pack □ 
From a support worker from Down’s Syndrome Scotland   □ 
Through the flyer in the Down’s Syndrome Scotland new parent pack □ 
From a community paediatric doctor      □ 
From a neonatal doctor       □ 
Through a friend        □ 
Through social media: please provide detail if you can   □ 






2. What initially interested you in the FADES Study? 
 
3. Why did you decide to take part in the FADES study? 
4. What did you think about the study website? (please circle on the scale below) 
 
Attractive  1 2 3 4 5  Unattractive 







5. How would you recommend we improve the information that is provided about the 
study? 
 
6. What improvements in the study do you think we could we make to encourage 
families to take part? 
 
7. If you have any further comments to make about the FADES study or any general 
comments about recruiting families who have recently had a baby with Down’s 









Appendix 20: Non-Engagement / Non- Participant Questionnaire  








Thank you so much for having contacted and shown an interest in the FADES study. We are 
trying to improve this study and also make recommendations for future research for babies 
with Down’s Syndrome.  
Why have I been contacted? 
We are contacting families who have either shown an interest in the FADES study but have 
not gone on to take part, or those that have started in the study but are no longer actively 
participating. We want to find out what initially interested them in FADES and why they did 




This will help us to improve the study and will help to inform future research with families 
who have a child with Down’s Syndrome. 
What am I being asked to do? 
If you would like to help us please complete this short anonymous questionnaire online it 
should take less than 10 minutes to complete. If you would prefer a paper version of the 
questionnaire please let us know and we will send this to you together with a stamped 
addressed envelope. 
Thank you  
 
 





1. How did you hear about the FADES Study? Please tick any that apply 
Through the Down’s Syndrome Association website    □ 
From the flyer in the Down’s Syndrome Association New Parent pack □ 
From a support worker from Down’s Syndrome Scotland   □ 
Through the flyer in the Down’s Syndrome Scotland new parent pack □ 
From a community paediatric doctor      □ 
From a neonatal doctor       □ 




Through social media: please provide detail if you can   □ 
Other: please provide detail if you can      □ 
 
2. What initially interested you in the FADES Study? 
 
3. Why did you feel unable to participate or continue in the study? Please tick all that 
apply and provide any further detail or comments below 
 
Our baby was too unwell       □ 
We meant to take part but did not get round to it    □ 
We decided not to take part because of the time that the study would involve
 □ 
We did not want to take the stool, urine and mouth brush samples  
 □ 
We did not want to take the blood samples     □ 
We were worried about completing the questionnaires   
 □ 
Other: Please describe in box below 
 








Attractive  1 2 3 4 5  Unattractive 
Clear to understand 1 2 3 4 5  Difficult to understand 
 
5. How would you recommend we improve the information that is provided about the 
study? 
 
6. What improvements in the study do you think we could we make to encourage 
families to take part? 
 
 
If you have any further comments to make about the FADES study or any general comments 








Appendix 21: Examples of errors corrected during study: 
 
• 9th September 2015 it was found that prior to this date the question Q2.14 “Were you 
given, or did your red book contain the specific Down’s Syndrome insert with growth 
charts for babies with Down’s Syndrome?” had not been available to all participants 
due to branching. It had not therefore been answered by everyone. If they had 
answered “no” to 2.8b it had skipped to 2.15 (paper version was also wrong). The 
online / REDCap questionnaire and paper questionnaire were both corrected 
appropriately to prevent participants being branched away from this question. 
Participants who had incorrectly missed this question were emailed to ask Q2.14 and 
they responded to the email. 
• 14th November 2016 – found that the age limit on the 12 month questionnaire was 
not enough. Some parents who were completing it late could not enter their child’s 
age, as up until this point the limits within that field only allowed up to 62 weeks to 
be entered onto the online/ REDCap questionnaire. The limits on this question was 




Appendix 22: Example of Variables Master Sheet  
Excerpt from 7 month master sheet  
Example from the 7 month questionnaire variable master sheet. The first column shows which variables were newly created. For example, the 
first two variables are variables which were too long straight from RedCAP and therefor had to be shortened. The other variables which say 
"NEW" were created from free text responses.  
 Renamed and new variables Old variable names from RedCAP  Question from Questionnaire 
 m7_spec_inv_bab_care_1_3_6 m7_speclsts_invol_babys_care_1_3___6 
Which specialists are involved in your baby's care? 
(choice=Other) 
 m7_spec_inv_bab_care_oth_1_3a m7_speclsts_invol_babys_care_other_1_3a If someone else please specify 
NEW m7_num_spc_inv  Number of specialists invoved in baby's care 
NEW m7_spec_inv_care_allergy_1_3acd  Allergy specialist 
NEW m7_spec_inv_care_audio_1_3acd  Audiologist 
NEW m7_spec_inv_care_Comnurse_1_3acd  Community nurse/ health visitor /Paediatric nurse 
NEW m7_spec_inv_care_cranio_1_3acd  Cranio-facial /head specialist 
NEW m7_spec_inv_care_ENT_1_3acd  Ear nose and throat speciallist (ENT) 
NEW m7_spec_inv_care_haemonc_1_3acd  Haematology/ oncology 
NEW m7_spec_inv_care_hepat_1_3acd  Hepatologist 
NEW m7_spec_inv_care_surg_1_3acd  Surgeons 
NEW m7_spec_inv_care_OT_1_3acd  Occupational Therapist 
NEW m7_spec_inv_care_opthal_1_3acd  Opthalmology 




NEW m7_spec_inv_care_Psych_1_3acd  Psychotherapist 
NEW m7_spec_inv_care_Physio_1_3acd  Physiotherapist 
NEW m7_spec_inv_care_stoma_1_3acd  Stoma nurse 
  m7_bby_cnd_heart_1_4a 
Since completing the last questionnaire has your baby been 
diagnosed with any of the following medical conditions:    A 
heart condition? 





Appendix 23: Antibiotic codes and answers 
 
Examples from questions:  
 

















Benzylpenicillin and gentamicin 
Trimethoprim (prophylaxis) 
 
Infections for which baby received antibiotics age 0-1 month (init_bby_age_antb_1_19c2b) 
what infection age 0-1 month 
Not known 
Suspected sepsis 
Help with chemo 
Prophylactic 













iv meropenem and teicoplanin 
cephalexin 
 














Benzylpenicillin and gentamicin 









Help with chemo 
Prophylactic 







Prophylaxis for chest 


















11. Cephalexin and Nitrofurantoin 
12. Co-amoxiclav and Metronidazole 
13. IV Benzylpenicillin 
14. IV Benzylpenicillin and Gentamicin 
15. IV Meropenem and Teicoplanin 
16. IV Meropenem and Teicoplanin and Cephalexin 
17. Anti-viral 
18. Not Known 
19. IV Benzylpenicillin, gentamicin and prophylactic trimethoprim 
20. IV Benzylpenicillin and Gentamicin and chloramphenicol 
21. IV Benzylpenicillin, gentamicin, metronidazole and prophylactic trimethoprim  
22. Amoxicillin and erythromycin 
23. IV co-amoxiclav and flucloxacillin 
24. Fucidin cream 
25. Erythromycin and penicillin 
26. Amoxicillin, azithromycin and vancomycin 
27. Co- amoxiclav, clindamycin and Tamiflu 
Stata coding :  
0 "None" 1 "Amoxicillin" 2 "Azithromycin" 3 "Cephalexin" 4 "Chloramphenicol" 5 
"Ciprofloxacin" 6 "Clarithromycin" 7 "Co-amoxiclav" 8 "Flucloxacillin" 9 "Penicillin" 10 
"Trimethoprim" 11 "Cephalexin and Nitrofurantoin" 12 "Co-amoxiclav and Metronidazole" /// 
13 "IV Benzylpenicillin" 14 "IV Benzylpenicillin and Gentamicin" 15 "IV Meropenem and 
Teicoplanin" 16 "IV Meropenem and Teicoplanin and Cephalexin" 17 "Anti-viral" 18 "Not 
Known" 19 "IV Benzylpenicillin, gentamicin and prophylactic trimethoprim" /// 
20 "IV Benzylpenicillin and Gentamicin and chloramphenicol" 21 "IV Benzylpenicillin, 
gentamicin, metronidazole and prophylactic trimethoprim" 22 “Amoxicillin and 
erythromycin” 23 “IV co-amoxiclav and flucloxacillin” 24 “Fusidin cream” 25 “Erythromycin 
and penicillin” 26 “Amoxicillin, azithromycin and vancomycin” 27 “Co- amoxiclav, clindamycin 
and Tamiflu” 
 
Codes for infections in baby/child 
1. Cellulitis 
2. Chest infection/ Bronchiolitis / cough 
3. Tonsillitis 
4. Umbilical infection 




6. Suspected sepsis in neonatal period / precautionary 
7. Suspected Meningitis 
8. Necrotising Enterocolitis  
9. Post Op infection 
10. Not Known 
11. Prophylaxis for chest 
12. Prophylaxis for surgery 
13. Prophylaxis UTI 
14. Prophylaxis other/ chemo 
15. Conjunctivitis 
16. Suspected sepsis and conjunctivitis 
17. Chest infection and cellulitis 
18. Chest infection and UTI prophylaxis 
19. Viral infection (unspecified) 
20. Central line infection – Streptococcal 
21. Viral infection (specified) 
22. Suspected meningitis, conjunctivitis, chest and ear infection 
23. UTI and C.Diff  
 
Stata coding:  
0 "No infection" 1 "Cellulitis" 2 "Chest infection/ Bronchiolitis/ Cough" 3 "Tonsilitis" 4 
"Umbilical Infection" 5 “Urinary Tract Infection(UTI)" 6 "Suspected Sepsis in the neonatal 
period / precautionary" 7 "Suspected meningitis" 8 "Necrotising Enterocolitis (NEC)" 9 " Post 
Op Infection" 10 "Not Known" 11 "Prophylaxis for chest" 12 "Prophylaxis for surgery" 13 
"Prophylaxis for UTI" 14 "Prophylaxis other/chemo" 15 “Conjunctivitis” 16 "Suspected Sepsis 
and Conjunctivitis" 17 "Chest infection and cellulitis" 18 "Chest infection and UTI prophylaxis" 
19 "Viral infection" 20 "Central line infection - Streptococcal" 21 “Viral infection (specified)” 
22 “Suspected meningitis, conjunctivitis, chest and ear infection” 23 “UTI and C.Diff” 
 
label define init_bby01_inf_1_19c2bcd 0 "No infection" 2 "Chest infection/ Bronchiolitis/ 









Appendix 24: Relative Abundance of Phyla, Classes, Order, Families and Genera 






Stacked bar chart showing Relative Abundance of Phyla, Classes, Order, Families and Genera 




Appendix 25: The Bland–Altman analysis for abundance of a)Firmicutes, 
b)Proteobacteria, c)Actinobacteria and d)Bactriodetes for the four 
different methods of sample collection compared to the frozen standard of 
immediate freezing. 
 
 Methodology compared to frozen standard  




Plain post Swab post Swab frozen 









 (-1019.8, 593) 

































BA analysis of the relative abundance of the four most abundant phyla for the four different 





The Bland–Altman plots for abundance of a)Firmicutes, b)Proteobacteria, 
c)Actinobacteria and d)Bactriodetes for the four different methods of sample collection 




Appendix 26: The BA analysis for abundance of 
a)Enterobacter, b)Bifidobacterium, c)Staphylococcusand d)Lactobacillus f
or the four different methods of sample collection compared to the frozen 
standard of immediate freezing. 
 
 Methodology compared to Frozen standard 
(Average difference, (95% Limit of Agreement) 
Genus OMNIgene•GUT 
 
Plain post Swab post Swab frozen 












17.3 (-54.4, 88.9) 













Bland Altman analysis of the relative abundance of Enterobacter, Staphylococcus, Lactobacillus 
and Bifidobacterium for the four different methods of sample collection compared to the gold 






The Bland–Altman plots for abundance of 
a)Enterobacter, b)Bifidobacterium, c)Staphylococcusand d)Lactobacillus for the four different methods 















Appendix 27:  Table Summarising the Study in relation to the features of a feasibility study  
 Supporting Against Amendments or improvements to be made for main 
study 
Ability to complete measures  
  
 
Comprehension Participants were able to follow the 
instructions for data collection.  
No major issues with either the 
questionnaires or sample collection 
were identified 
As data was collected at a distance via 
post and internet rather than face to 
face. Potentially the research team were 
unaware of those who did have issues 
with comprehension 
No changes made 
Capacity The research team were able to 
manage the data collection, storage 
of samples and sample analysis. 




There were no concerns raised 
about capacity 
Appropriateness 




Participants completed the detailed 
questionnaires and included extra 
detail in the free text boxes. 
 
A reasonable proportion of 
participants collected all the 
requested samples. 
The ethics committee and the DSA 
queried whether the questionnaires 
were too long. 
 
Due to the vast amount of data 
collected from the questionnaires, 
detailed analysis of all the data was not 
completed.  
 
Some participants completed the 
questionnaires but did not go on to 
collect the biological samples. 
The questionnaire was shortened during the 
planning stages but could be shortened further.  
 








The use of web-based 
questionnaires reduced the amount 
of missing data so this was minimal. 
The data was usable. 
 
As discussed in more detail in the 
sample collection section the 
proportion of samples that were 
collected and were usable was 
within the feasibility target. 
 
The collected samples were usable 
for analysis.  
Due to the incorrect branching of some 
questions, participants were unable to 
complete some questions. This is 
discussed in more detail for the relevant 
questions 
Correct the errors in the branching.  
 
Develop videos for demonstrating sample collection 
methods 




Retention  Retention of participants was good.   
Adherence to 
study procedures 
Participants followed the 
procedures well with no concerns. 
 
Flexibility with regards to the 
timings of data collection were built 
in to the protocol.  
When local collaborators recruited 
participants the EOI form was not 
always completed and this prevented 
participants being fully enrolled into the 
study. 
Inform local collaborators about the completion of 
the EOI form. 
Engagement Participants were very engaged as 
demonstrated by the high 







Time As participants complete the 
questionnaires and most samples 
are collected at home this reduces 
the amount of researcher time. 
Participants do spend considerable time 
completing questionnaires and 
collecting samples  
 
Organising and coordinating blood 
sample collection takes up a lot of 
researcher time with often multiple 
phone calls and emails. 
 
The approval process for multiple sites 
took up a large amount of time.  
Shorten questionnaires  
 
Now approvals are largely in place the time involved 
in liaising with sites has reduced. 
 
Burden There is flexibility built in to enable 
families to complete questionnaires 
and samples in their own time. 







The timing of blood sample 
collection is designed so that the 
participants do not need to go to a 
separate appointment. 
Acceptability and 
suitability of the 
procedures 
Participants collected samples 
without significant issues.  
 
Pilot studies for the collection of the 
urine and stool samples showed the 
suitability of the collection methods 












Appendix 28: FADES Newsletter (Example from March 2017)
The FADES study team are 
celebrating World Down Syndrome 
Day! 
 
The FADES study team have put on their best 
socks and baked cakes ready to celebrate World 
Down Syndrome Day. We will be raising money for 
the Down’s Syndrome Association and Down’s 
Syndrome Scotland, as well as raising awareness 
of research for children with Down’s syndrome. 
 
The FADES Study Team and their socks!! 
Dr Sam Leary, Professor Julian Hamilton-Shield, Georgina 




We are thrilled to say that we now have 55 
families enrolled in the FADES study. 
The information you have provided from the initial 
questionnaires will be presented as an oral 
presentation at the Royal College of Paediatrics 
and Child Health Conference in May.  
 
Professor Julian Hamilton–Shield met with 
Professor Eleanor Molloy (Trinity College 
University, Dublin) and Down's Syndrome nurse 
Fiona McGrane, (Trinity Centre, Tallaght Hospital 
Dublin) in March to discuss an extension of 
FADES recruitment to Ireland in the near future 
 FADES  Newsletter  





as a collaboration between the two groups to 




Amos our newest FADES participant 
 
We love to hear your stories and about your 
babies progress. Please do send us photos and 
updates that you would like to be included in the 
newsletter. Below Cheryl tells us about her 
experience of being in the FADES study. 
 
"We found out about the FADES study not long after 
Alexander was born, through our local Down 
syndrome support group. After I found out more 
about it, we were very keen to take part. The research 
being undertaken could be crucial to understanding 
the nutritional needs of children with Down 
syndrome.  
 
It is very easy to take part in the study. Every 6 
months, we fill in a questionnaire and they have a 
blood, stool and urine sample test.  
 
The extra support we have had with questions and 
queries around other areas of Alexander's health have 
been wonderful, and we feel privileged to be part of 
improving the lives of children with Down 
syndrome.  We would encourage anyone thinking 
about joining the study to take the plunge!" 
 
Children with Down’s Syndrome and 
Research 
We are very grateful to all of you who completed 
the survey asking for your views on FADES. These 
will help us to understand how to make it easier 
for families to get involved in research and will 
inform future studies.  
If you have not completed this survey but would 
still like to, please send us an email and we would 
be happy to forward you the link. 






Why are we collecting stool samples? 
Our gut contains trillions of bacterial cells called 
the microbiome. Research has shown that the 
microbiome plays a role in health and disease. We 
are interested to find out whether the gut 
microbiome in children with Down’s syndrome is 
different, and if this might have an effect on 
their risk of getting autoimmune conditions.  





The samples you collect at home are sent in the 
post back to us. During the time the samples are 
in the post we want to preserve them and stop the 
bacteria from growing. The new kit contains a 
liquid, which has been shown to preserve the stool 
microbiome at room temperature for several days.  
If you have any queries about collecting any of the 
samples or would like more details about any part 
of the study to feature in the next newsletter 
please let us know 
 
A BIG THANK YOU FROM FADES 
We want to take this opportunity to thank all our 
participants and their families, the Down’s 
Syndrome Association, Down’s Syndrome 
Scotland, the Down’s Syndrome Medical Interest 




Don’t forget to let your friends know about the FADES study, we are still looking for new families.  






Appendix 29: Supplementary Tables for Feeding and Medical Questionnaires. 
 
Length of hospital stay between questionnaires time points 
 From 7 month questionnaire 
(between initial and 7month 
questionnaire) 
From 12 month 
questionnaire 
(between 7 month and 12 
month questionnaire)  
Less than a week 37.7 % (20/53) 67.6 % (25/37) 
1 to <4 weeks 43.4 % (23/53) 18.9 % (7/37) 
1 to <2 months 7.6 % (4/53) 8.1 % (3/37) 
2 to <3 months 5.7 % (3/53) 0 
3 to <4 months 3.8 % (2/53) 0 
5 to <6 months 0 2.7 % (1/37) 
More than 6 months 2.9 % (1/53) 2.7 % (1/37) 
 






































g baby age 1 












6.7 %  
(4/60) 
75.0 % (6/8) 57.1 % (4/7) 






n/a   
Clarithromycin    n/a 1.6 % (1/61) 1.6 % (1/61) 
Co – amoxiclav    n/a 1.6 % (1/61) 1.6 % (1/61) 








 1.6 % 
(1/61) 
 n/a   
Anti-viral  1.6 % 
(1/61) 





  1.6 % 
(1/61) 









n/a 4.9% (3/61) 1.6 % (1/61) 




























Infants antibiotic use 
Received any antibiotics since birth    
Yes 51.7 % (31/60) 




Don’t Know 1.7 % (1/60) 
Number of antibiotic courses between birth and 




1 50.0 %  (15/30) 
2 33.33 %  (10/30) 
3 10.0 % (3/30) 
4 6.7 %  (2/30) 
Received antibiotics since completing initial 
questionnaire (initial to 7 month) 
28.0 %  (15/53) 
Number of antibiotic courses between birth and 
7 months mnth 
  
1 28.6 %  (4/14) 
2 21.4 %  (3/14) 
3 28.6 % (4/14) 
4 14.3 % (2/14) 
5 7.1 % (1/14) 
Received antibiotics since completing 7 month 
questionnaire (7 month to 12month) 
62.5 %  (25/40) 
Number of antibiotic courses that their child has 
had since completing the 7m questionnaire 
  




2 24.0 % (6/25) 
3 12.0 %  (3/25) 
4 8.0 %  (2/25) 
10 4.0 % (1/25) 
 
















Age 7- 9 
months 





Amoxicillin 1.6 % 
(1/61) 








Chloramphenicol  3.3 % 
(2/61) 
  











Flucloxacillin  1.6 % 
(1/61) 
  





IV benzylpenicillin 1.6 % 
(1/61) 
   
Amoxicillin, azithromycin 
and vancomycin 
   2.5 % 
(1/40) 
Co-amoxiclav, 
clindamycin and Tamiflu 
   2.5 % 
(1/40) 













   












































 n/a n/a n/a 
Umbilical infection 3.3 % 
(2/61) 





 n/a n/a n/a 
Chest infection / 











Conjunctivitis  3.3 % 
(2/61) 









 2.5 % (1/40) 
Cellulitis  1.6 % 
(1/61) 
   





  1.9% 
(1/54) 
 2.5 % (1/40) 
Viral infection 
(specified) 
  1.9% 
(1/54) 





























   
 














Doctor 11.5% (7/61) 
Health Visitor 18.0 %  (11/61) 
Midwife 65.6 %  (40/61) 
Nurse 3.3 %  (2/61) 
Other 3.3 %  (2/61) 
Where did you get specific advice regarding breastfeeding a baby with DS from   
DSA 3.3%  (2/61) 
Other 1.6 %  (1/61) 
Who helped put the baby to the breast (whilst in hospital)   
Midwife 51%  (31/61) 
Midwifery support worker 13.1 %  (8/61) 
Nurse 23.0 %  (14/61) 
Nursery nurse 6.6 %  (4/61) 
Healthcare assistant 6.6 % (4/61) 
Breastfeeding support group 4.9 %  (3/61) 
Partner, friend or relative 8.2 %  (5/61) 
Someone else 4.9 %  (3/61) 
Who helped with feeding problems whilst in hospital   
Midwife 37.7 %  (23/61) 
Midwifery support worker 13.1 %  (8/61) 
Nurse 34.4 %  (21/61) 
Nursery nurse 13.1 % (8/61) 
Healthcare assistant 6.6 % (4/61) 
Doctor / GP 3.1 %  (2/61) 




Peer supporter 1.6 % (1/61) 
Breastfeeding support group 4.9 % (3/61) 
Partner, friend or relative 6.6 % (4/61) 
Someone else 13.1 % (8/61) 
Source of help or information regarding feeding problems (after leaving hospital)   
Sure start / Children’s centre / children’s health clinic 8.2 %  (5/61) 
Peer supporter 6.6 %  (4/61) 
DSA 8.2 %  (5/61) 
Breastfeeding support group 8.2 %  (5/61) 
Partner, friend or relative 4.9 %  (3/61) 
Start4Life 1.6 %  (1/61) 
Books/leaflets/magazines 4.9 %  (3/61) 
The internet / web based resources 13.1 %  (8/61) 
Breastfeeding clinic 11.5 %  (7/61) 
Doctor / GP 8.2 %  (5/61) 
Health visitor 19.7 %  (12/61) 
Midwife 18.0 %  (11/61) 
Nurse 8.2 %  (5/61) 
Somewhere else 6.6 %  (4/61) 
Table: Feeding information and sources at different stages.  
 
Solid feeds and weaning  
The first type of solid food given to baby    




Vegetables (home prepared) 28.6 %  (14/49) 
Homemade food  6.1 %  (3/49) 
Baby rice 36.7 %  (18/49) 
Ready made baby food 2.0 %  (1/49) 
Any other food  16.3 %  (8/49) 
Source (s) of information on which types of solid 
feeds to start on used by the parents 
  
SureStart or Children’s Centre / Children’s 
Health Clinic 
24.1 %  (13/54) 
Partner / Friend or relative 7.4 %  (4/54) 
Voluntary or charitable organisation 1.9 % (1/54) 
Peer supporter 5.6 % (3/54) 
Breastfeeding support group 3.7 %  (2/54) 
Start4Life 13.0 % (7/54) 
Books / Leaflets / magazines 35.2 % (19/54) 
Internet / web based resources 20.4 %  (11/54) 
Health Visitor 46.3 %  (25/54) 
Midwife (including at antenatal sessions) 1.9 %  (1/54) 
Nurse 1.9 %  (1/54) 
Somewhere else 16.7 %  (9/54) 
Speech and language therapist 5.6 %  (3/54) 





Table: Weaning onto solids. Initial solid feeds and sources of information on solid feeds.  
 
 
Types of solid feeds ever given 
 At 7 months At 12 months 
Ready made baby 
food 
61.1 % (33/54) 80.0 % (32/40) 
Rusk 18.5 % (10/54) 40.0 % (16/40) 
Baby rice 66.7 % (36/54) 72.5 % (29/40) 
Fruit 83.3 % (45/54) 90.0 % (36/40) 
Vegetables 81.5 % (44/54) 90.0 % (36/40) 
Homemade food 64.8 % (35/54) 90.0 % (36/40) 
Other food 66.7 % (36/54) 97.5 % (39/40) 
 
 






Appendix 30: Urine C-peptide Creatinine Ratio (UCPCR nmol/mmol) levels in 
samples from participants N=54, followed longitudinally (total samples 
tested N=109).   
 
Urine C-peptide Creatinine Ratio (UCPCR nmol/mmol) levels in samples from participants 
N=54, followed longitudinally (total samples tested N=109).  The threshold for detection is 
≥0.03 nmol/mmol and the threshold for intermediate insulin excretion > 0.2 nmol/mmol.   
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